Analyte monitoring device and methods of use

Information

  • Patent Grant
  • 8409131
  • Patent Number
    8,409,131
  • Date Filed
    Wednesday, March 7, 2007
    17 years ago
  • Date Issued
    Tuesday, April 2, 2013
    11 years ago
Abstract
An analyte monitor includes a sensor, a sensor control unit, and a display unit. The sensor has, for example, a substrate, a recessed channel formed in the substrate, and conductive material disposed in the recessed channel to form a working electrode. The sensor control unit typically has a housing adapted for placement on skin and is adapted to receive a portion of an electrochemical sensor. The sensor control unit also includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The display unit has a receiver for receiving data transmitted by the transmitter of the sensor control unit and a display coupled to the receiver for displaying an indication of a level of an analyte. The analyte monitor may also be part of a drug delivery system to alter the level of the analyte based on the data obtained using the sensor.
Description
FIELD OF THE INVENTION

The present invention is, in general, directed to devices and methods for the in vivo monitoring of an analyte, such as glucose or lactate. More particularly, the present invention relates to devices and methods for the in vivo monitoring of an analyte using an electrochemical sensor to provide information to a patient about the level of the analyte.


BACKGROUND OF THE INVENTION

The monitoring of the level of glucose and other analytes, such as lactate or oxygen, in certain individuals is vitally important to their health. High or low levels of glucose or other analytes may have detrimental effects. The monitoring of glucose is particularly important to individuals with diabetes, as they must determine when insulin is needed to reduce glucose levels in their bodies or when additional glucose is needed to raise the level of glucose in their bodies.


A conventional technique used by many diabetics for personally monitoring their blood glucose level includes the periodic drawing of blood, the application of that blood to a test strip, and the determination of the blood glucose level using calorimetric, electrochemical, or photometric detection. This technique does not permit continuous or automatic monitoring of glucose levels in the body, but typically must be performed manually on a periodic basis. Unfortunately, the consistency with which the level of glucose is checked varies widely among individuals. Many diabetics find the periodic testing inconvenient and they sometimes forget to test their glucose level or do not have time for a proper test. In addition, some individuals wish to avoid the pain associated with the test. These situations may result in hyperglycemic or hypoglycemic episodes.


An in vivo glucose sensor that continuously or automatically monitors the individual's glucose level would enable individuals to more easily monitor their glucose, or other analyte, levels.


A variety of devices have been developed for continuous or automatic monitoring of analytes, such as glucose, in the blood stream or interstitial fluid. A number of these devices use electrochemical sensors which are directly implanted into a blood vessel or in the subcutaneous tissue of a patient. However, these devices are often difficult to reproducibly and inexpensively manufacture in large numbers. In addition, these devices are typically large, bulky, and/or inflexible, and many cannot be used effectively outside of a controlled medical facility, such as a hospital or a doctor's office, unless the patient is restricted in his activities.


Some devices include a sensor guide which rests on or near the skin of the patient and may be attached to the patient to hold the sensor in place. These sensor guides are typically bulky and do not allow for freedom of movement. In addition, the sensor guides or the sensors include cables or wires for connecting the sensor to other equipment to direct the signals from the sensors to an analyzer. The size of the sensor guides and presence of cables and wires hinders the convenient use of these devices for everyday applications. There is a need for a small, compact device that can operate the sensor and provide signals to an analyzer without substantially restricting the movements and activities of a patient.


The patient's comfort and the range of activities that can be performed while the sensor is implanted are important considerations in designing extended-use sensors for continuous or automatic in vivo monitoring of the level of an analyte, such as glucose. There is a need for a small, comfortable device which can continuously monitor the level of an analyte, such as glucose, while still permitting the patient to engage in normal activities. Continuous and/or automatic monitoring of the analyte can provide a warning to the patient when the level of the analyte is at or near a threshold level. For example, if glucose is the analyte, then the monitoring device might be configured to warn the patient of current or impending hyperglycemia or hypoglycemia. The patient can then take appropriate actions.


SUMMARY OF THE INVENTION

Generally, the present invention relates to methods and devices for the continuous and/or automatic in vivo monitoring of the level of an analyte using a subcutaneously implantable sensor. Many of these devices are small and comfortable when used, thereby allowing a wide range of activities. One embodiment is a sensor control unit having a housing adapted for placement on skin. The housing is also adapted to receive a portion of an electrochemical sensor. The sensor control unit includes two or more conductive contacts disposed on the housing and configured for coupling to two or more contact pads on the sensor. A transmitter is disposed in the housing and coupled to the plurality of conductive contacts for transmitting data obtained using the sensor. The sensor control unit may also include a variety of optional components, such as, for example, adhesive for adhering to the skin, a mounting unit, a receiver, a processing circuit, a power supply (e.g., a battery), an alarm system, a data storage unit, a watchdog circuit, and a measurement circuit. Other optional components are described below.


Another embodiment of the invention is a sensor assembly that includes the sensor control unit described above. The sensor assembly also includes a sensor having at least one working electrode and at least one contact pad coupled to the working electrode or electrodes. The sensor may also include optional components, such as, for example, a counter electrode, a counter/reference electrode, a reference electrode, and a temperature probe. Other components and options for the sensor are described below.


A further embodiment of the invention is an analyte monitoring system that includes the sensor control unit described above. The analyte monitoring system also includes a sensor that has at least one working electrode and at least one contact pad coupled to the working electrode or electrodes. The analyte monitoring system also includes a display unit that has a receiver for receiving data from the sensor control unit and a display coupled to the receiver for displaying an indication of the level of an analyte. The display unit may optionally include a variety of components, such as, for example, a transmitter, an analyzer, a data storage unit, a watchdog circuit, an input device, a power supply, a clock, a lamp, a pager, a telephone interface, a computer interface, an alarm or alarm system, a radio, and a calibration unit. Further components and options for the display unit are described below. In addition, the analyte monitoring system or a component of the analyte monitoring system may optionally include a processor capable of determining a drug or treatment protocol and/or a drug delivery system.


Yet another embodiment of the invention is an insertion kit for inserting an electrochemical sensor into a patient. The insertion kit includes an inserter. A portion of the inserter has a sharp, rigid, planer structure adapted to support the sensor during insertion of the electrochemical sensor. The insertion kit also includes an insertion gun having a port configured to accept the electrochemical sensor and the inserter. The insertion gun has a driving mechanism for driving the inserter and electrochemical sensor into the patient, and a retraction mechanism for removing the inserter while leaving the sensor within the patient.


Another embodiment is a method of using an electrochemical sensor. A mounting unit is adhered to the skin of a patient. An insertion gun is aligned with a port on the mounting unit. The electrochemical sensor is disposed within the insertion gun and then the electrochemical sensor is inserted into the skin of the patient using the insertion gun. The insertion gun is removed and a housing of the sensor control unit is mounted on the mounting base. A plurality of conductive contacts disposed on the housing is coupled to a plurality of contact pads disposed on the electrochemical sensor to prepare the sensor for use.


One embodiment of the invention is a method for detecting failures in an implanted analyte-responsive sensor. An analyte-responsive sensor is implanted into a patient. The analyte-responsive sensor includes N working electrodes, where N is an integer and is two or greater, and a common counter electrode. Signals generated at one of the N working electrodes and at the common counter electrode are then obtained and the sensor is determined to have failed if the signal from the common counter electrode is not N times the signal from one of the working electrodes, within a predetermined threshold limit.


Yet another embodiment is a method of calibrating an electrochemical sensor having one or more working electrodes implanted in a patient. A signal is generated from each of the working electrodes. Several conditions are tested to determine if calibration is appropriate. First, the signals from each of the one or more working electrodes should differ by less than a first threshold amount. Second, the signals from each of the one or more working electrodes should be within a predetermined range. And, third, a rate of change of the signals from each of the one or more working electrodes should be less than a second threshold amount. A calibration value is found assaying a calibration sample of a patient's body fluid. The calibration value is then related to at least one of the signals from the one or more working electrodes if the conditions described above are met.


A further embodiment is a method for monitoring a level of an analyte. A sensor is inserted into a skin of a patient and a sensor control unit is attached to the skin of the patient. Two or more conductive contacts on the sensor control unit are coupled to contact pads on the sensor. Then, using the sensor control unit, data is collected regarding a level of an analyte from signals generated by the sensor. The collected data is transmitted to a display unit and an indication of the level of the analyte is displayed on the display unit.


The above summary of the present invention is not intended to describe each disclosed embodiment or every implementation of the present invention. The Figures and the detailed description which follow more particularly exemplify these embodiments.





BRIEF DESCRIPTION OF THE DRAWINGS

The invention may be more completely understood in consideration of the following detailed description of various embodiments of the invention in connection with the accompanying drawings, in which:



FIG. 1 is a block diagram of one embodiment of a subcutaneous analyte monitor using a subcutaneously implantable analyte sensor, according to the invention;



FIG. 2 is a top view of one embodiment of an analyte sensor, according to the invention;



FIG. 3A is a cross-sectional view of the analyte sensor of FIG. 2;



FIG. 3B is a cross-sectional view of another embodiment of an analyte sensor, according to the invention;



FIG. 4A is a cross-sectional view of a third embodiment of an analyte sensor, according to the invention;



FIG. 4B is a cross-sectional view of a fourth embodiment of an analyte sensor, according to the invention;



FIG. 5 is an expanded top view of a tip portion of the analyte sensor of FIG. 2;



FIG. 6 is a cross-sectional view of a fifth embodiment of an analyte sensor, according to the invention;



FIG. 7 is an expanded top view of a tip-portion of the analyte sensor of FIG. 6;



FIG. 8 is an expanded bottom view of a tip-portion of the analyte sensor of FIG. 6;



FIG. 9 is a side view of the analyte sensor of FIG. 2;



FIG. 10 is a top view of the analyte sensor of FIG. 6;



FIG. 11 is a bottom view of the analyte sensor of FIG. 6;



FIG. 12 is an expanded side view of one embodiment of a sensor and an insertion device, according to the invention;



FIGS. 13A, 13B, 13C are cross-sectional views of three embodiments of the insertion device of FIG. 12;



FIG. 14 is a cross-sectional view of one embodiment of a on-skin sensor control unit, according to the invention;



FIG. 15 is a top view of a base of the on-skin sensor control unit of FIG. 14;



FIG. 16 is a bottom view of a cover of the on-skin sensor control unit of FIG. 14;



FIG. 17 is a perspective view of the on-skin sensor control unit of FIG. 14 on the skin of a patient;



FIG. 18A is a block diagram of one embodiment of an on-skin sensor control unit, according to the invention;



FIG. 18B is a block diagram of another embodiment of an on-skin sensor control unit, according to the invention;



FIGS. 19A, 19B, 19C, and 19D are cross-sectional views of four embodiments of conductive contacts disposed on an interior surface of a housing of an on-skin sensor control unit, according to the invention;



FIGS. 19E and 19F are cross-sectional views of two embodiments of conductive contacts disposed on an exterior surface of a housing of an on-skin sensor control unit, according to the invention;



FIGS. 20A and 20B are schematic diagrams of two embodiments of a current-to-voltage converter for use in an analyte monitoring device, according to the invention;



FIG. 21 is a block diagram of one embodiment of an open loop modulation system for use in an analyte monitoring device, according to the invention;



FIG. 22 is a block diagram of one embodiment of a receiver/display unit, according to the invention;



FIG. 23 is a front view of one embodiment of a receiver/display unit;



FIG. 24 is a front view of a second embodiment of a receiver/display unit;



FIG. 25 is a block diagram of one embodiment of a drug delivery system, according to the invention;



FIG. 26 is a perspective view of the internal structure of an insertion gun, according to the invention;



FIG. 27A is a top view of one embodiment of an on-skin sensor control unit, according to the invention;



FIG. 27B is a top view of one embodiment of a mounting unit of the on-skin sensor control unit of FIG. 27A;



FIG. 28A is a top view of another embodiment of an on-skin sensor control unit after insertion of an insertion device and a sensor, according to the invention;



FIG. 28B is a top view of one embodiment of a mounting unit of the on-skin sensor control unit of FIG. 28A;



FIG. 28C is a top view of one embodiment of a housing for at least a portion of the electronics of the on-skin sensor control unit of FIG. 28A;



FIG. 28D is a bottom view of the housing of FIG. 28C; and



FIG. 28E is a top view of the on-skin sensor control unit of FIG. 28A with a cover of the housing removed.





While the invention is amenable to various modifications and alternative forms, specifics thereof have been shown by way of example in the drawings and will be described in detail. It should be understood, however, that the intention is not to limit the invention to the particular embodiments described. On the contrary, the intention is to cover all modifications, equivalents, and alternatives falling within the spirit and scope of the invention as defined by the appended claims.


DETAILED DESCRIPTION OF THE INVENTION

The present invention is applicable to an analyte monitoring system using an implantable sensor for the in vivo determination of a concentration of an analyte, such as glucose or lactate, in a fluid. The sensor can be, for example, subcutaneously implanted in a patient for the continuous or periodic monitoring of an analyte in a patient's interstitial fluid. This can then be used to infer the glucose level in the patient's bloodstream. Other in vivo analyte sensors can be made, according to the invention, for insertion into a vein, artery, or other portion of the body containing fluid. The analyte monitoring system is typically configured for monitoring the level of the analyte over a time period which may range from days to weeks or longer.


The following definitions are provided for terms used herein:


A “counter electrode” refers to an electrode paired with the working electrode, through which passes a current equal in magnitude and opposite in sign to the current passing through the working electrode. In the context of the invention, the term “counter electrode” is meant to include counter electrodes which also function as reference electrodes (i.e., a counter/reference electrode).


An “electrochemical sensor” is a device configured to detect the presence and/or measure the level of an analyte in a sample via electrochemical oxidation and reduction reactions on the sensor. These reactions are transduced to an electrical signal that can be correlated to an amount, concentration, or level of an analyte in the sample.


“Electrolysis” is the electrooxidation or electroreduction of a compound either directly at an electrode or via one or more electron transfer agents.


A compound is “immobilized” on a surface when it is entrapped on or chemically bound to the surface.


A “non-leachable” or “non-releasable” compound or a compound that is “non-leachably disposed” is meant to define a compound that is affixed on the sensor such that it does not substantially diffuse away from the working surface of the working electrode for the period in which the sensor is used (e.g., the period in which the sensor is implanted in a patient or measuring a sample).


Components are “immobilized” within a sensor, for example, when the components are covalently, ionically, or coordinatively bound to constituents of the sensor and/or are entrapped in a polymeric or sol-gel matrix or membrane which precludes mobility.


An “electron transfer agent” is a compound that carries electrons between the analyte and the working electrode, either directly, or in cooperation with other electron transfer agents. One example of an electron transfer agent is a redox mediator.


A “working electrode” is an electrode at which the analyte (or a second compound whose level depends on the level of the analyte) is electrooxidized or electroreduced with or without the agency of an electron transfer agent.


A “working surface” is that portion of the working electrode which is coated with or is accessible to the electron transfer agent and configured for exposure to an analyte-containing fluid.


A “sensing layer” is a component of the sensor which includes constituents that facilitate the electrolysis of the analyte. The sensing layer may include constituents such as an electron transfer agent, a catalyst which catalyzes a reaction of the analyte to produce a response at the electrode, or both. In some embodiments of the sensor, the sensing layer is non-leachably disposed in proximity to or on the working electrode.


A “non-corroding” conductive material includes non-metallic materials, such as carbon and conductive polymers.


Analyte Sensor Systems


The analyte monitoring systems of the present invention can be utilized under a variety of conditions. The particular configuration of a sensor and other units used in the analyte monitoring system may depend on the use for which the analyte monitoring system is intended and the conditions under which the analyte monitoring system will operate. One embodiment of the analyte monitoring system includes a sensor configured for implantation into a patient or user. For example, implantation of the sensor may be made in the arterial or venous systems for direct testing of analyte levels in blood. Alternatively, a sensor may be implanted in the interstitial tissue for determining the analyte level in interstitial fluid. This level may be correlated and/or converted to analyte levels in blood or other fluids. The site and depth of implantation may affect the particular shape, components, and configuration of the sensor. Subcutaneous implantation may be preferred, in some cases, to limit the depth of implantation of the sensor. Sensors may also be implanted in other regions of the body to determine analyte levels in other fluids. Examples of suitable sensor for use in the analyte monitoring systems of the invention are described in U.S. Pat. No. 6,134,461, incorporated herein by reference.


One embodiment of the analyte monitoring system 40 for use with an implantable sensor 42, and particularly for use with a subcutaneously implantable sensor, is illustrated in block diagram form in FIG. 1. The analyte monitoring system 40 includes, at minimum, a sensor 42, a portion of which is configured for implantation (e.g., subcutaneous, venous, or arterial implantation) into a patient, and a sensor control unit 44. The sensor 42 is coupled to the sensor control unit 44 which is typically attached to the skin of a patient. The sensor control unit 44 operates the sensor 42, including, for example, providing a voltage across the electrodes of the sensor 42 and collecting signals from the sensor 42. The sensor control unit 44 may evaluate the signals from the sensor 42 and/or transmit the signals to one or more optional receiver/display units 46, 48 for evaluation. The sensor control unit 44 and/or the receiver/display units 46, 48 may display or otherwise communicate the current level of the analyte. Furthermore, the sensor control unit 44 and/or the receiver/display units 46, 48 may indicate to the patient, via, for example, an audible, visual, or other sensory-stimulating alarm, when the level of the analyte is at or near a threshold level. In some embodiments, an electrical shock can be delivered to the patient as a warning through one of the electrodes or the optional temperature probe of the sensor. For example, if glucose is monitored then an alarm may be used to alert the patient to a hypoglycemic or hyperglycemic glucose level and/or to impending hypoglycemia or hyperglycemia.


The Sensor


A sensor 42 includes at least one working electrode 58 formed on a substrate 50, as shown in FIG. 2. The sensor 42 may also include at least one counter electrode 60 (or counter/reference electrode) and/or at least one reference electrode 62 (see FIG. 8). The counter electrode 60 and/or reference electrode 62 may be formed on the substrate 50 or may be separate units. For example, the counter electrode and/or reference electrode may be formed on a second substrate which is also implanted in the patient or, for some embodiments of the implantable sensors, the counter electrode and/or reference electrode may be placed on the skin of the patient with the working electrode or electrodes being implanted into the patient. The use of an on-the-skin counter and/or reference electrode with an implantable working electrode is described in U.S. Pat. No. 5,593,852, incorporated herein by reference.


The working electrode or electrodes 58 are formed using conductive traces 52 disposed on the substrate 50. The counter electrode 60 and/or reference electrode 62, as well as other optional portions of the sensor 42, such as a temperature probe 66 (see FIG. 8), may also be formed using conductive traces 52 disposed on the substrate 50. These conductive traces 52 may be formed over a smooth surface of the substrate 50 or within channels 54 formed by, for example, embossing, indenting or otherwise creating a depression in the substrate 50.


A sensing layer 64 (see FIGS. 3A and 3B) is often formed proximate to or on at least one of the working electrodes 58 to facilitate the electrochemical detection of the analyte and the determination of its level in the sample fluid, particularly if the analyte cannot be electrolyzed at a desired rate and/or with a desired specificity on a bare electrode. The sensing layer 64 may include an electron transfer agent to transfer electrons directly or indirectly between the analyte and the working electrode 58. The sensing layer 64 may also contain a catalyst to catalyze a reaction of the analyte. The components of the sensing layer may be in a fluid or gel that is proximate to or in contact with the working electrode 58. Alternatively, the components of the sensing layer 64 may be disposed in a polymeric or sol-gel matrix that is proximate to or on the working electrode 58. Preferably, the components of the sensing layer 64 are non-leachably disposed within the sensor 42. More preferably, the components of the sensor 42 are immobilized within the sensor 42.


In addition to the electrodes 58, 60, 62 and the sensing layer 64, the sensor 42 may also include a temperature probe 66 (see FIGS. 6 and 8), a mass transport limiting layer 74 (see FIG. 9), a biocompatible layer 75 (see FIG. 9), and/or other optional components, as described below. Each of these items enhances the functioning of and/or results from the sensor 42, as discussed below.


The Substrate


The substrate 50 may be formed using a variety of non-conducting materials, including, for example, polymeric or plastic materials and ceramic materials. Suitable materials for a particular sensor 42 may be determined, at least in part, based on the desired use of the sensor 42 and properties of the materials.


In some embodiments, the substrate is flexible. For example, if the sensor 42 is configured for implantation into a patient, then the sensor 42 may be made flexible (although rigid sensors may also be used for implantable sensors) to reduce pain to the patient and damage to the tissue caused by the implantation of and/or the wearing of the sensor 42. A flexible substrate 50 often increases the patient's comfort and allows a wider range of activities. Suitable materials for a flexible substrate 50 include, for example, non-conducting plastic or polymeric materials and other non-conducting, flexible, deformable materials. Examples of useful plastic or polymeric materials include thermoplastics such as polycarbonates, polyesters (e.g., Mylar™ and polyethylene terephthalate (PET)), polyvinyl chloride (PVC), polyurethanes, polyethers, polyamides, polyimides, or copolymers of these thermoplastics, such as PETG (glycol-modified polyethylene terephthalate).


In other embodiments, the sensors 42 are made using a relatively rigid substrate 50 to, for example, provide structural support against bending or breaking. Examples of rigid materials that may be used as the substrate 50 include poorly conducting ceramics, such as aluminum oxide and silicon dioxide. One advantage of an implantable sensor 42 having a rigid substrate is that the sensor 42 may have a sharp point and/or a sharp edge to aid in implantation of a sensor 42 without an additional insertion device.


It will be appreciated that for many sensors 42 and sensor applications, both rigid and flexible sensors will operate adequately. The flexibility of the sensor 42 may also be controlled and varied along a continuum by changing, for example, the composition and/or thickness of the substrate 50.


In addition to considerations regarding flexibility, it is often desirable that implantable sensors 42 should have a substrate 50 which is non-toxic. Preferably, the substrate 50 is approved by one or more appropriate governmental agencies or private groups for in vivo use.


The sensor 42 may include optional features to facilitate insertion of an implantable sensor 42, as shown in FIG. 12. For example, the sensor 42 may be pointed at the tip 123 to ease insertion. In addition, the sensor 42 may include a barb 125 which assists in anchoring the sensor 42 within the tissue of the patient during operation of the sensor 42. However, the barb 125 is typically small enough that little damage is caused to the subcutaneous tissue when the sensor 42 is removed for replacement.


Although the substrate 50 in at least some embodiments has uniform dimensions along the entire length of the sensor 42, in other embodiments, the substrate 50 has a distal end 67 and a proximal end 65 with different widths 53, 55, respectively, as illustrated in FIG. 2. In these embodiments, the distal end 67 of the substrate 50 may have a relatively narrow width 53. For sensors 42 which are implantable into the subcutaneous tissue or another portion of a patient's body, the narrow width 53 of the distal end 67 of the substrate 50 may facilitate the implantation of the sensor 42. Often, the narrower the width of the sensor 42, the less pain the patient will feel during implantation of the sensor and afterwards.


For subcutaneously implantable sensors 42 which are designed for continuous or periodic monitoring of the analyte during normal activities of the patient, a distal end 67 of the sensor 42 which is to be implanted into the patient has a width 53 of 2 mm or less, preferably 1 mm or less, and more preferably 0.5 mm or less. If the sensor 42 does not have regions of different widths, then the sensor 42 will typically have an overall width of, for example, 2 mm, 1.5 mm, 1 mm, 0.5 mm, 0.25 mm, or less. However, wider or narrower sensors may be used. In particular, wider implantable sensors may be used for insertion into veins or arteries or when the movement of the patient is limited, for example, when the patient is confined in bed or in a hospital.


Returning to FIG. 2, the proximal end 65 of the sensor 42 may have a width 55 larger than the distal end 67 to facilitate the connection between contact pads 49 of the electrodes and contacts on a control unit. The wider the sensor 42 at this point, the larger the contact pads 49 can be made. This may reduce the precision needed to properly connect the sensor 42 to contacts on the control unit (e.g., sensor control unit 44 of FIG. 1). However, the maximum width of the sensor 42 may be constrained so that the sensor 42 remains small for the convenience and comfort of the patient and/or to fit the desired size of the analyte monitor. For example, the proximal end 65 of a subcutaneously implantable sensor 42, such as the sensor 42 illustrated in FIG. 1, may have a width 55 ranging from 0.5 mm to 15 mm, preferably from 1 mm to 10 mm, and more preferably from 3 mm to 7 mm. However, wider or narrower sensors may be used in this and other in vivo applications.


The thickness of the substrate 50 may be determined by the mechanical properties of the substrate material (e.g., the strength, modulus, and/or flexibility of the material), the desired use of the sensor 42 including stresses on the substrate 50 arising from that use, as well as the depth of any channels or indentations formed in the substrate 50, as discussed below. Typically, the substrate 50 of a subcutaneously implantable sensor 42 for continuous or periodic monitoring of the level of an analyte while the patient engages in normal activities has a thickness of 50 to 500 μm and preferably 100 to 300 μm. However, thicker and thinner substrates 50 may be used, particularly in other types of in vivo sensors 42.


The length of the sensor 42 may have a wide range of values depending on a variety of factors. Factors which influence the length of an implantable sensor 42 may include the depth of implantation into the patient and the ability of the patient to manipulate a small flexible sensor 42 and make connections between the sensor 42 and the sensor control unit 44. A subcutaneously implantable sensor 42 for the analyte monitor illustrated in FIG. 1 may have a length ranging from 0.3 to 5 cm, however, longer or shorter sensors may be used. The length of the narrow portion of the sensor 42 (e.g., the portion which is subcutaneously inserted into the patient), if the sensor 42 has narrow and wide portions, is typically about 0.25 to 2 cm in length. However, longer and shorter portions may be used. All or only a part of this narrow portion may be subcutaneously implanted into the patient. The lengths of other implantable sensors 42 will vary depending, at least in part, on the portion of the patient into which the sensor 42 is to be implanted or inserted.


Conductive Traces


At least one conductive trace 52 is formed on the substrate for use in constructing a working electrode 58. In addition, other conductive traces 52 may be formed on the substrate 50 for use as electrodes (e.g., additional working electrodes, as well as counter, counter/reference, and/or reference electrodes) and other components, such as a temperature probe. The conductive traces 52 may extend most of the distance along a length 57 of the sensor 50, as illustrated in FIG. 2, although this is not necessary. The placement of the conductive traces 52 may depend on the particular configuration of the analyte monitoring system (e.g., the placement of control unit contacts and/or the sample chamber in relation to the sensor 42). For implantable sensors, particularly subcutaneously implantable sensors, the conductive traces typically extend close to the tip of the sensor 42 to minimize the amount of the sensor that must be implanted.


The conductive traces 52 may be formed on the substrate 50 by a variety of techniques, including, for example, photolithography, screen printing, or other impact or non-impact printing techniques. The conductive traces 52 may also be formed by carbonizing conductive traces 52 in an organic (e.g., polymeric or plastic) substrate 50 using a laser. A description of some exemplary methods for forming the sensor 42 is provided in U.S. Pat. No. 6,103,033,incorporated herein by reference.


Another method for disposing the conductive traces 52 on the substrate 50 includes the formation of recessed channels 54 in one or more surfaces of the substrate 50 and the subsequent filling of these recessed channels 54 with a conductive material 56, as shown in FIG. 3A. The recessed channels 54 may be formed by indenting, embossing, or otherwise creating a depression in the surface of the substrate 50. Exemplary methods for forming channels and electrodes in a surface of a substrate can be found in U.S. Pat. No. 6,103,033. The depth of the channels is typically related to the thickness of the substrate 50. In one embodiment, the channels have depths in the range of about 12.5 to 75 μm (0.5 to 3 mils), and preferably about 25 to 50 μm (1 to 2 mils).


The conductive traces are typically formed using a conductive material 56 such as carbon (e.g., graphite), a conductive polymer, a metal or alloy (e.g., gold or gold alloy), or a metallic compound (e.g., ruthenium dioxide or titanium dioxide). The formation of films of carbon, conductive polymer, metal, alloy, or metallic compound are well-known and include, for example, chemical vapor deposition (CVD), physical vapor deposition, sputtering, reactive sputtering, printing, coating, and painting. The conductive material 56 which fills the channels 54 is often formed using a precursor material, such as a conductive ink or paste. In these embodiments, the conductive material 56 is deposited on the substrate 50 using methods such as coating, painting, or applying the material using a spreading instrument, such as a coating blade. Excess conductive material between the channels 54 is then removed by, for example, running a blade along the substrate surface.


In one embodiment, the conductive material 56 is a part of a precursor material, such as a conductive ink, obtainable, for example, from Ercon, Inc. (Wareham, Mass.), Metech, Inc. (Elverson, Pa.), E.I. du Pont de Nemours and Co. (Wilmington, Del.), Emca-Remex Products (Montgomeryville, Pa.), or MCA Services (Melbourn, Great Britain). The conductive ink is typically applied as a semiliquid or paste which contains particles of the carbon, metal, alloy, or metallic compound and a solvent or dispersant. After application of the conductive ink on the substrate 50 (e.g., in the channels 54), the solvent or dispersant evaporates to leave behind a solid mass of conductive material 56.


In addition to the particles of carbon, metal, alloy, or metallic compound, the conductive ink may also contain a binder. The binder may optionally be cured to further bind the conductive material 56 within the channel 54 and/or on the substrate 50. Curing the binder increases the conductivity of the conductive material 56. However, this is typically not necessary as the currents carried by the conductive material 56 within the conductive traces 52 are often relatively low (usually less than 1 μA and often less than 100 nA). Typical binders include, for example, polyurethane resins, cellulose derivatives, elastomers, and highly fluorinated polymers. Examples of elastomers include silicones, polymeric dienes, and acrylonitrile-butadiene-styrene (ABS) resins. One example of a fluorinated polymer binder is Teflon® (DuPont, Wilmington, Del.). These binders are cured using, for example, heat or light, including ultraviolet (UV) light. The appropriate curing method typically depends on the particular binder which is used.


Often, when a liquid or semiliquid precursor of the conductive material 56 (e.g., a conductive ink) is deposited in the channel 54, the precursor fills the channel 54. However, when the solvent or dispersant evaporates, the conductive material 56 which remains may lose volume such that the conductive material 56 may or may not continue to fill the channel 54. Preferred conductive materials 56 do not pull away from the substrate 50 as they lose volume, but rather decrease in height within the channel 54. These conductive materials 56 typically adhere well to the substrate 50 and therefore do not pull away from the substrate 50 during evaporation of the solvent or dispersant. Other suitable conductive materials 56 either adhere to at least a portion of the substrate 50 and/or contain another additive, such as a binder, which adheres the conductive material 56 to the substrate 50. Preferably, the conductive material 56 in the channels 54 is non-leachable, and more preferably immobilized on the substrate 50. In some embodiments, the conductive material 56 may be formed by multiple applications of a liquid or semiliquid precursor interspersed with removal of the solvent or dispersant.


In another embodiment, the channels 54 are formed using a laser. The laser carbonizes the polymer or plastic material. The carbon formed in this process is used as the conductive material 56. Additional conductive material 56, such as a conductive carbon ink, may be used to supplement the carbon formed by the laser.


In a further embodiment, the conductive traces 52 are formed by pad printing techniques. For example, a film of conductive material is formed either as a continuous film or as a coating layer deposited on a carrier film. This film of conductive material is brought between a print head and the substrate 50. A pattern on the surface of the substrate 50 is made using the print head according to a desired pattern of conductive traces 52. The conductive material is transferred by pressure and/or heat from the film of conductive material to the substrate 50. This technique often produces channels (e.g., depressions caused by the print head) in the substrate 50. Alternatively, the conductive material is deposited on the surface of the substrate 50 without forming substantial depressions.


In other embodiments, the conductive traces 52 are formed by non-impact printing techniques. Such techniques include electrophotography and magnetography. In these processes, an image of the conductive traces 52 is electrically or magnetically formed on a drum. A laser or LED may be used to electrically form an image. A magnetic recording head may be used to magnetically form an image. A toner material (e.g., a conductive material, such as a conductive ink) is then attracted to portions of the drum according to the image. The toner material is then applied to the substrate by contact between the drum and the substrate. For example, the substrate may be rolled over the drum. The toner material may then be dried and/or a binder in the toner material may be cured to adhere the toner material to the substrate.


Another non-impact printing technique includes ejecting droplets of conductive material onto the substrate in a desired pattern. Examples of this technique include ink jet printing and piezo jet printing. An image is sent to the printer which then ejects the conductive material (e.g., a conductive ink) according to the pattern. The printer may provide a continuous stream of conductive material or the printer may eject the conductive material in discrete amounts at the desired points.


Yet another non-impact printing embodiment of forming the conductive traces includes an ionographic process. In this process, a curable, liquid precursor, such as a photopolymerizable acrylic resin (e.g., Solimer 7501 from Cubital, Bad Kreuznach, Germany) is deposited over a surface of a substrate 50. A photomask having a positive or negative image of the conductive traces 52 is then used to cure the liquid precursor. Light (e.g., visible or ultraviolet light) is directed through the photomask to cure the liquid precursor and form a solid layer over the substrate according to the image on the photomask. Uncured liquid precursor is removed leaving behind channels 54 in the solid layer. These channels 54 can then be filled with conductive material 56 to form conductive traces 52.


Conductive traces 52 (and channels 54, if used) can be formed with relatively narrow widths, for example, in the range of 25 to 250 μm, and including widths of, for example, 250 μm, 150 μm, 100 μm, 75 μm, 50 μm, 25 μm or less by the methods described above. In embodiments with two or more conductive traces 52 on the same side of the substrate 50, the conductive traces 52 are separated by distances sufficient to prevent conduction between the conductive traces 52. The edge-to-edge distance between the conductive traces is preferably in the range of 25 to 250 μm and may be, for example, 150 μm, 100 μm, 75 μm, 50 μm, or less. The density of the conductive traces 52 on the substrate 50 is preferably in the range of about 150 to 700 μm/trace and may be as small as 667 μm/trace or less, 333 μm/trace or less, or even 167 μm/trace or less.


The working electrode 58 and the counter electrode 60 (if a separate reference electrode is used) are often made using a conductive material 56, such as carbon. Suitable carbon conductive inks are available from Ercon, Inc. (Wareham, Mass.), Metech, Inc. (Elverson, Pa.), E.I. du Pont de Nemours and Co. (Wilmington, Del.), Emca-Remex Products (Montgomeryville, Pa.), or MCA Services (Melbourn, Great Britain). Typically, the working surface 51 of the working electrode 58 is at least a portion of the conductive trace 52 that is in contact with the analyte-containing fluid (e.g., implanted in the patient).


The reference electrode 62 and/or counter/reference electrode are typically formed using conductive material 56 that is a suitable reference material, for example silver/silver chloride or a non-leachable redox couple bound to a conductive material, for example, a carbon-bound redox couple. Suitable silver/silver chloride conductive inks are available from Ercon, Inc. (Wareham, Mass.), Metech, Inc. (Elverson, Pa.), E.I. du Pont de Nemours and Co. (Wilmington, Del.), Emca-Remex Products (Montgomeryville, Pa.), or MCA Services (Melbourn, Great Britain). Silver/silver chloride electrodes illustrate a type of reference electrode that involves the reaction of a metal electrode with a constituent of the sample or body fluid, in this case, Cl.


Suitable redox couples for binding to the conductive material of the reference electrode include, for example, redox polymers (e.g., polymers having multiple redox centers.) It is preferred that the reference electrode surface be non-corroding so that an erroneous potential is not measured. Preferred conductive materials include less corrosive metals, such as gold and palladium. Most preferred are non-corrosive materials including non-metallic conductors, such as carbon and conducting polymers. A redox polymer can be adsorbed on or covalently bound to the conductive material of the reference electrode, such as a carbon surface of a conductive trace 52. Non-polymeric redox couples can be similarly bound to carbon or gold surfaces.


A variety of methods may be used to immobilize a redox polymer on an electrode surface. One method is adsorptive immobilization. This method is particularly useful for redox polymers with relatively high molecular weights. The molecular weight of a polymer may be increased, for example, by cross-linking.


Another method for immobilizing the redox polymer includes the functionalization of the electrode surface and then the chemical bonding, often covalently, of the redox polymer to the functional groups on the electrode surface. One example of this type of immobilization begins with a poly(4-vinylpyridine). The polymer's pyridine rings are, in part, complexed with a reducible/oxidizable species, such as [Os(bpy)2Cl]+/2+ where bpy is 2,2′-bipyridine. Part of the pyridine rings are quaternized by reaction with 2-bromoethylamine. The polymer is then crosslinked, for example, using a diepoxide, such as polyethylene glycol diglycidyl ether.


Carbon surfaces can be modified for attachment of a redox species or polymer, for example, by electroreduction of a diazonium salt. As an illustration, reduction of a diazonium salt formed upon diazotization of p-aminobenzoic acid modifies a carbon surface with phenylcarboxylic acid functional groups. These functional groups can then be activated by a carbodiimide, such as 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride. The activated functional groups are then bound with a amine-functionalized redox couple, such as the quaternized osmium-containing redox polymer described above or 2-aminoethylferrocene, to form the redox couple.


Similarly, gold can be functionalized by an amine, such as cystamine. A redox couple such as [Os(bpy)2(pyridine-4-carboxylate)Cl]0/+ is activated by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide hydrochloride to form a reactive O-acylisourea which reacts with the gold-bound amine to form an amide.


In one embodiment, in addition to using the conductive traces 52 as electrodes or probe leads, two or more of the conductive traces 52 on the substrate 50 are used to give the patient a mild electrical shock when, for example, the analyte level exceeds a threshold level. This shock may act as a warning or alarm to the patient to initiate some action to restore the appropriate level of the analyte.


The mild electrical shock is produced by applying a potential between any two conductive traces 52 that are not otherwise connected by a conductive path. For example, two of the electrodes 58, 60, 62 or one electrode 58, 60, 62 and the temperature probe 66 may be used to provide the mild shock. Preferably, the working electrode 58 and the reference electrode 62 are not used for this purpose as this may cause some damage to the chemical components on or proximate to the particular electrode (e.g., the sensing layer on the working electrode or the redox couple on the reference electrode).


The current used to produce the mild shock is typically 0.1 to 1 mA. Higher or lower currents may be used, although care should be taken to avoid harm to the patient. The potential between the conductive traces is typically 1 to 10 volts. However, higher or lower voltages may be used depending, for example, on the resistance of the conductive traces 52, the distance between the conductive traces 52 and the desired amount of current. When the mild shock is delivered, potentials at the working electrode 58 and across the temperature probe 66 may be removed to prevent harm to those components caused by unwanted conduction between the working electrode 58 (and/or temperature probe 66, if used) and the conductive traces 52 which provide the mild shock.


Contact Pads


Typically, each of the conductive traces 52 includes a contact pad 49. The contact pad 49 may simply be a portion of the conductive trace 52 that is indistinguishable from the rest of the trace 52 except that the contact pad 49 is brought into contact with the conductive contacts of a control unit (e.g., the sensor control unit 44 of FIG. 1). More commonly, however, the contact pad 49 is a region of the conductive trace 52 that has a larger width than other regions of the trace 52 to facilitate a connection with the contacts on the control unit. By making the contact pads 49 relatively large as compared with the width of the conductive traces 52, the need for precise registration between the contact pads 49 and the contacts on the control unit is less critical than with small contact pads.


The contact pads 49 are typically made using the same material as the conductive material 56 of the conductive traces 52. However, this is not necessary. Although metal, alloys, and metallic compounds may be used to form the contact pads 49, in some embodiments, it is desirable to make the contact pads 49 from a carbon or other non-metallic material, such as a conducting polymer. In contrast to metal or alloy contact pads, carbon and other non-metallic contact pads are not easily corroded if the contact pads 49 are in a wet, moist, or humid environment. Metals and alloys may corrode under these conditions, particularly if the contact pads 49 and contacts of the control unit are made using different metals or alloys. However, carbon and non-metallic contact pads 49 do not significantly corrode, even if the contacts of the control device are metal or alloy.


One embodiment of the invention includes a sensor 42 having contact pads 49 and a control unit 44 having conductive contacts (not shown). During operation of the sensor 42, the contact pads 49 and conductive contacts are in contact with each other. In this embodiment, either the contact pads 49 or the conductive contacts are made using a non-corroding, conductive material. Such materials include, for example, carbon and conducting polymers. Preferred non-corroding materials include graphite and vitreous carbon. The opposing contact pad or conductive contact is made using carbon, a conducting polymer, a metal, such as gold, palladium, or platinum group metal, or a metallic compound, such as ruthenium dioxide. This configuration of contact pads and conductive contacts typically reduces corrosion. Preferably, when the sensor is placed in a 3 mM, and more preferably, in a 100 mM, NaCl solution, the signal arising due to the corrosion of the contact pads and/or conductive contacts is less than 3% of the signal generated by the sensor when exposed to concentration of analyte in the normal physiological range. For at least some subcutaneous glucose sensors, the current generated by analyte in a normal physiological range ranges from 3 to 500 nA.


Each of the electrodes 58, 60, 62, as well as the two probe leads 68, 70 of the temperature probe 66 (described below), are connected to contact pads 49 as shown in FIGS. 10 and 11. In one embodiment (not shown), the contact pads 49 are on the same side of the substrate 50 as the respective electrodes or temperature probe leads to which the contact pads 49 are attached.


In other embodiments, the conductive traces 52 on at least one side are connected through vias in the substrate to contact pads 49a on the opposite surface of the substrate 50, as shown in FIGS. 10 and 11. An advantage of this configuration is that contact between the contacts on the control unit and each of the electrodes 58, 60, 62 and the probe leads 68,70 of the temperature probe 66 can be made from a single side of the substrate 50.


In yet other embodiments (not shown), vias through the substrate are used to provide contact pads on both sides of the substrate 50 for each conductive trace 52. The vias connecting the conductive traces 52 with the contact pads 49a can be formed by making holes through the substrate 50 at the appropriate points and then filling the holes with conductive material 56.


Exemplary Electrode Configurations


A number of exemplary electrode configurations are described below, however, it will be understood that other configurations may also be used. In one embodiment, illustrated in FIG. 3A, the sensor 42 includes two working electrodes 58a, 58b and one counter electrode 60, which also functions as a reference electrode. In another embodiment, the sensor includes one working electrode 58a, one counter electrode 60, and one reference electrode 62, as shown in FIG. 3B. Each of these embodiments is illustrated with all of the electrodes formed on the same side of the substrate 50.


Alternatively, one or more of the electrodes may be formed on an opposing side of the substrate 50. This may be convenient if the electrodes are formed using two different types of conductive material 56 (e.g., carbon and silver/silver chloride). Then, at least in some embodiments, only one type of conductive material 56 needs to be applied to each side of the substrate 50, thereby reducing the number of steps in the manufacturing process and/or easing the registration constraints in the process. For example, if the working electrode 58 is formed using a carbon-based conductive material 56 and the reference or counter/reference electrode is formed using a silver/silver chloride conductive material 56, then the working electrode and reference or counter/reference electrode may be formed on opposing sides of the substrate 50 for ease of manufacture.


In another embodiment, two working electrodes 58 and one counter electrode 60 are formed on one side of the substrate 50 and one reference electrode 62 and a temperature probe 66 are formed on an opposing side of the substrate 50, as illustrated in FIG. 6. The opposing sides of the tip of this embodiment of the sensor 42 are illustrated in FIGS. 7 and 8.


Sensing Layer


Some analytes, such as oxygen, can be directly electrooxidized or electroreduced on the working electrode 58. Other analytes, such as glucose and lactate, require the presence of at least one electron transfer agent and/or at least one catalyst to facilitate the electrooxidation or electroreduction of the analyte. Catalysts may also be used for those analytes, such as oxygen, that can be directly electrooxidized or electroreduced on the working electrode 58. For these analytes, each working electrode 58 has a sensing layer 64 formed proximate to or on a working surface of the working electrode 58. Typically, the sensing layer 64 is formed near or on only a small portion of the working electrode 58, often near a tip of the sensor 42. This limits the amount of material needed to form the sensor 42 and places the sensing layer 64 in the best position for contact with the analyte-containing fluid (e.g., a body fluid, sample fluid, or carrier fluid).


The sensing layer 64 includes one or more components designed to facilitate the electrolysis of the analyte. The sensing layer 64 may include, for example, a catalyst to catalyze a reaction of the analyte and produce a response at the working electrode 58, an electron transfer agent to indirectly or directly transfer electrons between the analyte and the working electrode 58, or both.


The sensing layer 64 may be formed as a solid composition of the desired components (e.g., an electron transfer agent and/or a catalyst). These components are preferably non-leachable from the sensor 42 and more preferably are immobilized on the sensor 42. For example, the components may be immobilized on a working electrode 58. Alternatively, the components of the sensing layer 64 may be immobilized within or between one or more membranes or films disposed over the working electrode 58 or the components may be immobilized in a polymeric or sol-gel matrix. Examples of immobilized sensing layers are described in U.S. Pat. Nos. 5,262,035, 5,264,104, 5,264,105, 5,320,725, 5,593,852, and 5,665,222, and PCT Patent Application No. PCT/US98/02403 entitled “Soybean Peroxidase Electrochemical Sensor”, filed on Feb. 11, 1998, published as WO-1998/035053, incorporated herein by reference.


In some embodiments, one or more of the components of the sensing layer 64 may be solvated, dispersed, or suspended in a fluid within the sensing layer 64, instead of forming a solid composition. The fluid may be provided with the sensor 42 or may be absorbed by the sensor 42 from the analyte-containing fluid. Preferably, the components which are solvated, dispersed, or suspended in this type of sensing layer 64 are non-leachable from the sensing layer. Non-leachability may be accomplished, for example, by providing barriers (e.g., the electrode, substrate, membranes, and/or films) around the sensing layer which prevent the leaching of the components of the sensing layer 64. One example of such a barrier is a microporous membrane or film which allows diffusion of the analyte into the sensing layer 64 to make contact with the components of the sensing layer 64, but reduces or eliminates the diffusion of the sensing layer components (e.g., an electron transfer agent and/or a catalyst) out of the sensing layer 64.


A variety of different sensing layer configurations can be used. In one embodiment, the sensing layer 64 is deposited on the conductive material 56 of a working electrode 58a, as illustrated in FIGS. 3A and 3B. The sensing layer 64 may extend beyond the conductive material 56 of the working electrode 58a. In some cases, the sensing layer 64 may also extend over the counter electrode 60 or reference electrode 62 without degrading the performance of the glucose sensor. For those sensors 42 which utilize channels 54 within which the conductive material 56 is deposited, a portion of the sensing layer 64 may be formed within the channel 54 if the conductive material 56 does not fill the channel 54.


A sensing layer 64 in direct contact with the working electrode 58a may contain an electron transfer agent to transfer electrons directly or indirectly between the analyte and the working electrode, as well as a catalyst to facilitate a reaction of the analyte. For example, a glucose, lactate, or oxygen electrode may be formed having a sensing layer which contains a catalyst, such as glucose oxidase, lactate oxidase, or laccase, respectively, and an electron transfer agent that facilitates the electrooxidation of the glucose, lactate, or oxygen, respectively.


In another embodiment, the sensing layer 64 is not deposited directly on the working electrode 58a. Instead, the sensing layer 64 is spaced apart from the working electrode 58a, as illustrated in FIG. 4A, and separated from the working electrode 58a by a separation layer 61. The separation layer 61 typically includes one or more membranes or films. In addition to separating the working electrode 58a from the sensing layer 64, the separation layer 61 may also act as a mass transport limiting layer or an interferent eliminating layer, as described below.


Typically, a sensing layer 64, which is not in direct contact with the working electrode 58a, includes a catalyst that facilitates a reaction of the analyte. However, this sensing layer 64 typically does not include an electron transfer agent that transfers electrons directly from the working electrode 58a to the analyte, as the sensing layer 64 is spaced apart from the working electrode 58a. One example of this type of sensor is a glucose or lactate sensor which includes an enzyme (e.g., glucose oxidase or lactate oxidase, respectively) in the sensing layer 64. The glucose or lactate reacts with a second compound (e.g., oxygen) in the presence of the enzyme. The second compound is then electrooxidized or electroreduced at the electrode. Changes in the signal at the electrode indicate changes in the level of the second compound in the fluid and are proportional to changes in glucose or lactate level and, thus, correlate to the analyte level.


In another embodiment, two sensing layers 63, 64 are used, as shown in FIG. 4B. Each of the two sensing layers 63, 64 may be independently formed on the working electrode 58a or in proximity to the working electrode 58a. One sensing layer 64 is typically, although not necessarily, spaced apart from the working electrode 58a. For example, this sensing layer 64 may include a catalyst which catalyzes a reaction of the analyte to form a product compound. The product compound is then electrolyzed in the second sensing layer 63 which may include an electron transfer agent to transfer electrons between the working electrode 58a and the product compound and/or a second catalyst to catalyze a reaction of the product compound to generate a signal at the working electrode 58a.


For example, a glucose or lactate sensor may include a first sensing layer 64 which is spaced apart from the working electrode and contains an enzyme, for example, glucose oxidase or lactate oxidase. The reaction of glucose or lactate in the presence of the appropriate enzyme forms hydrogen peroxide. A second sensing layer 63 is provided directly on the working electrode 58a and contains a peroxidase enzyme and an electron transfer agent to generate a signal at the electrode in response to the hydrogen peroxide. The level of hydrogen peroxide indicated by the sensor then correlates to the level of glucose or lactate. Another sensor which operates similarly can be made using a single sensing layer with both the glucose or lactate oxidase and the peroxidase being deposited in the single sensing layer. Examples of such sensors are described in U.S. Pat. No. 5,593,852, U.S. Pat. No. 5,665,222, and PCT Patent Application No. PCT/US98/02403 entitled “Soybean Peroxidase Electrochemical Sensor”, filed on Feb. 11, 1998, published as WO-1998/035053, incorporated herein by reference.


In some embodiments, one or more of the working electrodes 58b do not have a corresponding sensing layer 64, as shown in FIGS. 3A and 4A, or have a sensing layer (not shown) which does not contain one or more components (e.g., an electron transfer agent or catalyst) needed to electrolyze the analyte. The signal generated at this working electrode 58b typically arises from interferents and other sources, such as ions, in the fluid, and not in response to the analyte (because the analyte is not electrooxidized or electroreduced). Thus, the signal at this working electrode 58b corresponds to a background signal. The background signal can be removed from the analyte signal obtained from other working electrodes 58a that are associated with fully-functional sensing layers 64 by, for example, subtracting the signal at working electrode 58b from the signal at working electrode 58a.


Sensors having multiple working electrodes 58a may also be used to obtain more precise results by averaging the signals or measurements generated at these working electrodes 58a. In addition, multiple readings at a single working electrode 58a or at multiple working electrodes may be averaged to obtain more precise data.


Electron Transfer Agent


In many embodiments, the sensing layer 64 contains one or more electron transfer agents in contact with the conductive material 56 of the working electrode 58, as shown in FIGS. 3A and 3B. In some embodiments of the invention, there is little or no leaching of the electron transfer agent away from the working electrode 58 during the period in which the sensor 42 is implanted in the patient. A diffusing or leachable (i.e., releasable) electron transfer agent often diffuses into the analyte-containing fluid, thereby reducing the effectiveness of the electrode by reducing the sensitivity of the sensor over time. In addition, a diffusing or leaching electron transfer agent in an implantable sensor 42 may also cause damage to the patient. In these embodiments, preferably, at least 90%, more preferably, at least 95%, and, most preferably, at least 99%, of the electron transfer agent remains disposed on the sensor after immersion in the analyte-containing fluid for 24 hours, and, more preferably, for 72 hours. In particular, for an implantable sensor, preferably, at least 90%, more preferably, at least 95%, and most preferably, at least 99%, of the electron transfer agent remains disposed on the sensor after immersion in the body fluid at 37° C. for 24 hours, and, more preferably, for 72 hours.


In some embodiments of the invention, to prevent leaching, the electron transfer agents are bound or otherwise immobilized on the working electrode 58 or between or within one or more membranes or films disposed over the working electrode 58. The electron transfer agent may be immobilized on the working electrode 58 using, for example, a polymeric or sol-gel immobilization technique. Alternatively, the electron transfer agent may be chemically (e.g., ionically, covalently, or coordinatively) bound to the working electrode 58, either directly or indirectly through another molecule, such as a polymer, that is in turn bound to the working electrode 58.


Application of the sensing layer 64 on a working electrode 58a is one method for creating a working surface for the working electrode 58a, as shown in FIGS. 3A and 3B. The electron transfer agent mediates the transfer of electrons to electrooxidize or electroreduce an analyte and thereby permits a current flow between the working electrode 58 and the counter electrode 60 via the analyte. The mediation of the electron transfer agent facilitates the electrochemical analysis of analytes which are not suited for direct electrochemical reaction on an electrode.


In general, the preferred electron transfer agents are electroreducible and electrooxidizable ions or molecules having redox potentials that are a few hundred millivolts above or below the redox potential of the standard calomel electrode (SCE). Preferably, the electron transfer agents are not more reducing than about −150 mV and not more oxidizing than about +400 mV versus SCE.


The electron transfer agent may be organic, organometallic, or inorganic. Examples of organic redox species are quinones and species that in their oxidized state have quinoid structures, such as Nile blue and indophenol. Some quinones and partially oxidized quinhydrones react with functional groups of proteins such as the thiol groups of cysteine, the amine groups of lysine and arginine, and the phenolic groups of tyrosine which may render those redox species unsuitable for some of the sensors of the present invention because of the presence of the interfering proteins in an analyte-containing fluid. Usually substituted quinones and molecules with quinoid structure are less reactive with proteins and are preferred. A preferred tetrasubstituted quinone usually has carbon atoms in positions 1, 2, 3, and 4.


In general, electron transfer agents suitable for use in the invention have structures or charges which prevent or substantially reduce the diffusional loss of the electron transfer agent during the period of time that the sample is being analyzed. The preferred electron transfer agents include a redox species bound to a polymer which can in turn be immobilized on the working electrode. The bond between the redox species and the polymer may be covalent, coordinative, or ionic. Useful electron transfer agents and methods for producing them are described in U.S. Pat. Nos. 5,264,104; 5,356,786; 5,262,035; and 5,320,725, incorporated herein by reference. Although any organic or organometallic redox species can be bound to a polymer and used as an electron transfer agent, the preferred redox species is a transition metal compound or complex. The preferred transition metal compounds or complexes include osmium, ruthenium, iron, and cobalt compounds or complexes. The most preferred are osmium compounds and complexes. It will be recognized that many of the redox species described below may also be used, typically without a polymeric component, as electron transfer agents in a carrier fluid or in a sensing layer of a sensor where leaching of the electron transfer agent is acceptable.


One type of non-releasable polymeric electron transfer agent contains a redox species covalently bound in a polymeric composition. An example of this type of mediator is poly(vinylferrocene).


Another type of non-releasable electron transfer agent contains an ionically-bound redox species. Typically, this type of mediator includes a charged polymer coupled to an oppositely charged redox species. Examples of this type of mediator include a negatively charged polymer such as Nafion® (DuPont) coupled to a positively charged redox species such as an osmium or ruthenium polypyridyl cation. Another example of an ionically-bound mediator is a positively charged polymer such as quaternized poly(4-vinyl pyridine) or poly(1-vinyl imidazole) coupled to a negatively charged redox species such as ferricyanide or ferrocyanide. The preferred ionically-bound redox species is a highly charged redox species bound within an oppositely charged redox polymer.


In another embodiment of the invention, suitable non-releasable electron transfer agents include a redox species coordinatively bound to a polymer. For example, the mediator may be formed by coordination of an osmium or cobalt 2,2′-bipyridyl complex to poly(1-vinyl imidazole) or poly(4-vinyl pyridine).


The preferred electron transfer agents are osmium transition metal complexes with one or more ligands, each ligand having a nitrogen-containing heterocycle such as 2,2′-bipyridine, 1,10-phenanthroline, or derivatives thereof. Furthermore, the preferred electron transfer agents also have one or more ligands covalently bound in a polymer, each ligand having at least one nitrogen-containing heterocycle, such as pyridine, imidazole, or derivatives thereof. These preferred electron transfer agents exchange electrons rapidly between each other and the working electrodes 58 so that the complex can be rapidly oxidized and reduced.


One example of a particularly useful electron transfer agent includes (a) a polymer or copolymer having pyridine or imidazole functional groups and (b) osmium cations complexed with two ligands, each ligand containing 2,2′-bipyridine, 1,10-phenanthroline, or derivatives thereof, the two ligands not necessarily being the same. Preferred derivatives of 2,2′-bipyridine for complexation with the osmium cation are 4,4′-dimethyl-2,2′-bipyridine and mono-, di-, and polyalkoxy-2,2′-bipyridines, such as 4,4′-dimethoxy-2,2′-bipyridine. Preferred derivatives of 1,10-phenanthroline for complexation with the osmium cation are 4,7-dimethyl-1,10-phenanthroline and mono, di-, and polyalkoxy-1,10-phenanthrolines, such as 4,7-dimethoxy-1,10-phenanthroline. Preferred polymers for complexation with the osmium cation include polymers and copolymers of poly(1-vinyl imidazole) (referred to as “PVI”) and poly(4-vinyl pyridine) (referred to as “PVP”). Suitable copolymer substituents of poly(1-vinyl imidazole) include acrylonitrile, acrylamide, and substituted or quaternized N-vinyl imidazole. Most preferred are electron transfer agents with osmium complexed to a polymer or copolymer of poly(1-vinyl imidazole).


The preferred electron transfer agents have a redox potential ranging from −100 mV to about +150 mV versus the standard calomel electrode (SCE). Preferably, the potential of the electron transfer agent ranges from −100 mV to +150 mV and more preferably, the potential ranges from −50 mV to +50 mV. The most preferred electron transfer agents have osmium redox centers and a redox potential ranging from +50 mV to −150 mV versus SCE.


Catalyst


The sensing layer 64 may also include a catalyst which is capable of catalyzing a reaction of the analyte. The catalyst may also, in some embodiments, act as an electron transfer agent. One example of a suitable catalyst is an enzyme which catalyzes a reaction of the analyte. For example, a catalyst, such as a glucose oxidase, glucose dehydrogenase (e.g., pyrroloquinoline quinone glucose dehydrogenase (PQQ)), or oligosaccharide dehydrogenase, may be used when the analyte is glucose. A lactate oxidase or lactate dehydrogenase may be used when the analyte is lactate. Laccase may be used when the analyte is oxygen or when oxygen is generated or consumed in response to a reaction of the analyte.


Preferably, the catalyst is non-leachably disposed on the sensor, whether the catalyst is part of a solid sensing layer in the sensor or solvated in a fluid within the sensing layer. More preferably, the catalyst is immobilized within the sensor (e.g., on the electrode and/or within or between a membrane or film) to prevent unwanted leaching of the catalyst away from the working electrode 58 and into the patient. This may be accomplished, for example, by attaching the catalyst to a polymer, cross linking the catalyst with another electron transfer agent (which, as described above, can be polymeric), and/or providing one or more barrier membranes or films with pore sizes smaller than the catalyst.


As described above, a second catalyst may also be used. This second catalyst is often used to catalyze a reaction of a product compound resulting from the catalyzed reaction of the analyte. The second catalyst typically operates with an electron transfer agent to electrolyze the product compound to generate a signal at the working electrode. Alternatively, the second catalyst may be provided in an interferent-eliminating layer to catalyze reactions that remove interferents, as described below.


One embodiment of the invention is an electrochemical sensor in which the catalyst is mixed or dispersed in the conductive material 56 which forms the conductive trace 52 of a working electrode 58. This may be accomplished, for example, by mixing a catalyst, such as an enzyme, in a carbon ink and applying the mixture into a channel 54 on the surface of the substrate 50. Preferably, the catalyst is immobilized in the channel 53 so that it can not leach away from the working electrode 58. This may be accomplished, for example, by curing a binder in the carbon ink using a curing technique appropriate to the binder. Curing techniques include, for example, evaporation of a solvent or dispersant, exposure to ultraviolet light, or exposure to heat. Typically, the mixture is applied under conditions that do not substantially degrade the catalyst. For example, the catalyst may be an enzyme that is heat-sensitive. The enzyme and conductive material mixture should be applied and cured, preferably, without sustained periods of heating. The mixture may be cured using evaporation or UV curing techniques or by the exposure to heat that is sufficiently short that the catalyst is not substantially degraded.


Another consideration for in vivo analyte sensors is the thermostability of the catalyst. Many enzymes have only limited stability at biological temperatures. Thus, it may be necessary to use large amounts of the catalyst and/or use a catalyst that is thermostable at the necessary temperature (e.g., 37° C. or higher for normal body temperature). A thermostable catalyst may be defined as a catalyst which loses less than 5% of its activity when held at 37° C. for at least one hour, preferably, at least one day, and more preferably at least three days. One example of a thermostable catalyst is soybean peroxidase. This particular thermostable catalyst may be used in a glucose or lactate sensor when combined either in the same or separate sensing layers with glucose or lactate oxidase or dehydrogenase. A further description of thermostable catalysts and their use in electrochemical inventions is found in U.S. Pat. No. 5,665,222 and PCT Application No. PCT/US98/02403 entitled “Soybean Peroxidase Electrochemical Sensor”, filed on Feb. 11, 1998, published as WO-1998/035053.


Electrolysis of the Analyte


To electrolyze the analyte, a potential (versus a reference potential) is applied across the working and counter electrodes 58, 60. The minimum magnitude of the applied potential is often dependent on the particular electron transfer agent, analyte (if the analyte is directly electrolyzed at the electrode), or second compound (if a second compound, such as oxygen or hydrogen peroxide, whose level is dependent on the analyte level, is directly electrolyzed at the electrode). The applied potential usually equals or is more oxidizing or reducing, depending on the desired electrochemical reaction, than the redox potential of the electron transfer agent, analyte, or second compound, whichever is directly electrolyzed at the electrode. The potential at the working electrode is typically large enough to drive the electrochemical reaction to or near completion.


The magnitude of the potential may optionally be limited to prevent significant (as determined by the current generated in response to the analyte) electrochemical reaction of interferents, such as urate, ascorbate, and acetaminophen. The limitation of the potential may be obviated if these interferents have been removed in another way, such as by providing an interferent-limiting barrier, as described below, or by including a working electrode 58b (see FIG. 3A) from which a background signal may be obtained.


When a potential is applied between the working electrode 58 and the counter electrode 60, an electrical current will flow. The current is a result of the electrolysis of the analyte or a second compound whose level is affected by the analyte. In one embodiment, the electrochemical reaction occurs via an electron transfer agent and the optional catalyst. Many analytes B are oxidized (or reduced) to products C by an electron transfer agent species A in the presence of an appropriate catalyst (e.g., an enzyme). The electron transfer agent A is then oxidized (or reduced) at the electrode. Electrons are collected by (or removed from) the electrode and the resulting current is measured. This process is illustrated by reaction equations (1) and (2) (similar equations may be written for the reduction of the analyte B by a redox mediator A in the presence of a catalyst):




embedded image


As an example, an electrochemical sensor may be based on the reaction of a glucose molecule with two non-leachable ferricyanide anions in the presence of glucose oxidase to produce two non-leachable ferrocyanide anions, two hydrogen ions, and gluconolactone. The amount of glucose present is assayed by electrooxidizing the non-leachable ferrocyanide anions to non-leachable ferricyanide anions and measuring the current.


In another embodiment, a second compound whose level is affected by the analyte is electrolyzed at the working electrode. In some cases, the analyte D and the second compound, in this case, a reactant compound E, such as oxygen, react in the presence of the catalyst, as shown in reaction equation (3).




embedded image



The reactant compound E is then directly oxidized (or reduced) at the working electrode, as shown in reaction equation (4)




embedded image



Alternatively, the reactant compound E is indirectly oxidized (or reduced) using an electron transfer agent H (optionally in the presence of a catalyst), that is subsequently reduced or oxidized at the electrode, as shown in reaction equations (5) and (6).




embedded image


In either case, changes in the concentration of the reactant compound, as indicated by the signal at the working electrode, correspond inversely to changes in the analyte (i.e., as the level of analyte increase then the level of reactant compound and the signal at the electrode decreases.)


In other embodiments, the relevant second compound is a product compound F, as shown in reaction equation (3). The product compound F is formed by the catalyzed reaction of analyte D and then be directly electrolyzed at the electrode or indirectly electrolyzed using an electron transfer agent and, optionally, a catalyst. In these embodiments, the signal arising from the direct or indirect electrolysis of the product compound F at the working electrode corresponds directly to the level of the analyte (unless there are other sources of the product compound). As the level of analyte increases, the level of the product compound and signal at the working electrode increases.


Those skilled in the art will recognize that there are many different reactions that will achieve the same result; namely the electrolysis of an analyte or a compound whose level depends on the level of the analyte. Reaction equations (1) through (6) illustrate non-limiting examples of such reactions.


Temperature Probe


A variety of optional items may be included in the sensor. One optional item is a temperature probe 66 (FIGS. 8 and 11). The temperature probe 66 may be made using a variety of known designs and materials. One exemplary temperature probe 66 is formed using two probe leads 68, 70 connected to each other through a temperature-dependent element 72 that is formed using a material with a temperature-dependent characteristic. An example of a suitable temperature-dependent characteristic is the resistance of the temperature-dependent element 72.


The two probe leads 68, 70 are typically formed using a metal, an alloy, a semimetal, such as graphite, a degenerate or highly doped semiconductor, or a small-band gap semiconductor. Examples of suitable materials include gold, silver, ruthenium oxide, titanium nitride, titanium dioxide, indium doped tin oxide, tin doped indium oxide, or graphite. The temperature-dependent element 72 is typically made using a fine trace (e.g., a conductive trace that has a smaller cross-section than that of the probe leads 68, 70) of the same conductive material as the probe leads, or another material such as a carbon ink, a carbon fiber, or platinum, which has a temperature-dependent characteristic, such as resistance, that provides a temperature-dependent signal when a voltage source is attached to the two probe leads 68, 70 of the temperature probe 66. The temperature-dependent characteristic of the temperature-dependent element 72 may either increase or decrease with temperature. Preferably, the temperature dependence of the characteristic of the temperature-dependent element 72 is approximately linear with temperature over the expected range of biological temperatures (about 25 to 45° C.), although this is not required.


Typically, a signal (e.g., a current) having an amplitude or other property that is a function of the temperature can be obtained by providing a potential across the two probe leads 68, 70 of the temperature probe 66. As the temperature changes, the temperature-dependent characteristic of the temperature-dependent element 72 increases or decreases with a corresponding change in the signal amplitude. The signal from the temperature probe 66 (e.g., the amount of current flowing through the probe) may be combined with the signal obtained from the working electrode 58 by, for example, scaling the temperature probe signal and then adding or subtracting the scaled temperature probe signal from the signal at the working electrode 58. In this manner, the temperature probe 66 can provide a temperature adjustment for the output from the working electrode 58 to offset the temperature dependence of the working electrode 58.


One embodiment of the temperature probe includes probe leads 68, 70 formed as two spaced-apart channels with a temperature-dependent element 72 formed as a cross-channel connecting the two spaced-apart channels, as illustrated in FIG. 8. The two spaced-apart channels contain a conductive material, such as a metal, alloy, semimetal, degenerate semiconductor, or metallic compound. The cross-channel may contain the same material (provided the cross-channel has a smaller cross-section than the two spaced-apart channels) as the probe leads 68, 70. In other embodiments, the material in the cross-channel is different than the material of the probe leads 68, 70.


One exemplary method for forming this particular temperature probe includes forming the two spaced-apart channels and then filling them with the metallic or alloyed conductive material. Next, the cross-channel is formed and then filled with the desired material. The material in the cross-channel overlaps with the conductive material in each of the two spaced-apart channels to form an electrical connection.


For proper operation of the temperature probe 66, the temperature-dependent element 72 of the temperature probe 66 can not be shorted by conductive material formed between the two probe leads 68, 70. In addition, to prevent conduction between the two probe leads 68, 70 by ionic species within the body or sample fluid, a covering may be provided over the temperature-dependent element 72, and preferably over the portion of the probe leads 68, 70 that is implanted in the patient. The covering may be, for example, a non-conducting film disposed over the temperature-dependent element 72 and probe leads 68, 70 to prevent the ionic conduction. Suitable non-conducting films include, for example, Kapton™ polyimide films (DuPont, Wilmington, Del.).


Another method for eliminating or reducing conduction by ionic species in the body or sample fluid is to use an ac voltage source connected to the probe leads 68, 70. In this way, the positive and negative ionic species are alternately attracted and repelled during each half cycle of the ac voltage. This results in no net attraction of the ions in the body or sample fluid to the temperature probe 66. The maximum amplitude of the ac current through the temperature-dependent element 72 may then be used to correct the measurements from the working electrodes 58.


The temperature probe can be placed on the same substrate as the electrodes. Alternatively, a temperature probe may be placed on a separate substrate. In addition, the temperature probe may be used by itself or in conjunction with other devices.


Another embodiment of a temperature probe utilizes the temperature dependence of the conductivity of a solution (e.g., blood or interstitial fluid). Typically, the conductivity of an electrolyte-containing solution is dependent on the temperature of the solution, assuming that the concentration of electrolytes is relatively constant. Blood, interstitial fluid, and other bodily fluids are solutions with relatively constant levels of electrolytes. Thus, a sensor 42 can include two or more conductive traces (not shown) which are spaced apart by a known distance. A portion of these conductive traces is exposed to the solution and the conductivity between the exposed portions of the conductive traces is measured using known techniques (e.g., application of a constant or known current or potential and measurement of the resulting potential or current, respectively, to determine the conductivity).


A change in conductivity is related to a change in temperature. This relation can be modeled using linear, quadratic, exponential, or other relations. The parameters for this relationship typically do not vary significantly between most people. The calibration for the temperature probe can be determined by a variety of methods, including, for example, calibration of each sensor 42 using an independent method of determining temperature (e.g., a thermometer, an optical or electrical temperature detector, or the temperature probe 66, described above) or calibrating one sensor 42 and using that calibration for all other sensors in a batch based on uniformity in geometry.


Biocompatible Layer


An optional film layer 74 is formed over at least that portion of the sensor 42 which is subcutaneously inserted into the patient, as shown in FIG. 9. This optional film layer 74 may serve one or more functions. The film layer 74 prevents the penetration of large biomolecules into the electrodes. This is accomplished by using a film layer 74 having a pore size that is smaller than the biomolecules that are to be excluded. Such biomolecules may foul the electrodes and/or the sensing layer 64 thereby reducing the effectiveness of the sensor 42 and altering the expected signal amplitude for a given analyte concentration. The fouling of the working electrodes 58 may also decrease the effective life of the sensor 42. The biocompatible layer 75 may also prevent protein adhesion to the sensor 42, formation of blood clots, and other undesirable interactions between the sensor 42 and body.


For example, the sensor may be completely or partially coated on its exterior with a biocompatible coating. A preferred biocompatible coating is a hydrogel which contains at least 20 wt. % fluid when in equilibrium with the analyte-containing fluid. Examples of suitable hydrogels are described in U.S. Pat. No. 5,593,852, incorporated herein by reference, and include crosslinked polyethylene oxides, such as polyethylene oxide tetraacrylate.


Interferent-Eliminating Layer


An interferent-eliminating layer (not shown) may be included in the sensor 42. The interferent-eliminating layer may be incorporated in the biocompatible layer 75 or in the mass transport limiting layer 74 (described below) or may be a separate layer. Interferents are molecules or other species that are electroreduced or electrooxidized at the electrode, either directly or via an electron transfer agent, to produce a false signal. In one embodiment, a film or membrane prevents the penetration of one or more interferents into the region around the working electrodes 58. Preferably, this type of interferent-eliminating layer is much less permeable to one or more of the interferents than to the analyte.


The interferent-eliminating layer may include ionic components, such as Nafion®, incorporated into a polymeric matrix to reduce the permeability of the interferent-eliminating layer to ionic interferents having the same charge as the ionic components. For example, negatively charged compounds or compounds that form negative ions may be incorporated in the interferent-eliminating layer to reduce the permeation of negative species in the body or sample fluid.


Another example of an interferent-eliminating layer includes a catalyst for catalyzing a reaction which removes interferents. One example of such a catalyst is a peroxidase. Hydrogen peroxide reacts with interferents, such as acetaminophen, urate, and ascorbate. The hydrogen peroxide may be added to the analyte-containing fluid or may be generated in situ, by, for example, the reaction of glucose or lactate in the presence of glucose oxidase or lactate oxidase, respectively. Examples of interferent eliminating layers include a peroxidase enzyme crosslinked (a) using gluteraldehyde as a crosslinking agent or (b) oxidation of oligosaccharide groups in the peroxidase glycoenzyme with NaIO4, followed by coupling of the aldehydes formed to hydrazide groups in a polyacrylamide matrix to form hydrazones are describe in U.S. Pat. Nos. 5,262,305 and 5,356,786, incorporated herein by reference.


Mass Transport Limiting Layer


A mass transport limiting layer 74 may be included with the sensor to act as a diffusion-limiting barrier to reduce the rate of mass transport of the analyte, for example, glucose or lactate, into the region around the working electrodes 58. By limiting the diffusion of the analyte, the steady state concentration of the analyte in the proximity of the working electrode 58 (which is proportional to the concentration of the analyte in the body or sample fluid) can be reduced. This extends the upper range of analyte concentrations that can still be accurately measured and may also expand the range in which the current increases approximately linearly with the level of the analyte.


It is preferred that the permeability of the analyte through the film layer 74 vary little or not at all with temperature, so as to reduce or eliminate the variation of current with temperature. For this reason, it is preferred that in the biologically relevant temperature range from about 25° C. to about 45° C., and most importantly from 30° C. to 40° C., neither the size of the pores in the film nor its hydration or swelling change excessively. Preferably, the mass transport limiting layer is made using a film that absorbs less than 5 wt. % of fluid over 24 hours. This may reduce or obviate any need for a temperature probe. For implantable sensors, it is preferable that the mass transport limiting layer is made using a film that absorbs less than 5 wt. % of fluid over 24 hours at 37° C.


Particularly useful materials for the film layer 74 are membranes that do not swell in the analyte-containing fluid that the sensor tests. Suitable membranes include 3 to 20,000 nm diameter pores. Membranes having 5 to 500 nm diameter pores with well-defined, uniform pore sizes and high aspect ratios are preferred. In one embodiment, the aspect ratio of the pores is preferably two or greater and more preferably five or greater.


Well-defined and uniform pores can be made by track etching a polymeric membrane using accelerated electrons, ions, or particles emitted by radioactive nuclei. Most preferred are anisotropic, polymeric, track etched membranes that expand less in the direction perpendicular to the pores than in the direction of the pores when heated. Suitable polymeric membranes included polycarbonate membranes from Poretics (Livermore, Calif., catalog number 19401, 0.01 μm pore size polycarbonate membrane) and Corning Costar Corp. (Cambridge, Mass., Nucleopore™ brand membranes with 0.015 μm pore size). Other polyolefin and polyester films may be used. It is preferred that the permeability of the mass transport limiting membrane changes no more than 4%, preferably, no more than 3%, and, more preferably, no more than 2%, per ° C. in the range from 30° C. to 40° C. when the membranes resides in the subcutaneous interstitial fluid.


In some embodiments of the invention, the mass transport limiting layer 74 may also limit the flow of oxygen into the sensor 42. This can improve the stability of sensors 42 that are used in situations where variation in the partial pressure of oxygen causes non-linearity in sensor response. In these embodiments, the mass transport limiting layer 74 restricts oxygen transport by at least 40%, preferably at least 60%, and more preferably at least 80%, than the membrane restricts transport of the analyte. For a given type of polymer, films having a greater density (e.g., a density closer to that of the crystalline polymer) are preferred. Polyesters, such as polyethylene terephthalate, are typically less permeable to oxygen and are, therefore, preferred over polycarbonate membranes.


Anticlotting Agent


An implantable sensor may also, optionally, have an anticlotting agent disposed on a portion the substrate which is implanted into a patient. This anticlotting agent may reduce or eliminate the clotting of blood or other body fluid around the sensor, particularly after insertion of the sensor. Blood clots may foul the sensor or irreproducibly reduce the amount of analyte which diffuses into the sensor. Examples of useful anticlotting agents include heparin and tissue plasminogen activator (TPA), as well as other known anticlotting agents.


The anticlotting agent may be applied to at least a portion of that part of the sensor 42 that is to be implanted. The anticlotting agent may be applied, for example, by bath, spraying, brushing, or dipping. The anticlotting agent is allowed to dry on the sensor 42. The anticlotting agent may be immobilized on the surface of the sensor or it may be allowed to diffuse away from the sensor surface. Typically, the quantities of anticlotting agent disposed on the sensor are far below the amounts typically used for treatment of medical conditions involving blood clots and, therefore, have only a limited, localized effect.


Sensor Lifetime


The sensor 42 may be designed to be a replaceable component in an in vivo analyte monitor, and particularly in an implantable analyte monitor. Typically, the sensor 42 is capable of operation over a period of days. Preferably, the period of operation is at least one day, more preferably at least three days, and most preferably at least one week. The sensor 42 can then be removed and replaced with a new sensor. The lifetime of the sensor 42 may be reduced by the fouling of the electrodes or by the leaching of the electron transfer agent or catalyst. These limitations on the longevity of the sensor 42 can be overcome by the use of a biocompatible layer 75 or non-leachable electron transfer agent and catalyst, respectively, as described above.


Another primary limitation on the lifetime of the sensor 42 is the temperature stability of the catalyst. Many catalysts are enzymes, which are very sensitive to the ambient temperature and may degrade at temperatures of the patient's body (e.g., approximately 37° C. for the human body). Thus, robust enzymes should be used where available. The sensor 42 should be replaced when a sufficient amount of the enzyme has been deactivated to introduce an unacceptable amount of error in the measurements.


Insertion Device


An insertion device 120 can be used to subcutaneously insert the sensor 42 into the patient, as illustrated in FIG. 12. The insertion device 120 is typically formed using structurally rigid materials, such as metal or rigid plastic. Preferred materials include stainless steel and ABS (acrylonitrile-butadiene-styrene) plastic. In some embodiments, the insertion device 120 is pointed and/or sharp at the tip 121 to facilitate penetration of the skin of the patient. A sharp, thin insertion device may reduce pain felt by the patient upon insertion of the sensor 42. In other embodiments, the tip 121 of the insertion device 120 has other shapes, including a blunt or flat shape. These embodiments may be particularly useful when the insertion device 120 does not penetrate the skin but rather serves as a structural support for the sensor 42 as the sensor 42 is pushed into the skin.


The insertion device 120 may have a variety of cross-sectional shapes, as shown in FIGS. 13A, 13B, and 13C. The insertion device 120 illustrated in FIG. 13A is a flat, planar, pointed strip of rigid material which may be attached or otherwise coupled to the sensor 42 to ease insertion of the sensor 42 into the skin of the patient, as well as to provide structural support to the sensor 42 during insertion. The insertion devices 120 of FIGS. 13B and 13C are U- or V-shaped implements that support the sensor 42 to limit the amount that the sensor 42 may bend or bow during insertion. The cross-sectional width 124 of the insertion devices 120 illustrated in FIGS. 13B and 13C is typically 1 mm or less, preferably 700 μm or less, more preferably 500 μm or less, and most preferably 300 μm or less. The cross-sectional height 126 of the insertion device 120 illustrated in FIGS. 13B and 13C is typically about 1 mm or less, preferably about 700 μm or less, and more preferably about 500 μm or less.


The sensor 42 itself may include optional features to facilitate insertion. For example, the sensor 42 may be pointed at the tip 123 to ease insertion, as illustrated in FIG. 12. In addition, the sensor 42 may include a barb 125 which helps retain the sensor 42 in the subcutaneous tissue of the patient. The barb 125 may also assist in anchoring the sensor 42 within the subcutaneous tissue of the patient during operation of the sensor 42. However, the barb 125 is typically small enough that little damage is caused to the subcutaneous tissue when the sensor 42 is removed for replacement. The sensor 42 may also include a notch 127 that can be used in cooperation with a corresponding structure (not shown) in the insertion device to apply pressure against the sensor 42 during insertion, but disengage as the insertion device 120 is removed. One example of such a structure in the insertion device is a rod (not shown) between two opposing sides of an insertion device 120 and at an appropriate height of the insertion device 120.


In operation, the sensor 42 is placed within or next to the insertion device 120 and then a force is provided against the insertion device 120 and/or sensor 42 to carry the sensor 42 into the skin of the patient. In one embodiment, the force is applied to the sensor 42 to push the sensor into the skin, while the insertion device 120 remains stationary and provides structural support to the sensor 42. Alternatively, the force is applied to the insertion device 120 and optionally to the sensor 42 to push a portion of both the sensor 42 and the insertion device 120 through the skin of the patient and into the subcutaneous tissue. The insertion device 120 is optionally pulled out of the skin and subcutaneous tissue with the sensor 42 remaining in the subcutaneous tissue due to frictional forces between the sensor 42 and the patient's tissue. If the sensor 42 includes the optional barb 125, then this structure may also facilitate the retention of the sensor 42 within the interstitial tissue as the barb catches in the tissue.


The force applied to the insertion device 120 and/or the sensor 42 may be applied manually or mechanically. Preferably, the sensor 42 is reproducibly inserted through the skin of the patient. In one embodiment, an insertion gun is used to insert the sensor. One example of an insertion gun 200 for inserting a sensor 42 is shown in FIG. 26. The insertion gun 200 includes a housing 202 and a carrier 204. The insertion device 120 is typically mounted on the carrier 204 and the sensor 42 is pre-loaded into the insertion device 120. The carrier 204 drives the sensor 42 and, optionally, the insertion device 120 into the skin of the patient using, for example, a cocked or wound spring, a burst of compressed gas, an electromagnet repelled by a second magnet, or the like, within the insertion gun 200. In some instances, for example, when using a spring, the carrier 204 and insertion device may be moved, cocked, or otherwise prepared to be directed towards the skin of the patient.


After the sensor 42 is inserted, the insertion gun 200 may contain a mechanism which pulls the insertion device 120 out of the skin of the patient. Such a mechanism may use a spring, electromagnet, or the like to remove the insertion device 120.


The insertion gun may be reusable. The insertion device 120 is often disposable to avoid the possibility of contamination. Alternatively, the insertion device 120 may be sterilized and reused. In addition, the insertion device 120 and/or the sensor 42 may be coated with an anticlotting agent to prevent fouling of the sensor 42.


In one embodiment, the sensor 42 is injected between 2 to 12 mm into the interstitial tissue of the patient for subcutaneous implantation. Preferably, the sensor is injected 3 to 9 mm, and more preferably 5 to 7 mm, into the interstitial tissue. Other embodiments of the invention, may include sensors implanted in other portions of the patient, including, for example, in an artery, vein, or organ. The depth of implantation varies depending on the desired implantation target.


Although the sensor 42 may be inserted anywhere in the body, it is often desirable that the insertion site be positioned so that the on-skin sensor control unit 44 can be concealed. In addition, it is often desirable that the insertion site be at a place on the body with a low density of nerve endings to reduce the pain to the patient. Examples of preferred sites for insertion of the sensor 42 and positioning of the on-skin sensor control unit 44 include the abdomen, thigh, leg, upper arm, and shoulder.


An insertion angle is measured from the plane of the skin (i.e., inserting the sensor perpendicular to the skin would be a 90° insertion angle). Insertion angles usually range from 10 to 90°, typically from 15 to 60°, and often from 30 to 45°.


On-Skin Sensor Control Unit


The on-skin sensor control unit 44 is configured to be placed on the skin of a patient. The on-skin sensor control unit 44 is optionally formed in a shape that is comfortable to the patient and which may permit concealment, for example, under a patient's clothing. The thigh, leg, upper arm, shoulder, or abdomen are convenient parts of the patient's body for placement of the on-skin sensor control unit 44 to maintain concealment. However, the on-skin sensor control unit 44 may be positioned on other portions of the patient's body. One embodiment of the on-skin sensor control unit 44 has a thin, oval shape to enhance concealment, as illustrated in FIGS. 14-16. However, other shapes and sizes may be used.


The particular profile, as well as the height, width, length, weight, and volume of the on-skin sensor control unit 44 may vary and depends, at least in part, on the components and associated functions included in the on-skin sensor control unit 44, as discussed below. For example, in some embodiments, the on-skin sensor control unit 44 has a height of 1.3 cm or less, and preferably 0.7 cm or less. In some embodiments, the on-skin sensor control unit 44 has a weight of 90 grams or less, preferably 45 grams or less, and more preferably 25 grams or less. In some embodiments, the on-skin sensor control unit 44 has a volume of about 15 cm3 or less, preferably about 10 cm3 or less, more preferably about 5 cm3 or less, and most preferably about 2.5 cm3 or less.


The on-skin sensor control unit 44 includes a housing 45, as illustrated in FIGS. 14-16. The housing 45 is typically formed as a single integral unit that rests on the skin of the patient. The housing 45 typically contains most or all of the electronic components, described below, of the on-skin sensor control unit 44. The on-skin sensor control unit 44 usually includes no additional cables or wires to other electronic components or other devices. If the housing includes two or more parts, then those parts typically fit together to form a single integral unit.


The housing 45 of the on-skin sensor control unit 44, illustrated in FIGS. 14-16, may be formed using a variety of materials, including, for example, plastic and polymeric materials, particularly rigid thermoplastics and engineering thermoplastics. Suitable materials include, for example, polyvinyl chloride, polyethylene, polypropylene, polystyrene, ABS polymers, and copolymers thereof. The housing 45 of the on-skin sensor control unit 44 may be formed using a variety of techniques including, for example, injection molding, compression molding, casting, and other molding methods. Hollow or recessed regions may be formed in the housing 45 of the on-skin sensor control unit 44. The electronic components of the on-skin sensor control unit 44, described below, and/or other items, such as a battery or a speaker for an audible alarm, may be placed in the hollow or recessed areas.


In some embodiments, conductive contacts 80 are provided on the exterior of the housing 45. In other embodiments, the conductive contacts 80 are provided on the interior of the housing 45, for example, within a hollow or recessed region.


In some embodiments, the electronic components and/or other items are incorporated into the housing 45 of the on-skin sensor control unit 44 as the plastic or polymeric material is molded or otherwise formed. In other embodiments, the electronic components and/or other items are incorporated into the housing 45 as the molded material is cooling or after the molded material has been reheated to make it pliable. Alternatively, the electronic components and/or other items may be secured to the housing 45 using fasteners, such as screws, nuts and bolts, nails, staples, rivets, and the like or adhesives, such as contact adhesives, pressure sensitive adhesives, glues, epoxies, adhesive resins, and the like. In some cases, the electronic components and/or other items are not affixed to the housing 45 at all.


In some embodiments, the housing 45 of the on-skin sensor control unit 44 is a single piece. The conductive contacts 80 may be formed on the exterior of the housing 45 or on the interior of the housing 45 provided there is a port 78 in the housing 45 through which the sensor 42 can be directed to access the conductive contacts 80.


In other embodiments, the housing 45 of the on-skin sensor control unit 44 is formed in at least two separate portions that fit together to form the housing 45, for example, a base 74 and a cover 76, as illustrated in FIGS. 14-16. The two or more portions of the housing 45 may be entirely separate from each other. Alternatively, at least some of the two or more portions of the housing 45 may be connected together, for example, by a hinge, to facilitate the coupling of the portions to form the housing 45 of the on-skin sensor control unit 44.


These two or more separate portions of the housing 45 of the on-skin sensor control unit 44 may have complementary, interlocking structures, such as, for example, interlocking ridges or a ridge on one component and a complementary groove on another component, so that the two or more separate components may be easily and/or firmly coupled together. This may be useful, particularly if the components are taken apart and fit together occasionally, for example, when a battery or sensor 42 is replaced. However, other fasteners may also be used to couple the two or more components together, including, for example, screws, nuts and bolts, nails, staples, rivets, or the like. In addition, adhesives, both permanent or temporary, may be used including, for example, contact adhesives, pressure sensitive adhesives, glues, epoxies, adhesive resins, and the like.


Typically, the housing 45 is at least water resistant to prevent the flow of fluids into contact with the components in the housing, including, for example, the conductive contacts 80. Preferably, the housing is waterproof. In one embodiment, two or more components of the housing 45, for example, the base 74 and the cover 76, fit together tightly to form a hermetic, waterproof, or water resistant seal so that fluids can not flow into the interior of the on-skin sensor control unit 44. This may be useful to avoid corrosion currents and/or degradation of items within the on-skin sensor control unit 44, such as the conductive contacts, the battery, or the electronic components, particularly when the patient engages in such activities as showering, bathing, or swimming.


Water resistant, as used herein, means that there is no penetration of water through a water resistant seal or housing when immersed in water at a depth of one meter at sea level. Waterproof, as used herein, means that there is no penetration of water through the waterproof seal or housing when immersed in water at a depth of ten meters, and preferably fifty meters, at sea level. It is often desirable that the electronic circuitry, power supply (e.g., battery), and conductive contacts of the on-skin sensor control unit, as well as the contact pads of the sensor, are contained in a water resistant, and preferably, a waterproof, environment.


In addition to the portions of the housing 45, such as the base 74 and cover 76, there may be other individually-formed pieces of the on-skin sensor control unit 44, which may be assembled during or after manufacture. One example of an individually-formed piece is a cover for electronic components that fits a recess in the base 74 or cover 76. Another example is a cover for a battery provided in the base 74 or cover 76. These individually-formed pieces of the on-skin sensor control unit 44 may be permanently affixed, such as, for example, a cover for electronic components, or removably affixed, such as, for example, a removable cover for a battery, to the base 74, cover 76, or other component of the on-skin sensor control unit 44. Methods for affixing these individually-formed pieces include the use of fasteners, such as screws, nuts and bolts, staples, nails, rivets, and the like, frictional fasteners, such as tongue and groove structures, and adhesives, such as contact adhesives, pressure sensitive adhesives, glues, epoxies, adhesive resins, and the like.


One embodiment of the on-skin sensor control unit 44 is a disposable unit complete with a battery for operating the unit. There are no portions of the unit that the patient needs to open or remove, thereby reducing the size of the unit and simplifying its construction. The on-skin sensor control unit 44 optionally remains in a sleep mode prior to use to conserve the battery's power. The on-skin sensor control unit 44 detects that it is being used and activates itself. Detection of use may be through a number of mechanisms. These include, for example, detection of a change in resistance across the electrical contacts, actuation of a switch upon mating the on-skin sensor control unit 44 with a mounting unit 77 (see FIGS. 27A and 28A). The on-skin sensor control unit 44 is typically replaced when it no longer operates within threshold limits, for example, if the battery or other power source does not generate sufficient power. Often this embodiment of the on-skin sensor control unit 44 has conductive contacts 80 on the exterior of the housing 45. Once the sensor 42 is implanted in the patient, the sensor control unit 44 is placed over the sensor 42 with the conductive contacts 80 in contact with the contact pads 49 of the sensor 42.


The on-skin sensor control unit 44 is typically attached to the skin 75 of the patient, as illustrated in FIG. 17. The on-skin sensor control unit 44 may be attached by a variety of techniques including, for example, by adhering the on-skin sensor control unit 44 directly to the skin 75 of the patient with an adhesive provided on at least a portion of the housing 45 of the on-skin sensor control unit 44 which contacts the skin 75 or by suturing the on-skin sensor control unit 44 to the skin 75 through suture openings (not shown) in the sensor control unit 44.


Another method of attaching the housing 45 of the on-skin sensor control unit 44 to the skin 75 includes using a mounting unit, 77. The mounting unit 77 is often a part of the on-skin sensor control unit 44. One example of a suitable mounting unit 77 is a double-sided adhesive strip, one side of which is adhered to a surface of the skin of the patient and the other side is adhered to the on-skin sensor control unit 44. In this embodiment, the mounting unit 77 may have an optional opening 79 which is large enough to allow insertion of the sensor 42 through the opening 79. Alternatively, the sensor may be inserted through a thin adhesive and into the skin.


A variety of adhesives may be used to adhere the on-skin sensor control unit 44 to the skin 75 of the patient, either directly or using the mounting unit 77, including, for example, pressure sensitive adhesives (PSA) or contact adhesives. Preferably, an adhesive is chosen which is not irritating to all or a majority of patients for at least the period of time that a particular sensor 42 is implanted in the patient. Alternatively, a second adhesive or other skin-protecting compound may be included with the mounting unit so that a patient, whose skin is irritated by the adhesive on the mounting unit 77, can cover his skin with the second adhesive or other skin-protecting compound and then place the mounting unit 77 over the second adhesive or other skin-protecting compound. This should substantially prevent the irritation of the skin of the patient because the adhesive on the mounting unit 77 is no longer in contact with the skin, but is instead in contact with the second adhesive or other skin-protecting compound.


When the sensor 42 is changed, the on-skin sensor control unit 44 may be moved to a different position on the skin 75 of the patient, for example, to avoid excessive irritation. Alternatively, the on-skin sensor control unit 44 may remain at the same place on the skin of the patient until it is determined that the unit 44 should be moved.


Another embodiment of a mounting unit 77 used in an on-skin sensor control unit 44 is illustrated in FIGS. 27A and 27B. The mounting unit 77 and a housing 45 of an on-skin sensor control unit 44 are mounted together in, for example, an interlocking manner, as shown in FIG. 27A. The mounting unit 77 is formed, for example, using plastic or polymer materials, including, for example, polyvinyl chloride, polyethylene, polypropylene, polystyrene, ABS polymers, and copolymers thereof. The mounting unit 77 may be formed using a variety of techniques including, for example, injection molding, compression molding, casting, and other molding methods.


The mounting unit 77 typically includes an adhesive on a bottom surface of the mounting unit 77 to adhere to the skin of the patient or the mounting unit 77 is used in conjunction with, for example, double-sided adhesive tape or the like. The mounting unit 77 typically includes an opening 79 through which the sensor 42 is inserted, as shown in FIG. 27B. The mounting unit 77 may also include a support structure 220 for holding the sensor 42 in place and against the conductive contacts 80 on the on-skin sensor control unit 42. The mounting unit 77, also, optionally, includes a positioning structure 222, such as an extension of material from the mounting unit 77, that corresponds to a structure (not shown), such as an opening, on the sensor 42 to facilitate proper positioning of the sensor 42, for example, by aligning the two complementary structures.


In another embodiment, a coupled mounting unit 77 and housing 45 of an on-skin sensor control unit 44 is provided on an adhesive patch 204 with an optional cover 206 to protect and/or confine the housing 45 of the on-skin sensor control unit 44, as illustrated in FIG. 28A. The optional cover may contain an adhesive or other mechanism for attachment to the housing 45 and/or mounting unit 77. The mounting unit 77 typically includes an opening 49 through which a sensor 42 is disposed, as shown in FIG. 28B. The opening 49 may optionally be configured to allow insertion of the sensor 42 through the opening 49 using an insertion device 120 or insertion gun 200 (see FIG. 26). The housing 45 of the on-skin sensor control unit 44 has a base 74 and a cover 76, as illustrated in FIG. 28C. A bottom view of the housing 45, as shown in FIG. 28D, illustrates ports 230 through which conductive contacts (not shown) extend to connect with contact pads on the sensor 42. A board 232 for attachment of circuit components may optionally be provided within the on-skin sensor control unit 44, as illustrated in FIG. 28E.


In some embodiments, the adhesive on the on-skin sensor control unit 44 and/or on any of the embodiments of the mounting unit 77 is water resistant or waterproof to permit activities such as showering and/or bathing while maintaining adherence of the on-skin sensor control unit 44 to the skin 75 of the patient and, at least in some embodiments, preventing water from penetrating into the sensor control unit 44. The use of a water resistant or waterproof adhesive combined with a water resistant or waterproof housing 45 protects the components in the sensor control unit 44 and the contact between the conductive contacts 80 and the sensor 42 from damage or corrosion. An example of a non-irritating adhesive that repels water is Tegaderm (3M, St. Paul, Minn.).


In one embodiment, the on-skin sensor control unit 44 includes a sensor port 78 through which the sensor 42 enters the subcutaneous tissue of the patient, as shown in FIGS. 14 to 16. The sensor 42 may be inserted into the subcutaneous tissue of the patient through the sensor port 78. The on-skin sensor control unit 44 may then be placed on the skin of the patient with the sensor 42 being threaded through the sensor port 78. If the housing 45 of the sensor 42 has, for example, a base 74 and a cover 76, then the cover 76 may be removed to allow the patient to guide the sensor 42 into the proper position for contact with the conductive contacts 80.


Alternatively, if the conductive contacts 80 are within the housing 45 the patient may slide the sensor 42 into the housing 45 until contact is made between the contact pads 49 and the conductive contacts 80. The sensor control unit 44 may have a structure which obstructs the sliding of the sensor 42 further into the housing once the sensor 42 is properly positioned with the contact pads 49 in contact with the conductive contacts 80.


In other embodiments, the conductive contacts 80 are on the exterior of the housing 45 (see e.g., FIGS. 27A-27B and 28A-28E). In these embodiments, the patient guides the contacts pads 49 of the sensor 42 into contact with the conductive contacts 80. In some cases, a guiding structure may be provided on the housing 45 which guides the sensor 42 into the proper position. An example of such a structure includes a set of guiding rails extending from the housing 45 and having the shape of the sensor 42.


In some embodiments, when the sensor 42 is inserted using an insertion device 120 (see FIG. 12), the tip of the insertion device 120 or optional insertion gun 200 (see FIG. 26) is positioned against the skin or the mounting unit 77 at the desired insertion point. In some embodiments, the insertion device 120 is positioned on the skin without any guide. In other embodiments, the insertion device 120 or insertion gun 200 is positioned using guides (not shown) in the mounting unit 77 or other portion of the on-skin sensor control unit 44. In some embodiments, the guides, opening 79 in the mounting unit 77 and/or sensor port 78 in the housing 45 of the on-skin sensor control unit 44 have a shape which is complementary to the shape of the tip of the insertion device 120 and/or insertion gun 200 to limit the orientation of the insertion device 120 and/or insertion gun 200 relative to the opening 79 and/or sensor port 78. The sensor can then be subcutaneously inserted into the patient by matching the complementary shape of the opening 79 or sensor port 78 with the insertion device 120 and/or insertion gun 200.


In some embodiments, the shapes of a) the guides, opening 79, or sensor port 78, and (b) the insertion device 120 or insertion gun 200 are configured such that the two shapes can only be matched in a single orientation. This aids in inserting the sensor 42 in the same orientation each time a new sensor is inserted into the patient. This uniformity in insertion orientation may be required in some embodiments to ensure that the contact pads 49 on the sensor 42 are correctly aligned with appropriate conductive contacts 80 on the on-skin sensor control unit 44. In addition, the use of the insertion gun, as described above, may ensure that the sensor 42 is inserted at a uniform, reproducible depth.


The sensor 42 and the electronic components within the on-skin sensor control unit 44 are coupled via conductive contacts 80, as shown in FIGS. 14-16. The one or more working electrodes 58, counter electrode 60 (or counter/reference electrode), optional reference electrode 62, and optional temperature probe 66 are attached to individual conductive contacts 80. In the illustrated embodiment of FIGS. 14-16, the conductive contacts 80 are provided on the interior of the on-skin sensor control unit 44. Other embodiments of the on-skin sensor control unit 44 have the conductive contacts disposed on the exterior of the housing 45. The placement of the conductive contacts 80 is such that they are in contact with the contact pads 49 on the sensor 42 when the sensor 42 is properly positioned within the on-skin sensor control unit 44.


In the illustrated embodiment of FIGS. 14-16, the base 74 and cover 76 of the on-skin sensor control unit 44 are formed such that, when the sensor 42 is within the on-skin sensor control unit 44 and the base 74 and cover 76 are fitted together, the sensor 42 is bent. In this manner, the contact pads 49 on the sensor 42 are brought into contact with the conductive contacts 80 of the on-skin sensor control unit 44. The on-skin sensor control unit 44 may optionally contain a support structure 82 to hold, support, and/or guide the sensor 42 into the correct position.


Non-limiting examples of suitable conductive contacts 80 are illustrated in FIGS. 19A-19D. In one embodiment, the conductive contacts 80 are pins 84 or the like, as illustrated in FIG. 19A, which are brought into contact with the contact pads 49 on the sensor 42 when the components of the on-skin sensor control unit 44, for example, the base 74 and cover 76, are fitted together. A support 82 may be provided under the sensor 42 to promote adequate contact between the contact pads 49 on the sensor 42 and the pins 84. The pins are typically made using a conductive material, such as a metal or alloy, for example, copper, stainless steel, or silver. Each pin has a distal end that extends from the on-skin sensor control unit 44 for contacting the contact pads 49 on the sensor 42. Each pin 84 also has a proximal end that is coupled to a wire or other conductive strip that is, in turn, coupled to the rest of the electronic components (e.g., the voltage source 95 and measurement circuit 96 of FIGS. 18A and 18B) within the on-skin sensor control unit 44. Alternatively, the pins 84 may be coupled directly to the rest of the electronics.


In another embodiment, the conductive contacts 80 are formed as a series of conducting regions 88 with interspersed insulating regions 90, as illustrated in FIG. 19B. The conducting regions 88 may be as large or larger than the contact pads 49 on the sensor 42 to alleviate registration concerns. However, the insulating regions 90 should have sufficient width so that a single conductive region 88 does not overlap with two contact pads 49 as determined based on the expected variation in the position of the sensor 42 and contact pads 49 with respect to the conductive contacts 80. The conducting regions 88 are formed using materials such as metals, alloys, or conductive carbon. The insulating regions 90 may be formed using known insulating materials including, for example, insulating plastic or polymer materials.


In a further embodiment, a unidirectional conducting adhesive 92 may be used between the contact pads 49 on the sensor 42 and conductive contacts 80 implanted or otherwise formed in the on-skin sensor control unit 44, as shown in FIG. 19C.


In yet another embodiment, the conductive contacts 80 are conductive members 94 that extend from a surface of the on-skin sensor control unit 44 to contact the contact pads 49, as shown in FIG. 19D. A variety of different shapes may be used for these members, however, they should be electrically insulated from each other. The conductive members 94 may be made using metal, alloy, conductive carbon, or conducting plastics and polymers.


Any of the exemplary conductive contacts 80 described above may extend from either the upper surface of the interior of the on-skin sensor control unit 44, as illustrated in FIG. 19A-19C, or from the lower surface of the interior of the on-skin sensor control unit 44, as illustrated in FIG. 19D, or from both the upper and lower surfaces of the interior of the on-skin sensor control unit 44, particularly when the sensor 42 has contact pads 49 on both sides of the sensor.


Conductive contacts 80 on the exterior of the housing 45 may also have a variety of shapes as indicated in FIGS. 19E and 19F. For example, the conductive contacts 80 may be embedded in (FIG. 19E) or extending out of (FIG. 19F) the housing 45.


The conductive contacts 80 are preferably made using a material which will not corrode due to contact with the contact pads 49 of the sensor 42. Corrosion may occur when two different metals are brought in contact. Thus, if the contact pads 49 are formed using carbon then the preferred conductive contacts 80 may be made using any material, including metals or alloys. However, if any of the contact pads 49 are made with a metal or alloy then the preferred conductive contacts 80 for coupling with the metallic contact pads are made using a non-metallic conductive material, such as conductive carbon or a conductive polymer, or the conductive contacts 80 and the contact pads 49 are separated by a non-metallic material, such as a unidirectional conductive adhesive.


In one embodiment, electrical contacts are eliminated between the sensor 42 and the on-skin sensor control unit 44. Power is transmitted to the sensor via inductive coupling, using, for example, closely space antennas (e.g., facing coils) (not shown) on the sensor and the on-skin sensor control unit. Changes in the electrical characteristics of the sensor control unit 44 (e.g., current) induce a changing magnetic field in the proximity of the antenna. The changing magnetic field induces a current in the antenna of the sensor. The close proximity of the sensor and on-skin sensor control unit results in reasonably efficient power transmission. The induced current in the sensor may be used to power potentiostats, operational amplifiers, capacitors, integrated circuits, transmitters, and other electronic components built into the sensor structure. Data is transmitted back to the sensor control unit, using, for example, inductive coupling via the same or different antennas and/or transmission of the signal via a transmitter on the sensor. The use of inductive coupling can eliminate electrical contacts between the sensor and the on-skin sensor control unit. Such contacts are commonly a source of noise and failure. Moreover, the sensor control unit may then be entirely sealed which may increase the waterproofing of the on-skin sensor control unit.


An exemplary on-skin sensor control unit 44 can be prepared and used in the following manner. A mounting unit 77 having adhesive on the bottom is applied to the skin. An insertion gun 200 (see FIG. 26) carrying the sensor 42 and the insertion device 120 is positioned against the mounting unit 77. The insertion gun 200 and mounting unit 77 are optionally designed such that there is only one position in which the two properly mate. The insertion gun 200 is activated and a portion of the sensor 42 and optionally a portion of the insertion device 120 are driven through the skin into, for example, the subcutaneous tissue. The insertion gun 200 withdraws the insertion device 200, leaving the portion of the sensor 42 inserted through the skin. The housing 45 of the on-skin control unit 44 is then coupled to the mounting unit 77. Optionally, the housing 45 and the mounting unit 77 are formed such that there is only one position in which the two properly mate. The mating of the housing 45 and the mounting unit 77 establishes contact between the contact pads 49 (see e.g., FIG. 2) on the sensor 42 and the conductive contacts 80 on the on-skin sensor control unit 44. Optionally, this action activates the on-skin sensor control unit 44 to begin operation.


On-Skin Control Unit Electronics


The on-skin sensor control unit 44 also typically includes at least a portion of the electronic components that operate the sensor 42 and the analyte monitoring device system 40. One embodiment of the electronics in the on-skin control unit 44 is illustrated as a block diagram in FIG. 18A. The electronic components of the on-skin sensor control unit 44 typically include a power supply 95 for operating the on-skin control unit 44 and the sensor 42, a sensor circuit 97 for obtaining signals from and operating the sensor 42, a measurement circuit 96 that converts sensor signals to a desired format, and a processing circuit 109 that, at minimum, obtains signals from the sensor circuit 97 and/or measurement circuit 96 and provides the signals to an optional transmitter 98. In some embodiments, the processing circuit 109 may also partially or completely evaluate the signals from the sensor 42 and convey the resulting data to the optional transmitter 98 and/or activate an optional alarm system 94 (see FIG. 18B) if the analyte level exceeds a threshold. The processing circuit 109 often includes digital logic circuitry.


The on-skin sensor control unit 44 may optionally contain a transmitter 98 for transmitting the sensor signals or processed data from the processing circuit 109 to a receiver/display unit 46, 48; a data storage unit 102 for temporarily or permanently storing data from the processing circuit 109; a temperature probe circuit 99 for receiving signals from and operating a temperature probe 66; a reference voltage generator 101 for providing a reference voltage for comparison with sensor-generated signals; and/or a watchdog circuit 103 that monitors the operation of the electronic components in the on-skin sensor control unit 44.


Moreover, the sensor control unit 44 often includes digital and/or analog components utilizing semiconductor devices, such as transistors. To operate these semiconductor devices, the on-skin control unit 44 may include other components including, for example, a bias control generator 105 to correctly bias analog and digital semiconductor devices, an oscillator 107 to provide a clock signal, and a digital logic and timing component 109 to provide timing signals and logic operations for the digital components of the circuit.


As an example of the operation of these components, the sensor circuit 97 and the optional temperature probe circuit 99 provide raw signals from the sensor 42 to the measurement circuit 96. The measurement circuit 96 converts the raw signals to a desired format, using for example, a current-to-voltage converter, current-to-frequency converter, and/or a binary counter or other indicator that produces a signal proportional to the absolute value of the raw signal. This may be used, for example, to convert the raw signal to a format that can be used by digital logic circuits. The processing circuit 109 may then, optionally, evaluate the data and provide commands to operate the electronics.



FIG. 18B illustrates a block diagram of another exemplary on-skin control unit 44 that also includes optional components such as a receiver 99 to receive, for example, calibration data; a calibration storage unit (not shown) to hold, for example, factory-set calibration data, calibration data obtained via the receiver 99 and/or operational signals received, for example, from a receiver/display unit 46, 48 or other external device; an alarm system 104 for warning the patient; and a deactivation switch 111 to turn off the alarm system.


Functions of the analyte monitoring system 40 and the sensor control unit 44 may be implemented using either software routines, hardware components, or combinations thereof. The hardware components may be implemented using a variety of technologies, including, for example, integrated circuits or discrete electronic components. The use of integrated circuits typically reduces the size of the electronics, which in turn may result in a smaller on-skin sensor control unit 44.


The electronics in the on-skin sensor control unit 44 and the sensor 42 are operated using a power supply 95. One example of a suitable power supply 95 is a battery, for example, a thin circular battery, such as those used in many watches, hearing aids, and other small electronic devices. Preferably, the battery has a lifetime of at least 30 days, more preferably, a lifetime of at least three months, and most preferably, a lifetime of at least one year. The battery is often one of the largest components in the on-skin control unit 44, so it is often desirable to minimize the size of the battery. For example, a preferred battery's thickness is 0.5 mm or less, preferably 0.35 mm or less, and most preferably 0.2 mm or less. Although multiple batteries may be used, it is typically preferred to use only one battery.


The sensor circuit 97 is coupled via the conductive contacts 80 of the sensor control unit 44 to one or more sensors 42, 42′. Each of the sensors represents, at minimum, a working electrode 58, a counter electrode 60 (or counter/reference electrode), and an optional reference electrode 62. When two or more sensors 42, 42′ are used, the sensors typically have individual working electrodes 58, but may share a counter electrode 60, counter/reference electrode, and/or reference electrode 52.


The sensor circuit 97 receives signals from and operates the sensor 42 or sensors 42, 42′. The sensor circuit 97 may obtain signals from the sensor 42 using amperometric, coulometric, potentiometric, voltammetric, and/or other electrochemical techniques. The sensor circuit 97 is exemplified herein as obtaining amperometric signals from the sensor 42, however, it will be understood that the sensor circuit can be appropriately configured for obtaining signals using other electrochemical techniques. To obtain amperometric measurements, the sensor circuit 97 typically includes a potentiostat that provides a constant potential to the sensor 42. In other embodiments, the sensor circuit 97 includes an amperostat that supplies a constant current to the sensor 42 and can be used to obtain coulometric or potentiometric measurements.


The signal from the sensor 42 generally has at least one characteristic, such as, for example, current, voltage, or frequency, which varies with the concentration of the analyte. For example, if the sensor circuit 97 operates using amperometry, then the signal current varies with analyte concentration. The measurement circuit 96 may include circuitry which converts the information-carrying portion of the signal from one characteristic to another. For example, the measurement circuit 96 may include a current-to-voltage or current-to-frequency converter. The purpose of this conversion may be to provide a signal that is, for example, more easily transmitted, readable by digital circuits, and/or less susceptible to noise contributions.


One example of a standard current-to-voltage converter is provided in FIG. 20A. In this converter, the signal from the sensor 42 is provided at one input terminal 134 of an operational amplifier 130 (“op amp”) and coupled through a resistor 138 to an output terminal 136. This particular current-to-voltage converter 131 may, however, be difficult to implement in a small CMOS chip because resistors are often difficult to implement on an integrated circuit. Typically, discrete resistor components are used. However, the used of discrete components increases the space needed for the circuitry.


An alternative current-to-voltage converter 141 is illustrated in FIG. 20B. This converter includes an op amp 140 with the signal from the sensor 42 provided at input terminal 144 and a reference potential provided at input terminal 142. A capacitor 145 is placed between the input terminal 144 and the output terminal 146. In addition, switches 147a, 147b, 149a, and 149b are provided to allow the capacitor to charge and discharge at a rate determined by a clock (CLK) frequency. In operation, during one half cycle, switches 147a and 147b close and switches 149a and 149b open allowing the capacitor 145 to charge due to the attached potential V1. During the other half cycle, switches 147a and 147b open and switches 149a and 149b close to ground and allow the capacitor 145 to partially or fully discharge. The reactive impedance of the capacitor 145 is analogous to the resistance of the resistor 138 (see FIG. 20A), allowing the capacitor 145 to emulate a resistor. The value of this “resistor” depends on the capacitance of the capacitor 145 and the clock frequency. By altering the clock frequency, the reactive impedance (“resistance value”) of the capacitor changes. The value of the impedance (“resistance”) of the capacitor 145 may be altered by changing the clock frequency. Switches 147a, 147b, 149a, and 149b may be implemented in a CMOS chip using, for example, transistors.


A current-to-frequency converter may also be used in the measurement circuit 96. One suitable current-to-frequency converter includes charging a capacitor using the signal from the sensor 42. When the potential across the capacitor exceeds a threshold value, the capacitor is allowed to discharge. Thus, the larger the current from the sensor 42, the quicker the threshold potential is achieved. This results in a signal across the capacitor that has an alternating characteristic, corresponding to the charging and discharging of the capacitor, having a frequency which increases with an increase in current from the sensor 42.


In some embodiments, the analyte monitoring system 40 includes two or more working electrodes 58 distributed over one or more sensors 42. These working electrodes 58 may be used for quality control purposes. For example, the output signals and/or analyzed data derived using the two or more working electrodes 58 may be compared to determine if the signals from the working electrodes agree within a desired level of tolerance. If the output signals do not agree, then the patient may be alerted to replace the sensor or sensors. In some embodiments, the patient is alerted only if the lack of agreement between the two sensors persists for a predetermined period of time. The comparison of the two signals may be made for each measurement or at regular intervals. Alternatively or additionally, the comparison may be initiated by the patient or another person. Moreover, the signals from both sensors may be used to generate data or one signal may be discarded after the comparison.


Alternatively, if, for example, two working electrodes 58 have a common counter electrode 60 and the analyte concentration is measured by amperometry, then the current at the counter electrode 60 should be twice the current at each of the working electrodes, within a predetermined tolerance level, if the working electrodes are operating properly. If not, then the sensor or sensors should be replaced, as described above.


An example of using signals from only one working electrode for quality control includes comparing consecutive readings obtained using the single working electrode to determine if they differ by more than a threshold level. If the difference is greater than the threshold level for one reading or over a period of time or for a predetermined number of readings within a period of time then the patient is alerted to replace the sensor 42. Typically, the consecutive readings and/or the threshold level are determined such that all expected excursions of the sensor signal are within the desired parameters (i.e., the sensor control unit 44 does not consider true changes in analyte concentration to be a sensor failure).


The sensor control unit 44 may also optionally include a temperature probe circuit 99. The temperature probe circuit 99 provides a constant current through (or constant potential) across the temperature probe 66. The resulting potential (or current) varies according to the resistance of the temperature dependent element 72.


The output from the sensor circuit 97 and optional temperature probe circuit is coupled into a measurement circuit 96 that obtains signals from the sensor circuit 97 and optional temperature probe circuit 99 and, at least in some embodiments, provides output data in a form that, for example can be read by digital circuits. The signals from the measurement circuit 96 are sent to the processing circuit 109, which in turn may provide data to an optional transmitter 98. The processing circuit 109 may have one or more of the following functions: 1) transfer the signals from the measurement circuit 96 to the transmitter 98, 2) transfer signals from the measurement circuit 96 to the data storage circuit 102, 3) convert the information-carrying characteristic of the signals from one characteristic to another (when, for example, that has not been done by the measurement circuit 96), using, for example, a current-to-voltage converter, a current-to-frequency converter, or a voltage-to-current converter, 4) modify the signals from the sensor circuit 97 using calibration data and/or output from the temperature probe circuit 99, 5) determine a level of an analyte in the interstitial fluid, 6) determine a level of an analyte in the bloodstream based on the sensor signals obtained from interstitial fluid, 7) determine if the level, rate of change, and/or acceleration in the rate of change of the analyte exceeds or meets one or more threshold values, 8) activate an alarm if a threshold value is met or exceeded, 9) evaluate trends in the level of an analyte based on a series of sensor signals, 10) determine a dose of a medication, and 11) reduce noise and/or errors, for example, through signal averaging or comparing readings from multiple working electrodes 58.


The processing circuit 109 may be simple and perform only one or a small number of these functions or the processing circuit 109 may be more sophisticated and perform all or most of these functions. The size of the on-skin sensor control unit 44 may increase with the increasing number of functions and complexity of those functions that the processing circuit 109 performs. Many of these functions may not be performed by a processing circuit 109 in the on-skin sensor control unit 44, but may be performed by another analyzer 152 in the receiver/display units 46, 48 (see FIG. 22).


One embodiment of the measurement circuit 96 and/or processing circuit 109 provides as output data, the current flowing between the working electrode 58 and the counter electrode 60. The measurement circuit 96 and/or processing circuit 109 may also provide as output data a signal from the optional temperature probe 66 which indicates the temperature of the sensor 42. This signal from the temperature probe 66 may be as simple as a current through the temperature probe 66 or the processing circuit 109 may include a device that determines a resistance of the temperature probe 66 from the signal obtained from the measurement circuit 96 for correlation with the temperature of the sensor 42. The output data may then be sent to a transmitter 98 that then transmits this data to at least one receiver/display device 46,48.


Returning to the processing circuit 109, in some embodiments processing circuit 109 is more sophisticated and is capable of determining the analyte concentration or some measure representative of the analyte concentration, such as a current or voltage value. The processing circuit 109 may incorporate the signal of the temperature probe to make a temperature correction in the signal or analyzed data from the working electrode 58. This may include, for example, scaling the temperature probe measurement and adding or subtracting the scaled measurement to the signal or analyzed data from the working electrode 58. The processing circuit 109 may also incorporate calibration data which has been received from an external source or has been incorporated into the processing circuit 109, both of which are described below, to correct the signal or analyzed data from the working electrode 58. Additionally, the processing circuit 109 may include a correction algorithm for converting interstitial analyte level to blood analyte level. The conversion of interstitial analyte level to blood analyte level is described, for example, in Schmidtke, et al., “Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat after Injection of Insulin”, Proc. of the Nat'l Acad. of Science, 95, 294-299 (1998) and Quinn, et al., “Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3 mm Amperometric Microsensors”, Am. J. Physiol., 269 (Endocrinol. Metab. 32), E155-E161 (1995), incorporated herein by reference.


In some embodiments, the data from the processing circuit 109 is analyzed and directed to an alarm system 94 (see FIG. 18B) to warn the user. In at least some of these embodiments, a transmitter is not used as the sensor control unit performs all of the needed functions including analyzing the data and warning the patient.


However, in many embodiments, the data (e.g., a current signal, a converted voltage or frequency signal, or fully or partially analyzed data) from processing circuit 109 is transmitted to one or more receiver/display units 46, 48 using a transmitter 98 in the on-skin sensor control unit 44. The transmitter has an antenna 93, such as a wire or similar conductor, formed in the housing 45. The transmitter 98 is typically designed to transmit a signal up to about 2 meters or more, preferably up to about 5 meters or more, and more preferably up to about 10 meters or more. when transmitting to a small receiver/display unit 46, such as a palm-size, belt-worn receiver. The effective range is longer when transmitting to a unit with a better antenna, such as a bedside receiver. As described in detail below, suitable examples of receiver/display units 46, 48 include units that can be easily worn or carried or units that can be placed conveniently on, for example, a nightstand when the patient is sleeping.


The transmitter 98 may send a variety of different signals to the receiver/display units 46, 48, typically, depending on the sophistication of the processing circuit 109. For example, the processing circuit 109 may simply provide raw signals, for example, currents from the working electrodes 58, without any corrections for temperature or calibration, or the processing circuit 109 may provide converted signals which are obtained, for example, using a current-to-voltage converter 131 or 141 or a current-to-frequency converter. The raw measurements or converted signals may then be processed by an analyzer 152 (see FIG. 22) in the receiver/display units 46, 48 to determine the level of an analyte, optionally using temperature and calibration corrections. In another embodiment, the processing circuit 109 corrects the raw measurements using, for example, temperature and/or calibration information and then the transmitter 98 sends the corrected signal, and optionally, the temperature and/or calibration information, to the receiver/display units 46, 48. In yet another embodiment, the processing circuit 109 calculates the analyte level in the interstitial fluid and/or in the blood (based on the interstitial fluid level) and transmits that information to the one or more receiver/display units 46, 48, optionally with any of the raw data and/or calibration or temperature information. In a further embodiment, the processing circuit 109 calculates the analyte concentration, but the transmitter 98 transmits only the raw measurements, converted signals, and/or corrected signals.


One potential difficulty that may be experienced with the on-skin sensor control unit 44 is a change in the transmission frequency of the transmitter 98 over time. To overcome this potential difficulty, the transmitter may include optional circuitry that can return the frequency of the transmitter 98 to the desired frequency or frequency band. One example of suitable circuitry is illustrated in FIG. 21 as a block diagram of an open loop modulation system 200. The open loop modulation system 200 includes a phase detector (PD) 210, a charge pump (CHGPMP) 212, a loop filter (L.F.) 214, a voltage controlled oscillator (VCO) 216, and a divide by M circuit (÷M) 218 to form the phase-locked loop 220.


The analyte monitoring device 40 uses an open loop modulation system 200 for RF communication between the transmitter 98 and a receiver of, for example, the one or more receiver/display units 46, 48. This open loop modulation system 200 is designed to provide a high reliability RF link between a transmitter and its associated receiver. The system employs frequency modulation (FM), and locks the carrier center frequency using a conventional phase-locked loop (PLL) 220. In operation, the phase-locked loop 220 is opened prior to the modulation. During the modulation the phase-locked loop 220 remains open for as long as the center frequency of the transmitter is within the receiver's bandwidth. When the transmitter detects that the center frequency is going to move outside of the receiver bandwidth, the receiver is signaled to stand by while the center frequency is captured. Subsequent to the capture, the transmission will resume. This cycle of capturing the center frequency, opening the phase-locked loop 220, modulation, and recapturing the center frequency will repeat for as many cycles as required.


The loop control 240 detects the lock condition of the phase-locked loop 220 and is responsible for closing and opening the phase-locked loop 220. The totalizer 250 in conjunction with the loop control 240, detects the status of the center frequency. The modulation control 230 is responsible for generating the modulating signal. A transmit amplifier 260 is provided to ensure adequate transmit signal power. The reference frequency is generated from a very stable signal source (not shown), and is divided down by N through the divide by N block (÷N) 270. Data and control signals are received by the open loop modulation system 200 via the DATA BUS 280, and the CONTROL BUS 290.


The operation of the open loop modulation system 200 begins with the phase-locked loop 220 in closed condition. When the lock condition is detected by the loop control 240, the phase-locked loop 220 is opened and the modulation control 230 begins generating the modulating signal. The totalizer 250 monitors the VCO frequency (divided by M), for programmed intervals. The monitored frequency is compared to a threshold programmed in the totalizer 250. This threshold corresponds to the 3 dB cut off frequencies of the receiver's intermediate frequency stage. When the monitored frequency approaches the thresholds, the loop control 240 is notified and a stand-by code is transmitted to the receiver and the phase-locked loop 220 is closed.


At this point the receiver is in the wait mode. The loop control 240 in the transmitter closes the phase-locked loop 220. Then, modulation control 230 is taken off line, the monitored value of the totalizer 250 is reset, and the phase-locked loop 220 is locked. When the loop control 240 detects a lock condition, the loop control 240 opens the phase-locked loop 220, the modulation control 230 is brought on line and the data transmission to the receiver will resume until the center frequency of the phase-locked loop 220 approaches the threshold values, at which point the cycle of transmitting the stand-by code begins. The ÷N 270 and ÷M 218 blocks set the frequency channel of the transmitter.


Accordingly, the open loop modulation system 200 provides a reliable low power FM data transmission for an analyte monitoring system. The open loop modulation system 200 provides a method of wide band frequency modulation, while the center frequency of the carrier is kept within receiver bandwidth. The effect of parasitic capacitors and inductors pulling the center frequency of the transmitter is corrected by the phase-locked loop 220. Further, the totalizer 250 and loop control 240 provide a new method of center frequency drift detection. Finally, the open loop modulation system 200 is easily implemented in CMOS process.


The rate at which the transmitter 98 transmits data may be the same rate at which the sensor circuit 97 obtains signals and/or the processing circuit 109 provides data or signals to the transmitter 98. Alternatively, the transmitter 98 may transmit data at a slower rate. In this case, the transmitter 98 may transmit more than one datapoint in each transmission. Alternatively, only one datapoint may be sent with each data transmission, the remaining data not being transmitted. Typically, data is transmitted to the receiver/display unit 46, 48 at least every hour, preferably, at least every fifteen minutes, more preferably, at least every five minutes, and most preferably, at least every one minute. However, other data transmission rates may be used. In some embodiments, the processing circuit 109 and/or transmitter 98 are configured to process and/or transmit data at a faster rate when a condition is indicated, for example, a low level or high level of analyte or impending low or high level of analyte. In these embodiments, the accelerated data transmission rate is typically at least every five minutes and preferably at least every minute.


In addition to a transmitter 98, an optional receiver 99 may be included in the on-skin sensor control unit 44. In some cases, the transmitter 98 is a transceiver, operating as both a transmitter and a receiver. The receiver 99 may be used to receive calibration data for the sensor 42. The calibration data may be used by the processing circuit 109 to correct signals from the sensor 42. This calibration data may be transmitted by the receiver/display unit 46, 48 or from some other source such as a control unit in a doctor's office. In addition, the optional receiver 99 may be used to receive a signal from the receiver/display units 46, 48, as described above, to direct the transmitter 98, for example, to change frequencies or frequency bands, to activate or deactivate the optional alarm system 94 (as described below), and/or to direct the transmitter 98 to transmit at a higher rate.


Calibration data may be obtained in a variety of ways. For instance, the calibration data may simply be factory-determined calibration measurements which can be input into the on-skin sensor control unit 44 using the receiver 99 or may alternatively be stored in a calibration data storage unit 100 within the on-skin sensor control unit 44 itself (in which case a receiver 99 may not be needed). The calibration data storage unit 100 may be, for example, a readable or readable/writeable memory circuit.


Alternative or additional calibration data may be provided based on tests performed by a doctor or some other professional or by the patient himself. For example, it is common for diabetic individuals to determine their own blood glucose concentration using commercially available testing kits. The results of this test is input into the on-skin sensor control unit 44 either directly, if an appropriate input device (e.g., a keypad, an optical signal receiver, or a port for connection to a keypad or computer) is incorporated in the on-skin sensor control unit 44, or indirectly by inputting the calibration data into the receiver/display unit 46, 48 and transmitting the calibration data to the on-skin sensor control unit 44.


Other methods of independently determining analyte levels may also be used to obtain calibration data. This type of calibration data may supplant or supplement factory-determined calibration values.


In some embodiments of the invention, calibration data may be required at periodic intervals, for example, every eight hours, once a day, or once a week, to confirm that accurate analyte levels are being reported. Calibration may also be required each time a new sensor 42 is implanted or if the sensor exceeds a threshold minimum or maximum value or if the rate of change in the sensor signal exceeds a threshold value. In some cases, it may be necessary to wait a period of time after the implantation of the sensor 42 before calibrating to allow the sensor 42 to achieve equilibrium. In some embodiments, the sensor 42 is calibrated only after it has been inserted. In other embodiments, no calibration of the sensor 42 is needed.


The on-skin sensor control unit 44 and/or a receiver/display unit 46, 48 may include an auditory or visual indicator that calibration data is needed, based, for example, on a predetermined periodic time interval between calibrations or on the implantation of a new sensor 42. The on-skin sensor control unit 44 and/or receiver display/units 46, 48 may also include an auditory or visual indicator to remind the patient that information, such as analyte levels, reported by the analyte monitoring device 40, may not be accurate because a calibration of the sensor 42 has not been performed within the predetermined periodic time interval and/or after implantation of a new sensor 42.


The processing circuit 109 of the on-skin sensor control unit 44 and/or an analyzer 152 of the receiver/display unit 46, 48 may determine when calibration data is needed and if the calibration data is acceptable. The on-skin sensor control unit 44 may optionally be configured to not allow calibration or to reject a calibration point if, for example, 1) a temperature reading from the temperature probe indicates a temperature that is not within a predetermined acceptable range (e.g., 30 to 42° C. or 32 to 40° C.) or that is changing rapidly (for example, 0.2° C./minute, 0.5° C./minute, or 0.7° C./minute or greater); 2) two or more working electrodes 58 provide uncalibrated signals that are not within a predetermined range (e.g., within 10% or 20%) of each other; 3) the rate of change of the uncalibrated signal is above a threshold rate (e.g., 0.25 mg/dL per minute or 0.5 mg/dL per minute or greater); 4) the uncalibrated signal exceeds a threshold maximum value (e.g., 5, 10, 20, or 40 nA) or is below a threshold minimum value (e.g., 0.05, 0.2, 0.5, or 1 nA); 5) the calibrated signal exceeds a threshold maximum value (e.g., a signal corresponding to an analyte concentration of 200 mg/dL, 250 mg/dL, or 300 mg/dL) or is below a threshold minimum value (e.g., a signal corresponding to an analyte concentration of 50 mg/dL, 65 mg/dL, or 80 mg/dL); and/or 6) an insufficient amount of time has elapsed since implantation (e.g., 10 minutes or less, 20 minutes or less, or 30 minutes or less).


The processing circuit 109 or an analyzer 152 may also request another calibration point if the values determined using the sensor data before and after the latest calibration disagree by more than a threshold amount, indicating that the calibration may be incorrect or that the sensor characteristics have changed radically between calibrations. This additional calibration point may indicate the source of the difference.


The on-skin sensor control unit 44 may include an optional data storage unit 102 which may be used to hold data (e.g., measurements from the sensor or processed data) from the processing circuit 109 permanently or, more typically, temporarily. The data storage unit 102 may hold data so that the data can be used by the processing circuit 109 to analyze and/or predict trends in the analyte level, including, for example, the rate and/or acceleration of analyte level increase or decrease. The data storage unit 102 may also or alternatively be used to store data during periods in which a receiver/display unit 46, 48 is not within range. The data storage unit 102 may also be used to store data when the transmission rate of the data is slower than the acquisition rate of the data. For example, if the data acquisition rate is 10 points/min and the transmission is 2 transmissions/min, then one to five points of data could be sent in each transmission depending on the desired rate for processing datapoints. The data storage unit 102 typically includes a readable/writeable memory storage device and typically also includes the hardware and/or software to write to and/or read the memory storage device.


The on-skin sensor control unit 44 may include an optional alarm system 104 that, based on the data from the processing circuit 109, warns the patient of a potentially detrimental condition of the analyte. For example, if glucose is the analyte, than the on-skin sensor control unit 44 may include an alarm system 104 that warns the patient of conditions such as hypoglycemia, hyperglycemia, impending hypoglycemia, and/or impending hyperglycemia. The alarm system 104 is triggered when the data from the processing circuit 109 reaches or exceeds a threshold value. Examples of threshold values for blood glucose levels are about 60, 70, or 80 mg/dL for hypoglycemia; about 70, 80, or 90 mg/dL for impending hypoglycemia; about 130, 150, 175, 200, 225, 250, or 275 mg/dL for impending hyperglycemia; and about 150, 175, 200, 225, 250, 275, or 300 mg/dL for hyperglycemia. The actual threshold values that are designed into the alarm system 104 may correspond to interstitial fluid glucose concentrations or electrode measurements (e.g., current values or voltage values obtained by conversion of current measurements) that correlate to the above-mentioned blood glucose levels. The analyte monitor device may be configured so that the threshold levels for these or any other conditions may be programmable by the patient and/or a medical professional.


A threshold value is exceeded if the datapoint has a value that is beyond the threshold value in a direction indicating a particular condition. For example, a datapoint which correlates to a glucose level of 200 mg/dL exceeds a threshold value for hyperglycemia of 180 mg/dL, because the datapoint indicates that the patient has entered a hyperglycemic state. As another example, a datapoint which correlates to a glucose level of 65 mg/dL exceeds a threshold value for hypoglycemia of 70 mg/dL because the datapoint indicates that the patient is hypoglycemic as defined by the threshold value. However, a datapoint which correlates to a glucose level of 75 mg/dL would not exceed the same threshold value for hypoglycemia because the datapoint does not indicate that particular condition as defined by the chosen threshold value.


An alarm may also be activated if the sensor readings indicate a value that is beyond a measurement range of the sensor 42. For glucose, the physiologically relevant measurement range is typically about 50 to 250 mg/dL, preferably about 40-300 mg/dL and ideally 30-400 mg/dL, of glucose in the interstitial fluid.


The alarm system 104 may also, or alternatively, be activated when the rate of change or acceleration of the rate of change in analyte level increase or decrease reaches or exceeds a threshold rate or acceleration. For example, in the case of a subcutaneous glucose monitor, the alarm system might be activated if the rate of change in glucose concentration exceeds a threshold value which might indicate that a hyperglycemic or hypoglycemic condition is likely to occur.


The optional alarm system 104 may be configured to activate when a single data point meets or exceeds a particular threshold value. Alternatively, the alarm may be activated only when a predetermined number of datapoints spanning a predetermined amount of time meet or exceed the threshold value. As another alternative, the alarm may be activated only when the datapoints spanning a predetermined amount of time have an average value which meets or exceeds the threshold value. Each condition that can trigger an alarm may have a different alarm activation condition. In addition, the alarm activation condition may change depending on current conditions (e.g., an indication of impending hyperglycemia may alter the number of datapoints or the amount of time that is tested to determine hyperglycemia).


The alarm system 104 may contain one or more individual alarms. Each of the alarms may be individually activated to indicate one or more conditions of the analyte. The alarms may be, for example, auditory or visual. Other sensory-stimulating alarm systems may be used including alarm systems which heat, cool, vibrate, or produce a mild electrical shock when activated. In some embodiments, the alarms are auditory with a different tone, note, or volume indicating different conditions. For example, a high note might indicate hyperglycemia and a low note might indicate hypoglycemia. Visual alarms may use a difference in color, brightness, or position on the on-skin sensor control device 44 to indicate different conditions. In some embodiments, an auditory alarm system is configured so that the volume of the alarm increases over time until the alarm is deactivated.


In some embodiments, the alarm may be automatically deactivated after a predetermined time period. In other embodiments, the alarm may be configured to deactivate when the data no longer indicate that the condition which triggered the alarm exists. In these embodiments, the alarm may be deactivated when a single data point indicates that the condition no longer exists or, alternatively, the alarm may be deactivated only after a predetermined number of datapoints or an average of datapoints obtained over a given period of time indicate that the condition no longer exists.


In some embodiments, the alarm may be deactivated manually by the patient or another person in addition to or as an alternative to automatic deactivation. In these embodiments a switch 101 is provided which when activated turns off the alarm. The switch 101 may be operatively engaged (or disengaged depending on the configuration of the switch) by, for example, operating an actuator on the on-skin sensor control unit 44 or the receiver/display unit 46, 48. In some cases, an actuator may be provided on two or more units 44, 46, 48, any of which may be actuated to deactivate the alarm. If the switch 101 and or actuator is provided on the receiver/display unit 46, 48 then a signal may be transmitted from the receiver/display unit 46, 48 to the receiver 98 on the on-skin sensor control unit 44 to deactivate the alarm.


A variety of switches 101 may be used including, for example, a mechanical switch, a reed switch, a Hall effect switch, a Gigantic Magnetic Ratio (GMR) switch (the resistance of the GMR switch is magnetic field dependent) and the like. Preferably, the actuator used to operatively engage (or disengage) the switch is placed on the on-skin sensor control unit 44 and configured so that no water can flow around the button and into the housing. One example of such a button is a flexible conducting strip that is completely covered by a flexible polymeric or plastic coating integral to the housing. In an open position the flexible conducting strip is bowed and bulges away from the housing. When depressed by the patient or another person, the flexible conducting strip is pushed directly toward a metal contact and completes the circuit to shut off the alarm.


For a reed or GMR switch, a piece of magnetic material, such as a permanent magnet or an electromagnet, in a flexible actuator that is bowed or bulges away from the housing 45 and the reed or GMR switch is used. The reed or GMR switch is activated (to deactivate the alarm) by depressing the flexible actuator bringing the magnetic material closer to the switch and causing an increase in the magnetic field within the switch.


In some embodiments of the invention, the analyte monitoring device 40 includes only an on-skin control unit 44 and a sensor 42. In these embodiments, the processing circuit 109 of the on-skin sensor control unit 44 is able to determine a level of the analyte and activate an alarm system 104 if the analyte level exceeds a threshold. The on-skin control unit 44, in these embodiments, has an alarm system 104 and may also include a display, such as those discussed below with respect to the receiver/display units 46, 48. Preferably, the display is an LCD or LED display. The on-skin control unit 44 may not have a transmitter, unless, for example, it is desirable to transmit data, for example, to a control unit in a doctor's office.


The on-skin sensor control unit 44 may also include a reference voltage generator 101 to provide an absolute voltage or current for use in comparison to voltages or currents obtained from or used with the sensor 42. An example of a suitable reference voltage generator is a band-gap reference voltage generator that uses, for example, a semiconductor material with a known band-gap. Preferably, the band-gap is temperature insensitive over the range of temperatures that the semiconductor material will experience during operation. Suitable semiconductor materials includes gallium, silicon and silicates.


A bias current generator 105 may be provided to correctly bias solid-state electronic components. An oscillator 107 may be provided to produce a clock signal that is typically used with digital circuitry.


The on-skin sensor control unit 44 may also include a watchdog circuit 103 that tests the circuitry, particularly, any digital circuitry in the control unit 44 to determine if the circuitry is operating correctly. Non-limiting examples of watchdog circuit operations include: a) generation of a random number by the watchdog circuit, storage of the number in a memory location, writing the number to a register in the watchdog circuit, and recall of the number to compare for equality; b) checking the output of an analog circuit to determine if the output exceeds a predetermined dynamic range; c) checking the output of a timing circuit for a signal at an expected pulse interval. Other examples of functions of a watchdog circuit are known in the art. If the watchdog circuit detects an error that watchdog circuit may activate an alarm and/or shut down the device.


Receiver/Display Unit


One or more receiver/display units 46, 48 may be provided with the analyte monitoring device 40 for easy access to the data generated by the sensor 42 and may, in some embodiments, process the signals from the on-skin sensor control unit 44 to determine the concentration or level of analyte in the subcutaneous tissue. Small receiver/display units 46 may be carried by the patient. These units 46 may be palm-sized and/or may be adapted to fit on a belt or within a bag or purse that the patient carries. One embodiment of the small receiver/display unit 46 has the appearance of a pager, for example, so that the user is not identified as a person using a medical device. Such receiver/display units may optionally have one-way or two-way paging capabilities.


Large receiver/display units 48 may also be used. These larger units 48 may be designed to sit on a shelf or nightstand. The large receiver/display unit 48 may be used by parents to monitor their children while they sleep or to awaken patients during the night. In addition, the large receiver/display unit 48 may include a lamp, clock, or radio for convenience and/or for activation as an alarm. One or both types of receiver/display units 46, 48 may be used.


The receiver/display units 46, 48, as illustrated in block form at FIG. 22, typically include a receiver 150 to receive data from the on-skin sensor control unit 44, an analyzer 152 to evaluate the data, a display 154 to provide information to the patient, and an alarm system 156 to warn the patient when a condition arises. The receiver/display units 46, 48 may also optionally include a data storage device 158, a transmitter 160, and/or an input device 162. The receiver/display units 46,48 may also include other components (not shown), such as a power supply (e.g., a battery and/or a power supply that can receive power from a wall outlet), a watchdog circuit, a bias current generator, and an oscillator. These additional components are similar to those described above for the on-skin sensor control unit 44.


In one embodiment, a receiver/display unit 48 is a bedside unit for use by a patient at home. The bedside unit includes a receiver and one or more optional items, including, for example, a clock, a lamp, an auditory alarm, a telephone connection, and a radio. The bedside unit also has a display, preferably, with large numbers and/or letters that can be read across a room. The unit may be operable by plugging into an outlet and may optionally have a battery as backup. Typically, the bedside unit has a better antenna than a small palm-size unit, so the bedside unit's reception range is longer.


When an alarm is indicated, the bedside unit may activate, for example, the auditory alarm, the radio, the lamp, and/or initiate a telephone call. The alarm may be more intense than the alarm of a small palm-size unit to, for example, awaken or stimulate a patient who may be asleep, lethargic, or confused. Moreover, a loud alarm may alert a parent monitoring a diabetic child at night.


The bedside unit may have its own data analyzer and data storage. The data may be communicated from the on-skin sensor unit or another receiver/display unit, such as a palm-size or small receiver/display unit. Thus, at least one unit has all the relevant data so that the data can be downloaded and analyzed without significant gaps.


Optionally, the beside unit has an interface or cradle into which a small receiver/display unit may be placed. The bedside unit may be capable of utilizing the data storage and analysis capabilities of the small receiver/display unit and/or receive data from the small receiver/display unit in this position. The bedside unit may also be capable of recharging a battery of the small receiver/display unit.


The receiver 150 typically is formed using known receiver and antenna circuitry and is often tuned or tunable to the frequency or frequency band of the transmitter 98 in the on-skin sensor control unit 44. Typically, the receiver 150 is capable of receiving signals from a distance greater than the transmitting distance of the transmitter 98. The small receiver/display unit 46 can typically receive a signal from an on-skin sensor control unit 44 that is up to 2 meters, preferably up to 5 meters, and more preferably up to 10 meters or more, away. A large receiver/display unit 48, such as a bedside unit, can typically receive a receive a signal from an on-skin sensor control unit 44 that is up to 5 meters distant, preferably up to 10 meters distant, and more preferably up to 20 meters distant or more.


In one embodiment, a repeater unit (not shown) is used to boost a signal from an on-skin sensor control unit 44 so that the signal can be received by a receiver/display unit 46, 48 that may be distant from the on-skin sensor control unit 44. The repeater unit is typically independent of the on-skin sensor control unit 44, but, in some cases, the repeater unit may be configured to attach to the on-skin sensor control unit 44. Typically, the repeater unit includes a receiver for receiving the signals from the on-skin sensor control unit 44 and a transmitter for transmitting the received signals. Often the transmitter of the repeater unit is more powerful than the transmitter of the on-skin sensor control unit, although this is not necessary. The repeater unit may be used, for example, in a child's bedroom for transmitting a signal from an on-skin sensor control unit on the child to a receiver/display unit in the parent's bedroom for monitoring the child's analyte levels. Another exemplary use is in a hospital with a display/receiver unit at a nurse's station for monitoring on-skin sensor control unit(s) of patients.


The presence of other devices, including other on-skin sensor control units, may create noise or interference within the frequency band of the transmitter 98. This may result in the generation of false data. To overcome this potential difficulty, the transmitter 98 may also transmit a code to indicate, for example, the beginning of a transmission and/or to identify, preferably using a unique identification code, the particular on-skin sensor control unit 44 in the event that there is more than one on-skin sensor control unit 44 or other transmission source within range of the receiver/display unit 46, 48. The provision of an identification code with the data may reduce the likelihood that the receiver/display unit 46, 48 intercepts and interprets signals from other transmission sources, as well as preventing “crosstalk” with different on-skin sensor control units 44. The identification code may be provided as a factory-set code stored in the sensor control unit 44. Alternatively, the identification code may be randomly generated by an appropriate circuit in the sensor control unit 44 or the receiver/display unit 46, 48 (and transmitted to the sensor control unit 44) or the identification code may be selected by the patient and communicated to the sensor control unit 44 via a transmitter or an input device coupled to the sensor control unit 44.


Other methods may be used to eliminate “crosstalk” and to identify signals from the appropriate on-skin sensor control unit 44. In some embodiments, the transmitter 98 may use encryption techniques to encrypt the datastream from the transmitter 98. The receiver/display unit 46, 48 contains the key to decipher the encrypted data signal. The receiver/display unit 46, 48 then determines when false signals or “crosstalk” signals are received by evaluation of the signal after it has been deciphered. For example, the analyzer 152 in the one or more receiver/display units 46, 48 compares the data, such as current measurements or analyte levels, with expected measurements (e.g., an expected range of measurements corresponding to physiologically relevant analyte levels). Alternatively, an analyzer in the receiver/display units 46, 48 searches for an identification code in the decrypted data signal.


Another method to eliminate “crosstalk”, which is typically used in conjunction with the identification code or encryption scheme, includes providing an optional mechanism in the on-skin sensor control unit 44 for changing transmission frequency or frequency bands upon determination that there is “crosstalk”. This mechanism for changing the transmission frequency or frequency band may be initiated by the receiver/display unit automatically, upon detection of the possibility of cross-talk or interference, and/or by a patient manually. For automatic initiation, the receiver/display unit 46, 48 transmits a signal to the optional receiver 99 on the on-skin sensor control unit 44 to direct the transmitter 98 of the on-skin sensor control unit 44 to change frequency or frequency band.


Manual initiation of the change in frequency or frequency band may be accomplished using, for example, an actuator (not shown) on the receiver/display unit 46, 48 and/or on the on-skin sensor control unit 44 which a patient operates to direct the transmitter 98 to change frequency or frequency band. The operation of a manually initiated change in transmission frequency or frequency band may include prompting the patient to initiate the change in frequency or frequency band by an audio or visual signal from the receiver/display unit 46, 48 and/or on-skin sensor control unit 44.


Returning to the receiver 150, the data received by the receiver 150 is then sent to an analyzer 152. The analyzer 152 may have a variety of functions, similar to the processor circuit 109 of the on-skin sensor control unit 44, including 1) modifying the signals from the sensor 42 using calibration data and/or measurements from the temperature probe 66, 2) determining a level of an analyte in the interstitial fluid, 3) determining a level of an analyte in the bloodstream based on the sensor measurements in the interstitial fluid, 4) determining if the level, rate of change, and/or acceleration in the rate of change of the analyte exceeds or meets one or more threshold values, 5) activating an alarm system 156 and/or 94 if a threshold value is met or exceeded, 6) evaluating trends in the level of an analyte based on a series of sensor signals, 7) determine a dose of a medication, and 8) reduce noise or error contributions (e.g., through signal averaging or comparing readings from multiple electrodes). The analyzer 152 may be simple and perform only one or a small number of these functions or the analyzer 152 may perform all or most of these functions.


The output from the analyzer 152 is typically provided to a display 154. A variety of displays 154 may be used including cathode ray tube displays (particularly for larger units), LED displays, or LCD displays. The display 154 may be monochromatic (e.g., black and white) or polychromatic (i.e., having a range of colors). The display 154 may contain symbols or other indicators that are activated under certain conditions (e.g., a particular symbol may become visible on the display when a condition, such as hyperglycemia, is indicated by signals from the sensor 42). The display 154 may also contain more complex structures, such as LCD or LED alphanumeric structures, portions of which can be activated to produce a letter, number, or symbol. For example, the display 154 may include region 164 to display numerically the level of the analyte, as illustrated in FIG. 23. In one embodiment, the display 154 also provides a message to the patient to direct the patient in an action. Such messages may include, for example. “Eat Sugar”, if the patient is hypoglycemic, or “Take Insulin”, if the patient is hyperglycemic.


One example of a receiver/display unit 46, 48 is illustrated in FIG. 23. The display 154 of this particular receiver/display unit 46, 48 includes a portion 164 which displays the level of the analyte, for example, the blood glucose concentration, as determined by the processing circuit 109 and/or the analyzer 152 using signals from the sensor 42. The display also includes various indicators 166 which may be activated under certain conditions. For example, the indicator 168 of a glucose monitoring device may be activated if the patient is hyperglycemic. Other indicators may be activated in the cases of hypoglycemia (170), impending hyperglycemia (172), impending hypoglycemia (174), a malfunction, an error condition, or when a calibration sample is needed (176). In some embodiments, color coded indicators may be used. Alternatively, the portion 164 which displays the blood glucose concentration may also include a composite indicator 180 (see FIG. 24), portions of which may be appropriately activated to indicate any of the conditions described above.


The display 154 may also be capable of displaying a graph 178 of the analyte level over a period of time, as illustrated in FIG. 24. Examples of other graphs that may be useful include graphs of the rate of change or acceleration in the rate of change of the analyte level over time. In some embodiments, the receiver/display unit is configured so that the patient may choose the particular display (e.g., blood glucose concentration or graph of concentration versus time) that the patient wishes to view. The patient may choose the desired display mode by pushing a button or the like, for example, on an optional input device 162.


The receiver/display units 46, 48 also typically include an alarm system 156. The options for configuration of the alarm system 156 are similar to those for the alarm system 104 of the on-skin sensor control unit 44. For example, if glucose is the analyte, than the on-skin sensor control unit 44 may include an alarm system 156 that warns the patient of conditions such as hypoglycemia, hyperglycemia, impending hypoglycemia, and/or impending hyperglycemia. The alarm system 156 is triggered when the data from the analyzer 152 reaches or exceeds a threshold value. The threshold values may correspond to interstitial fluid glucose concentrations or sensor signals (e.g., current or converted voltage values) which correlate to the above-mentioned blood glucose levels.


The alarm system 156 may also, or alternatively, be activated when the rate or acceleration of an increase or decrease in analyte level reaches or exceeds a threshold value. For example, in the case of a subcutaneous glucose monitor, the alarm system 156 might be activated if the rate of change in glucose concentration exceeds a threshold value which might indicate that a hyperglycemic or hypoglycemic condition is likely to occur.


The alarm system 156 may be configured to activate when a single data point meets or exceeds a particular threshold value. Alternatively, the alarm may be activated only when a predetermined number of datapoints spanning a predetermined amount of time meet or exceed the threshold value. As another alternative, the alarm may be activated only when the datapoints spanning a predetermined amount of time have an average value which meets or exceeds the threshold value. Each condition that can trigger an alarm may have a different alarm activation condition. In addition, the alarm activation condition may change depending on current conditions (e.g., an indication of impending hyperglycemia may alter the number of datapoints or the amount of time that is tested to determine hyperglycemia).


The alarm system 156 may contain one or more individual alarms. Each of the alarms may be individually activated to indicate one or more conditions of the analyte. The alarms may be, for example, auditory or visual. Other sensory-stimulating alarm systems by be used including alarm systems 156 that direct the on-skin sensor control unit 44 to heat, cool, vibrate, or produce a mild electrical shock. In some embodiments, the alarms are auditory with a different tone, note, or volume indicating different conditions. For example, a high note might indicate hyperglycemia and a low note might indicate hypoglycemia. Visual alarms may also use a difference in color or brightness to indicate different conditions. In some embodiments, an auditory alarm system might be configured so that the volume of the alarm increases over time until the alarm is deactivated.


In some embodiments, the alarms may be automatically deactivated after a predetermined time period. In other embodiments, the alarms may be configured to deactivate when the data no longer indicate that the condition which triggered the alarm exists. In these embodiments, the alarms may be deactivated when a single data point indicates that the condition no longer exists or, alternatively, the alarm may be deactivated only after a predetermined number of datapoints or an average of datapoints obtained over a given period of time indicate that the condition no longer exists.


In yet other embodiments, the alarm may be deactivated manually by the patient or another person in addition to or as an alternative to automatic deactivation. In these embodiments, a switch is provided which when activated turns off the alarm. The switch may be operatively engaged (or disengaged depending on the configuration of the switch) by, for example, pushing a button on the receiver/display unit 46, 48. One configuration of the alarm system 156 has automatic deactivation after a period of time for alarms that indicate an impending condition (e.g., impending hypoglycemia or hyperglycemia) and manual deactivation of alarms which indicate a current condition (e.g., hypoglycemia or hyperglycemia).


The receiver/display units 46, 48 may also include a number of optional items. One item is a data storage unit 158. The data storage unit 158 may be desirable to store data for use if the analyzer 152 is configured to determine trends in the analyte level. The data storage unit 158 may also be useful to store data that may be downloaded to another receiver/display unit, such as a large display unit 48. Alternatively, the data may be downloaded to a computer or other data storage device in a patient's home, at a doctor's office, etc. for evaluation of trends in analyte levels. A port (not shown) may be provided on the receiver/display unit 46, 48 through which the stored data may be transferred or the data may be transferred using an optional transmitter 160. The data storage unit 158 may also be activated to store data when a directed by the patient via, for example, the optional input device 162. The data storage unit 158 may also be configured to store data upon occurrence of a particular event, such as a hyperglycemic or hypoglycemic episode, exercise, eating, etc. The storage unit 158 may also store event markers with the data of the particular event. These event markers may be generated either automatically by the display/receiver unit 46, 48 or through input by the patient.


The receiver/display unit 46, 48 may also include an optional transmitter 160 which can be used to transmit 1) calibration information, 2) a signal to direct the transmitter 98 of the on-skin sensor control unit 44 to change transmission frequency or frequency bands, and/or 3) a signal to activate an alarm system 104 on the on-skin sensor control unit 44, all of which are described above. The transmitter 160 typically operates in a different frequency band than the transmitter 98 of the on-skin sensor control unit 44 to avoid cross-talk between the transmitters 98, 160. Methods may be used to reduce cross-talk and the reception of false signals, as described above in connection with the transmitter 98 of the on-skin sensor control unit 44. In some embodiments, the transmitter 160 is only used to transmit signals to the sensor control unit 44 and has a range of less than one foot, and preferably less than six inches. This then requires the patient or another person to hold the receiver/display unit 46 near the sensor control unit 44 during transmission of data, for example, during the transmission of calibration information. Transmissions may also be performed using methods other than RE transmission, including optical or wire transmission.


In addition, in some embodiments of the invention, the transmitter 160 may be configured to transmit data to another receiver/display unit 46, 48 or some other receiver. For example, a small receiver/display unit 46 may transmit data to a large receiver/display unit 48, as illustrated in FIG. 1. As another example, a receiver/display unit 46, 48 may transmit data to a computer in the patient's home or at a doctor's office. Moreover, the transmitter 160 or a separate transmitter may direct a transmission to another unit or to a telephone or other communications device that alerts a doctor or other individual when an alarm is activated and/or if, after a predetermined time period, an activated alarm has not been deactivated, suggesting that the patient may require assistance. In some embodiments, the receiver/display unit is capable of one-way or two-way paging and/or is coupled to a telephone line to send and/or receive messages from another, such as a health professional monitoring the patient.


Another optional component for the receiver/display unit 46, 48 is an input device 162, such as a keypad or keyboard. The input device 162 may allow numeric or alphanumeric input. The input device 162 may also include buttons, keys, or the like which initiate functions of and/or provide input to the analyte monitoring device 40. Such functions may include initiating a data transfer, manually changing the transmission frequency or frequency band of the transmitter 98, deactivating an alarm system 104, 156, inputting calibration data, and/or indicating events to activate storage of data representative of the event.


Another embodiment of the input device 162 is a touch screen display. The touch screen display may be incorporated into the display 154 or may be a separate display. The touch screen display is activated when the patient touches the screen at a position indicated by a “soft button” which corresponds to a desired function. Touch screen displays are well known.


In addition, the analyte monitoring device 40 may include password protection to prevent the unauthorized transmission of data to a terminal or the unauthorized changing of settings for the device 40. A patient may be prompted by the display 154 to input the password using the input device 162 whenever a password-protected function is initiated.


Another function that may be activated by the input device 162 is a deactivation mode. The deactivation mode may indicate that the receiver/display unit 46, 48 should no longer display a portion or all of the data. In some embodiments, activation of the deactivation mode may even deactivate the alarm systems 104, 156. Preferably, the patient is prompted to confirm this particular action. During the deactivation mode, the processing circuit 109 and/or analyzer 152 may stop processing data or they may continue to process data and not report it for display and may optionally store the data for later retrieval.


Alternatively, a sleep mode may be entered if the input device 162 has not been activated for a predetermined period of time. This period of time may be adjustable by the patient or another individual. In this sleep mode, the processing circuit 109 and/or analyzer 152 typically continue to obtain measurements and process data, however, the display is not activated. The sleep mode may be deactivated by actions, such as activating the input device 162. The current analyte reading or other desired information may then be displayed.


In one embodiment, a receiver/display unit 46 initiates an audible or visual alarm when the unit 46 has not received a transmission from the on-skin sensor control unit within a predetermined amount of time. The alarm typically continues until the patient responds and/or a transmission is received. This can, for example, remind a patient if the receiver/display unit 46 is inadvertently left behind.


In another embodiment, the receiver/display unit 46, 48 is integrated with a calibration unit (not shown). For example, the receiver/display unit 46, 48 may, for example, include a conventional blood glucose monitor. Another useful calibration device utilizing electrochemical detection of analyte concentration is described in U.S. patent application Ser. No. 08/795,767, incorporated herein by reference. Other devices may be used including those that operate using, for example, electrochemical and colorimetric blood glucose assays, assays of interstitial or dermal fluid, and/or non-invasive optical assays. When a calibration of the implanted sensor is needed, the patient uses the integrated in vitro monitor to generate a reading. The reading may then, for example, automatically be sent by the transmitter 160 of the receiver/display unit 46, 48 to calibrate the sensor 42.


Integration with a Drug Administration System



FIG. 25 illustrates a block diagram of a sensor-based drug delivery system 250 according to the present invention. The system may provide a drug to counteract the high or low level of the analyte in response to the signals from one or more sensors 252. Alternatively, the system monitors the drug concentration to ensure that the drug remains within a desired therapeutic range. The drug delivery system includes one or more (and preferably two or more) subcutaneously implanted sensors 252, an on-skin sensor control unit 254, a receiver/display unit 256, a data storage and controller module 258, and a drug administration system 260. In some cases, the receiver/display unit 256, data storage and controller module 258, and drug administration system 260 may be integrated in a single unit. The sensor-based drug delivery system 250 uses data from the one or more sensors 252 to provide necessary input for a control algorithm/mechanism in the data storage and controller module 258 to adjust the administration of drugs. As an example, a glucose sensor could be used to control and adjust the administration of insulin.


In FIG. 25, sensor 252 produces signals correlated to the level of the drug or analyte in the patient. The level of the analyte will depend on the amount of drug delivered by the drug administration system. A processor 262 in the on-skin sensor control unit 254, as illustrated in FIG. 25, or in the receiver/display unit 256 determines the level of the analyte, and possibly other information, such as the rate or acceleration of the rate in the increase or decrease in analyte level. This information is then transmitted to the data storage and controller module 258 using a transmitter 264 in the on-skin sensor control unit 254, as illustrated in FIG. 25, or a non-integrated receiver/display unit 256.


If the drug delivery system 250 has two or more sensors 252, the data storage and controller module 258 may verify that the data from the two or more sensors 252 agrees within predetermined parameters before accepting the data as valid. This data may then be processed by the data storage and controller module 258, optionally with previously obtained data, to determine a drug administration protocol. The drug administration protocol is then executed using the drug administration system 260, which may be an internal or external infusion pump, syringe injector, transdermal delivery system (e.g., a patch containing the drug placed on the skin), or inhalation system. Alternatively, the drug storage and controller module 258 may provide a the drug administration protocol so that the patient or another person may provide the drug to the patient according to the profile.


In one embodiment of the invention, the data storage and controller module 258 is trainable. For example, the data storage and controller module 258 may store glucose readings over a predetermined period of time, e.g., several weeks. When an episode of hypoglycemia or hyperglycemia is encountered, the relevant history leading to such event may be analyzed to determine any patterns which might improve the system's ability to predict future episodes. Subsequent data might be compared to the known patterns to predict hypoglycemia or hyperglycemia and deliver the drug accordingly. In another embodiment, the analysis of trends is performed by an external system or by the processing circuit 109 in the on-skin sensor control unit 254 or the analyzer 152 in the receiver/display unit 256 and the trends are incorporated in the data storage and controller 258.


In one embodiment, the data storage and controller module 258, processing circuit 109, and/or analyzer 152 utilizes patient-specific data from multiple episodes to predict a patient's response to future episodes. The multiple episodes used in the prediction are typically responses to a same or similar external or internal stimulus. Examples of stimuli include periods of hypoglycemia or hyperglycemia (or corresponding conditions for analytes other than glucose), treatment of a condition, drug delivery (e.g., insulin for glucose), food intake, exercise, fasting, change in body temperature, elevated or lowered body temperature (e.g., fever), and diseases, viruses, infections, and the like. By analyzing multiple episodes, the data storage and controller module 258, processing circuit 109, and/or analyzer 152 can predict the course of a future episode and provide, for example, a drug administration protocol or administer a drug based on this analysis. An input device (not shown) may be used by the patient or another person to indicate when a particular episode is occurring so that, for example, the data storage and controller module 258, processing circuit 109, and/or analyzer 152 can tag the data as resulting from a particular episode, for use in further analyses.


In addition, the drug delivery system 250 may be capable of providing on-going drug sensitivity feedback. For example, the data from the sensor 252 obtained during the administration of the drug by the drug administration system 260 may provide data about the individual patient's response to the drug which can then be used to modify the current drug administration protocol accordingly, both immediately and in the future. An example of desirable data that can be extracted for each patient includes the patient's characteristic time constant for response to drug administration (e.g., how rapidly the glucose concentration falls when a known bolus of insulin is administered). Another example is the patient's response to administration of various amounts of a drug (e.g., a patient's drug sensitivity curve). The same information may be stored by the drug storage and controller module and then used to determine trends in the patient's drug response, which may be used in developing subsequent drug administration protocols, thereby personalizing the drug administration process for the needs of the patient.


The present invention should not be considered limited to the particular examples described above, but rather should be understood to cover all aspects of the invention as fairly set out in the attached claims. Various modifications, equivalent processes, as well as numerous structures to which the present invention may be applicable will be readily apparent to those of skill in the art to which the present invention is directed upon review of the instant specification. The claims are intended to cover such modifications and devices.

Claims
  • 1. An integrated therapy management device, comprising: a housing comprising: a receiver unit configured to receive one or more signals related to an analyte level from an analyte sensor;a data controller in communication with the receiver unit and configured to process the one or more signals related to the analyte level to determine a dose of a desired medicant; anda drug administration system in communication with the data controller to deliver the dose of the desired medicant, the drug administration system being part of a drug delivery system that is configured to determine a drug sensitivity feedback based on the one or more signals related to the analyte level; anda display coupled to the housing and configured to display data related to one or more of the determined dose of the desired medicant, the delivered dose of the desired medicant, or the analyte level; wherein the data controller, the receiver unit and the drug administration system are integrated as a single unit in the housing;wherein the data controller is configured to tag the one or more signals which are related to an episode of hyperglycemic condition or hypoglycemic condition for use in a data analysis of the episode of hyperglycemic condition or hypoglycemic condition;wherein the data controller is trainable such that the data controller is configured to analyze the tagged data associated with the episode of hyperglycemic condition or hypoglycemic condition to determine one or more patterns associated with the one or more of the hyperglycemic or hypoglycemic conditions, to determine the one or more patterns in response to the delivered medicant and the one or more signals related to the analyte level, and to provide a drug administration protocol based on the determined one or more patterns in response to the delivered medicant and the one or more signals related to the analyte level; and furtherwherein the drug administration system is configured to deliver a modified dose of desired medicant based upon the one or more patterns of the one or more of the hyperglycemic or hypoglycemic conditions determined by the data controller.
  • 2. The device of claim 1, wherein the receiver unit includes one of a transmitter, a receiver, or a transceiver.
  • 3. The device of claim 1 wherein the drug administration system is an insulin delivery unit.
  • 4. The device of claim 3 wherein the insulin delivery unit includes an external infusion pump.
  • 5. The device of claim 1 wherein the display is configured to display therapy related data.
  • 6. The device of claim 5 wherein the therapy related data includes one or more monitored analyte level or the drug administration protocol.
  • 7. The system of claim 1 wherein the drug delivery system is configured to provide an on-going drug sensitivity feedback.
  • 8. The system of claim 1 wherein the drug administration system modifies the dose of the desired medicant based on the drug sensitivity feedback.
  • 9. The system of claim 1 wherein the drug sensitivity feedback is based at least in part on the one or more signals associated with the received analyte level.
  • 10. The device of claim 1 wherein the data controller is configured to determine a characteristic time constant based upon the one or more signals related to the analyte level and the delivered dose of the desired medicant, and to modify the drug administration protocol based upon the characteristic time constant.
  • 11. The device of claim 10 wherein the drug administration protocol is modified in real-time.
  • 12. The device of claim 10 wherein the drug administration protocol is modified at a future time.
  • 13. The device of claim 1 wherein the data controller is configured to receive data associated with the episode of hyperglycemic condition or hypoglycemic condition from an input unit.
  • 14. A computer-implemented method, comprising: receiving, at a receiver unit, one or more signals related to an analyte level from an analyte sensor;processing, using a data controller in communication with the receiver unit, the one or more signals related to the analyte level to determine a dose of a desired medicant;delivering, using a drug administration system in communication with the data controller, the dose of the desired medicant, wherein the drug administration system is part of a drug delivery system;determining, using the drug delivery system, a drug sensitivity feedback based on the one or more signals related to the analyte level; anddisplaying, using a display, data related to one or more of the determined dose of the desired medicant, the delivered dose of the desired medicant, or the analyte level; wherein the receiver unit, the data controller, and the drug administration system are integrated as a single unit in a housing, and the display is coupled to the housing;wherein the one or more signals which are related to an episode of hyperglycemic condition or hypoglycemic condition are tagged, using the data controller, for use in a data analysis of the episode of hyperglycemic condition or hypoglycemic condition;wherein the data controller is trainable such that the tagged data associated with the episode of hyperglycemic condition or hypoglycemic condition is analyzed, using the data controller, to determine one or more patterns associated with the one or more of the hyperglycemic or hypoglycemic conditions, to determine the one or more patterns in response to the delivered medicant and the one or more signals related to the analyte level, and to provide a drug administration protocol based on the determined one or more patterns in response to the delivered medicant and the one or more signals related to the analyte level;wherein a modified dose of the desired medicant is delivered, using the drug administration system, based upon the determined one or more patterns of the one or more of the hyperglycemic or hypoglycemic conditions.
  • 15. The method of claim 14 further including displaying therapy related data including the drug administration protocol.
  • 16. The method of claim 14 further including providing an on-going drug sensitivity feedback.
  • 17. The method of claim 14 wherein the drug sensitivity feedback is based at least in part on the one or more signals associated with the received analyte level.
  • 18. The method of claim 14 further including determining a characteristic time constant based upon the one or more signals related to the analyte level and the delivered dose of the desired medicant, and modifying the drug administration protocol based upon the characteristic time constant.
  • 19. The method of claim 18 wherein the drug administration protocol is modified in real-time.
  • 20. The method of claim 18 wherein the drug administration protocol is modified at a future time.
RELATED APPLICATIONS

This application is a continuation of pending application Ser. No. 10/420,057 filed Apr. 18, 2003 which is a continuation of application Ser. No. 09/667,199 filed Sep. 21, 2000, now U.S. Pat. No. 6,565,509 B1, which is a continuation of application Ser. No. 09/070,677 filed Apr. 30, 1998 now U.S. Pat. No. 6,175,752 B1, the disclosure of each of which are incorporated herein by reference for all purposes, and each of which are assigned to assignee, Abbott Diabetes Care, Inc., of Alameda, Calif.

US Referenced Citations (2391)
Number Name Date Kind
2402306 Turkel Jun 1946 A
2719797 Rosenblatt et al. Oct 1955 A
3132123 Harris, Jr. et al. May 1964 A
3210578 Sherer Oct 1965 A
3219533 Mullins Nov 1965 A
3260656 Ross, Jr. Jul 1966 A
3282875 Connolly et al. Nov 1966 A
3304413 Lehmann et al. Feb 1967 A
3310606 Fritz Mar 1967 A
3381371 Russell May 1968 A
3397191 Beckerbauer Aug 1968 A
3635926 Gresham et al. Jan 1972 A
3651318 Czekajewski Mar 1972 A
3652475 Wada et al. Mar 1972 A
3653841 Klein Apr 1972 A
3698386 Fried Oct 1972 A
3719564 Lilly, Jr. et al. Mar 1973 A
3768014 Smith et al. Oct 1973 A
3775182 Patton et al. Nov 1973 A
3776832 Oswin et al. Dec 1973 A
3785939 Hsu Jan 1974 A
3791871 Rowley Feb 1974 A
3826244 Salcman et al. Jul 1974 A
3837339 Aisenberg et al. Sep 1974 A
3838033 Mindt et al. Sep 1974 A
3851018 Kelly Nov 1974 A
3898984 Mandel et al. Aug 1975 A
3919051 Koch et al. Nov 1975 A
3926760 Allen et al. Dec 1975 A
3929971 Roy Dec 1975 A
3930889 Ruggiero et al. Jan 1976 A
3933593 Sternberg Jan 1976 A
3943918 Lewis Mar 1976 A
3957613 Macur May 1976 A
3964974 Banauch et al. Jun 1976 A
3966580 Janata et al. Jun 1976 A
3972320 Kalman Aug 1976 A
3979274 Newman Sep 1976 A
3982530 Storch Sep 1976 A
4008717 Kowarski Feb 1977 A
4016866 Lawton Apr 1977 A
4024312 Korpman May 1977 A
4032729 Koistinen Jun 1977 A
4036749 Anderson Jul 1977 A
4037563 Pflueger et al. Jul 1977 A
4040908 Clark, Jr. Aug 1977 A
4052754 Homsey Oct 1977 A
4055175 Clemens et al. Oct 1977 A
4059406 Fleet Nov 1977 A
4059708 Heiss, Jr. et al. Nov 1977 A
4067322 Johnson Jan 1978 A
4073713 Newman Feb 1978 A
4076596 Connery et al. Feb 1978 A
4076656 White et al. Feb 1978 A
4098574 Dappen Jul 1978 A
4100048 Pompei et al. Jul 1978 A
4120292 LeBlanc, Jr. et al. Oct 1978 A
4129128 McFarlane Dec 1978 A
4146029 Ellinwood, Jr. Mar 1979 A
4151845 Clemens May 1979 A
4154231 Russell May 1979 A
4168205 Danninger et al. Sep 1979 A
4172770 Semersky et al. Oct 1979 A
4178916 McNamara Dec 1979 A
4184429 Widmer Jan 1980 A
4193982 Avrameas et al. Mar 1980 A
4197840 Beck et al. Apr 1980 A
4206755 Klein Jun 1980 A
4215703 Willson Aug 1980 A
4224125 Nakamura et al. Sep 1980 A
4240438 Updike et al. Dec 1980 A
4240889 Yoda et al. Dec 1980 A
4241438 Kern Dec 1980 A
4245634 Albisser et al. Jan 1981 A
4247297 Berti et al. Jan 1981 A
4253469 Aslan Mar 1981 A
4255500 Hooke Mar 1981 A
4259540 Sabia Mar 1981 A
4271449 Grogan Jun 1981 A
4275225 Krespan Jun 1981 A
4282872 Franetzki et al. Aug 1981 A
4294258 Bernard Oct 1981 A
4318784 Higgins et al. Mar 1982 A
4324257 Albarda et al. Apr 1982 A
4327725 Cortese et al. May 1982 A
4331869 Rollo May 1982 A
4335255 Krespan Jun 1982 A
4340458 Lerner et al. Jul 1982 A
4344438 Schultz Aug 1982 A
4345603 Schulman Aug 1982 A
4352960 Dormer et al. Oct 1982 A
4353888 Sefton Oct 1982 A
4356074 Johnson Oct 1982 A
4357282 Anderson et al. Nov 1982 A
4360019 Portner et al. Nov 1982 A
4365637 Johnson Dec 1982 A
4366033 Richter et al. Dec 1982 A
4374013 Enfors Feb 1983 A
4375399 Havas et al. Mar 1983 A
4384586 Christiansen May 1983 A
4388166 Suzuki et al. Jun 1983 A
4390621 Bauer Jun 1983 A
4392933 Nakamura et al. Jul 1983 A
4401122 Clark, Jr. Aug 1983 A
4403847 Chrestensen Sep 1983 A
4403984 Ash et al. Sep 1983 A
4404066 Johnson Sep 1983 A
4407288 Langer et al. Oct 1983 A
4407959 Tsuji et al. Oct 1983 A
4415666 D'Orazio et al. Nov 1983 A
4417588 Houghton et al. Nov 1983 A
4418148 Oberhardt Nov 1983 A
4419535 O'Hara Dec 1983 A
4420564 Tsuji et al. Dec 1983 A
4425920 Bourland et al. Jan 1984 A
4427004 Miller et al. Jan 1984 A
4427770 Chen et al. Jan 1984 A
4431004 Bessman et al. Feb 1984 A
4431507 Nankai et al. Feb 1984 A
4436094 Cerami Mar 1984 A
4440175 Wilkins Apr 1984 A
4442841 Uehara et al. Apr 1984 A
4443218 DeCant, Jr. et al. Apr 1984 A
4444892 Malmros Apr 1984 A
4450842 Zick et al. May 1984 A
4458686 Clark, Jr. Jul 1984 A
4461691 Frank Jul 1984 A
4467811 Clark, Jr. Aug 1984 A
4469110 Slama Sep 1984 A
4476003 Frank et al. Oct 1984 A
4477314 Richter et al. Oct 1984 A
4478976 Goertz et al. Oct 1984 A
4483924 Tsuji et al. Nov 1984 A
4484987 Gough Nov 1984 A
4494950 Fischell Jan 1985 A
4498843 Schneider et al. Feb 1985 A
4499249 Nakagawa et al. Feb 1985 A
4506680 Stokes Mar 1985 A
4512348 Uchigaki et al. Apr 1985 A
RE31916 Oswin et al. Jun 1985 E
4522690 Venkatasetty Jun 1985 A
4524114 Samuels et al. Jun 1985 A
4526661 Steckhan et al. Jul 1985 A
4526948 Resnick Jul 1985 A
4527240 Kvitash Jul 1985 A
4530696 Bisera et al. Jul 1985 A
4534356 Papadakis Aug 1985 A
4534825 Koning et al. Aug 1985 A
4538616 Rogoff Sep 1985 A
4543955 Schroeppel Oct 1985 A
4544869 Pittaway Oct 1985 A
4545382 Higgins et al. Oct 1985 A
4552840 Riffer Nov 1985 A
4554927 Fussell Nov 1985 A
4560534 Kung et al. Dec 1985 A
4561443 Hogrefe et al. Dec 1985 A
4569589 Neufeld Feb 1986 A
4571292 Liu et al. Feb 1986 A
4573994 Fischell et al. Mar 1986 A
4577642 Stokes Mar 1986 A
4578215 Bradley Mar 1986 A
4581336 Malloy et al. Apr 1986 A
4583976 Ferguson Apr 1986 A
4595011 Phillips Jun 1986 A
4595479 Kimura et al. Jun 1986 A
4614760 Homan et al. Sep 1986 A
4619754 Niki et al. Oct 1986 A
4619793 Lee Oct 1986 A
4627445 Garcia et al. Dec 1986 A
4627908 Miller Dec 1986 A
4633878 Bombardien Jan 1987 A
4633881 Moore et al. Jan 1987 A
4637403 Garcia et al. Jan 1987 A
RE32361 Duggan Feb 1987 E
4648408 Hutcheson et al. Mar 1987 A
4650547 Gough Mar 1987 A
4653513 Dombrowski Mar 1987 A
4654197 Lilja et al. Mar 1987 A
4655880 Liu Apr 1987 A
4655885 Hill et al. Apr 1987 A
4658463 Sugita et al. Apr 1987 A
4663824 Kenmochi May 1987 A
4671288 Gough Jun 1987 A
4672970 Uchida et al. Jun 1987 A
4674652 Aten et al. Jun 1987 A
4679562 Luksha Jul 1987 A
4680268 Clark, Jr. Jul 1987 A
4681111 Silvian Jul 1987 A
4682602 Prohaska Jul 1987 A
4684537 Graetzel et al. Aug 1987 A
4685463 Williams Aug 1987 A
4686624 Blum et al. Aug 1987 A
4698582 Braun et al. Oct 1987 A
4699157 Shonk Oct 1987 A
4703756 Gough et al. Nov 1987 A
4711245 Higgins et al. Dec 1987 A
4711251 Stokes Dec 1987 A
4714462 DiDomenico Dec 1987 A
4714874 Morris et al. Dec 1987 A
4717673 Wrighton et al. Jan 1988 A
4718893 Dorman Jan 1988 A
4721601 Wrighton et al. Jan 1988 A
4721677 Clark, Jr. Jan 1988 A
4726378 Kaplan Feb 1988 A
4726716 McGuire Feb 1988 A
4731051 Fischell Mar 1988 A
4731726 Allen, III Mar 1988 A
4747828 Tseo May 1988 A
4749985 Corsberg Jun 1988 A
4750496 Reinhart Jun 1988 A
4753652 Langer et al. Jun 1988 A
4755173 Konopka Jul 1988 A
4757022 Shults et al. Jul 1988 A
4758323 Davis et al. Jul 1988 A
4759371 Franetzki Jul 1988 A
4759828 Young et al. Jul 1988 A
4764416 Ueyama et al. Aug 1988 A
4776904 Charlton et al. Oct 1988 A
4776944 Janata et al. Oct 1988 A
4777953 Ash et al. Oct 1988 A
4779618 Mund et al. Oct 1988 A
4781798 Gough Nov 1988 A
4784736 Lonsdale et al. Nov 1988 A
4787398 Garcia et al. Nov 1988 A
4787837 Bell Nov 1988 A
4795707 Niiyama et al. Jan 1989 A
4796634 Huntsman et al. Jan 1989 A
4803243 Fujimoto et al. Feb 1989 A
4803625 Fu et al. Feb 1989 A
4803726 Levine et al. Feb 1989 A
4805624 Yao et al. Feb 1989 A
4805625 Wyler Feb 1989 A
4810470 Burkhardt et al. Mar 1989 A
4813424 Wilkins Mar 1989 A
4815469 Cohen et al. Mar 1989 A
4820399 Senda et al. Apr 1989 A
4821733 Peck Apr 1989 A
4822337 Newhouse et al. Apr 1989 A
4826810 Aoki May 1989 A
4830959 McNeil et al. May 1989 A
4832034 Pizziconi et al. May 1989 A
4832797 Vadgama et al. May 1989 A
4835372 Gombrich et al. May 1989 A
RE32947 Dormer et al. Jun 1989 E
4836904 Armstrong et al. Jun 1989 A
4837049 Byers et al. Jun 1989 A
4838887 Idriss Jun 1989 A
4840893 Hill et al. Jun 1989 A
RE32974 Porat et al. Jul 1989 E
4844076 Lesho et al. Jul 1989 A
4845035 Fanta et al. Jul 1989 A
4848351 Finch Jul 1989 A
4849458 Reed et al. Jul 1989 A
4852573 Kennedy Aug 1989 A
4854322 Ash et al. Aug 1989 A
4856340 Garrison Aug 1989 A
4857713 Brown Aug 1989 A
4858617 Sanders Aug 1989 A
4870561 Love et al. Sep 1989 A
4871351 Feingold Oct 1989 A
4871440 Nagata et al. Oct 1989 A
4874499 Smith et al. Oct 1989 A
4874500 Madou et al. Oct 1989 A
4875486 Rapoport et al. Oct 1989 A
4882013 Turner et al. Nov 1989 A
4883057 Broderick Nov 1989 A
4886740 Vadgama Dec 1989 A
4889744 Quaid Dec 1989 A
4890620 Gough Jan 1990 A
4890621 Hakky Jan 1990 A
4891104 Liston et al. Jan 1990 A
4894137 Takizawa et al. Jan 1990 A
4896142 Aycox et al. Jan 1990 A
4897162 Lewandowski et al. Jan 1990 A
4897173 Nankai et al. Jan 1990 A
4897457 Nakamura et al. Jan 1990 A
4899839 Dessertine et al. Feb 1990 A
4900405 Otagawa et al. Feb 1990 A
4902294 Gosserez Feb 1990 A
4907857 Giuliani et al. Mar 1990 A
4909908 Ross et al. Mar 1990 A
4911794 Parce et al. Mar 1990 A
4917800 Lonsdale et al. Apr 1990 A
4919114 Miyazaki Apr 1990 A
4919141 Zier et al. Apr 1990 A
4919767 Vadgama et al. Apr 1990 A
4919770 Preidel et al. Apr 1990 A
4920969 Suzuki May 1990 A
4920977 Haynes May 1990 A
4923586 Katayama et al. May 1990 A
4925268 Iyer et al. May 1990 A
4927407 Dorman May 1990 A
4927516 Yamaguchi et al. May 1990 A
4929426 Bodai et al. May 1990 A
4931795 Gord Jun 1990 A
4934369 Maxwell Jun 1990 A
4935105 Churchouse Jun 1990 A
4935345 Guilbeau et al. Jun 1990 A
4936956 Wrighton Jun 1990 A
4938860 Wogoman Jul 1990 A
4942127 Wada et al. Jul 1990 A
4944299 Silvian Jul 1990 A
4945045 Forrest et al. Jul 1990 A
4950378 Nagata Aug 1990 A
4953552 DeMarzo Sep 1990 A
4954129 Giuliani et al. Sep 1990 A
4955861 Enegren et al. Sep 1990 A
4957115 Selker Sep 1990 A
4958148 Olson Sep 1990 A
4958632 Duggan Sep 1990 A
4963245 Weetall Oct 1990 A
4963595 Ward et al. Oct 1990 A
4968400 Shimomura et al. Nov 1990 A
4969468 Byers et al. Nov 1990 A
4970145 Bennetto et al. Nov 1990 A
4974592 Branco Dec 1990 A
4974929 Curry Dec 1990 A
4975175 Karube et al. Dec 1990 A
4979509 Hakky Dec 1990 A
4984929 Rock et al. Jan 1991 A
4986271 Wilkins Jan 1991 A
4986671 Sun et al. Jan 1991 A
4988341 Columbus et al. Jan 1991 A
4988758 Fukuda et al. Jan 1991 A
4990845 Gord Feb 1991 A
4991582 Byers et al. Feb 1991 A
4992794 Brouwers Feb 1991 A
4994068 Hufnagle Feb 1991 A
4994167 Shults et al. Feb 1991 A
4995402 Smith et al. Feb 1991 A
5001054 Wagner Mar 1991 A
5002054 Ash et al. Mar 1991 A
5002055 Merki et al. Mar 1991 A
5002572 Picha Mar 1991 A
5007427 Suzuki et al. Apr 1991 A
5007929 Quaid Apr 1991 A
5014718 Mitchen May 1991 A
5016172 Dessertine May 1991 A
5016201 Bryan et al. May 1991 A
5016631 Hogrefe May 1991 A
5019974 Beckers May 1991 A
5027499 Prohaska Jul 1991 A
5029583 Meserol et al. Jul 1991 A
5030333 Clark, Jr. Jul 1991 A
5034112 Murase et al. Jul 1991 A
5034192 Wrighton et al. Jul 1991 A
5035860 Kleingeld et al. Jul 1991 A
5036860 Leigh et al. Aug 1991 A
5036861 Sembrowich et al. Aug 1991 A
5037527 Hayashi et al. Aug 1991 A
5047044 Smith et al. Sep 1991 A
5049487 Phillips et al. Sep 1991 A
5050612 Matsumura Sep 1991 A
5055171 Peck Oct 1991 A
5058592 Whisler Oct 1991 A
5059654 Hou et al. Oct 1991 A
5063081 Cozzette et al. Nov 1991 A
5067491 Taylor et al. Nov 1991 A
5068536 Rosenthal Nov 1991 A
5070535 Hochmair et al. Dec 1991 A
5072732 Rapoport et al. Dec 1991 A
5073500 Saito et al. Dec 1991 A
5074977 Cheung et al. Dec 1991 A
5076273 Schoendorfer et al. Dec 1991 A
5077476 Rosenthal Dec 1991 A
5078854 Burgess et al. Jan 1992 A
5082550 Rishpon et al. Jan 1992 A
5082786 Nakamoto Jan 1992 A
5084828 Kaufman et al. Jan 1992 A
5088981 Howson et al. Feb 1992 A
5089112 Skotheim et al. Feb 1992 A
5094951 Rosenberg Mar 1992 A
5095904 Seligman et al. Mar 1992 A
5096560 Takai et al. Mar 1992 A
5096836 Macho et al. Mar 1992 A
5097834 Skrabal Mar 1992 A
5101814 Palti Apr 1992 A
5106365 Hernandez Apr 1992 A
5108564 Szuminsky et al. Apr 1992 A
5108819 Heller et al. Apr 1992 A
5109850 Blanco et al. May 1992 A
5111539 Hiruta et al. May 1992 A
5111818 Suzuki et al. May 1992 A
5114678 Crawford et al. May 1992 A
5120420 Nankai et al. Jun 1992 A
5120421 Glass et al. Jun 1992 A
5126034 Carter et al. Jun 1992 A
5126247 Palmer et al. Jun 1992 A
5130009 Marsoner et al. Jul 1992 A
5131441 Simpson et al. Jul 1992 A
5133856 Yamaguchi et al. Jul 1992 A
5134391 Okada Jul 1992 A
5135003 Souma Aug 1992 A
5137028 Nishimura Aug 1992 A
5139023 Stanley et al. Aug 1992 A
5140393 Hijikihigawa et al. Aug 1992 A
5140985 Schroeder et al. Aug 1992 A
5141868 Shanks et al. Aug 1992 A
5147725 Pinchuk Sep 1992 A
5153827 Coutre et al. Oct 1992 A
5160418 Mullen Nov 1992 A
5161532 Joseph Nov 1992 A
5165407 Wilson et al. Nov 1992 A
5168046 Hamamoto et al. Dec 1992 A
5171689 Kawaguri et al. Dec 1992 A
5174291 Schoonen et al. Dec 1992 A
5176632 Bernardi Jan 1993 A
5176644 Srisathapat et al. Jan 1993 A
5176662 Bartholomew et al. Jan 1993 A
5182707 Cooper et al. Jan 1993 A
5184359 Tsukamura et al. Feb 1993 A
5185256 Nankai et al. Feb 1993 A
5190038 Polson et al. Mar 1993 A
5190041 Palti Mar 1993 A
5192415 Yoshioka et al. Mar 1993 A
5192416 Wang et al. Mar 1993 A
5193539 Schulman et al. Mar 1993 A
5193540 Schulman et al. Mar 1993 A
5197322 Indravudh Mar 1993 A
5198192 Saito et al. Mar 1993 A
5198367 Aizawa et al. Mar 1993 A
5198771 Fidler et al. Mar 1993 A
5200051 Cozzette et al. Apr 1993 A
5202261 Musho et al. Apr 1993 A
5205920 Oyama et al. Apr 1993 A
5206145 Cattell Apr 1993 A
5208147 Kagenow et al. May 1993 A
5208154 Weaver et al. May 1993 A
5209229 Gilli May 1993 A
5215887 Saito Jun 1993 A
5216597 Beckers Jun 1993 A
5217442 Davis Jun 1993 A
5217595 Smith et al. Jun 1993 A
5226423 Tenerz et al. Jul 1993 A
5227042 Zawodzinski et al. Jul 1993 A
5229282 Yoshioka et al. Jul 1993 A
5231988 Wernicke et al. Aug 1993 A
5232668 Grant et al. Aug 1993 A
5234835 Nestor et al. Aug 1993 A
5235003 Ward et al. Aug 1993 A
5243696 Carr et al. Sep 1993 A
5243983 Tarr et al. Sep 1993 A
5246867 Lakowicz et al. Sep 1993 A
5249576 Goldberger et al. Oct 1993 A
5250439 Musho et al. Oct 1993 A
5251126 Kahn et al. Oct 1993 A
5257971 Lord et al. Nov 1993 A
5257980 Van Antwerp et al. Nov 1993 A
5259769 Cruise et al. Nov 1993 A
5261401 Baker et al. Nov 1993 A
5262035 Gregg et al. Nov 1993 A
5262305 Heller et al. Nov 1993 A
5264092 Skotheim et al. Nov 1993 A
5264103 Yoshioka et al. Nov 1993 A
5264104 Gregg et al. Nov 1993 A
5264106 McAleer et al. Nov 1993 A
5265888 Yamamoto et al. Nov 1993 A
5266179 Nankai et al. Nov 1993 A
5269212 Peters et al. Dec 1993 A
5269891 Colin Dec 1993 A
5271736 Picha Dec 1993 A
5271815 Wong Dec 1993 A
5272060 Hamamoto et al. Dec 1993 A
5275159 Griebel Jan 1994 A
5276610 Maeda et al. Jan 1994 A
5278079 Gubinski et al. Jan 1994 A
5279294 Anderson et al. Jan 1994 A
5279543 Glikfeld et al. Jan 1994 A
5281319 Kaneko et al. Jan 1994 A
5282848 Schmitt Feb 1994 A
5282950 Dietze et al. Feb 1994 A
5284140 Allen et al. Feb 1994 A
5284156 Schramm et al. Feb 1994 A
5284570 Savage et al. Feb 1994 A
5284748 Mroczkowski et al. Feb 1994 A
5285513 Kaufman et al. Feb 1994 A
5285792 Sjoquist et al. Feb 1994 A
5286362 Hoenes et al. Feb 1994 A
5286364 Yacynych et al. Feb 1994 A
5288636 Pollmann et al. Feb 1994 A
5291887 Stanley et al. Mar 1994 A
5293546 Tadros et al. Mar 1994 A
5298144 Spokane Mar 1994 A
5299571 Mastrototaro Apr 1994 A
5304127 Kawahara et al. Apr 1994 A
5304468 Phillips et al. Apr 1994 A
5307263 Brown Apr 1994 A
5309919 Snell et al. May 1994 A
5310469 Cunningham et al. May 1994 A
5310885 Maier et al. May 1994 A
5312361 Zadini et al. May 1994 A
5312762 Guiseppi-Elie May 1994 A
5314450 Thompson May 1994 A
5314471 Brauker et al. May 1994 A
5316008 Suga et al. May 1994 A
5318521 Slettenmark Jun 1994 A
5320098 Davidson Jun 1994 A
5320725 Gregg et al. Jun 1994 A
5322063 Allen et al. Jun 1994 A
5324303 Strong et al. Jun 1994 A
5324316 Schulman et al. Jun 1994 A
5324322 Grill et al. Jun 1994 A
5326356 Della Valle et al. Jul 1994 A
5326449 Cunningham Jul 1994 A
5328460 Lord et al. Jul 1994 A
5330521 Cohen Jul 1994 A
5330634 Wong et al. Jul 1994 A
5331555 Hashimoto et al. Jul 1994 A
5331966 Bennett et al. Jul 1994 A
5332479 Uenoyama et al. Jul 1994 A
5336204 Matyas Aug 1994 A
5337258 Dennis Aug 1994 A
5337747 Neftel Aug 1994 A
5340722 Wolfbeis et al. Aug 1994 A
5342409 Mullett Aug 1994 A
5342789 Chick et al. Aug 1994 A
5343869 Pross et al. Sep 1994 A
5344454 Clarke et al. Sep 1994 A
5348788 White Sep 1994 A
5350407 McClure et al. Sep 1994 A
5352348 Young et al. Oct 1994 A
5352351 White Oct 1994 A
5354319 Wyborny et al. Oct 1994 A
5354447 Uenoyama et al. Oct 1994 A
5354449 Band et al. Oct 1994 A
5356348 Bellio et al. Oct 1994 A
5356786 Heller et al. Oct 1994 A
5358514 Schulman et al. Oct 1994 A
5362307 Guy et al. Nov 1994 A
5364797 Olson et al. Nov 1994 A
5366609 White et al. Nov 1994 A
5368028 Palti Nov 1994 A
5368224 Richardson et al. Nov 1994 A
5368562 Blomquist et al. Nov 1994 A
5370622 Livingston et al. Dec 1994 A
5371687 Holmes, II et al. Dec 1994 A
5371734 Fischer Dec 1994 A
5372133 Hogen Esch Dec 1994 A
5372719 Afejan et al. Dec 1994 A
5375604 Kelly et al. Dec 1994 A
5376070 Purvis et al. Dec 1994 A
5376251 Kaneko et al. Dec 1994 A
5377258 Bro Dec 1994 A
5378628 Gratzel et al. Jan 1995 A
5379238 Stark Jan 1995 A
5380422 Negishi et al. Jan 1995 A
5380536 Hubbell et al. Jan 1995 A
5382346 Uenoyama et al. Jan 1995 A
5384028 Ito Jan 1995 A
5387327 Khan Feb 1995 A
5390671 Lord et al. Feb 1995 A
5391250 Cheney, II et al. Feb 1995 A
5393903 Gratzel et al. Feb 1995 A
5395504 Saurer et al. Mar 1995 A
5397848 Yang et al. Mar 1995 A
5399823 McCusker Mar 1995 A
5400782 Beaubiah Mar 1995 A
5401376 Foos et al. Mar 1995 A
5405510 Betts et al. Apr 1995 A
5407554 Saurer Apr 1995 A
5408999 Singh et al. Apr 1995 A
5410471 Alyfuku et al. Apr 1995 A
5410474 Fox Apr 1995 A
5411536 Armstrong May 1995 A
5411647 Johnson et al. May 1995 A
5411866 Luong May 1995 A
5413690 Kost et al. May 1995 A
5422246 Koopal et al. Jun 1995 A
5425717 Mohiuddin Jun 1995 A
5426032 Phillips et al. Jun 1995 A
5429129 Lovejoy et al. Jul 1995 A
5429735 Johnson et al. Jul 1995 A
5431160 Wilkins Jul 1995 A
5431691 Snell et al. Jul 1995 A
5431806 Suzuki et al. Jul 1995 A
5431921 Thombre Jul 1995 A
5433710 Van Antwerp et al. Jul 1995 A
5437973 Vadgama et al. Aug 1995 A
5437999 Diebold et al. Aug 1995 A
5438984 Schoendorfer Aug 1995 A
5445611 Eppstein et al. Aug 1995 A
5445920 Saito Aug 1995 A
5448992 Kupershmidt Sep 1995 A
5451260 Versteeg et al. Sep 1995 A
5452173 Brannon et al. Sep 1995 A
5453199 Afejan et al. Sep 1995 A
5453278 Chan et al. Sep 1995 A
5456692 Smith, Jr. et al. Oct 1995 A
5456940 Funderburk Oct 1995 A
5458140 Eppstein et al. Oct 1995 A
5460618 Harreld Oct 1995 A
5462051 Oka et al. Oct 1995 A
5462064 D'Angelo et al. Oct 1995 A
5462525 Srisathapat et al. Oct 1995 A
5462645 Albery et al. Oct 1995 A
5466218 Srisathapat et al. Nov 1995 A
5466356 Schneider et al. Nov 1995 A
5469846 Khan Nov 1995 A
5472317 Field et al. Dec 1995 A
5473990 Anderson et al. Dec 1995 A
5474552 Palti Dec 1995 A
5476460 Montalvo Dec 1995 A
5476488 Morgan et al. Dec 1995 A
5476776 Wilkins Dec 1995 A
5477855 Schindler et al. Dec 1995 A
5482008 Stafford et al. Jan 1996 A
5482473 Lord et al. Jan 1996 A
5484404 Schulman et al. Jan 1996 A
5487751 Radons et al. Jan 1996 A
5491474 Suni et al. Feb 1996 A
5494562 Maley et al. Feb 1996 A
5496453 Uenoyama et al. Mar 1996 A
5497772 Schulman et al. Mar 1996 A
5501665 Jhuboo et al. Mar 1996 A
5501956 Wada et al. Mar 1996 A
5502396 Desarzens et al. Mar 1996 A
5505709 Funderburk et al. Apr 1996 A
5505713 Van Antwerp et al. Apr 1996 A
5507288 Bocker et al. Apr 1996 A
5508171 Walling et al. Apr 1996 A
5508203 Fuller et al. Apr 1996 A
5509410 Hill et al. Apr 1996 A
5513636 Palti May 1996 A
5514103 Srisathapat et al. May 1996 A
5514253 Davis et al. May 1996 A
5518006 Mawhirt et al. May 1996 A
5518601 Foos et al. May 1996 A
5520731 Esser et al. May 1996 A
5520787 Hanagan et al. May 1996 A
5522865 Schulman et al. Jun 1996 A
5525511 D'Costa Jun 1996 A
5526120 Jina et al. Jun 1996 A
5527288 Gross et al. Jun 1996 A
5527307 Srisathapat et al. Jun 1996 A
5529676 Maley et al. Jun 1996 A
5531679 Schulman et al. Jul 1996 A
5531878 Vadgama et al. Jul 1996 A
5538007 Gorman Jul 1996 A
5538511 Van Antwerp et al. Jul 1996 A
5540828 Yacynych Jul 1996 A
5544651 Wilk Aug 1996 A
5545152 Funderburk et al. Aug 1996 A
5545191 Mann et al. Aug 1996 A
5545220 Andrews et al. Aug 1996 A
5545223 Neuenfeldt et al. Aug 1996 A
5549113 Halleck et al. Aug 1996 A
5549115 Morgan et al. Aug 1996 A
5549675 Neuenfeldt et al. Aug 1996 A
5551427 Altman Sep 1996 A
5551953 Lattin et al. Sep 1996 A
5552027 Birkle et al. Sep 1996 A
5553616 Ham et al. Sep 1996 A
5554166 Lange et al. Sep 1996 A
5556524 Albers Sep 1996 A
5558640 Pfeiler et al. Sep 1996 A
5560357 Faupel et al. Oct 1996 A
5562713 Silvian Oct 1996 A
5564439 Picha Oct 1996 A
5565085 Ikeda et al. Oct 1996 A
5567302 Song et al. Oct 1996 A
5568806 Cheney, II et al. Oct 1996 A
5569186 Lord et al. Oct 1996 A
5569212 Brown Oct 1996 A
5569462 Martinson et al. Oct 1996 A
5571395 Park et al. Nov 1996 A
5571682 Jacobs et al. Nov 1996 A
5573506 Vasko Nov 1996 A
5573647 Maley et al. Nov 1996 A
5575895 Ikeda et al. Nov 1996 A
5575930 Tietje-Girault et al. Nov 1996 A
5580527 Bell et al. Dec 1996 A
5580794 Allen Dec 1996 A
5582184 Erickson et al. Dec 1996 A
5582593 Hultman Dec 1996 A
5582697 Ikeda et al. Dec 1996 A
5582698 Flaherty et al. Dec 1996 A
5584813 Livingston et al. Dec 1996 A
5584876 Bruchman et al. Dec 1996 A
5586553 Halili et al. Dec 1996 A
5587273 Yan et al. Dec 1996 A
5588560 Benedict et al. Dec 1996 A
5589045 Hyodo Dec 1996 A
5589133 Suzuki Dec 1996 A
5589326 Deng et al. Dec 1996 A
5589563 Ward et al. Dec 1996 A
5590651 Shaffer et al. Jan 1997 A
5593390 Castellano et al. Jan 1997 A
5593440 Brauker et al. Jan 1997 A
5593852 Heller et al. Jan 1997 A
5594906 Holmes, II et al. Jan 1997 A
5596150 Arndt et al. Jan 1997 A
5596994 Bro Jan 1997 A
5601435 Quy Feb 1997 A
5601694 Maley et al. Feb 1997 A
5605152 Slate et al. Feb 1997 A
5607565 Azarnia et al. Mar 1997 A
5611900 Worden et al. Mar 1997 A
5615671 Schoonen et al. Apr 1997 A
5616222 Maley et al. Apr 1997 A
5617851 Lipkovker Apr 1997 A
5623925 Swenson et al. Apr 1997 A
5624537 Turner et al. Apr 1997 A
5628309 Brown May 1997 A
5628310 Rao et al. May 1997 A
5628890 Carter et al. May 1997 A
5629981 Nerlikar May 1997 A
5637095 Nason et al. Jun 1997 A
5640470 Lyer et al. Jun 1997 A
5640764 Strojnik Jun 1997 A
5640954 Pfeiffer et al. Jun 1997 A
5642365 Murakami et al. Jun 1997 A
5643212 Coutre et al. Jul 1997 A
5647853 Feldmann et al. Jul 1997 A
5650062 Ikeda et al. Jul 1997 A
5651767 Schulman et al. Jul 1997 A
5651869 Yoshioka et al. Jul 1997 A
5653735 Chen et al. Aug 1997 A
5653756 Clarke et al. Aug 1997 A
5653863 Glenshaw et al. Aug 1997 A
5658250 Blomquist et al. Aug 1997 A
5658330 Carlisle et al. Aug 1997 A
5660163 Schulman et al. Aug 1997 A
5662694 Lidman et al. Sep 1997 A
5665065 Colman et al. Sep 1997 A
5667983 Abel et al. Sep 1997 A
5670031 Hintsche et al. Sep 1997 A
5676820 Wang et al. Oct 1997 A
5678571 Brown Oct 1997 A
5679690 Andre et al. Oct 1997 A
5680858 Hansen et al. Oct 1997 A
5682233 Brinda Oct 1997 A
5682884 Hill et al. Nov 1997 A
5683562 Schaffar et al. Nov 1997 A
5686717 Knowles et al. Nov 1997 A
5686829 Girault Nov 1997 A
5694952 Lidman et al. Dec 1997 A
5695473 Olsen Dec 1997 A
5695623 Michel et al. Dec 1997 A
5695947 Guo et al. Dec 1997 A
5695949 Galen et al. Dec 1997 A
5696314 McCaffrey et al. Dec 1997 A
5701894 Cherry et al. Dec 1997 A
5704354 Preidel et al. Jan 1998 A
5704922 Brown Jan 1998 A
5706807 Picha Jan 1998 A
5707502 McCaffrey et al. Jan 1998 A
5708247 McAleer et al. Jan 1998 A
5710011 Forrow et al. Jan 1998 A
5710630 Essenpreis et al. Jan 1998 A
5711001 Bussan et al. Jan 1998 A
5711297 Iliff et al. Jan 1998 A
5711861 Ward et al. Jan 1998 A
5711862 Sakoda et al. Jan 1998 A
5711868 Maley et al. Jan 1998 A
5713353 Castano Feb 1998 A
5713888 Neuenfeldt et al. Feb 1998 A
5714123 Sohrab Feb 1998 A
5718234 Warden et al. Feb 1998 A
5720720 Laske et al. Feb 1998 A
5720733 Brown Feb 1998 A
5720862 Hamamoto et al. Feb 1998 A
5721783 Anderson Feb 1998 A
5722397 Eppstein Mar 1998 A
5727548 Hill et al. Mar 1998 A
5728074 Castellano et al. Mar 1998 A
5728352 Poto et al. Mar 1998 A
5730124 Yamauchi Mar 1998 A
5730654 Brown Mar 1998 A
5730714 Guy et al. Mar 1998 A
5733336 Neuenfeldt et al. Mar 1998 A
5735273 Kurnik et al. Apr 1998 A
5735285 Albert et al. Apr 1998 A
5739039 Girault et al. Apr 1998 A
5741211 Renirie et al. Apr 1998 A
5741319 Woloszko et al. Apr 1998 A
5741330 Brauker et al. Apr 1998 A
5741634 Nozoe et al. Apr 1998 A
5741688 Oxenboll et al. Apr 1998 A
5743262 Lepper, Jr. et al. Apr 1998 A
5746217 Erickson et al. May 1998 A
5746697 Swedlow et al. May 1998 A
5747453 Holladay et al. May 1998 A
5747669 Suzuki May 1998 A
5748103 Flach et al. May 1998 A
5749832 Vadgama et al. May 1998 A
5749907 Mann May 1998 A
5750926 Schulman et al. May 1998 A
5756632 Ward et al. May 1998 A
5759364 Charlton et al. Jun 1998 A
5766151 Valley et al. Jun 1998 A
5770028 Maley et al. Jun 1998 A
5771001 Cobb Jun 1998 A
5771890 Tamada Jun 1998 A
5771891 Gozani Jun 1998 A
5772586 Heinonen et al. Jun 1998 A
5776106 Matyas Jul 1998 A
5777060 Van Antwerp Jul 1998 A
5779665 Mastrototaro et al. Jul 1998 A
5781455 Hyodo Jul 1998 A
5782814 Brown et al. Jul 1998 A
5782912 Brauker et al. Jul 1998 A
5785681 Indravudh Jul 1998 A
5786439 Van Antwerp et al. Jul 1998 A
5786584 Button et al. Jul 1998 A
5787900 Butler et al. Aug 1998 A
5788678 Van Antwerp Aug 1998 A
5791344 Schulman et al. Aug 1998 A
5792117 Brown Aug 1998 A
5792668 Fuller et al. Aug 1998 A
5795543 Poto et al. Aug 1998 A
5795774 Matsumoto et al. Aug 1998 A
5798065 Picha Aug 1998 A
5800387 Duffy et al. Sep 1998 A
5800420 Gross et al. Sep 1998 A
5800529 Brauker et al. Sep 1998 A
5804047 Karube et al. Sep 1998 A
5804048 Wong et al. Sep 1998 A
5806517 Gerhardt et al. Sep 1998 A
5807315 Van Antwerp et al. Sep 1998 A
5807375 Gross et al. Sep 1998 A
5807406 Brauker et al. Sep 1998 A
5811487 Schulz, Jr. et al. Sep 1998 A
5814599 Mitragotri et al. Sep 1998 A
5820551 Hill et al. Oct 1998 A
5820570 Erickson et al. Oct 1998 A
5820622 Gross et al. Oct 1998 A
5822715 Worthington et al. Oct 1998 A
5823802 Bartley Oct 1998 A
5825488 Kohl et al. Oct 1998 A
5827179 Lichter et al. Oct 1998 A
5827183 Kurnik et al. Oct 1998 A
5827184 Netherly et al. Oct 1998 A
5828943 Brown Oct 1998 A
5830132 Robinson Nov 1998 A
5830341 Gilmartin Nov 1998 A
5832448 Brown Nov 1998 A
5833603 Kovacs et al. Nov 1998 A
5834224 Ruger et al. Nov 1998 A
5836887 Oka et al. Nov 1998 A
5836989 Shelton Nov 1998 A
5837454 Cozzette et al. Nov 1998 A
5837546 Allen et al. Nov 1998 A
5837728 Purcell Nov 1998 A
5840020 Heinonen et al. Nov 1998 A
5840148 Campbell et al. Nov 1998 A
5840240 Stenoien et al. Nov 1998 A
5842983 Abel et al. Dec 1998 A
5843140 Strojnik Dec 1998 A
5844862 Cocatre-Zilgien Dec 1998 A
5846702 Deng et al. Dec 1998 A
5846744 Athey et al. Dec 1998 A
5848991 Gross et al. Dec 1998 A
5851197 Marano et al. Dec 1998 A
5854078 Asher et al. Dec 1998 A
5854189 Kruse et al. Dec 1998 A
5857967 Frid et al. Jan 1999 A
5857983 Douglas et al. Jan 1999 A
5860917 Comanor et al. Jan 1999 A
5861009 Armstrong et al. Jan 1999 A
5861019 Sun et al. Jan 1999 A
5862803 Besson et al. Jan 1999 A
5871465 Vasko Feb 1999 A
5871499 Hahn et al. Feb 1999 A
5871514 Wiklund et al. Feb 1999 A
5872713 Douglas et al. Feb 1999 A
5872820 Upadrasta Feb 1999 A
5873990 Wojciechowski et al. Feb 1999 A
5876484 Raskin et al. Mar 1999 A
5879163 Brown et al. Mar 1999 A
5879311 Duchon et al. Mar 1999 A
5879373 Roper et al. Mar 1999 A
5880829 Kauhaniemi et al. Mar 1999 A
5882494 Van Antwerp Mar 1999 A
5885211 Eppstein et al. Mar 1999 A
5885245 Lynch et al. Mar 1999 A
5885429 Friese et al. Mar 1999 A
5887133 Brown et al. Mar 1999 A
5895235 Droz Apr 1999 A
5895371 Levitas et al. Apr 1999 A
5897493 Brown Apr 1999 A
5897578 Wiklund et al. Apr 1999 A
5898025 Burg et al. Apr 1999 A
5899855 Brown May 1999 A
5899931 Deschamp et al. May 1999 A
5904708 Goedeke May 1999 A
5913310 Brown Jun 1999 A
5913827 Gorman Jun 1999 A
5913998 Butler et al. Jun 1999 A
5914026 Blubaugh, Jr. et al. Jun 1999 A
5916445 Hjerten et al. Jun 1999 A
5917346 Gord Jun 1999 A
5918603 Brown Jul 1999 A
5919215 Wiklund et al. Jul 1999 A
5924979 Swedlow et al. Jul 1999 A
5925021 Castellano et al. Jul 1999 A
5928130 Schmidt Jul 1999 A
5931791 Saltzstein et al. Aug 1999 A
5931814 Alex et al. Aug 1999 A
5933136 Brown Aug 1999 A
5935099 Peterson et al. Aug 1999 A
5935785 Reber et al. Aug 1999 A
5940801 Brown Aug 1999 A
5942979 Luppino Aug 1999 A
5944661 Swette et al. Aug 1999 A
5945345 Blatt et al. Aug 1999 A
5947749 Rathburn Sep 1999 A
5947921 Johnson et al. Sep 1999 A
5948512 Kubota et al. Sep 1999 A
5950632 Reber et al. Sep 1999 A
5951300 Brown Sep 1999 A
5951492 Douglas et al. Sep 1999 A
5951521 Mastrototaro et al. Sep 1999 A
5951836 McAleer et al. Sep 1999 A
5954643 Van Antwerp Sep 1999 A
5954685 Tierney Sep 1999 A
5954700 Kovelman Sep 1999 A
5954954 Houck et al. Sep 1999 A
5956501 Brown Sep 1999 A
5957854 Besson et al. Sep 1999 A
5957890 Mann et al. Sep 1999 A
5957903 Mirzaee et al. Sep 1999 A
5957958 Schulman et al. Sep 1999 A
5959050 Mosbach et al. Sep 1999 A
5960403 Brown Sep 1999 A
5961451 Reber et al. Oct 1999 A
5963132 Yoakum Oct 1999 A
5964804 Brauker et al. Oct 1999 A
5964993 Blubaugh, Jr. et al. Oct 1999 A
5965380 Heller et al. Oct 1999 A
5968839 Blatt et al. Oct 1999 A
5971922 Arita et al. Oct 1999 A
5971941 Simons et al. Oct 1999 A
5972199 Heller et al. Oct 1999 A
5974124 Schlueter, Jr. et al. Oct 1999 A
5976085 Kimball et al. Nov 1999 A
5977476 Guha et al. Nov 1999 A
5981294 Blatt et al. Nov 1999 A
5985129 Gough et al. Nov 1999 A
5987352 Klein et al. Nov 1999 A
5987353 Khatchatrian et al. Nov 1999 A
5989409 Kurnik et al. Nov 1999 A
5994476 Shin et al. Nov 1999 A
5995860 Sun et al. Nov 1999 A
5995869 Cormier et al. Nov 1999 A
5997475 Bortz Dec 1999 A
5997476 Brown Dec 1999 A
5997501 Gross et al. Dec 1999 A
5998791 Matsumora Dec 1999 A
5999848 Gord et al. Dec 1999 A
5999849 Gord et al. Dec 1999 A
6001067 Shults et al. Dec 1999 A
6001471 Bries et al. Dec 1999 A
6002954 Van Antwerp et al. Dec 1999 A
6002961 Mitragotri et al. Dec 1999 A
6004441 Fujiwara et al. Dec 1999 A
6007845 Domb et al. Dec 1999 A
6011984 Van Antwerp et al. Jan 2000 A
6013113 Mika Jan 2000 A
6014577 Henning et al. Jan 2000 A
6015390 Krag Jan 2000 A
6016448 Busacker et al. Jan 2000 A
6017435 Hassard et al. Jan 2000 A
6018678 Mitragotri et al. Jan 2000 A
6020110 Williams et al. Feb 2000 A
6023629 Tamada Feb 2000 A
6024699 Surwit et al. Feb 2000 A
6026320 Carlson et al. Feb 2000 A
6027445 Von Bahr Feb 2000 A
6027459 Shain et al. Feb 2000 A
6027692 Galen et al. Feb 2000 A
6032059 Henning et al. Feb 2000 A
6032199 Lim et al. Feb 2000 A
6033866 Guo et al. Mar 2000 A
6034622 Levine Mar 2000 A
6035237 Schulman et al. Mar 2000 A
6036924 Simons et al. Mar 2000 A
6040194 Chick et al. Mar 2000 A
6041253 Kost et al. Mar 2000 A
6043437 Schulman et al. Mar 2000 A
6046056 Parce et al. Apr 2000 A
6048691 Maracas Apr 2000 A
6049727 Crothall Apr 2000 A
6051372 Bayerl et al. Apr 2000 A
6051389 Ahl et al. Apr 2000 A
6056718 Funderburk et al. May 2000 A
6057377 Sasaki et al. May 2000 A
6059946 Yukawa et al. May 2000 A
6063459 Velte May 2000 A
6063637 Arnold et al. May 2000 A
6065154 Hulings et al. May 2000 A
6066083 Slater et al. May 2000 A
6066243 Anderson et al. May 2000 A
6066448 Wohlstadter et al. May 2000 A
6067474 Schulman et al. May 2000 A
6068615 Brown et al. May 2000 A
6071249 Cunningham et al. Jun 2000 A
6071251 Cunningham et al. Jun 2000 A
6071294 Simons et al. Jun 2000 A
6071391 Gotoh et al. Jun 2000 A
6071406 Tsou Jun 2000 A
6073049 Alt et al. Jun 2000 A
6074725 Kennedy Jun 2000 A
6081735 Diab et al. Jun 2000 A
6081736 Colvin et al. Jun 2000 A
6083523 Dionne et al. Jul 2000 A
6083710 Heller et al. Jul 2000 A
6088608 Schulman et al. Jul 2000 A
6091975 Daddona et al. Jul 2000 A
6091976 Pfeiffer et al. Jul 2000 A
6093156 Cunningham et al. Jul 2000 A
6093167 Houben et al. Jul 2000 A
6093172 Funderburk et al. Jul 2000 A
6097831 Wieck et al. Aug 2000 A
6099484 Douglas et al. Aug 2000 A
6101478 Brown Aug 2000 A
6103033 Say et al. Aug 2000 A
6103533 Hassard et al. Aug 2000 A
6106780 Douglas et al. Aug 2000 A
6107083 Collins et al. Aug 2000 A
6110148 Brown et al. Aug 2000 A
6110152 Kovelman Aug 2000 A
6113537 Castano Sep 2000 A
6113578 Brown Sep 2000 A
6115634 Donders et al. Sep 2000 A
6117290 Say Sep 2000 A
6119028 Schulman et al. Sep 2000 A
6120676 Heller et al. Sep 2000 A
6121009 Heller et al. Sep 2000 A
6122351 Schlueter, Jr. et al. Sep 2000 A
6122536 Sun et al. Sep 2000 A
6123827 Wong et al. Sep 2000 A
6123902 Koch et al. Sep 2000 A
6125978 Ando et al. Oct 2000 A
6134461 Say et al. Oct 2000 A
6134504 Douglas et al. Oct 2000 A
6135978 Houben et al. Oct 2000 A
6139718 Kurnik et al. Oct 2000 A
6141573 Kurnik et al. Oct 2000 A
6142939 Eppstein et al. Nov 2000 A
6142972 Cheikh Nov 2000 A
6143164 Heller et al. Nov 2000 A
6144837 Quy Nov 2000 A
6144869 Berner et al. Nov 2000 A
6144871 Saito et al. Nov 2000 A
6144922 Douglas et al. Nov 2000 A
6148094 Kinsella Nov 2000 A
6150128 Uretsky Nov 2000 A
6151586 Brown Nov 2000 A
6153062 Saito et al. Nov 2000 A
6153069 Pottgen et al. Nov 2000 A
6154675 Juran et al. Nov 2000 A
6154676 Levine Nov 2000 A
6159147 Lichter et al. Dec 2000 A
6161095 Brown Dec 2000 A
6162611 Heller et al. Dec 2000 A
6162639 Douglas Dec 2000 A
6164284 Schulman et al. Dec 2000 A
6167362 Brown et al. Dec 2000 A
6167614 Tuttle et al. Jan 2001 B1
6168563 Brown Jan 2001 B1
6168568 Gavriely Jan 2001 B1
6169155 Alvarez et al. Jan 2001 B1
6170318 Lewis Jan 2001 B1
6171294 Southam et al. Jan 2001 B1
6175752 Say et al. Jan 2001 B1
6180416 Kurnik et al. Jan 2001 B1
6186145 Brown Feb 2001 B1
6187062 Oweis et al. Feb 2001 B1
6189536 Martinez et al. Feb 2001 B1
6192891 Gravel et al. Feb 2001 B1
6193873 Ohara et al. Feb 2001 B1
6196970 Brown Mar 2001 B1
6198957 Green Mar 2001 B1
6200265 Walsh et al. Mar 2001 B1
6200772 Vadgama et al. Mar 2001 B1
6201979 Kurnik et al. Mar 2001 B1
6201980 Darrow et al. Mar 2001 B1
6201993 Kruse et al. Mar 2001 B1
6206841 Cunningham et al. Mar 2001 B1
6206856 Mahurkar Mar 2001 B1
6207400 Kwon Mar 2001 B1
6208894 Schulman et al. Mar 2001 B1
6210272 Brown Apr 2001 B1
6210976 Sabbadini Apr 2001 B1
6212416 Ward et al. Apr 2001 B1
6212424 Robinson Apr 2001 B1
6214185 Offenbacher et al. Apr 2001 B1
6216033 Southam et al. Apr 2001 B1
6219565 Cupp et al. Apr 2001 B1
6219574 Cormier et al. Apr 2001 B1
6223083 Rosar Apr 2001 B1
6223471 Barber May 2001 B1
6224745 Baltruschat May 2001 B1
6230051 Cornier et al. May 2001 B1
6230059 Duffin May 2001 B1
6231879 Li et al. May 2001 B1
6232130 Wolf May 2001 B1
6232370 Kubota et al. May 2001 B1
6232783 Merrill May 2001 B1
6233080 Brenner et al. May 2001 B1
6233471 Berner et al. May 2001 B1
6233539 Brown May 2001 B1
6238813 Maile et al. May 2001 B1
6239925 Ardrey et al. May 2001 B1
6241704 Peterson et al. Jun 2001 B1
6241862 McAleer et al. Jun 2001 B1
6241863 Monbouquette Jun 2001 B1
6246330 Nielsen Jun 2001 B1
6246992 Brown Jun 2001 B1
6248065 Brown Jun 2001 B1
6248067 Causey, III et al. Jun 2001 B1
6248093 Moberg Jun 2001 B1
6251260 Heller et al. Jun 2001 B1
6251280 Dai et al. Jun 2001 B1
6252032 Van Antwerp et al. Jun 2001 B1
6253804 Safabash Jul 2001 B1
6254586 Mann et al. Jul 2001 B1
6256522 Schultz Jul 2001 B1
6256643 Cork et al. Jul 2001 B1
6259587 Sheldon et al. Jul 2001 B1
6259937 Schulman et al. Jul 2001 B1
6260022 Brown Jul 2001 B1
6264825 Blackburn et al. Jul 2001 B1
6266645 Simpson Jul 2001 B1
6267724 Taylor Jul 2001 B1
6268161 Han et al. Jul 2001 B1
6268913 Rising Jul 2001 B1
6270445 Dean, Jr. et al. Aug 2001 B1
6272364 Kurnik Aug 2001 B1
6272480 Tresp et al. Aug 2001 B1
6274285 Gries et al. Aug 2001 B1
6274686 Mosbach Aug 2001 B1
6275717 Gross et al. Aug 2001 B1
6280416 Van Antwerp et al. Aug 2001 B1
6280587 Matsumoto Aug 2001 B1
6281006 Heller et al. Aug 2001 B1
6283943 Dy et al. Sep 2001 B1
6284126 Kurnik et al. Sep 2001 B1
6284478 Heller et al. Sep 2001 B1
6285897 Kilcoyne et al. Sep 2001 B1
6289238 Besson et al. Sep 2001 B1
6293925 Safabash et al. Sep 2001 B1
6294281 Heller Sep 2001 B1
6295463 Stenzler Sep 2001 B1
6295506 Heinonen et al. Sep 2001 B1
6298254 Tamada Oct 2001 B2
6299578 Kurnik et al. Oct 2001 B1
6299757 Feldman et al. Oct 2001 B1
6300002 Webb et al. Oct 2001 B1
6301499 Carlson et al. Oct 2001 B1
6302855 Lav et al. Oct 2001 B1
6304766 Colvin, Jr. et al. Oct 2001 B1
6306104 Cunningham et al. Oct 2001 B1
6309351 Kurnik et al. Oct 2001 B1
6309384 Harrington et al. Oct 2001 B1
6309526 Fujiwara et al. Oct 2001 B1
6309884 Cooper et al. Oct 2001 B1
6310110 Markowitz et al. Oct 2001 B1
6312388 Marcovecchio et al. Nov 2001 B1
6315721 Schulman et al. Nov 2001 B2
6315738 Nishikawa et al. Nov 2001 B1
6319540 Van Antwerp et al. Nov 2001 B1
6319566 Polanyi et al. Nov 2001 B1
6320357 Peters et al. Nov 2001 B1
6324428 Weinberg et al. Nov 2001 B1
6325978 Labuda et al. Dec 2001 B1
6325979 Hahn et al. Dec 2001 B1
6326160 Dunn et al. Dec 2001 B1
6329161 Heller et al. Dec 2001 B1
6329929 Weijand et al. Dec 2001 B1
6330426 Brown et al. Dec 2001 B2
6330464 Colvin, Jr. et al. Dec 2001 B1
6331518 Hemm et al. Dec 2001 B2
6333189 Holladay et al. Dec 2001 B1
6334778 Brown Jan 2002 B1
6336900 Alleckson et al. Jan 2002 B1
6338790 Feldman et al. Jan 2002 B1
6340421 Vachon et al. Jan 2002 B1
6340588 Nova et al. Jan 2002 B1
6341232 Conn et al. Jan 2002 B1
6343225 Clark, Jr. Jan 2002 B1
6352505 Bortz Mar 2002 B1
6356774 Bernstein et al. Mar 2002 B1
6356776 Berner et al. Mar 2002 B1
6358237 Paukovits et al. Mar 2002 B1
6360888 McIvor et al. Mar 2002 B1
6363282 Nichols et al. Mar 2002 B1
6365670 Fry Apr 2002 B1
6366793 Bell et al. Apr 2002 B1
6366794 Moussy et al. Apr 2002 B1
6368141 Van Antwerp et al. Apr 2002 B1
6368272 Porumbescu Apr 2002 B1
6368274 Van Antwerp et al. Apr 2002 B1
6370410 Kurnik et al. Apr 2002 B2
6370941 Nakamura Apr 2002 B2
6377894 Deweese et al. Apr 2002 B1
6379301 Worthington et al. Apr 2002 B1
6379317 Kintzig et al. Apr 2002 B1
6383767 Polak May 2002 B1
6387048 Schulman et al. May 2002 B1
6391643 Chen et al. May 2002 B1
6393318 Conn et al. May 2002 B1
6394952 Anderson et al. May 2002 B1
6398562 Butler et al. Jun 2002 B1
6398727 Bui et al. Jun 2002 B1
6402689 Scarantino et al. Jun 2002 B1
6402691 Peddicord et al. Jun 2002 B1
6405066 Essenpreis et al. Jun 2002 B1
6406066 Uegane Jun 2002 B1
6406426 Reuss et al. Jun 2002 B1
6409674 Brockway et al. Jun 2002 B1
6413393 Van Antwerp et al. Jul 2002 B1
6416471 Kumar et al. Jul 2002 B1
6416651 Millar Jul 2002 B1
6418332 Mastrototaro et al. Jul 2002 B1
6418346 Nelson et al. Jul 2002 B1
6424847 Mastrototaro et al. Jul 2002 B1
6424867 Snell et al. Jul 2002 B1
6427088 Bowman, IV et al. Jul 2002 B1
6434409 Pfeiffer et al. Aug 2002 B1
6438414 Conn et al. Aug 2002 B1
6440068 Brown et al. Aug 2002 B1
6441747 Khair et al. Aug 2002 B1
6442433 Linberg Aug 2002 B1
6442637 Hawkins et al. Aug 2002 B1
6443942 Van Antwerp et al. Sep 2002 B2
6447448 Ishikawa et al. Sep 2002 B1
6447542 Weadock Sep 2002 B1
6454710 Ballerstadt et al. Sep 2002 B1
6459917 Gowda et al. Oct 2002 B1
6461496 Feldman et al. Oct 2002 B1
6462162 Van Antwerp et al. Oct 2002 B2
6464687 Ishikawa et al. Oct 2002 B1
6464848 Matsumoto Oct 2002 B1
6464849 Say et al. Oct 2002 B1
6466810 Ward et al. Oct 2002 B1
6468222 Mault et al. Oct 2002 B1
6469526 Franklin Oct 2002 B1
6471645 Warkentin et al. Oct 2002 B1
6471689 Joseph et al. Oct 2002 B1
6472122 Schulman et al. Oct 2002 B1
6475180 Peterson et al. Nov 2002 B2
6475750 Han et al. Nov 2002 B1
6477392 Honigs et al. Nov 2002 B1
6477395 Schulman et al. Nov 2002 B2
6478736 Mault Nov 2002 B1
6480730 Darrow et al. Nov 2002 B2
6481440 Gielen et al. Nov 2002 B2
6482158 Mault Nov 2002 B2
6482604 Kwon Nov 2002 B2
6484045 Holker et al. Nov 2002 B1
6484046 Say et al. Nov 2002 B1
6485138 Kubota et al. Nov 2002 B1
6485465 Moberg et al. Nov 2002 B2
6487429 Hockersmith et al. Nov 2002 B2
6494830 Wessel Dec 2002 B1
6496728 Li et al. Dec 2002 B2
6498043 Schulman et al. Dec 2002 B1
6498941 Jackson Dec 2002 B1
6505059 Kollias et al. Jan 2003 B1
6510329 Heckel Jan 2003 B2
6512939 Colvin et al. Jan 2003 B1
6513532 Mault et al. Feb 2003 B2
6514460 Fendrock Feb 2003 B1
6514718 Heller et al. Feb 2003 B2
6515593 Stark et al. Feb 2003 B1
6520326 McIvor et al. Feb 2003 B2
6520997 Pekkarinen et al. Feb 2003 B1
6526298 Khalil et al. Feb 2003 B1
6527729 Turcott Mar 2003 B1
6528584 Kennedy et al. Mar 2003 B2
6529755 Kurnik et al. Mar 2003 B2
6529772 Carlson et al. Mar 2003 B2
6530915 Eppstein et al. Mar 2003 B1
6534322 Sabbadini Mar 2003 B1
6534323 Sabbadini Mar 2003 B1
6534711 Pollack Mar 2003 B1
6535753 Raskas Mar 2003 B1
6537243 Henning et al. Mar 2003 B1
6537318 Ita et al. Mar 2003 B1
6540675 Aceti et al. Apr 2003 B2
6541107 Zhong et al. Apr 2003 B1
6544212 Galley et al. Apr 2003 B2
6545085 Kilgour et al. Apr 2003 B2
6546268 Ishikawa et al. Apr 2003 B1
6546269 Kurnik Apr 2003 B1
6547839 Zhang et al. Apr 2003 B2
6549796 Sohrab Apr 2003 B2
6551276 Mann et al. Apr 2003 B1
6551494 Feldman et al. Apr 2003 B1
6551496 Moles et al. Apr 2003 B1
6553241 Mannheimer et al. Apr 2003 B2
6553244 Lesho et al. Apr 2003 B2
6554798 Mann et al. Apr 2003 B1
6558320 Causey, III et al. May 2003 B1
6558321 Burd et al. May 2003 B1
6558351 Steil et al. May 2003 B1
6560471 Heller et al. May 2003 B1
6561978 Conn et al. May 2003 B1
6562001 Lebel et al. May 2003 B2
6564105 Starkweather et al. May 2003 B2
6565509 Plante et al. May 2003 B1
6569309 Otsuka et al. May 2003 B2
6569521 Sheridan et al. May 2003 B1
6571128 Lebel et al. May 2003 B2
6571200 Mault May 2003 B1
6572545 Knobbe et al. Jun 2003 B2
6574490 Abbink et al. Jun 2003 B2
6575905 Knobbe et al. Jun 2003 B2
6576101 Heller et al. Jun 2003 B1
6576117 Iketaki et al. Jun 2003 B1
6577893 Besson et al. Jun 2003 B1
6577899 Lebel et al. Jun 2003 B2
6579242 Bui et al. Jun 2003 B2
6579498 Eglise Jun 2003 B1
6579690 Bonnecaze et al. Jun 2003 B1
6584335 Haar et al. Jun 2003 B1
6585644 Lebel et al. Jul 2003 B2
6585675 O'Mahony et al. Jul 2003 B1
6585763 Keilman et al. Jul 2003 B1
6587705 Berner et al. Jul 2003 B1
6588644 Simon Jul 2003 B2
6589205 Meadows Jul 2003 B1
6589229 Connelly et al. Jul 2003 B1
6591125 Buse et al. Jul 2003 B1
6591126 Roeper et al. Jul 2003 B2
6594514 Berner et al. Jul 2003 B2
6595919 Berner et al. Jul 2003 B2
6595929 Stivoric et al. Jul 2003 B2
6599406 Kawanaka et al. Jul 2003 B1
6602678 Kwon et al. Aug 2003 B2
6602909 Jarowski Aug 2003 B1
6605072 Struys et al. Aug 2003 B2
6605200 Mao et al. Aug 2003 B1
6605201 Mao et al. Aug 2003 B1
6607509 Bobroff et al. Aug 2003 B2
6607658 Heller et al. Aug 2003 B1
6610012 Mault Aug 2003 B2
6612306 Mault Sep 2003 B1
6612984 Kerr Sep 2003 B1
6613379 Ward et al. Sep 2003 B2
6615078 Burson et al. Sep 2003 B1
6616819 Liamos et al. Sep 2003 B1
6618603 Varalli et al. Sep 2003 B2
6618934 Feldman et al. Sep 2003 B1
6620106 Mault Sep 2003 B2
6627058 Chan Sep 2003 B1
6629776 Bell et al. Oct 2003 B2
6629934 Mault et al. Oct 2003 B2
6633772 Ford et al. Oct 2003 B2
6635014 Starkweather et al. Oct 2003 B2
6635167 Batman et al. Oct 2003 B1
6638772 Douglas et al. Oct 2003 B1
6641533 Causey, III et al. Nov 2003 B2
6642015 Vachon et al. Nov 2003 B2
6644321 Behm Nov 2003 B1
6645142 Braig et al. Nov 2003 B2
6645181 Lavi et al. Nov 2003 B1
6648821 Lebel et al. Nov 2003 B2
6653091 Dunn et al. Nov 2003 B1
6654625 Say et al. Nov 2003 B1
6659948 Lebel et al. Dec 2003 B2
6668196 Villegas et al. Dec 2003 B1
6671554 Gibson et al. Dec 2003 B2
6673596 Sayler et al. Jan 2004 B1
6673625 Satcher, Jr. et al. Jan 2004 B2
6682938 Satcher, Jr. et al. Jan 2004 B1
6683040 Bragulla et al. Jan 2004 B2
6683535 Utke Jan 2004 B1
6687522 Tamada Feb 2004 B2
6687546 Lebel et al. Feb 2004 B2
6689056 Kilcoyne et al. Feb 2004 B1
6689091 Bui et al. Feb 2004 B2
6689265 Heller et al. Feb 2004 B2
6693069 Merz et al. Feb 2004 B2
6694158 Polak Feb 2004 B2
6694191 Starkweather et al. Feb 2004 B2
6695860 Ward et al. Feb 2004 B1
6699218 Flaherty et al. Mar 2004 B2
6699383 Lemire et al. Mar 2004 B2
6702857 Brauker et al. Mar 2004 B2
6702972 Markle Mar 2004 B1
6704587 Kumar et al. Mar 2004 B1
6705833 Tam et al. Mar 2004 B2
6708049 Berson et al. Mar 2004 B1
6711423 Colvin, Jr. Mar 2004 B2
6721587 Gough Apr 2004 B2
6723046 Lichtenstein et al. Apr 2004 B2
6728560 Kollias et al. Apr 2004 B2
6730200 Stewart et al. May 2004 B1
6731976 Penn et al. May 2004 B2
6733446 Lebel et al. May 2004 B2
6733655 Davies et al. May 2004 B1
6734162 Van Antwerp et al. May 2004 B2
6736777 Kim et al. May 2004 B2
6737401 Kim et al. May 2004 B2
6738654 Sohrab May 2004 B2
6740075 Lebel et al. May 2004 B2
6741163 Roberts May 2004 B1
6741876 Scecina et al. May 2004 B1
6741877 Shults et al. May 2004 B1
6743635 Neel et al. Jun 2004 B2
6749587 Flaherty Jun 2004 B2
6750311 Van Antwerp et al. Jun 2004 B1
6758810 Lebel et al. Jul 2004 B2
6764581 Forrow et al. Jul 2004 B1
6766183 Walsh et al. Jul 2004 B2
6766201 Von Arx et al. Jul 2004 B2
6768425 Flaherty et al. Jul 2004 B2
6770030 Schaupp et al. Aug 2004 B1
6770729 Van Antwerp et al. Aug 2004 B2
6771995 Kurnik et al. Aug 2004 B2
6773563 Matsumoto Aug 2004 B2
6773565 Kunimoto et al. Aug 2004 B2
6773671 Lewis et al. Aug 2004 B1
6780297 Matsumoto et al. Aug 2004 B2
6780871 Glick et al. Aug 2004 B2
6784274 Van Antwerp et al. Aug 2004 B2
6790178 Mault et al. Sep 2004 B1
6793802 Lee et al. Sep 2004 B2
6794195 Colvin, Jr. Sep 2004 B2
6799149 Hartlaub Sep 2004 B2
6800451 Daniloff et al. Oct 2004 B2
6800488 Khan et al. Oct 2004 B2
6801041 Karinka et al. Oct 2004 B2
6801420 Talbot et al. Oct 2004 B2
6802957 Jung et al. Oct 2004 B2
6804544 Van Antwerp et al. Oct 2004 B2
6809507 Morgan et al. Oct 2004 B2
6809653 Mann et al. Oct 2004 B1
6809807 Erickson et al. Oct 2004 B1
6810290 Lebel et al. Oct 2004 B2
6811533 Lebel et al. Nov 2004 B2
6811534 Bowman, IV et al. Nov 2004 B2
6811659 Vachon Nov 2004 B2
6812031 Carlsson Nov 2004 B1
6813516 Ujhelyi et al. Nov 2004 B2
6813519 Lebel et al. Nov 2004 B2
6814843 Bhullar et al. Nov 2004 B1
6815186 Clark, Jr. Nov 2004 B2
6816742 Kim et al. Nov 2004 B2
6827829 Kawanaka et al. Dec 2004 B2
6830549 Bui et al. Dec 2004 B2
6835553 Han et al. Dec 2004 B2
RE38681 Kurnik et al. Jan 2005 E
6837858 Cunningham et al. Jan 2005 B2
6840912 Kloepfer et al. Jan 2005 B2
6844023 Schulman et al. Jan 2005 B2
6849237 Housefield et al. Feb 2005 B2
6850790 Berner et al. Feb 2005 B2
6852500 Hoss et al. Feb 2005 B1
6852694 Van Antwerp et al. Feb 2005 B2
6853854 Proniewicz et al. Feb 2005 B1
6855115 Fonseca et al. Feb 2005 B2
6856928 Harmon Feb 2005 B2
6858403 Han et al. Feb 2005 B2
6862465 Shults et al. Mar 2005 B2
6862466 Ackerman Mar 2005 B2
6867051 Anderson et al. Mar 2005 B1
6869413 Langley et al. Mar 2005 B2
6872200 Mann et al. Mar 2005 B2
6873268 Lebel et al. Mar 2005 B2
6875386 Ward et al. Apr 2005 B1
6879849 Begic Apr 2005 B2
6881378 Zimmer et al. Apr 2005 B1
6881551 Heller et al. Apr 2005 B2
6882940 Potts et al. Apr 2005 B2
6885883 Parris et al. Apr 2005 B2
6891317 Pei et al. May 2005 B2
6892085 McIvor et al. May 2005 B2
6893552 Wang et al. May 2005 B1
6895263 Shin et al. May 2005 B2
6899683 Mault et al. May 2005 B2
6899684 Mault et al. May 2005 B2
6902905 Burson et al. Jun 2005 B2
6904301 Raskas Jun 2005 B2
6907127 Kravitz et al. Jun 2005 B1
6915147 Lebel et al. Jul 2005 B2
6918874 Hatch et al. Jul 2005 B1
6922578 Eppstein et al. Jul 2005 B2
6922584 Wang et al. Jul 2005 B2
RE38775 Kurnik et al. Aug 2005 E
6923764 Aceti et al. Aug 2005 B2
6923936 Swanson et al. Aug 2005 B2
6925317 Samuels et al. Aug 2005 B1
6925393 Kalatz et al. Aug 2005 B1
6927246 Noronha et al. Aug 2005 B2
6931327 Goode, Jr. et al. Aug 2005 B2
6932084 Estes et al. Aug 2005 B2
6932894 Mao et al. Aug 2005 B2
6936006 Sabra Aug 2005 B2
6936029 Mann et al. Aug 2005 B2
6940590 Colvin, Jr. et al. Sep 2005 B2
6941163 Ford et al. Sep 2005 B2
6946299 Neel et al. Sep 2005 B2
6946996 Koyama Sep 2005 B2
6949816 Brown et al. Sep 2005 B2
6950708 Bowman IV et al. Sep 2005 B2
6951631 Catt et al. Oct 2005 B1
6952603 Gerber et al. Oct 2005 B2
6952604 DeNuzzio et al. Oct 2005 B2
6953693 Neel et al. Oct 2005 B2
6954673 Von Arx et al. Oct 2005 B2
6955650 Mault et al. Oct 2005 B2
6957102 Silver et al. Oct 2005 B2
6957107 Rogers et al. Oct 2005 B2
6958691 Anderson et al. Oct 2005 B1
6958705 Lebel et al. Oct 2005 B2
6959247 Neel et al. Oct 2005 B2
6964871 Bell et al. Nov 2005 B2
6965791 Hitchcock et al. Nov 2005 B1
6968294 Gutta et al. Nov 2005 B2
6968375 Brown Nov 2005 B1
6972080 Tomioka et al. Dec 2005 B1
6973706 Say et al. Dec 2005 B2
6974437 Lebel et al. Dec 2005 B2
6978182 Mazar et al. Dec 2005 B2
6979326 Mann et al. Dec 2005 B2
6990366 Say et al. Jan 2006 B2
6991096 Gottlieb et al. Jan 2006 B2
6997907 Safabash et al. Feb 2006 B2
6997920 Mann et al. Feb 2006 B2
6998247 Monfre et al. Feb 2006 B2
6999810 Berner et al. Feb 2006 B2
7003336 Holker et al. Feb 2006 B2
7003341 Say et al. Feb 2006 B2
7004901 Fish Feb 2006 B2
7005048 Watanabe et al. Feb 2006 B1
7005857 Stiene et al. Feb 2006 B2
7011630 Desai et al. Mar 2006 B2
7016721 Lee et al. Mar 2006 B2
7018366 Easter Mar 2006 B2
7018568 Tierney Mar 2006 B2
7022072 Fox et al. Apr 2006 B2
7024236 Ford et al. Apr 2006 B2
7024245 Lebel et al. Apr 2006 B2
7025743 Mann et al. Apr 2006 B2
7029444 Shin et al. Apr 2006 B2
7034677 Steinthal et al. Apr 2006 B2
7039810 Nichols May 2006 B1
7041057 Faupel et al. May 2006 B1
7041468 Drucker et al. May 2006 B2
7045054 Buck et al. May 2006 B1
7049277 Bragulla et al. May 2006 B2
7052472 Miller et al. May 2006 B1
7052483 Wojcik May 2006 B2
7056302 Douglas Jun 2006 B2
7058437 Buse et al. Jun 2006 B2
7060059 Keith et al. Jun 2006 B2
7070580 Nielsen Jul 2006 B2
7072718 VonArx et al. Jul 2006 B2
7072802 Hartlaub Jul 2006 B2
7074307 Simpson et al. Jul 2006 B2
7077328 Krishnaswamy et al. Jul 2006 B2
7081195 Simpson et al. Jul 2006 B2
7082334 Boute et al. Jul 2006 B2
7098803 Mann et al. Aug 2006 B2
7108778 Simpson et al. Sep 2006 B2
7109878 Mann et al. Sep 2006 B2
7110803 Shults et al. Sep 2006 B2
7112265 McAleer et al. Sep 2006 B1
7113821 Sun et al. Sep 2006 B1
7115884 Walt et al. Oct 2006 B1
7133710 Acosta et al. Nov 2006 B2
7134999 Brauker et al. Nov 2006 B2
7135100 Lau et al. Nov 2006 B1
7136689 Shults et al. Nov 2006 B2
7137964 Flaherty Nov 2006 B2
7150975 Tamada et al. Dec 2006 B2
7153265 Vachon Dec 2006 B2
7160251 Neel et al. Jan 2007 B2
7160678 Kayyem et al. Jan 2007 B1
7163511 Conn et al. Jan 2007 B2
7166074 Reghabi et al. Jan 2007 B2
7169289 Schulein et al. Jan 2007 B2
7171274 Starkweather et al. Jan 2007 B2
7177690 Woods et al. Feb 2007 B2
7183068 Burson et al. Feb 2007 B2
7183102 Monfre et al. Feb 2007 B2
7187528 Talbot et al. Mar 2007 B2
7189341 Li et al. Mar 2007 B2
7190988 Say et al. Mar 2007 B2
7192450 Brauker et al. Mar 2007 B2
7198606 Boecker et al. Apr 2007 B2
7203549 Schommer et al. Apr 2007 B2
7207974 Safabash et al. Apr 2007 B2
7215991 Besson et al. May 2007 B2
7225535 Feldman et al. Jun 2007 B2
7226978 Tapsak et al. Jun 2007 B2
7228163 Ackerman Jun 2007 B2
7233817 Yen Jun 2007 B2
7241265 Cummings et al. Jul 2007 B2
7248912 Gough et al. Jul 2007 B2
7248929 Meadows et al. Jul 2007 B2
7261691 Asomani Aug 2007 B1
7267665 Steil et al. Sep 2007 B2
7276029 Goode, Jr. et al. Oct 2007 B2
7278983 Ireland et al. Oct 2007 B2
7295867 Berner et al. Nov 2007 B2
7299082 Feldman et al. Nov 2007 B2
7310544 Brister et al. Dec 2007 B2
7318816 Bobroff et al. Jan 2008 B2
7324012 Mann et al. Jan 2008 B2
7329239 Safabash et al. Feb 2008 B2
7344499 Prausnitz et al. Mar 2008 B1
7347973 Douglas et al. Mar 2008 B2
7354420 Steil et al. Apr 2008 B2
7364592 Carr-Brendel et al. Apr 2008 B2
7366556 Brister et al. Apr 2008 B2
7379765 Petisce et al. May 2008 B2
7384396 Samuels et al. Jun 2008 B2
7399277 Saidara et al. Jul 2008 B2
7402153 Steil et al. Jul 2008 B2
7406105 DelMain et al. Jul 2008 B2
7417164 Suri Aug 2008 B2
7424318 Brister et al. Sep 2008 B2
7426408 DeNuzzio et al. Sep 2008 B2
7460898 Brister et al. Dec 2008 B2
7467003 Brister et al. Dec 2008 B2
7467065 Neel et al. Dec 2008 B2
7471972 Rhodes et al. Dec 2008 B2
7494465 Brister et al. Feb 2009 B2
7497827 Brister et al. Mar 2009 B2
7519408 Rasdal et al. Apr 2009 B2
7519478 Bartkowiak et al. Apr 2009 B2
7523004 Bartkowiak et al. Apr 2009 B2
7525298 Morgan et al. Apr 2009 B2
7545272 Goodnow et al. Jun 2009 B2
7547281 Hayes et al. Jun 2009 B2
7583990 Goode, Jr. et al. Sep 2009 B2
7587287 Connolly et al. Sep 2009 B2
7591801 Brauker et al. Sep 2009 B2
7599726 Goode, Jr. et al. Oct 2009 B2
7613491 Boock et al. Nov 2009 B2
7615007 Shults et al. Nov 2009 B2
7618369 Hayter et al. Nov 2009 B2
7624028 Brown Nov 2009 B1
7632228 Brauker et al. Dec 2009 B2
7637868 Saint et al. Dec 2009 B2
7640048 Dobbles et al. Dec 2009 B2
7651596 Petisce et al. Jan 2010 B2
7654956 Brister et al. Feb 2010 B2
7657297 Simpson et al. Feb 2010 B2
7689437 Teller et al. Mar 2010 B1
7711402 Shults et al. May 2010 B2
7713574 Brister et al. May 2010 B2
7715893 Kamath et al. May 2010 B2
7761130 Simpson et al. Jul 2010 B2
7771352 Shults et al. Aug 2010 B2
7774145 Brauker et al. Aug 2010 B2
7775975 Brister et al. Aug 2010 B2
7778680 Goode, Jr. et al. Aug 2010 B2
7783333 Brister et al. Aug 2010 B2
7792562 Shults et al. Sep 2010 B2
7797028 Goode, Jr. et al. Sep 2010 B2
7819161 Neel et al. Oct 2010 B2
7826981 Goode, Jr. et al. Nov 2010 B2
7828728 Boock et al. Nov 2010 B2
7831287 Brister et al. Nov 2010 B2
7835777 Shults et al. Nov 2010 B2
7857760 Brister et al. Dec 2010 B2
7860545 Shults et al. Dec 2010 B2
7875293 Shults et al. Jan 2011 B2
7881763 Brauker et al. Feb 2011 B2
7883015 Ackermann et al. Feb 2011 B2
7885697 Brister et al. Feb 2011 B2
7896809 Simpson et al. Mar 2011 B2
7899511 Shults et al. Mar 2011 B2
7901354 Shults et al. Mar 2011 B2
7901394 Ireland et al. Mar 2011 B2
7914450 Goode et al. Mar 2011 B2
7914460 Melker et al. Mar 2011 B2
7925321 Goode et al. Apr 2011 B2
7933639 Goode et al. Apr 2011 B2
7955261 Goode et al. Jun 2011 B2
7955856 Neel et al. Jun 2011 B2
7959569 Goode et al. Jun 2011 B2
7979104 Kamath et al. Jul 2011 B2
7986986 Goode et al. Jul 2011 B2
8160669 Brauker et al. Apr 2012 B2
20010011224 Brown Aug 2001 A1
20010016310 Brown et al. Aug 2001 A1
20010016682 Berner et al. Aug 2001 A1
20010016683 Darrow et al. Aug 2001 A1
20010020124 Tamada Sep 2001 A1
20010029340 Mault et al. Oct 2001 A1
20010032278 Brown et al. Oct 2001 A1
20010037060 Thompson et al. Nov 2001 A1
20010037069 Carlson et al. Nov 2001 A1
20010039504 Linberg et al. Nov 2001 A1
20010041830 Varalli et al. Nov 2001 A1
20010044581 Mault Nov 2001 A1
20010044588 Mault Nov 2001 A1
20010047125 Quy Nov 2001 A1
20010049096 Brown Dec 2001 A1
20010049470 Mault et al. Dec 2001 A1
20010051768 Schulman et al. Dec 2001 A1
20010056328 Trippel et al. Dec 2001 A1
20020002326 Causey, III et al. Jan 2002 A1
20020002328 Tamada Jan 2002 A1
20020004640 Conn et al. Jan 2002 A1
20020009810 O'Connor et al. Jan 2002 A1
20020010414 Coston et al. Jan 2002 A1
20020016530 Brown Feb 2002 A1
20020016535 Martin et al. Feb 2002 A1
20020019022 Dunn et al. Feb 2002 A1
20020019330 Murray et al. Feb 2002 A1
20020019586 Teller et al. Feb 2002 A1
20020019748 Brown Feb 2002 A1
20020022883 Burg Feb 2002 A1
20020023852 McIvor et al. Feb 2002 A1
20020026111 Ackerman Feb 2002 A1
20020026937 Mault Mar 2002 A1
20020027164 Mault et al. Mar 2002 A1
20020028995 Mault Mar 2002 A1
20020040208 Flaherty et al. Apr 2002 A1
20020042090 Heller et al. Apr 2002 A1
20020042561 Schulman et al. Apr 2002 A1
20020043471 Ikeda et al. Apr 2002 A1
20020045808 Ford et al. Apr 2002 A1
20020047867 Mault et al. Apr 2002 A1
20020049482 Fabian et al. Apr 2002 A1
20020053637 Conn et al. May 2002 A1
20020055673 Van Antwerp et al. May 2002 A1
20020062069 Mault May 2002 A1
20020063060 Gascoyne et al. May 2002 A1
20020065453 Lesho et al. May 2002 A1
20020068858 Braig et al. Jun 2002 A1
20020068860 Clark, Jr. Jun 2002 A1
20020072858 Cheng Jun 2002 A1
20020077765 Mault Jun 2002 A1
20020077766 Mault Jun 2002 A1
20020081559 Brown et al. Jun 2002 A1
20020083461 Hutcheson et al. Jun 2002 A1
20020084196 Liamos et al. Jul 2002 A1
20020087056 Aceti et al. Jul 2002 A1
20020091312 Berner et al. Jul 2002 A1
20020099282 Knobbe et al. Jul 2002 A1
20020099997 Piret Jul 2002 A1
20020103425 Mault Aug 2002 A1
20020107433 Mault Aug 2002 A1
20020107476 Mann et al. Aug 2002 A1
20020109600 Mault et al. Aug 2002 A1
20020109621 Khair et al. Aug 2002 A1
20020111547 Knobbe et al. Aug 2002 A1
20020119711 Van Antwerp et al. Aug 2002 A1
20020124017 Mault Sep 2002 A1
20020128594 Das et al. Sep 2002 A1
20020130042 Moerman et al. Sep 2002 A1
20020133378 Mault et al. Sep 2002 A1
20020151796 Koulik Oct 2002 A1
20020151816 Rich et al. Oct 2002 A1
20020155615 Novikov et al. Oct 2002 A1
20020161286 Gerber et al. Oct 2002 A1
20020161288 Shin et al. Oct 2002 A1
20020169369 Ward et al. Nov 2002 A1
20020177764 Sohrab Nov 2002 A1
20020182241 Borenstein et al. Dec 2002 A1
20020188185 Sohrab Dec 2002 A1
20020188216 Kayyali et al. Dec 2002 A1
20020193885 Legeay et al. Dec 2002 A1
20020198513 Lebel et al. Dec 2002 A1
20030004457 Andersson Jan 2003 A1
20030006669 Pei et al. Jan 2003 A1
20030023171 Sato et al. Jan 2003 A1
20030023182 Mault et al. Jan 2003 A1
20030023317 Brauker et al. Jan 2003 A1
20030028089 Galley et al. Feb 2003 A1
20030028120 Mault et al. Feb 2003 A1
20030032077 Itoh et al. Feb 2003 A1
20030032867 Crothall et al. Feb 2003 A1
20030032868 Graskov et al. Feb 2003 A1
20030032874 Rhodes et al. Feb 2003 A1
20030036773 Whitehurst et al. Feb 2003 A1
20030040683 Rule et al. Feb 2003 A1
20030042137 Mao et al. Mar 2003 A1
20030050537 Wessel Mar 2003 A1
20030050546 Desai et al. Mar 2003 A1
20030059631 Al-Lamee Mar 2003 A1
20030065254 Schulman et al. Apr 2003 A1
20030065257 Mault et al. Apr 2003 A1
20030065273 Mault et al. Apr 2003 A1
20030065274 Mault et al. Apr 2003 A1
20030065275 Mault et al. Apr 2003 A1
20030065308 Lebel et al. Apr 2003 A1
20030070548 Clausen Apr 2003 A1
20030076082 Morgan et al. Apr 2003 A1
20030078481 McIvor et al. Apr 2003 A1
20030078560 Miller et al. Apr 2003 A1
20030097082 Purdy et al. May 2003 A1
20030100040 Bonnecaze et al. May 2003 A1
20030100821 Heller et al. May 2003 A1
20030105407 Pearce et al. Jun 2003 A1
20030108976 Braig et al. Jun 2003 A1
20030117296 Seely Jun 2003 A1
20030125612 Fox et al. Jul 2003 A1
20030125613 Enegren et al. Jul 2003 A1
20030130616 Steil et al. Jul 2003 A1
20030134347 Heller et al. Jul 2003 A1
20030135100 Kim et al. Jul 2003 A1
20030135333 Aceti et al. Jul 2003 A1
20030138674 Zeikus et al. Jul 2003 A1
20030153820 Berner et al. Aug 2003 A1
20030153821 Berner et al. Aug 2003 A1
20030158472 Sohrab Aug 2003 A1
20030158707 Doi Aug 2003 A1
20030168338 Gao et al. Sep 2003 A1
20030175806 Rule et al. Sep 2003 A1
20030176183 Drucker et al. Sep 2003 A1
20030176933 Lebel et al. Sep 2003 A1
20030181794 Rini et al. Sep 2003 A1
20030181851 Mann et al. Sep 2003 A1
20030181852 Mann et al. Sep 2003 A1
20030187338 Say et al. Oct 2003 A1
20030187525 Mann et al. Oct 2003 A1
20030188427 Say et al. Oct 2003 A1
20030191376 Samuels et al. Oct 2003 A1
20030191431 Mann et al. Oct 2003 A1
20030195403 Berner et al. Oct 2003 A1
20030195462 Mann et al. Oct 2003 A1
20030199744 Buse et al. Oct 2003 A1
20030199791 Boecker et al. Oct 2003 A1
20030199903 Boecker et al. Oct 2003 A1
20030208110 Mault et al. Nov 2003 A1
20030208113 Mault et al. Nov 2003 A1
20030208133 Mault Nov 2003 A1
20030208409 Mault Nov 2003 A1
20030211625 Cohan Nov 2003 A1
20030212317 Kovatchev et al. Nov 2003 A1
20030212346 Yuzhakov et al. Nov 2003 A1
20030212347 Sohrab Nov 2003 A1
20030212364 Mann et al. Nov 2003 A1
20030212379 Bylund et al. Nov 2003 A1
20030217966 Tapsak et al. Nov 2003 A1
20030225437 Ferguson Dec 2003 A1
20030226695 Mault Dec 2003 A1
20030229514 Brown Dec 2003 A2
20030232370 Trifiro Dec 2003 A1
20030235817 Bartkowiak et al. Dec 2003 A1
20040010207 Flaherty et al. Jan 2004 A1
20040011671 Shults et al. Jan 2004 A1
20040015063 DeNuzzio et al. Jan 2004 A1
20040015134 Lavi et al. Jan 2004 A1
20040018486 Dunn et al. Jan 2004 A1
20040024327 Brodnick Feb 2004 A1
20040030285 Lavi et al. Feb 2004 A1
20040030294 Mahurkar Feb 2004 A1
20040039256 Kawatahara et al. Feb 2004 A1
20040039298 Abreu Feb 2004 A1
20040039406 Jessen Feb 2004 A1
20040040840 Mao et al. Mar 2004 A1
20040045879 Shults et al. Mar 2004 A1
20040054263 Moerman et al. Mar 2004 A1
20040059201 Ginsberg Mar 2004 A1
20040068230 Estes et al. Apr 2004 A1
20040069164 Nakamura et al. Apr 2004 A1
20040072357 Stiene et al. Apr 2004 A1
20040073095 Causey, III et al. Apr 2004 A1
20040074785 Holker Apr 2004 A1
20040078219 Kaylor Apr 2004 A1
20040096959 Stiene et al. May 2004 A1
20040106857 Gough Jun 2004 A1
20040106858 Say et al. Jun 2004 A1
20040106859 Say et al. Jun 2004 A1
20040108226 Polychronakos et al. Jun 2004 A1
20040122353 Shahmirian et al. Jun 2004 A1
20040122489 Mazar et al. Jun 2004 A1
20040133131 Kuhn et al. Jul 2004 A1
20040133164 Funderburk et al. Jul 2004 A1
20040138588 Saikley et al. Jul 2004 A1
20040143173 Reghabi et al. Jul 2004 A1
20040152187 Haight et al. Aug 2004 A1
20040152622 Keith et al. Aug 2004 A1
20040153585 Kawatahara et al. Aug 2004 A1
20040162473 Sohrab Aug 2004 A1
20040164961 Bal et al. Aug 2004 A1
20040167383 Kim et al. Aug 2004 A1
20040167801 Say et al. Aug 2004 A1
20040171921 Say et al. Sep 2004 A1
20040172284 Sullivan et al. Sep 2004 A1
20040173472 Jung et al. Sep 2004 A1
20040176913 Kawatahara et al. Sep 2004 A1
20040186362 Brauker et al. Sep 2004 A1
20040186365 Jin et al. Sep 2004 A1
20040193025 Steil et al. Sep 2004 A1
20040193090 Lebel et al. Sep 2004 A1
20040199059 Brauker et al. Oct 2004 A1
20040202576 Aceti et al. Oct 2004 A1
20040204687 Mogensen et al. Oct 2004 A1
20040219664 Heller et al. Nov 2004 A1
20040225338 Lebel et al. Nov 2004 A1
20040236200 Say et al. Nov 2004 A1
20040236251 Roe et al. Nov 2004 A1
20040248204 Moerman Dec 2004 A1
20040249250 McGee et al. Dec 2004 A1
20040249253 Racchini et al. Dec 2004 A1
20040249254 Racchini et al. Dec 2004 A1
20040249999 Connolly et al. Dec 2004 A1
20040253736 Stout et al. Dec 2004 A1
20040254429 Yang Dec 2004 A1
20040254433 Bandis et al. Dec 2004 A1
20040254434 Goodnow et al. Dec 2004 A1
20040260363 Von Arx et al. Dec 2004 A1
20040263354 Mann et al. Dec 2004 A1
20050003470 Nelson et al. Jan 2005 A1
20050004439 Shin et al. Jan 2005 A1
20050006122 Burnette Jan 2005 A1
20050010087 Banet et al. Jan 2005 A1
20050010265 Baru Fassio et al. Jan 2005 A1
20050010269 Lebel et al. Jan 2005 A1
20050027177 Shin et al. Feb 2005 A1
20050027179 Berner et al. Feb 2005 A1
20050027180 Goode, Jr. et al. Feb 2005 A1
20050027181 Goode, Jr. et al. Feb 2005 A1
20050027182 Siddiqui et al. Feb 2005 A1
20050027462 Goode, Jr. et al. Feb 2005 A1
20050027463 Goode, Jr. et al. Feb 2005 A1
20050031689 Shults et al. Feb 2005 A1
20050033132 Shults et al. Feb 2005 A1
20050038332 Saidara et al. Feb 2005 A1
20050038680 McMahon Feb 2005 A1
20050043598 Goode, Jr. et al. Feb 2005 A1
20050043894 Fernandez Feb 2005 A1
20050049473 Desai et al. Mar 2005 A1
20050051427 Brauker et al. Mar 2005 A1
20050051440 Simpson et al. Mar 2005 A1
20050054909 Petisce et al. Mar 2005 A1
20050056551 White et al. Mar 2005 A1
20050056552 Simpson et al. Mar 2005 A1
20050090607 Tapsak et al. Apr 2005 A1
20050096519 DeNuzzio et al. May 2005 A1
20050101847 Routt et al. May 2005 A1
20050103625 Rhodes et al. May 2005 A1
20050112169 Brauker et al. May 2005 A1
20050113653 Fox et al. May 2005 A1
20050113657 Alarcon et al. May 2005 A1
20050113658 Jacobson et al. May 2005 A1
20050115832 Simpson et al. Jun 2005 A1
20050118726 Schultz et al. Jun 2005 A1
20050121322 Say et al. Jun 2005 A1
20050124873 Shults et al. Jun 2005 A1
20050131346 Douglas Jun 2005 A1
20050133368 Davies et al. Jun 2005 A1
20050137471 Haar et al. Jun 2005 A1
20050139489 Davies et al. Jun 2005 A1
20050143635 Kamath et al. Jun 2005 A1
20050143636 Zhang et al. Jun 2005 A1
20050143675 Neel et al. Jun 2005 A1
20050148003 Keith et al. Jul 2005 A1
20050154271 Rasdal et al. Jul 2005 A1
20050161346 Simpson et al. Jul 2005 A1
20050171503 Van Den Berghe et al. Aug 2005 A1
20050171513 Mann et al. Aug 2005 A1
20050173245 Feldman et al. Aug 2005 A1
20050176136 Burd et al. Aug 2005 A1
20050177036 Shults et al. Aug 2005 A1
20050181012 Saint et al. Aug 2005 A1
20050182306 Sloan Aug 2005 A1
20050182451 Griffin et al. Aug 2005 A1
20050183954 Hitchcock et al. Aug 2005 A1
20050187720 Goode et al. Aug 2005 A1
20050192557 Brauker et al. Sep 2005 A1
20050195930 Spital et al. Sep 2005 A1
20050199494 Say et al. Sep 2005 A1
20050203360 Brauker et al. Sep 2005 A1
20050203707 Tsutsui et al. Sep 2005 A1
20050211571 Schulein et al. Sep 2005 A1
20050214892 Kovatchev et al. Sep 2005 A1
20050215871 Feldman et al. Sep 2005 A1
20050215872 Berner et al. Sep 2005 A1
20050239154 Feldman et al. Oct 2005 A1
20050239156 Drucker et al. Oct 2005 A1
20050242479 Petisce et al. Nov 2005 A1
20050245795 Goode, Jr. et al. Nov 2005 A1
20050245799 Brauker et al. Nov 2005 A1
20050251083 Carr-Brendel et al. Nov 2005 A1
20050261563 Zhou et al. Nov 2005 A1
20050261660 Choi Nov 2005 A1
20050267780 Ray et al. Dec 2005 A1
20050271546 Gerber et al. Dec 2005 A1
20050271547 Gerber et al. Dec 2005 A1
20050272640 Doyle, III et al. Dec 2005 A1
20050272985 Kotulla et al. Dec 2005 A1
20050272989 Shah et al. Dec 2005 A1
20050277164 Drucker et al. Dec 2005 A1
20050287620 Heller et al. Dec 2005 A1
20060001538 Kraft et al. Jan 2006 A1
20060001550 Mann et al. Jan 2006 A1
20060001551 Kraft et al. Jan 2006 A1
20060003398 Heller et al. Jan 2006 A1
20060004271 Peyser et al. Jan 2006 A1
20060007017 Mann et al. Jan 2006 A1
20060015020 Neale et al. Jan 2006 A1
20060015024 Brister et al. Jan 2006 A1
20060016700 Brister et al. Jan 2006 A1
20060019327 Brister et al. Jan 2006 A1
20060020186 Brister et al. Jan 2006 A1
20060020187 Brister et al. Jan 2006 A1
20060020188 Kamath et al. Jan 2006 A1
20060020189 Brister et al. Jan 2006 A1
20060020190 Kamath et al. Jan 2006 A1
20060020191 Brister et al. Jan 2006 A1
20060020192 Brister et al. Jan 2006 A1
20060025663 Talbot et al. Feb 2006 A1
20060031094 Cohen et al. Feb 2006 A1
20060036139 Brister et al. Feb 2006 A1
20060036140 Brister et al. Feb 2006 A1
20060036141 Kamath et al. Feb 2006 A1
20060036142 Brister et al. Feb 2006 A1
20060036143 Brister et al. Feb 2006 A1
20060036144 Brister et al. Feb 2006 A1
20060036145 Brister et al. Feb 2006 A1
20060036187 Vos et al. Feb 2006 A1
20060040402 Brauker et al. Feb 2006 A1
20060047215 Newman et al. Mar 2006 A1
20060052679 Kotulla et al. Mar 2006 A1
20060058602 Kwiatkowski et al. Mar 2006 A1
20060063218 Bartkowiak et al. Mar 2006 A1
20060068208 Tapsak et al. Mar 2006 A1
20060074564 Bartkowiak et al. Apr 2006 A1
20060086624 Tapsak et al. Apr 2006 A1
20060093556 Gonda et al. May 2006 A1
20060100588 Brunnberg et al. May 2006 A1
20060155180 Brister et al. Jul 2006 A1
20060173444 Choy et al. Aug 2006 A1
20060183984 Dobbles et al. Aug 2006 A1
20060183985 Brister et al. Aug 2006 A1
20060189856 Petisce et al. Aug 2006 A1
20060189863 Peyser et al. Aug 2006 A1
20060195029 Shults et al. Aug 2006 A1
20060198864 Shults et al. Sep 2006 A1
20060200019 Petisce et al. Sep 2006 A1
20060200020 Brister et al. Sep 2006 A1
20060200022 Brauker et al. Sep 2006 A1
20060211921 Brauker et al. Sep 2006 A1
20060222566 Brauker et al. Oct 2006 A1
20060224108 Brauker et al. Oct 2006 A1
20060235285 Brister et al. Oct 2006 A1
20060247985 Liamos et al. Nov 2006 A1
20060258761 Boock et al. Nov 2006 A1
20060258929 Goode, Jr. et al. Nov 2006 A1
20060270922 Brauker et al. Nov 2006 A1
20060270923 Brauker et al. Nov 2006 A1
20070016381 Kamath et al. Jan 2007 A1
20070017805 Hodges et al. Jan 2007 A1
20070027381 Stafford Feb 2007 A1
20070027384 Brister et al. Feb 2007 A1
20070027385 Brister et al. Feb 2007 A1
20070032706 Kamath et al. Feb 2007 A1
20070032717 Brister et al. Feb 2007 A1
20070032718 Shults et al. Feb 2007 A1
20070038044 Dobbles et al. Feb 2007 A1
20070045902 Brauker et al. Mar 2007 A1
20070049873 Hansen et al. Mar 2007 A1
20070060814 Stafford Mar 2007 A1
20070066873 Kamath et al. Mar 2007 A1
20070078320 Stafford Apr 2007 A1
20070078321 Mazza et al. Apr 2007 A1
20070093704 Brister et al. Apr 2007 A1
20070106135 Sloan et al. May 2007 A1
20070149873 Say et al. Jun 2007 A1
20070149874 Say et al. Jun 2007 A1
20070151869 Heller et al. Jul 2007 A1
20070161879 Say et al. Jul 2007 A1
20070161880 Say et al. Jul 2007 A1
20070163880 Woo et al. Jul 2007 A1
20070173711 Shah et al. Jul 2007 A1
20070179370 Say et al. Aug 2007 A1
20070179372 Say et al. Aug 2007 A1
20070191699 Say et al. Aug 2007 A1
20070191700 Say et al. Aug 2007 A1
20070197889 Brister et al. Aug 2007 A1
20070197890 Boock et al. Aug 2007 A1
20070200254 Curry Aug 2007 A1
20070202672 Curry Aug 2007 A1
20070203408 Say et al. Aug 2007 A1
20070203410 Say et al. Aug 2007 A1
20070203411 Say et al. Aug 2007 A1
20070203966 Brauker et al. Aug 2007 A1
20070208244 Brauker et al. Sep 2007 A1
20070208245 Brauker et al. Sep 2007 A1
20070208246 Brauker et al. Sep 2007 A1
20070208247 Say et al. Sep 2007 A1
20070213610 Say et al. Sep 2007 A1
20070213611 Simpson et al. Sep 2007 A1
20070215491 Heller et al. Sep 2007 A1
20070218097 Heller et al. Sep 2007 A1
20070232879 Brister et al. Oct 2007 A1
20070235331 Simpson et al. Oct 2007 A1
20070244380 Say et al. Oct 2007 A1
20070249919 Say et al. Oct 2007 A1
20070249920 Say et al. Oct 2007 A1
20070249922 Peyser et al. Oct 2007 A1
20070259217 Logan Nov 2007 A1
20080021436 Wolpert et al. Jan 2008 A1
20080021666 Goode, Jr. et al. Jan 2008 A1
20080033254 Kamath et al. Feb 2008 A1
20080033271 Say et al. Feb 2008 A1
20080045824 Tapsak et al. Feb 2008 A1
20080071156 Brister et al. Mar 2008 A1
20080076997 Peyser et al. Mar 2008 A1
20080083617 Simpson et al. Apr 2008 A1
20080086039 Heller et al. Apr 2008 A1
20080086040 Heller et al. Apr 2008 A1
20080086041 Heller et al. Apr 2008 A1
20080086042 Brister et al. Apr 2008 A1
20080086043 Heller et al. Apr 2008 A1
20080086044 Brister et al. Apr 2008 A1
20080086273 Shults et al. Apr 2008 A1
20080091094 Heller et al. Apr 2008 A1
20080091095 Heller et al. Apr 2008 A1
20080091096 Say et al. Apr 2008 A1
20080108942 Brister et al. May 2008 A1
20080154101 Jain et al. Jun 2008 A1
20080167543 Say et al. Jul 2008 A1
20080183061 Goode, Jr. et al. Jul 2008 A1
20080183399 Goode, Jr. et al. Jul 2008 A1
20080187655 Markle et al. Aug 2008 A1
20080188722 Markle et al. Aug 2008 A1
20080188725 Markle et al. Aug 2008 A1
20080188731 Brister et al. Aug 2008 A1
20080189051 Goode, Jr. et al. Aug 2008 A1
20080194935 Brister et al. Aug 2008 A1
20080194936 Goode, Jr. et al. Aug 2008 A1
20080194937 Goode, Jr. et al. Aug 2008 A1
20080194938 Brister et al. Aug 2008 A1
20080195232 Carr-Brendel et al. Aug 2008 A1
20080195967 Goode, Jr. et al. Aug 2008 A1
20080197024 Simpson et al. Aug 2008 A1
20080200788 Brister et al. Aug 2008 A1
20080200789 Brister et al. Aug 2008 A1
20080200791 Simpson et al. Aug 2008 A1
20080208025 Shults et al. Aug 2008 A1
20080210557 Heller et al. Sep 2008 A1
20080214914 Say et al. Sep 2008 A1
20080214915 Brister et al. Sep 2008 A1
20080214918 Brister et al. Sep 2008 A1
20080228051 Shults et al. Sep 2008 A1
20080228054 Shults et al. Sep 2008 A1
20080242961 Brister et al. Oct 2008 A1
20080262329 Say et al. Oct 2008 A1
20080262469 Brister et al. Oct 2008 A1
20080269672 Say et al. Oct 2008 A1
20080275313 Brister et al. Nov 2008 A1
20080287764 Rasdal et al. Nov 2008 A1
20080287765 Rasdal et al. Nov 2008 A1
20080287766 Rasdal et al. Nov 2008 A1
20080296155 Shults et al. Dec 2008 A1
20080305009 Gamsey et al. Dec 2008 A1
20080305506 Suri Dec 2008 A1
20080306368 Goode, Jr. et al. Dec 2008 A1
20080306434 Dobbles et al. Dec 2008 A1
20080306435 Kamath et al. Dec 2008 A1
20080306444 Brister et al. Dec 2008 A1
20080319292 Say et al. Dec 2008 A1
20090011449 Karinka et al. Jan 2009 A1
20090012379 Goode, Jr. et al. Jan 2009 A1
20090018418 Markle et al. Jan 2009 A1
20090018424 Kamath et al. Jan 2009 A1
20090018426 Markle et al. Jan 2009 A1
20090030294 Petisce et al. Jan 2009 A1
20090030297 Miller et al. Jan 2009 A1
20090036758 Brauker et al. Feb 2009 A1
20090036763 Brauker et al. Feb 2009 A1
20090043181 Brauker et al. Feb 2009 A1
20090043182 Brauker et al. Feb 2009 A1
20090043525 Brauker et al. Feb 2009 A1
20090043541 Brauker et al. Feb 2009 A1
20090043542 Brauker et al. Feb 2009 A1
20090045055 Rhodes et al. Feb 2009 A1
20090061528 Suri Mar 2009 A1
20090062633 Brauker et al. Mar 2009 A1
20090062634 Say et al. Mar 2009 A1
20090062635 Brauker et al. Mar 2009 A1
20090069655 Say et al. Mar 2009 A1
20090069656 Say et al. Mar 2009 A1
20090069657 Say et al. Mar 2009 A1
20090069658 Say et al. Mar 2009 A1
20090076356 Simpson et al. Mar 2009 A1
20090076360 Brister et al. Mar 2009 A1
20090076361 Kamath et al. Mar 2009 A1
20090081803 Gamsey et al. Mar 2009 A1
20090089999 Say et al. Apr 2009 A1
20090093696 Say et al. Apr 2009 A1
20090099432 Say et al. Apr 2009 A1
20090099434 Liu et al. Apr 2009 A1
20090099435 Say et al. Apr 2009 A1
20090099436 Brister et al. Apr 2009 A1
20090124877 Goode, Jr. et al. May 2009 A1
20090124878 Goode, Jr. et al. May 2009 A1
20090124879 Brister et al. May 2009 A1
20090124964 Leach et al. May 2009 A1
20090131768 Simpson et al. May 2009 A1
20090131769 Leach et al. May 2009 A1
20090131776 Simpson et al. May 2009 A1
20090131777 Simpson et al. May 2009 A1
20090137886 Shariati et al. May 2009 A1
20090137887 Shariati et al. May 2009 A1
20090143659 Li et al. Jun 2009 A1
20090143660 Brister et al. Jun 2009 A1
20090156919 Brister et al. Jun 2009 A1
20090156924 Shariati et al. Jun 2009 A1
20090163781 Say et al. Jun 2009 A1
20090163788 Say et al. Jun 2009 A1
20090163789 Say et al. Jun 2009 A1
20090163790 Brister et al. Jun 2009 A1
20090163791 Brister et al. Jun 2009 A1
20090171179 Say et al. Jul 2009 A1
20090173628 Say et al. Jul 2009 A1
20090177054 Say et al. Jul 2009 A1
20090177055 Say et al. Jul 2009 A1
20090177056 Say et al. Jul 2009 A1
20090177057 Say et al. Jul 2009 A1
20090177058 Say et al. Jul 2009 A1
20090177059 Say et al. Jul 2009 A1
20090177060 Say et al. Jul 2009 A1
20090177061 Say et al. Jul 2009 A1
20090177062 Say et al. Jul 2009 A1
20090177063 Say et al. Jul 2009 A1
20090177064 Say et al. Jul 2009 A1
20090177065 Say et al. Jul 2009 A1
20090177066 Say et al. Jul 2009 A1
20090177143 Markle et al. Jul 2009 A1
20090178459 Li et al. Jul 2009 A1
20090182212 Say et al. Jul 2009 A1
20090182213 Say et al. Jul 2009 A1
20090182214 Say et al. Jul 2009 A1
20090182215 Say et al. Jul 2009 A1
20090182217 Li et al. Jul 2009 A1
20090187088 Say et al. Jul 2009 A1
20090187089 Say et al. Jul 2009 A1
20090187090 Say et al. Jul 2009 A1
20090187091 Say et al. Jul 2009 A1
20090187092 Say et al. Jul 2009 A1
20090187093 Say et al. Jul 2009 A1
20090187094 Say et al. Jul 2009 A1
20090187095 Say et al. Jul 2009 A1
20090192366 Mensinger et al. Jul 2009 A1
20090192368 Say et al. Jul 2009 A1
20090192369 Say et al. Jul 2009 A1
20090192370 Say et al. Jul 2009 A1
20090192371 Say et al. Jul 2009 A1
20090192372 Say et al. Jul 2009 A1
20090192373 Say et al. Jul 2009 A1
20090192374 Say et al. Jul 2009 A1
20090192375 Say et al. Jul 2009 A1
20090192376 Say et al. Jul 2009 A1
20090192377 Say et al. Jul 2009 A1
20090192378 Say et al. Jul 2009 A1
20090192379 Say et al. Jul 2009 A1
20090192380 Shariati et al. Jul 2009 A1
20090192722 Shariati et al. Jul 2009 A1
20090192724 Brauker et al. Jul 2009 A1
20090192745 Kamath et al. Jul 2009 A1
20090192751 Kamath et al. Jul 2009 A1
20090198115 Say et al. Aug 2009 A1
20090198116 Say et al. Aug 2009 A1
20090198175 Say et al. Aug 2009 A1
20090203978 Say et al. Aug 2009 A1
20090203981 Brauker et al. Aug 2009 A1
20090204341 Brauker et al. Aug 2009 A1
20090209838 Say et al. Aug 2009 A1
20090216100 Ebner et al. Aug 2009 A1
20090216101 Say et al. Aug 2009 A1
20090216103 Brister et al. Aug 2009 A1
20090227940 Say et al. Sep 2009 A1
20090227941 Say et al. Sep 2009 A1
20090228214 Say et al. Sep 2009 A1
20090240120 Mensinger et al. Sep 2009 A1
20090240128 Mensinger et al. Sep 2009 A1
20090240193 Mensinger et al. Sep 2009 A1
20090242399 Kamath et al. Oct 2009 A1
20090242425 Kamath et al. Oct 2009 A1
20090247855 Boock et al. Oct 2009 A1
20090247856 Boock et al. Oct 2009 A1
20090264719 Markle et al. Oct 2009 A1
20090287073 Boock et al. Nov 2009 A1
20090287074 Shults et al. Nov 2009 A1
20090299155 Yang et al. Dec 2009 A1
20090299156 Simpson et al. Dec 2009 A1
20090299162 Brauker et al. Dec 2009 A1
20090299276 Brauker et al. Dec 2009 A1
20100010324 Brauker et al. Jan 2010 A1
20100010331 Brauker et al. Jan 2010 A1
20100010332 Brauker et al. Jan 2010 A1
20100016687 Brauker et al. Jan 2010 A1
20100016698 Rasdal et al. Jan 2010 A1
20100022855 Brauker et al. Jan 2010 A1
20100030038 Brauker et al. Feb 2010 A1
20100030053 Goode, Jr. et al. Feb 2010 A1
20100030484 Brauker et al. Feb 2010 A1
20100030485 Brauker et al. Feb 2010 A1
20100036215 Goode, Jr. et al. Feb 2010 A1
20100036216 Goode, Jr. et al. Feb 2010 A1
20100036222 Goode, Jr. et al. Feb 2010 A1
20100036223 Goode, Jr. et al. Feb 2010 A1
20100036224 Goode, Jr. et al. Feb 2010 A1
20100036225 Goode, Jr. et al. Feb 2010 A1
20100041971 Goode, Jr. et al. Feb 2010 A1
20100045465 Brauker et al. Feb 2010 A1
20100049024 Saint et al. Feb 2010 A1
20100063373 Kamath et al. Mar 2010 A1
20100076283 Simpson et al. Mar 2010 A1
20100081908 Dobbles et al. Apr 2010 A1
20100081910 Brister et al. Apr 2010 A1
20100087724 Brauker et al. Apr 2010 A1
20100094111 Heller et al. Apr 2010 A1
20100096259 Zhang et al. Apr 2010 A1
20100099970 Shults et al. Apr 2010 A1
20100099971 Shults et al. Apr 2010 A1
20100119693 Tapsak et al. May 2010 A1
20100121169 Petisce et al. May 2010 A1
20100145172 Petisce et al. Jun 2010 A1
20100160760 Shults et al. Jun 2010 A1
20100161269 Kamath et al. Jun 2010 A1
20100168540 Kamath et al. Jul 2010 A1
20100168541 Kamath et al. Jul 2010 A1
20100168542 Kamath et al. Jul 2010 A1
20100168543 Kamath et al. Jul 2010 A1
20100168544 Kamath et al. Jul 2010 A1
20100168545 Kamath et al. Jul 2010 A1
20100168546 Kamath et al. Jul 2010 A1
20100168657 Kamath et al. Jul 2010 A1
20100174157 Brister et al. Jul 2010 A1
20100174158 Kamath et al. Jul 2010 A1
20100174163 Brister et al. Jul 2010 A1
20100174164 Brister et al. Jul 2010 A1
20100174165 Brister et al. Jul 2010 A1
20100174166 Brister et al. Jul 2010 A1
20100174167 Kamath et al. Jul 2010 A1
20100174168 Goode et al. Jul 2010 A1
20100179399 Goode et al. Jul 2010 A1
20100179400 Brauker et al. Jul 2010 A1
20100179401 Rasdal et al. Jul 2010 A1
20100179402 Goode et al. Jul 2010 A1
20100179404 Kamath et al. Jul 2010 A1
20100179405 Goode et al. Jul 2010 A1
20100179406 Goode et al. Jul 2010 A1
20100179407 Goode et al. Jul 2010 A1
20100179408 Kamath et al. Jul 2010 A1
20100179409 Kamath et al. Jul 2010 A1
20100185065 Goode et al. Jul 2010 A1
20100185069 Brister et al. Jul 2010 A1
20100185070 Brister et al. Jul 2010 A1
20100185071 Simpson et al. Jul 2010 A1
20100185072 Goode et al. Jul 2010 A1
20100185073 Goode et al. Jul 2010 A1
20100185074 Goode et al. Jul 2010 A1
20100185075 Brister et al. Jul 2010 A1
20100191082 Brister et al. Jul 2010 A1
20100198035 Kamath et al. Aug 2010 A1
20100198036 Kamath et al. Aug 2010 A1
20100204555 Shults et al. Aug 2010 A1
20100204559 Shults et al. Aug 2010 A1
20100212583 Brister et al. Aug 2010 A1
20100214104 Goode, Jr. et al. Aug 2010 A1
20100217106 Goode, Jr. et al. Aug 2010 A1
20100217555 Kamath et al. Aug 2010 A1
20100217557 Kamath et al. Aug 2010 A1
20100223013 Kamath et al. Sep 2010 A1
20100223022 Kamath et al. Sep 2010 A1
20100223023 Kamath et al. Sep 2010 A1
20100228109 Kamath et al. Sep 2010 A1
20100228497 Kamath et al. Sep 2010 A1
20100234707 Goode, Jr. et al. Sep 2010 A1
20100234796 Kamath et al. Sep 2010 A1
20100235106 Kamath et al. Sep 2010 A1
20100240975 Goode, Jr. et al. Sep 2010 A1
20100240976 Goode, Jr. et al. Sep 2010 A1
20100261987 Kamath et al. Oct 2010 A1
20100274107 Boock et al. Oct 2010 A1
20100280341 Boock et al. Nov 2010 A1
20100286496 Simpson et al. Nov 2010 A1
20100298684 Leach et al. Nov 2010 A1
20100305869 Brauker et al. Dec 2010 A1
20100324403 Brister et al. Dec 2010 A1
20100331644 Neale et al. Dec 2010 A1
20100331648 Kamath et al. Dec 2010 A1
20100331655 Kamath et al. Dec 2010 A1
20100331656 Mensinger et al. Dec 2010 A1
20100331657 Mensinger et al. Dec 2010 A1
20110004085 Mensinger et al. Jan 2011 A1
20110009727 Mensinger et al. Jan 2011 A1
20110024043 Boock et al. Feb 2011 A1
20110024307 Simpson et al. Feb 2011 A1
20110027127 Simpson et al. Feb 2011 A1
20110027453 Boock et al. Feb 2011 A1
20110027458 Boock et al. Feb 2011 A1
20110028815 Simpson et al. Feb 2011 A1
20110028816 Simpson et al. Feb 2011 A1
20110046467 Simpson et al. Feb 2011 A1
Foreign Referenced Citations (272)
Number Date Country
2002246889 Dec 2005 AU
2433144 Aug 2002 CA
1735375 Feb 2006 CN
100407988 Aug 2008 CN
2903216 Aug 1979 DE
227029 Sep 1985 DE
3934299 Oct 1990 DE
4234553 Jan 1995 DE
4401400 Jul 1995 DE
0010375 Apr 1980 EP
1579690 Nov 1980 EP
0026995 Apr 1981 EP
0048090 Mar 1982 EP
0078636 May 1983 EP
0080304 Jun 1983 EP
0096228 Dec 1983 EP
0096288 Dec 1983 EP
0098592 Jan 1984 EP
0107634 May 1984 EP
0125139 Nov 1984 EP
0127958 Dec 1984 EP
0136362 Apr 1985 EP
0170375 Feb 1986 EP
0177743 Apr 1986 EP
0184909 Jun 1986 EP
0206218 Dec 1986 EP
0230472 Aug 1987 EP
0241309 Oct 1987 EP
0245073 Nov 1987 EP
0255291 Feb 1988 EP
0278647 Aug 1988 EP
0284518 Sep 1988 EP
0320109 Jun 1989 EP
0353328 Feb 1990 EP
0359831 Mar 1990 EP
0368209 May 1990 EP
0368290 May 1990 EP
0390390 Oct 1990 EP
0396788 Nov 1990 EP
0400918 Dec 1990 EP
0453283 Oct 1991 EP
0470290 Feb 1992 EP
0476980 Mar 1992 EP
0504835 Sep 1992 EP
0512122 Nov 1992 EP
0534074 Mar 1993 EP
0535898 Apr 1993 EP
0539625 May 1993 EP
0563795 Oct 1993 EP
0561966 Oct 1994 EP
0286118 Jan 1995 EP
0653718 May 1995 EP
0727891 Aug 1996 EP
0776628 Jun 1997 EP
0800082 Oct 1997 EP
0817809 Jan 1998 EP
0838230 Apr 1998 EP
0880936 Dec 1998 EP
0885932 Dec 1998 EP
0967788 Dec 1999 EP
0970655 Jan 2000 EP
0995805 Apr 2000 EP
1034734 Sep 2000 EP
1048264 Nov 2000 EP
1077634 Feb 2001 EP
1078258 Feb 2001 EP
1355568 Oct 2003 EP
2187555 May 2010 EP
2201969 Jun 2010 EP
2305107 Apr 2011 EP
2305108 Apr 2011 EP
2656423 Jun 1991 FR
2760962 Sep 1998 FR
1394171 May 1975 GB
1442303 Jul 1976 GB
1579690 Nov 1980 GB
1599241 Sep 1981 GB
2073891 Oct 1981 GB
2149918 Jun 1985 GB
2154003 Aug 1985 GB
2194892 Mar 1988 GB
2204408 Nov 1988 GB
2225637 Jun 1990 GB
2254436 Oct 1992 GB
54-041191 Apr 1979 JP
55-010581 Jan 1980 JP
55-010583 Jan 1980 JP
55-010584 Jan 1980 JP
55-012406 Jan 1980 JP
56-163447 Dec 1981 JP
57-070448 Apr 1982 JP
60-173457 Sep 1985 JP
60-173458 Sep 1985 JP
60-173459 Sep 1985 JP
60-210243 Oct 1985 JP
61-090050 May 1986 JP
62-083649 Apr 1987 JP
62-083849 Apr 1987 JP
62-085855 Apr 1987 JP
62-114747 May 1987 JP
63-058149 Mar 1988 JP
63-128252 May 1988 JP
63-139246 Jun 1988 JP
63-259457 Oct 1988 JP
63-294799 Dec 1988 JP
63-317757 Dec 1988 JP
63-317758 Dec 1988 JP
1-114746 May 1989 JP
1-114747 May 1989 JP
1-124060 May 1989 JP
1-134244 May 1989 JP
1-156658 Jun 1989 JP
2-062958 Mar 1990 JP
2-120655 May 1990 JP
2-287145 Nov 1990 JP
2-310457 Dec 1990 JP
3-026956 Feb 1991 JP
3-028752 Feb 1991 JP
3-202764 Sep 1991 JP
5-072171 Mar 1993 JP
5-196595 Aug 1993 JP
6-190050 Jul 1994 JP
7-055757 Mar 1995 JP
7-072585 Mar 1995 JP
7-275227 Oct 1995 JP
8-154903 Jun 1996 JP
8-285814 Nov 1996 JP
8-285815 Nov 1996 JP
9-021778 Jan 1997 JP
9-101280 Apr 1997 JP
9-285459 Nov 1997 JP
9-512200 Dec 1997 JP
10-170471 Jun 1998 JP
11-153575 Jun 1999 JP
11-192886 Jul 1999 JP
2000-000231 Jan 2000 JP
2000-060826 Feb 2000 JP
2000-116628 Apr 2000 JP
2002-189015 Jul 2002 JP
2003-108679 Apr 2003 JP
2004-520898 Jul 2004 JP
2007-203092 Aug 2007 JP
2008-062072 Mar 2008 JP
1281988 Jan 1987 SU
WO-8505119 Nov 1985 WO
WO-8600513 Jan 1986 WO
WO-8605339 Sep 1986 WO
WO-8700513 Jan 1987 WO
WO-8706040 Oct 1987 WO
WO-8902246 Mar 1989 WO
WO-8902720 Apr 1989 WO
WO-8905119 Jun 1989 WO
WO-8908713 Sep 1989 WO
WO-9000367 Jan 1990 WO
WO-9000738 Jan 1990 WO
WO-9005300 May 1990 WO
WO-9005910 May 1990 WO
WO-9010861 Sep 1990 WO
WO-9013021 Nov 1990 WO
WO-9101680 Feb 1991 WO
WO-9104704 Apr 1991 WO
WO-9115993 Oct 1991 WO
WO-9204153 Mar 1992 WO
WO-9207525 May 1992 WO
WO-9210584 Jun 1992 WO
WO-9213271 Aug 1992 WO
WO-9305703 Apr 1993 WO
WO-9314693 Aug 1993 WO
WO-9319701 Oct 1993 WO
WO-9323744 Nov 1993 WO
WO-9420602 Sep 1994 WO
WO-9422367 Oct 1994 WO
WO-9427140 Nov 1994 WO
WO-9506240 Mar 1995 WO
WO-9507109 Mar 1995 WO
WO-9601611 Jan 1996 WO
WO-9607908 Mar 1996 WO
WO-9614026 May 1996 WO
WO-9625089 Aug 1996 WO
WO-9630431 Oct 1996 WO
WO-9632076 Oct 1996 WO
WO-9635370 Nov 1996 WO
WO-9636296 Nov 1996 WO
WO-9701986 Jan 1997 WO
WO-9702847 Jan 1997 WO
WO-9706727 Feb 1997 WO
WO-9719344 May 1997 WO
WO-9720207 Jun 1997 WO
WO-9728737 Aug 1997 WO
WO-9741421 Nov 1997 WO
WO-9742882 Nov 1997 WO
WO-9742883 Nov 1997 WO
WO-9742886 Nov 1997 WO
WO-9742888 Nov 1997 WO
WO-9743962 Nov 1997 WO
WO-9746868 Dec 1997 WO
WO-9809167 Mar 1998 WO
WO-9810699 Mar 1998 WO
WO-9819159 May 1998 WO
WO-9824358 Jun 1998 WO
WO-9824366 Jun 1998 WO
WO-9852045 Nov 1998 WO
WO-9852293 Nov 1998 WO
WO-9856293 Dec 1998 WO
WO-9905966 Feb 1999 WO
WO-9913574 Mar 1999 WO
WO-9932883 Jul 1999 WO
WO-9948419 Sep 1999 WO
WO-9956613 Nov 1999 WO
WO-9958051 Nov 1999 WO
WO-9958973 Nov 1999 WO
WO-0013580 Mar 2000 WO
WO-0018294 Apr 2000 WO
WO-0019887 Apr 2000 WO
WO-0020626 Apr 2000 WO
WO-0032098 Jun 2000 WO
WO-0033065 Jun 2000 WO
WO-0049940 Aug 2000 WO
WO-0059370 Oct 2000 WO
WO-0059373 Oct 2000 WO
WO-0062664 Oct 2000 WO
WO-0062665 Oct 2000 WO
WO-0074753 Dec 2000 WO
WO-0078210 Dec 2000 WO
WO-0078992 Dec 2000 WO
WO-0112158 Feb 2001 WO
WO-0120019 Mar 2001 WO
WO-0120334 Mar 2001 WO
WO-0124038 Apr 2001 WO
WO-0133216 May 2001 WO
WO-0134243 May 2001 WO
WO-0143660 Jun 2001 WO
WO-01052727 Jul 2001 WO
WO-01052935 Jul 2001 WO
WO-01054753 Aug 2001 WO
WO-01057238 Aug 2001 WO
WO-01057239 Aug 2001 WO
WO-01058348 Aug 2001 WO
WO-01067009 Sep 2001 WO
WO-0168901 Sep 2001 WO
WO-0169222 Sep 2001 WO
WO-0188524 Nov 2001 WO
WO-0188534 Nov 2001 WO
WO-0216905 Feb 2002 WO
WO-0217210 Feb 2002 WO
WO-0224065 Mar 2002 WO
WO-02058537 Aug 2002 WO
WO-02078512 Oct 2002 WO
WO-02082989 Oct 2002 WO
WO-02100266 Dec 2002 WO
WO-03072269 Sep 2003 WO
WO-03076893 Sep 2003 WO
WO-03082091 Oct 2003 WO
WO-03101862 Dec 2003 WO
WO-2004061420 Jul 2004 WO
WO-2005041766 May 2005 WO
WO-2005065542 Jul 2005 WO
WO-2005089103 Sep 2005 WO
WO-2005026689 Oct 2005 WO
WO-2006105146 Oct 2006 WO
WO-2006119084 Nov 2006 WO
WO-2007002189 Jan 2007 WO
WO-2007016399 Feb 2007 WO
WO-2007027381 Mar 2007 WO
WO-2007027788 Mar 2007 WO
WO-2007053832 May 2007 WO
WO-2007056638 May 2007 WO
WO-2007120363 Oct 2007 WO
WO-2009029662 Mar 2009 WO
WO-2011002692 Jan 2011 WO
WO-2011002693 Jan 2011 WO
WO-2011002694 Jan 2011 WO
Non-Patent Literature Citations (859)
Entry
Abel, P. U., et al., “Biosensors for In Vivo Glucose Measurement: Can We Cross the Experimental Stage”, Biosensors and Bioelectronics, vol. 17, 2002, pp. 1059-1070.
Abruna, H. D., et al., “Rectifying Interfaces Using Two-Layer Films of Electrochemically Polymerized Vinylpyridine and Vinylbipyridine Complexes of Ruthenium and Iron on Electrodes”, Journal of the American Chemical Society, vol. 103, No. 1, 1981, pp. 1-5.
Albery, W. J., et al., “Amperometric Enzyme Electrodes Part II: Conducting Salts as Electrode Materials for the Oxidation of Glucose Oxidase”, Journal of ElectroAnalytical Chemistry, vol. 194, 1985, pp. 223-235.
Albery, W. J., et al., “Amperometric Enzyme Electrodes”, Philosophical Transactions of The Royal Society of London, vol. 316, 1987, pp. 107-119.
Alcock, S. J., et al., “Continuous Analyte Monitoring to Aid Clinical Practice”, IEEE Engineering in Medicine and Biology Magazine, 1994, pp. 319-325.
Anderson, L. B., et al., “Thin-Layer Electrochemistry: Steady-State Methods of Studying Rate Processes”, Journal of ElectroAnalytical Chemistry, vol. 10, 1965, pp. 295-305.
Armour, J. C., et al., “Application of Chronic Intravascular Blood Glucose Sensor in Dogs”, Diabetes, vol. 39, 1990, pp. 1519-1526.
Asberg, P., et al., “Hydrogels of a Conducting Conjugated Polymer as 3-D Enzyme Electrode”, Biosensors & Bioelectronics, vol. 19, 2003, pp. 199-207.
Atanasov, P., et al., “Biosensor for Continuous Glucose Monitoring”, Biotechnology and Bioengineering, vol. 43, 1994, pp. 262-266.
Atanasov, P., et al., “Implantation of a Refillable Glucose Monitoring-Telemetry Device”, Biosensors & Bioelectronics, vol. 12, No. 7, 1997, pp. 669-680.
Aussedat, B., et al., “A User-Friendly Method for Calibrating a Subcutaneous Glucose Sensor-Based Hypoglycaemic Alarm”, Biosensors & Bioelectronics, vol. 12, No. 11, 1997, pp. 1061-1071.
Baker, D. A., et al., “Dynamic Concentration Challenges for Biosensor Characterization”, Biosensors & Bioelectronics, vol. 8, 1993, pp. 433-441.
Baker, D. A., et al., “Dynamic Delay and Maximal Dynamic Error in Continuous Biosensors”, Analytical Chemistry, vol. 68, No. 8, 1996, pp. 1292-1297.
Bani Amer, M. M., “An Accurate Amperometric Glucose Sensor Based Glucometer with Eliminated Cross-Sensitivity”, Journal of Medical Engineering & Technology, vol. 26, No. 5, 2002, pp. 208-213.
Bard, A. J., et al., Electrochemical Methods, 1980, pp. 173-175.
Bartlett, P. N., et al., “Covalent Binding of Electron Relays to Glucose Oxidase”, Journal of the Chemical Society, Chemical Communications, 1987, pp. 1603-1604.
Bartlett, P. N., et al., “Modification of Glucose Oxidase by Tetrathiqfulvalen”, Journal of the Chemical Society, Chemical Communications, 1990, pp. 1135-1136.
Bartlett, P. N., et al., “Strategies for the Development of Amperometric Enzyme Electrodes”, Biosensors, vol. 3, 1987/1988, pp. 359-379.
Beach, R. D., et al., “Subminiature Implantable Potentiostat and Modified Commercial Telemetry Device for Remote Glucose Monitoring”, IEEE Transactions on Instrumentation and Measurement, vol. 28, No. 28, No. 6, 1999, pp. 1239-1245.
Beech, W. A., “AX.25 Link Access Protocol for Amateur packet Radio”, Tucson Amateur Packet Radio Corporation, 1998, pp. 1-133.
Bennion, N., et al., “Alternate Site Glucose Testing: A Crossover Design”, Diabetes Technology & Therapeutics, vol. 4, No. 1, 2002, pp. 25-33.
Bindra, D. S., et al., “Design and in Vitro Studies of a Needle-Type Glucose Sensor for Subcutaneous Monitoring”, Analytical Chemistry, vol. 63, No. 17, 1991, pp. 1692-1696.
Bindra, D. S., et al., “Pulsed Amperometric Detection of Glucose in Biological Fluids at a Surface-Modified Gold Electrode”, Analytical Chemistry, vol. 61, No. 22, 1989, pp. 2566-2570.
Bisenberger, M., et al., “A Triple-Step Potential Waveform at Enzyme Multisensors with Thick-Film Gold Electrodes for Detection of Glucose and Sucrose”, Sensors and Actuators B9, vol. 28, 1995, pp. 181-189.
Bland, J. M., et al., “A Note on the Use of the Intraclass Correlation Coefficient in the Evaluation of Agreement Between Two Methods of Measurement”, Computers in Biology and Medicine, vol. 20, No. 5, 1990, pp. 337-340.
Bland, J. M., et al., “Statistical Methods for Assessing Agreement Between Two Methods of Clinical Measurement”, The Lancet, 1986, pp. 307-310.
Blank, T. B., et al., “Clinical Results From a Non-Invasive Blood Glucose Monitor”, Optical Diagnostics and Sensing of Biological Fluids and Glucose and Cholesterol Monitoring II, Proceedings of SPIE, vol. 4624, 2002, pp. 1-10.
Bobbioni-Harsch, E., et al., “Lifespan of Subcutaneous Glucose Sensors and Their Performances During Dynamic Glycaemia Changes in Rats”, Journal of Biomedical Engineering, vol. 15, 1993, pp. 457-463.
Bode, B. W., “Clinical Utility of the Continuous Glucose Monitoring System”, Diabetes Technology & Therapeutics, vol. 2, Sup. 1, 2000, pp. S35-S41.
Bode, B. W., et al., “Continuous Glucose Monitoring Used to Adjust Diabetes Therapy Improves Glycosylated Hemoglobin: A Pilot Study”, Diabetes Research and Clinical Practice, vol. 46, 1999, pp. 183-190.
Bode, B. W., et al., “Using the Continuous Glucose Monitoring System to Improve the Management of Type I Diabetes”, Diabetes Technology & Therapeutics, vol. 2, Sup. 1, 2000, pp. S43-S48.
Boedeker Plastics, Inc., “Polyethylene Specifications”, Web Page of Boedeker.com, 2007, pp. 1-3.
Bolinder, J., et al., “Microdialysis Measurement of the Absolute Glucose Concentration in Subcutaneous Adipose Tissue Allowing Glucose Monitoring in Diabetic Patients”, Diabetologia, vol. 35, 1992, pp. 1177-1180.
Bolinder, J., et al., “Self-Monitoring of Blood Glucose in Type I Diabetic Patients: Comparison with Continuous Microdialysis Measurements of Glucose in Subcutaneous Adipose Tissue During Ordinary Life Conditions”, Diabetes Care, vol. 20, No. 1, 1997, pp. 64-70.
Bott, A. W., “A Comparison of Cyclic Voltammetry and Cyclic Staircase Voltammetry”, Current Separations, vol. 16, No. 1, 1997, pp. 23-26.
Bott, A. W., “Electrochemical Methods for the Determination of Glucose”, Current Separations, vol. 17, No. 1, 1998, pp. 25-31.
Bowman, L., et al., “The Packaging of Implantable Integrated Sensors”, IEEE Transactions on Biomedical Engineering, vol. 33, No. 2, 1986, pp. 248-255.
Brandt, J., et al., “Covalent Attachment of Proteins to Polysaccharide Carriers by Means of Benzoquinone”, Biochimica et Biophysica Acta, vol. 386, 1975, pp. 196-202.
Brauker, J., et al., “Sustained Expression of High Levels of Human Factor IX from Human Cells Implanted Within an Immunoisolation Device into Athymic Rodents”, Human Gene Therapyvol. 9, No. 6, 1998, pp. 879-888.
Bremer, T. M., et al., “Benchmark Data from the Literature for Evaluation of New Glucose Sensing Technologies”, Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 409-418.
Bremer, T., et al., “Is Blood Glucose Predictable from Previous Values?”, Diabetes, vol. 48, 1999, pp. 445-451.
Brooks, S. L., et al., “Development of an On-Line Glucose Sensor for Fermentation Monitoring”, Biosensors, vol. 3, 1987/1988, pp. 45-56.
Brownlee, M., et al., “A Glucose-Controlled Insulin-Delivery System: Semisynthetic Insulin Bound to Lectin”, Science, vol. 206, 1979, 1190-1191.
Cai, Q., et al., “A Wireless, Remove Query Glucose Biosensor Based on a pH-Sensitive Polymer”, Analytical Chemistry, vol. 76, No. 14, 2004, pp. 4038-4043.
Cass, A. E., et al., “Ferricinum Ion As An Electron Acceptor for Oxido-Reductases”, Journal of ElectroAnalytical Chemistry, vol. 190, 1985, pp. 117-127.
Cass, A. E., et al., “Ferrocene-Medicated Enzyme Electrode for Amperometric Determination of Glucose”, Analytical Chemistry, vol. 56, No. 4, 1984, 667-671.
Castner, J. F., et al., “Mass Transport and Reaction Kinetic Parameters Determined Electrochemically for Immobilized Glucose Oxidase”, Biochemistry, vol. 23 No. 10, 1984, 2203-2210.
Chen, J. C., et al., “A Comparison of MAC Protocols for Wireless Local Networks Based on battery Power Consumption”, IEEE, 1998, pp. 150-157.
Chen, T., et al., “Defining the Period of Recovery of the Glucose Concentration After Its Local Perturbation by the Implantation of a Miniature Sensor”, Clinical Chemistry and Laboratory Medicine, vol. 40, No. 8, 2002, pp. 486-489.
Chia, C. W., et al., “Glucose Sensors: Toward Closed Loop Insulin Delivery”, Endocrinology and Metabolism Clinics of North America, vol. 33, 2004, pp. 175-195.
Choleau, C., et al., “Calibration of a Subcutaneous Amperometric Glucose Sensor Implanted for 7 Days in Diabetic Patients Part 2: Superiority of the One-Point Calibration Method”, Biosensors and Bioelectronics, vol. 17, 2002, pp. 647-654.
Choleau, C., et al., “Calibration of a Subcutaneous Amperometric Glucose Sensor Part 1: Effect of Measurement Uncertainties on the Determination of Sensor Sensitivity and Background Current”, Biosensors and Bioelectronics, vol. 17, 2002, pp. 641-646.
Claremont, D. J., et al., “Biosensors for Continuous In Vivo Glucose Monitoring”, Proceedings of the Annual International Conference of the IEEE Engineering in Medicine and Biology Society, vol. 10, 1988.
Clark Jr., L. C., et al., “Differential Anodic Enzyme Polarography for the Measurement of Glucose”, Oxygen Transport to Tissue: Instrumentation, Methods, and Physiology, 1973, pp. 127-133.
Clark Jr., L. C., et al., “Electrode Systems for Continuous Monitoring in Cardiovascular Surgery”, Annals New York Academy of Sciences, 1962, pp. 29-45.
Clark Jr., L. C., et al., “Long-term Stability of Electroenzymatic Glucose Sensors Implanted in Mice”, American Society of Artificial Internal Organs Transactions, vol. XXXIV, 1988, pp. 259-265.
Clarke, W. L., et al., “Evaluating Clinical Accuracy of Systems for Self-Monitoring of Blood Glucose”, Diabetes Care, vol. 10, No. 5, 1987, pp. 622-628.
Complaint, “Abbott Diabetes Care, Inc. v. Dexcom, Inc.”, filed Aug. 11, 2005.
Complaint, Amended, “Abbott Diabetes Care, Inc. v. Dexcom, Inc.”, filed Jun. 27, 2006.
Cox, D. J., et al., “Accuracy of Perceiving Blood Glucose in IDDM”, Diabetes Care, vol. 8, No. 6, 1985, pp. 529-536.
Csoregi, E., et al., “Amperometric Microbiosensors for Detection of Hydrogen Peroxide and Glucose Based on Peroxidase-Modified Carbon Fibers”, Electroanalysis, vol. 6, 1994, pp. 925-933.
Csoregi, E., et al., “Design and Optimization of a Selective Subcutaneously Implantable Glucose Electrode Based on ‘Wired’ Glucose Oxidase”, Analytical Chemistry, vol. 67, No. 7, 1995, pp. 1240-1244.
Csoregi, E., et al., “Design, Characterization, and One-Point in Vivo Calibration of a Subcutaneously Implanted Glucose Electrode”, Analytical Chemistry, vol. 66 No. 19, 1994, pp. 3131-3138.
Csoregi, E., et al., “On-Line Glucose Monitoring by Using Microdialysis Sampling and Amperometric Detection Based on ‘Wired’ Glucose Oxidase in Carbon Paste”, Mikrochimica Acta, vol. 121, 1995, pp. 31-40.
D'Arrigo, G., et al., “Porous-Si Based Bio Reactors for Glucose Monitoring and Drugs Production”, Proceedings of SPIE: Microfluids, BioMEMS, and Medical Microsystems, vol. 4982, 2003, pp. 178-184.
Dai, W. S., et al., “Hydrogel Membranes with Mesh Size Asymmetry Based on the Gradient Crosslinking of Poly(vinyl alcohol),” Journal of Membrane Science, vol. 156, 1999, pp. 67-79.
Davis, G., “Electrochemical Techniques for the Development of Amperometric Biosensors”, Biosensors, vol. 1, 1985, pp. 161-178.
Degani, Y., et al., “Direct Electrical Communication Between Chemically Modified Enzymes and Metal Electrodes. 1. Electron Transfer from Glucose Oxidase to Metal Electrodes via Electron Relays, Bound Covalently to the Enzyme”, The Journal of Physical Chemistry, vol. 91, No. 6, 1987, pp. 1285-1289.
Degani, Y., et al., “Direct Electrical Communication Between Chemically Modified Enzymes and Metal Electrodes. 2. Methods for Bonding Electron-Transfer Relays to Glucose Oxidase and D-Amino-Acid Oxidase”, Journal of the American Chemical Society, vol. 110, No. 8, 1988, pp. 2615-2620.
Degani, Y., et al., “Electrical Communication Between Redox Centers of Glucose Oxidase and Electrodes via Electrostatically and Covalently Bound Redox Polymers”, Journal of the American Chemical Society, vol. 111, 1989, pp. 2357-2358.
Denisevich, P., et al., “Unidirectional Current Flow and Charge State Trapping at Redox Polymer Interfaces on Bilayer Electrodes: Principles, Experimental Demonstration, and Theory”, Journal of the American Chemical Society, vol. 103, 1981, pp. 4727-4737.
Dicks, J. M., et al., “Ferrocene Modified Polypyrrole with Immobilised Glucose Oxidase and its Application in Amperometric Glucose Microbiosensors”, Annales de Biologie Clinique, vol. 47, 1989, pp. 607-619.
Dixon, B. M., et al., “Characterization In Vitro and In Vivo of the Oxygen Dependence of an Enzyme/Polymer Biosensors for Monitoring Brain Glucose”, Journal of Neuroscience Methods, vol. 119, 2002, pp. 135-142.
Ellis, C. D., et al., “Selectivity and Directed Charge Transfer through an Electroactive Metallopolymer Film”, Journal of the American Chemical Society, vol. 103, No. 25, 1981, pp. 7480-7483.
El-Sa'Ad, L., et al., “Moisture Absorption by Epoxy Resins: The Reverse Thermal Effect”, Journal of Materials Science, vol. 25, No. 8, 1990, pp. 3577-3582.
Engstrom, R. C., “Electrochemical Pretreatment of Glassy Carbon Electrodes”, Analytical Chemistry, vol. 54, No. 13, 1982, pp. 2310-2314.
Engstrom, R. C., et al., “Characterization of Electrochemically Pretreated Glassy Carbon Electrodes”, Analytical Chemistry, vol. 56, No. 2, 1984, pp. 136-141.
Ernst, H., et al., “Reliable Glucose Monitoring Through the Use of Microsystem Technology”, Analytical and Bioanalytical Chemistry, vol. 373, 2002, pp. 758-761.
Fare, T. L., et al., “Functional Characterization of a Conducting Polymer-Based Immunoassay System”, Biosensors & Bioelectronics, vol. 13, No. 3-4, 1998, pp. 459-470.
Feldman, B., et al., “A Continuous Glucose Sensor Based on Wired Enzyme™ Technology—Results from a 3-Day Trial in Patients with Type 1 Diabetes”, Diabetes Technology & Therapeutics, vol. 5, No. 5, 2003, pp. 769-779.
Feldman, B., et al., “Correlation of Glucose Concentrations in Interstitial Fluid and Venous Blood During Periods of Rapid Glucose Change”, Abbott Diabetes Care, Inc. Freestyle Navigator Continuous Glucose Monitor Pamphlet.
Feldman, B., et al., “Electron Transfer Kinetics at Redox Polymer/Solution Interfaces Using Microelectrodes and Twin Electrode Thin Layer Cells”, Journal of ElectroAnalytical Chemistry, vol. 194, 1985, pp. 63-81.
Fischer, H., et al., “Intramolecular Electron Transfer Medicated by 4,4′-Bypyridine and Related Bridging Groups”, Journal of the American Chemical Society, vol. 98, No. 18, 1976, pp. 5512-5517.
Flentge, F., et al., “An Enzyme-Reactor for Electrochemical Monitoring of Choline and Acetylcholine: Applications in High-Performance Liquid Chromatography, Bran Tissue, Microdialysis and Cerebrospinal Fluid,” Analytical Biochemistry, vol. 204, 1992, pp. 305-310.
Foulds, N. C., et al., “Enzyme Entrapment in Electrically Conducting Polymers: Immobilisation of Glucose Oxidase in Polypyrrole and its Application in Amperometric Glucose Sensors”, Journal of the Chemical Society, Faraday Transactions 1, vol. 82, 1986, pp. 1259-1264.
Foulds, N. C., et al , “Immobilization of Glucose Oxidase in Ferrocene-Modified Pyrrole Polymers”, Analytical Chemistry, vol. 60, No. 22, 1988, pp. 2473-2478.
Frew, J. E., et al., “Electron-Transfer Biosensors”, Philosophical Transactions of The Royal Society of London, vol. 316, 1987, pp. 95-106.
Frohnauer, M. K., et al., “Graphical Human Insulin Time-Activity Profiles Using Standardized Definitions”, Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 419-429.
Frost, M. C., et al., “Implantable Chemical Sensors for Real-Time Clinical Monitoring: Progress and Challenges”, Current Opinion in Chemical Biology, vol. 6, 2002, pp. 633-641.
Garg, S. K., et al., “Correlation of Fingerstick Blood Glucose Measurements with GlucoWatch Biographer Glucose Results in Young Subjects with Type 1 Diabetes”, Diabetes Care, vol. 22, No. 10, 1999, pp. 1708-1714.
Garg, S. K., et al., “Improved Glucose Excursions Using an Implantable Real-Time Continuous Glucose Sensor in Adults with Type 1 Diabetes”, Diabetes Care, vol. 27, No. 3, 2004, pp. 734-738.
Geller, R. L., et al., “Use of an Immunoisolation Device for Cell Transplantation and Tumor Immunotherapy”, Annals of the New York Academy of Sciences, vol. 831, 1997, pp. 438-451.
Gerritsen, M., “Problems Associated with Subcutaneously Implanted Glucose Sensors”, Diabetes Care, vol. 23, No. 2, 2000, pp. 143-145.
Gerritsen, M., et al., “Influence of Inflammatory Cells and Serum on the Performance of Implantable Glucose Sensors”, Journal of Biomedical materials Research, vol. 54, 2001, pp. 69-75.
Gerritsen, M., et al., “Performance of Subcutaneously Implanted glucose Sensors for Continuous Monitoring”, The Netherlands Journal of Medicine, vol. 54, 1999, pp. 167-179.
Gilligan, B. J., “et al., Evaluation of a Subcutaneous Glucose Sensor Out to 3 Months in a Dog Model”, Diabetes Care, vol. 17, No. 8, 1994, pp. 882-887.
Gilligan, B. J., et al., “Feasibility of Continuous Long-Term Glucose Monitoring from a Subcutaneous Glucose Sensor in Humans”, Diabetes Technology & Therapeutics, vol. 6, No. 3, 2004, pp. 378-386.
Godsland, I. F., et al., “Maximizing the Success Rate of Minimal Model Insulin Sensitivity Measurement in Humans: The Importance of Basal Glucose Levels,” Clinical Science, vol. 101, 2001, pp. 1-9.
Gorton, L., et al., “Selective Detection in Flow Analysis Based on the Combination of Immobilized Enzymes and Chemically Modified Electrodes”, Analytica Chimica Acta, vol. 250, 1991, pp. 203-248.
Gough, D. A., et al., “Immobilized Glucose Oxidase in Implantable Glucose Sensor Technology”, Diabetes Technology & Therapeutics, vol. 2, No. 3, 2000, pp. 377-380.
Graham, N. B., “Poly(ethylene oxide) and Related Hydrogels,” Hydrogels in Medicine and Pharmacy, vol. II: Polymers, Chapter 4, 1987, pp. 95-113.
Grant, R., et al., Grant & Hackh's Chemical Dictionary, 1987, pp. 88, 89, 389, 390, 398.
Gregg, B. A., et al., “Cross-Linked Redox Gels Containing Glucose Oxidase for Amperometric Bionsensor Applications”, Analytical Chemistry, vol. 62, No. 3, 1990, pp. 258-263.
Gregg, B. A., et al., “Redox Polymer Films Containing Enzymes. 1. A Redox-Conducting Epoxy Cement: Synthesis, Characterization, and Electrocatalytic Oxidation of Hydroquinone”, Journal of Physical Chemistry, vol. 95, No. 15, 1991, 5970-5975.
Gross, T. M., et al., “Efficacy and Reliability of the Continuous Glucose Monitoring System”, Diabetes Technology & Therapeutics, vol. 2, Sup. 1, 2000, pp. S19-S26.
Gross, T. M., et al., “Performance Evaluation of the MiniMed® Continuous Glucose Monitoring System During Patient Home Use”, Diabetes Technology & Therapeutics, vol. 2, No. 1, 2000, pp. 49-56.
Hale, P. D., et al., “A New Class of Amperometric Biosensor Incorporating a Polymeric Electron-Transfer Mediator”, Journal of the American Chemical Society, vol. 111, No. 9, 1989, pp. 3482-3484.
Hall, S. B., et al., “Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes: Part I: An Absorption-Controlled Mechanism”, Electrochimica Acta, vol. 43, No. 5-6, 1998, pp. 579-588.
Hall, S. B., et al., “Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes: Part II: Effect of Potential”, Electrochimica Acta, vol. 43, No. 14-15, 1998, pp. 2015-2024.
Hall, S. B., et al., “Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes: Part III: Effect of Temperature”, Electrochimica Acta, vol. 44, 1999, pp. 2455-2462.
Hall, S. B., et al., “Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes: Part IV: Phosphate Buffer Dependence”, Electrochimica Acta, vol. 44, 1999, pp. 4573-4582.
Hall, S. B., et al., “Electrochemical Oxidation of Hydrogen Peroxide at Platinum Electrodes: Part V: Inhibition by Chloride”, Electrochimica Acta, vol. 45, 2000, pp. 3573-3579.
Hamilton, “Hamilton Needle Gauge Index”, www.hamiltoncompany.com.
Harrison, D. J., et al., “Characterization of Perfluorosulfonic Acid Polymer Coated Enzyme Electrodes and a Miniatureized Integrated Potentiostat for Glucose Analysis in Whole Blood”, Analytical Chemistry, vol. 60, No. 19, 1988, pp. 2002-2007.
Hawkridge, F. M., et al., “Indirect Coulometric Titration of Biological Electron Transport Components”, Analytical Chemistry, vol. 45, No. 7, 1973, pp. 1021-1027.
Heise, T., et al., “Hypoglycemia Warning Signal and Glucose Sensors: Requirements and Concepts”, Diabetes Technology & Therapeutics, vol. 5, No. 4, 2003, pp. 563-571.
Heller, A., “Electrical Connection Enzyme Redox Centers to Electrodes”, Journal of Physical Chemistry, vol. 96, No. 9, 1990, pp. 3579-3587.
Heller, A., “Electrical Wiring of Redox Enzymes”, Accounts of Chemical Research vol. 23, No. 5, 1990, 128-134.
Heller, A., “Implanted Electrochemical Glucose Sensors for the Management of Diabetes”, Annual Review of Biomedical Engineering, vol. 1, 1999, pp. 153-175.
Heller, A., “Plugging Metal Connectors into Enzymes”, Nature Biotechnology, vol. 21, No. 6, 2003, pp. 631-632.
Heller, A., et al., “Amperometric Biosensors Based on Three-Dimensional Hydrogel-Forming Epoxy Networks”, Sensors and Actuators B, vol. 13-14, 1993, pp. 180-183.
Hitchman, M. L., “Measurement of Dissolved Oxygen: Chapter 3: Principles of Voltammetry”, Chemical Analysis, vol. 49, 1978, pp. 34-123.
Hrapovic, S., et al., “Picoamperometric Detection of Glucose at Ultrasmall Platinum-Based Biosensors: Preparation Characterization”, Analytical Chemistry, vol. 75, No. 14, 2003, pp. 3308-3315.
Huang, C. J., et al., “Electrochemical Generation of Oxygen”,Electrochemistry Research laboratory, 1972, pp. 1-115.
Ianniello, R. M., et al , “Differential Pulse Voltammetric Study of Direct Electron Transfer in Glucose Oxidase Chemically Modified Graphite Electrodes”, Analytical Chemistry, vol. 54, No. 7, 1982, pp. 1098-1101.
Ianniello, R. M., et al., “Immobilized Enzyme Chemically Modified Electrode as an Amperometric Sensor”, Analytical Chemistry, vol. 53, No. 13, pp. 2090-2095.
Ikeda, T., et al., “Glucose Oxidase-Immobilized Benzoquinone-Carbon Paste Electrode as a Glucose Sensor”, Agricultural and Biological Chemistry, vol. 49, No. 2, 1985, pp. 541-543.
Ikeda, T., et al., “Kinetics Outer-Sphere Electron Transfers Between Metal Complexes in Solutions and Polymeric Flims on Modified Electrodes”, Journal of the American Chemical Society, vol. 103, No. 25, 1981, pp. 7422-7425.
Ishikawa, M., et al., “Initial Evaluation of a 290-μm Diameter Subcutaneous Glucose Sensor: Glucose Monitoring with a Biocompatible, Flexible-Wire, Enzyme-Based Amperometric Microsensor in Diabetic and Nondiabetic Humans”, Journal of Diabetes and Its Complications, vol. 12, 1998, pp. 295-301.
Jablecki, M., et al., “Simulations of the Frequency Response of Implantable Glucose Sensors”, Analytical Chemistry, vol. 72, No. 8, 2000, pp. 1853-1859.
Jaremko, J., et al., “Advances Toward the Implantable Artificial Pancreas for Treatment of Diabetes”, Diabetes Care, vol. 21, No. 3, 1998, pp. 444-450.
Jensen, M. B., et al., “Fast Wave Forms for Pulsed Electrochemical Detection of Glucose by Incorporation of Reductive Desorption of Oxidation Products”, Analytical Chemistry, vol. 69, No. 9, 1997, pp. 1776-1781.
Jeutter, D. C., “A Transcutaneous Implanted Battery Recharging and Biotelemeter Power Switching System”, IEEE Transactions on Biomedical Engineering, vol. 29, No. 5, 1982, pp. 314-321.
Johnson, J. M., et al., “Potential-Dependent Enzymatic Activity in an Enzyme Thin-Layer Cell”, Analytical Chemistry, vol. 54, No. 8, 1982, pp. 1377-1383.
Johnson, K. W., “Reproducible Electrodeposition of Biomolecules for the Fabrication of Miniature Electroenzymatic Biosensors”, Sensors and Actuators B, vol. 5, 1991, pp. 85-89.
Johnson, K. W., et al., “In vivo Evaluation of an Electroenzymatic Glucose Sensor Implanted in Subcutaneous Tissue”, Biosensors & Bioelectronics, vol. 7, 1992, pp. 709-714.
Johnson, P. C., “Peripheral Circulation”, John Wiley & Sons, 1978, pp. 198.
Jonsson, G., et al., “An Amperometric Glucose Sensor Made by Modification of a Graphite Electrode Surface With Immobilized Glucose Oxidase and Adsorbed Mediator”, Biosensors, vol. 1, 1985, pp. 355-368.
Josowicz, M., et al., “Electrochemical Pretreatment of Thin Film Platinum Electrodes”, Journal of the Electrochemical Society, vol. 135 No. 1, 1988, pp. 112-115.
Jovanovic, L., “The Role of Continuous Glucose Monitoring in Gestational Diabetes Mellitus”, Diabetes Technology & Therapeutics, vol. 2, Sup. 1, 2000, pp. S67-S71.
Jungheim, K., et al., “How Rapid Does Glucose Concentration Change in Daily Life of Patients with Type 1 Diabetes?”, pp. 250.
Jungheim, K., et al., “Risky Delay of Hypoglycemia Detection by Glucose Monitoring at the Arm”, Diabetes Care, vol. 24, No. 7, 2001, pp. 1303-1304.
Kang, S. K., et al., “In Vitro and Short-Term In Vivo Characteristics of a Kel-F Thin Film Modified Glucose Sensor”, Analytical Sciences, vol. 19, 2003, pp. 1481-1486.
Kaplan, S. M., “Wiley Electrical and Electronics Engineering Dictionary”, IEEE Press, 2004, pp. 141, 142, 548, 549.
Kargol, M., et al., “Studies on the Structural Properties of Porous Membranes: Measurement of Linear Dimensions of Solutes”, Biophysical Chemistry, vol. 91, 2001, pp. 263-271.
Katakis, I., et al., “Electrostatic Control of the Electron Transfer Enabling Binding of Recombinant Glucose Oxidase and Redox Polyelectrolytes”, Journal of the American Chemical Society, vol. 116, No. 8, 1994, pp. 3617-3618.
Katakis, I., et al., “L-α-Glycerophosphate and L-Lactate Electrodes Based on the Electrochemical ‘Wiring’ of Oxidases”, Analytical Chemistry, vol. 64, No. 9, 1992, pp. 1008-1013.
Kaufman, F. R., “Role of the Continuous Glucose Monitoring System in Pediatric Patients”, Diabetes Technology & Therapeutics, vol. 2, Sup. 1, 2000, pp. S49-S52.
Kemp, G. J., “Theoretical Aspects of One-Point Calibration: Causes and Effects of Some Potential Errors, and Their Dependence on Concentration,” Clinical Chemistry, vol. 30, No. 7, 1984, pp. 1163-1167.
Kenausis, G., et al., “‘Wiring’ of Glucose Oxidase and Lactate Oxidase Within a Hydrogel Made with Poly(vinyl pyridine) complexed with [Os(4,4′-dimethoxy-2,2′-bipyridine)2C1]+/2+”, Journal of the Chemical Society, Faraday Transactions, vol. 92, No. 20, 1996, pp. 4131-4136.
Kerner, W., “Implantable Glucose Sensors: Present Status and Future Developments”, Experimental and Clinical Endocrinology & Diabetes, vol. 109, Supplement 2, 2001, pp. S341-S346.
Kerner, W., et al., “The Function of a Hydrogen Peroxide-Detecting Electroenzymatic Glucose Electrode is Markedly Impaired in Human Subcutaneous Tissue and Plasma,” Biosensors & Bioelectronics, vol. 8, 1993, pp. 473-482.
Korf, J., et al., “Monitoring of Glucose and Lactate Using Microdialysis: Applications in Neonates and Rat Brain,” Developmental Neuroscience, vol. 15, 1993, pp. 240-246.
Koschinsky, T., et al., “New Approach to Technical and Clinical Evaluation of Devices for Self-Monitoring of Blood Glucose”, Diabetes Care, vol. 11, No. 9, 1988, pp. 619-629.
Koschinsky, T., et al., “Sensors for Glucose Monitoring: Technical and Clinical Aspects” Diabetes Metabolism Research and Reviews, vol. 17, 2001, pp. 113-123.
Koudelka, M., et al., “In-Vivo Behaviour of Hypodermically Implanted Microfabricated Glucose Sensors”, Biosensors & Bioelectronics, vol. 6, 1991, pp. 31-36.
Kovatchev, B. P., et al., “Evaluating the Accuracy of Continuous Glucose-Monitoring Sensors”, Diabetes Care, vol. 27, No. 8, 2004, pp. 1922-1928.
Kraver, K. L., et al., “A Mixed-Signal Sensor Interface Miciroinstrument”, Sensors and Actuators A, vol. 91, 2001, pp. 266-277.
Krouwer, J. S., “Setting Performance Goals and Evaluating Total Analytical error for Diagnostic Assays”, Clinical Chemistry, vol. 48, No. 6, 2002, pp. 919-927.
Kruger, D., et al., “Psychological Motivation and Patient Education: A Role for Continuous Glucose Monitoring”, Diabetes Technology & Therapeutics, vol. 2, Sup. 1, 2000, pp. S93-S97.
Kulys, J., et al., “Mediatorless Peroxidase Electrode and Preparation of Bienzyme Sensors”, Bioelectrochemistry and Bioenergetics, vol. 24, 1990, pp. 305-311.
Kurnik, R. T., et al., “Application of the Mixtures of Experts Algorithm for Signal Processing in a Noninvasive Glucose Monitoring System” Sensors and Actuators B, vol. 60, 1990, pp. 19-26.
Lacourse, W. R., et al., “Optimization of Waveforms for Pulsed Amperometric Detection of Carbohydrates Based on Pulsed Voltammetry”, Analytical Chemistry, vol. 65, No. 1, 1993, pp. 50-55.
Lager, W., et al., “Implantable Electrocatalytic Glucose Sensor”, Hormone Metabolic Research, vol. 26, 1994, pp. 526-530.
Laurell, T., “A Continuous Glucose Monitoring System Based on Microdialysis”, Journal of Medical Engineering & Technology, vol. 16, No. 5, 1992, pp. 187-193.
Lee, E., et al., “Effects of Pore Size, Void Volume, and Pore Connectivity on Tissue Responses to Porous Silicone Implants”, Transactions on the Twenty-Fifth Annual Meeting of the Society for Biomaterials, vol. 22, 1999, pp. 171.
Lerner, H., et al., “An Implantable Electrochemical Glucose Sensor”, Annals of the New York Academy of Sciences, vol. 428, 1984, pp. 263-278.
Leypoldt, J. K., et al., “Model of a Two-Substrate Enzyme Electrode for Glucose”, Analytical Chemistry, vol. 56, No. 14, 1984, pp. 2896-2904.
Lindner, E., et al., “Flexible (Kapton-Based) Microsensor Arrays of High Stability for Cardiovascular Applications”, Journal of the Chemical Society, Faraday Transactions, vol. 89, No. 2, 1993, pp. 361-367.
Liu, W., et al., “A Neuro-Stimulus Chip with Telemetry Unit for Retinal Prosthetic Device”, IEEE Journal of Solid-State Circuits, vol. 35, No. 10, 2000, pp. 1487-1497.
Lortz, J., et al., “What is Bluetooth? We Explain The Newest Short-Range Connectivity Technology”, Smart Computing Learning Series, Wireless Computing, vol. 8, Issue 5, 2002, pp. 72-74.
Luong, J. H. T., et al., “Solubilization of Multiwall Carbon Nanotubes by 3-Aminopropyltriethoxysilane Towards the Fabrication of Electrochemical Biosensors with Promoted Electron Transfer”. Electroanalysis, vol. 16, No. 1-2, 2004, pp. 132-139.
Lynch, S. M., et al., “Estimation-Based Model Predictive Control of Blood Glucose in Type I Diabetics: A Simulation Study”, Proceedings of the IEEE 27th Annual Northeast Bioengineering Conference, 2001, pp. 79-80.
Lynn, P. A., “Recursive Digital Filters for Biological Signals”, Medical and Biological Engineering, vol. 9, 1971, pp. 37-43.
Maidan, R., et al., “Elimination of Electrooxidizable Interferant-Produced Currents in Amperometric Biosensors”, Analytical Chemistry, vol. 64, No. 23, 1992, pp. 2889-2896.
Makale, M. T., et al., “Tissue Window Chamber System for Validation of Implanted Oxygen Sensors”, American Journal of Physiology: Heart and Circulatory Physiology, vol. 284, 2003, pp. H2288-H2294.
Malin, S. F., et al., “Noninvasive Prediction of Glucose by Near-Infrared Diffuse Reflectance Spectoscopy”, Clinical Chemistry, vol. 45, No. 9, 1999, pp. 1651-1658.
Mancy, K. H., et al., “A Galvanic Cell Oxygen Analyzer”, Journal of Electroanalytical Chemistry, vol. 4, 1962, pp. 65-92.
Maran, A., et al., “Continuous Glucose Monitoring in Diabetic Patients”, Diabetes Care, vol. 25 No. 2, 2002, pp. 347-352.
March, W. F., “Dealing with the Delay”, Diabetes Technology & Therapeutics, vol. 4, No. 1, 2002, pp. 49-50.
Marko-Varga, G., et al., “Enzyme-Based Biosensor as a Selective Detection Unit in Column Liquid Chromatography”, Journal of Chromatography A, vol. 660, 1994, pp. 153-167.
Martin, R. F., “General Deming Regression for Estimating Systematic Bias and Its Confidence Interval in Method-Comparison Studies”, Clinical Chemistry, vol. 46, No. 1, 2000, pp. 100-104.
Mastrototaro, J. J., “The MiniMed Continuous Glucose Monitoring System”, Diabetes Technology & Therapeutics, vol. 2, Sup. 1, 2000, pp. S13-S18.
Mastrototaro, J. J., et al., “An Electroenzymatic Glucose Sensor Fabricated on a Flexible Substrate”, Sensors and Actuators B, vol. 5, 1991, pp. 139-144.
Mastrototaro, J. J., et al., “Reproducibility of the Continuous Glucose Monitoring System Matches Previous Reports and the Intended Use of the Product” and “Response to Mastrototaro and Gross”, Diabetes Care, vol. 26, No. 1, 2003, pp. 256-257.
Mauras, N., et al., “Lack of Accuracy of Continuous Glucose Sensors in Healthy, Nondiabetic Children: Results of the Diabetes Research in Children Network (DirecNet) Accuracy Study,” Journal of Pediatrics, 2004, pp. 770-775.
McCartney, L. J., et al., “Near-Infrared Fluorescence Lifetime Assay for Serum Glucose Based on Allophycocyanin-Labeled Concanavalin A”, Analytical Biochemistry, vol. 292, 2001, pp. 216-221.
McGarraugh, G., et al., “Glucose Measurements Using Blood Extracted from the Forearm and the Finger”, TheraSense, Inc., 16 Pages.
McGarraugh, G., et al., “Physiological Influences on Off-Finger Glucose Testing”, Diabetes Technology & Therapeutics, vol. 3, No. 3, 2001, pp. 367-376.
McGrath, M. J., et al., “The Use of Differential Measurements with a Glucose Biosensor for Interference Compensation During Glucose Determinations by Flow Injection Analysis”, Biosensors & Bioelectronics, vol. 10, 1995, pp. 937-943.
McKean, B. D., et al., “A Telemetry-Instrumentation System for Chronically Implanted Glucose and Oxygen Sensors”, IEEE Transactions on Biomedical Engineering, vol. 35, No. 7, 1988, pp. 526-532.
McNeil, C. J., et al., “Thermostable Reduced Nicotinamide Adenine Dinucleotide Oxidase: Application to Amperometric Enzyme Assay”, Analytical Chemistry, vol. 61, No. 1, 1989, pp. 25-29.
Memoli, A., et al., “A Comparison Between Different Immobilized Glucoseoxidase-Based Electrodes”, Journal of Pharmaceutical and Biomedical Analysis, vol. 29, 2002, pp. 1045-1052.
Metzger, M., et al., “Reproducibility of Glucose Measurements Using the Glucose Sensor”, Diabetes Care, vol. 25, No. 6, 2002, pp. 1185-1191.
Miller, K. M., et al., “Generation of IL1-like Activity in Response to Biomedical Polymer Implants: A Comparison of In Vitro and In Vivo Models”, Journal of Biomedical Materials Research, vol. 23, 1989, pp. 1007-1026.
Miller, K. M., et al., “Human Monocyte/Macrophage Activation and Interleukin 1 Generation by Biomedical Polymers”, Journal of Biomedical Materials Research, vol. 22, 1988, pp. 713-731.
Miller, K. M., et al., “In Vitro Stimulation of Fibroblast Activity by Factors Generated from Human Monocytes Activated by Biomedical Polymers”, Journal of Biomedical Materials Research, vol. 23, 1989, pp. 911-930.
Miyawaki, O., et al., “Electrochemical and Glucose Oxidase Coenzyme Activity of Flavin Adenine Dinucleotide Covalently Attached to Glassy Carbon at the Adenine Amino Group”, Biochimica et Biophysica Acta, vol. 838, 1985, pp. 60-68.
Moatti-Sirat, D., et al., “Evaluating In Vitro and In Vivo the Interference of Ascorbate and Acetaminophen on Glucose Detection by a Needle-Type Glucose Sensor”, Biosensors & Bioelectronics, vol. 7, 1992, pp. 345-352.
Moatti-Sirat, D., et al., “Reduction of Acetaminophen Interference in Glucose Sensors by a Composite Nafion Membrane: Demonstration in Rats and Man”, Diabetologia, vol. 37, 1994, pp. 610-616.
Moatti-Sirat, D., et al., “Towards Continuous Glucose Monitoring: In Vivo Evaluation of a Miniaturized Glucose Sensor Implanted for Several Days in Rat Subcutaneous Tissue”, Diabetologia, vol. 35, 1992, pp. 224-330.
Monsod, T. P., et al., “Do Sensor Glucose Levels Accurately Predict Plasma Glucose Concentrations During Hypoglycemia and Hyperinsulinemia?” Diabetes Care, vol. 25, No. 5, 2002, pp. 889-893.
Moussy, F., et al., “A Miniaturized Nafion-Based Glucose Sensor: In Vitro and In Vivo Evaluation in Dogs”, The International Journal of Artificial Organs, vol. 17, No. 2, 1994, pp. 88-94.
Mowery, K. A., et al., “Preparation and Characterization of Hydrophobic Polymeric Films that are Thromboresistant via Nitric Oxide Release”, Biomaterials, vol. 21, 2000, pp. 9-21.
Nagy, G., et al., “A New Type of Enzyme Electrode: The Ascorbic Acid Eliminator Electrode”, Life Sciences, vol. 31, No. 23, 1982, pp. 2611-2616.
Nakamura, S., et al., “Effect of Periodate Oxidation on the Structure and Properties of Glucose Oxidase”, Biochimica et Biophysica Acta., vol. 445, 1976, pp. 294-308.
Nam, Y. S., et al., “A Novel Fabrication Method of Macroporous Biodegradable Polymer Scaffolds Using Gas Foaming Salt as a Porogen Additive”, Journal of Biomedical Materials Research, vol. 53, 2000, pp. 1-7.
Nappholz, T. A., “Programmers for Implants: A Need for Radical Change”, 18th Annual International Conference of the IEEE Engineering in Medicine and Biology SocietyAmsterdam, 1996, pp. 1274-1275.
Narasimham, K., et al., “p-Benzoquinone Activation of Metal Oxide Electrodes for Attachment of Enzymes”, Enzyme and Microbial Technology, vol. 7, 1985, pp. 283-286.
Neuburger, G. G., et al., “Pulsed Amperometric Detection of Carbohydrates at Gold Electrodes with a Two-Step Potential Waveform”, Analytical Chemistry, vol. 59, No. 1, 1987, pp. 150-154.
Notice of Intent to Issue Ex Parte Reexamination Certificate in U.S. Patent Re-Examination Application No. 90/008,457 mailed Mar. 13, 2008.
Office Action in U.S. Appl. No. 09/447,227 mailed Apr. 4, 2006.
Office Action in U.S. Appl. No. 09/447,227 mailed Aug. 1, 2006.
Office Action in U.S. Appl. No. 09/447,227 mailed Aug. 15, 2001.
Office Action in U.S. Appl. No. 09/447,227 mailed Jan. 16, 2003.
Office Action in U.S. Appl. No. 09/447,227 mailed Jan. 17, 2002.
Office Action in U.S. Appl. No. 09/447,227 mailed Jul. 15, 2002.
Office Action in U.S. Appl. No. 09/447,227 mailed Jul. 17, 2007.
Office Action in U.S. Appl. No. 09/447,227 mailed Jul. 9, 2003.
Office Action in U.S. Appl. No. 09/447,227 mailed Mar. 9, 2007.
Office Action in U.S. Appl. No. 09/447,227 mailed Nov. 28, 2003.
Office Action in U.S. Appl. No. 09/447,227 mailed Sep. 22, 2005.
Office Action in U.S. Appl. No. 09/916,711 mailed Dec. 23, 2004.
Office Action in U.S. Appl. No. 09/916,711 mailed Feb. 11, 2004.
Office Action in U.S. Appl. No. 09/916,711 mailed Feb. 14, 2006.
Office Action in U.S. Appl. No. 09/916,711 mailed Jul. 1, 2005.
Office Action in U.S. Appl. No. 09/916,711 mailed Jul. 23, 2004.
Office Action in U.S. Appl. No. 09/916,711 mailed Sep. 24, 2003.
Office Action in U.S. Appl. No. 09/916,711 mailed Sep. 5, 2006.
Office Action in U.S. Appl. No. 10/153,356 mailed Aug. 12, 2004.
Office Action in U.S. Appl. No. 10/153,356 mailed Aug. 29, 2006.
Office Action in U.S. Appl. No. 10/153,356 mailed Feb. 17, 2004.
Office Action in U.S. Appl. No. 10/153,356 mailed Mar. 10, 2006.
Office Action in U.S. Appl. No. 10/153,356 mailed Mar. 15, 2005.
Office Action in U.S. Appl. No. 10/153,356 mailed Mar. 7, 2007.
Office Action in U.S. Appl. No. 10/153,356 mailed Oct. 6, 2005.
Office Action in U.S. Appl. No. 10/632,537 mailed Dec. 21, 2004.
Office Action in U.S. Appl. No. 10/632,537 mailed Oct. 20, 2004.
Office Action in U.S. Appl. No. 10/633,329 mailed Jul. 30, 2007.
Office Action in U.S. Appl. No. 10/633,329 mailed Mar. 26, 2007.
Office Action in U.S. Appl. No. 10/633,329 mailed Oct. 5, 2006.
Office Action in U.S. Appl. No. 10/633,404 mailed Feb. 12, 2007.
Office Action in U.S. Appl. No. 10/646,333 mailed Feb. 24, 2006.
Office Action in U.S. Appl. No. 10/646,333 mailed Jun. 6, 2005.
Office Action in U.S. Appl. No. 10/646,333 mailed Sep. 22, 2004.
Office Action in U.S. Appl. No. 10/695,636 mailed Dec. 6, 2005.
Office Action in U.S. Appl. No. 10/695,636 mailed Mar. 14, 2007.
Office Action in U.S. Appl. No. 10/695,636 mailed May 22, 2006.
Office Action in U.S. Appl. No. 10/789,359 mailed Nov. 27, 2006.
Office Action in U.S. Appl. No. 10/838,912 mailed Sep. 21, 2007.
Office Action in U.S. Appl. No. 10/896,639 mailed Apr. 11, 2007.
Office Action in U.S. Appl. No. 10/896,639 mailed Apr. 6, 2006.
Office Action in U.S. Appl. No. 10/896,639 mailed Aug. 22, 2006.
Office Action in U.S. Appl. No. 10/896,639 mailed Oct. 5, 2007.
Office Action in U.S. Appl. No. 10/896,639 mailed Sep. 23, 2005.
Office Action in U.S. Appl. No. 10/896,772 mailed Dec. 14, 2005.
Office Action in U.S. Appl. No. 10/896,772 mailed Jan. 11, 2005.
Office Action in U.S. Appl. No. 10/896,772 mailed Jul. 19, 2005.
Office Action in U.S. Appl. No. 10/896,772 mailed May 22, 2006.
Office Action in U.S. Appl. No. 10/897,312 mailed Feb. 9, 2006.
Office Action in U.S. Appl. No. 10/897,377 mailed May 11, 2006.
Office Action in U.S. Appl. No. 10/897,377 mailed Oct. 18, 2005.
Office Action in U.S. Appl. No. 10/991,966 mailed Nov. 28, 2007.
Office Action in U.S. Appl. No. 11/007,635 mailed Jan. 27, 2006.
Office Action in U.S. Appl. No. 11/021,046 mailed Dec. 26, 2007.
Office Action in U.S. Appl. No. 11/034,343 mailed Nov. 1, 2007.
Office Action in U.S. Appl. No. 11/077,714 mailed Apr. 10, 2007.
Office Action in U.S. Appl. No. 11/077,714 mailed Jan. 10, 2008.
Office Action in U.S. Appl. No. 11/077,714 mailed Jul. 27, 2007.
Office Action in U.S. Appl. No. 11/077,714 mailed Oct. 11, 2006.
Office Action in U.S. Appl. No. 11/077,715 mailed Apr. 10, 2007.
Office Action in U.S. Appl. No. 11/077,715 mailed Jul. 26, 2007.
Office Action in U.S. Appl. No. 11/077,715 mailed Oct. 31, 2006.
Office Action in U.S. Appl. No. 11/077,740 mailed Jun. 1, 2007.
Office Action in U.S. Appl. No. 11/077,740 mailed Nov. 1, 2007.
Office Action in U.S. Appl. No. 11/077,759 mailed May 17, 2007.
Office Action in U.S. Appl. No. 11/077,763 mailed Jan. 30, 2007.
Office Action in U.S. Appl. No. 11/077,765 mailed Dec. 31, 2007.
Office Action in U.S. Appl. No. 11/077,883 mailed Oct. 9, 2007.
Office Action in U.S. Appl. No. 11/078,230 mailed Sep. 18, 2007.
Office Action in U.S. Appl. No. 11/157,746 mailed Jan. 3, 2008.
Office Action in U.S. Appl. No. 11/334,876 mailed Oct. 4, 2006.
Office Action in U.S. Appl. No. 11/334,876 mailed Sep. 25, 2007.
Office Action in U.S. Appl. No. 11/543,539 mailed Dec. 12, 2007.
Office Action in U.S. Appl. No. 11/543,539 mailed May 23, 2007.
Office Action in U.S. Appl. No. 11/543,683 mailed Dec. 12, 2007.
Office Action in U.S. Appl. No. 11/543,683 mailed May 18, 2007.
Office Action in U.S. Appl. No. 11/543,707 mailed Dec. 12, 2007.
Office Action in U.S. Appl. No. 11/543,707 mailed May 18, 2007.
Office Action in U.S. Appl. No. 11/543,734 mailed Dec. 17, 2007.
Office Action in U.S. Appl. No. 11/543,734 mailed Jun. 5, 2007.
Office Action in U.S. Patent Re-Examination Application No. 90/007,903 mailed Feb. 13, 2008.
Office Action in U.S. Patent Re-Examination Application No. 90/007,910 mailed Feb. 13, 2008.
Ohara, T. J., “Osmium Bipyridyl Redox Polymers Used in Enzyme Electrodes”, Platinum Metals Review, vol. 39, No. 2, 1995, pp. 54-62.
Ohara, T. J., et al., “‘Wired’ Enzyme Electrodes for Amperometric Determination of Glucose or Lactate in the Presence of Interfering Substances”, Analytical Chemistry, vol. 66, No. 15, 1994, pp. 2451-2457.
Ohara, T. J., et al., “Glucose Electrodes Based on Cross-Linked [Os(bpy)2C1]+/2+Complexed Poly(1-Vinylimidazole) Films”, Analytical Chemistry, vol. 65, No. 23, 1993, pp. 3512-3517.
Okuda, J., et al., “Mutarotase Effect on Micro Determinations of D-Glucose and Its Anomers with β-D-Glucose Oxidase”, Analytical Biochemistry, vol. 43, 1971, pp. 312-315.
Olievier, C. N., et al., “In Vivo Measurement of Carbon Dioxide Tension with a Miniature Electrodes”, Pflugers Archiv: European Journal of Physiology, vol. 373, 1978, pp. 269-272.
Paddock, R. M., et al., “Electrocatalytic Reduction of Hydrogen Peroxide via Direct Electron Transfer From Pyrolytic Graphite Electrodes to Irreversibly Adsorbed Cyctochrome C Peroxidase”, Journal of ElectroAnalytical Chemistry, vol. 260, 1989, pp. 487-494.
Palleschi, G., et al., “A Study of Interferences in Glucose Measurements in Blood by Hydrogen Peroxide Based Glucose Probes”, Analytical Biochemistry, vol. 159, 1986, pp. 114-121.
Palmisano, F., et al., “Simultaneous Monitoring of Glucose and Lactate by an Interference and Cross-Talk Free Dual Electrode Amperometric Biosensor Based on Electropolymerized Thin Films”, Biosensors & Bioelectronics, vol. 15, 2000, pp. 531-539.
Pankratov, I., et al., “Sol-Gel Derived Renewable-Surface Biosensors”, Journal of ElectroAnalytical Chemistry, vol. 393, 1995, pp. 35-41.
Panteleon, A. E., et al., “The Role of the Independent Variable to Glucose Sensor Calibration”, Diabetes Technology & Therapeutics, vol. 5, No. 3, 2003, pp. 401-410.
Parker, R. S., et al., “A Model-Based Algorithm for Blood Glucose Control in Type I Diabetic Patients”, IEEE Transactions on Biomedical Engineering, vol. 46, No. 2, 1999, pp. 148-157.
Patel, H., et al., “Amperometric Glucose Sensors Based on Ferrocene Containing Polymeric Electron Transfer Systems—A Preliminary Report”, Biosensors and Bioelectronics, vol. 18, 2003, pp. 1073-1076.
Pathak, C., et al., “Rapid Photopolymerization of Immunoprotective Gels in Contact with Cells and Tissue”, Journal of the American Chemical Society, vol. 114, No. 21, 1992, pp. 8311-8312.
Pichert, J. W., et al., “Issues for the Coming Age of Continuous Glucose Monitoring”, The Diabetic Educator, vol. 26, No. 6, 2000, pp. 969-980.
Pickup, J. C., et al., “Responses and Calibration of Amperometric Glucose Sensors Implanted in the Subcutaneous Tissue of Man”, Acta Diabetologica, vol. 30, 1993, pp. 143-148.
Pickup, J., “Developing Glucose Sensors for In Vivo Use”, Tibtech, vol. 11, 1993, pp. 285-291.
Pickup, J., et al., “Implantable Glucose Sensors: Choosing the Appropriate Sensing Strategy”, Biosensors, vol. 3, 1987/1988, pp. 335-346.
Pickup, J., et al., “In Vivo Molecular Sensing in Diabetes Mellitus: An Implantable Glucose Sensor with Direct Electron Transfer”, Diabetologia, vol. 32, 1989, pp. 213-217.
Pickup, J., et al., “Potentially-Implantable, Amperometric Glucose Sensors with Mediated Electron Transfer: Improving the Operating Stability”, Biosensors, vol. 4, 1989, pp. 109-119.
Pishko, M. V., et al., “Amperometric Glucose Microelectrodes Prepared Through Immobilization of Glucose Oxidase in Redox Hydrogels”, Analytical Chemistry, vol. 63, No. 20, 1991, pp. 2268-2272.
Pitzer, K. R., et al., “Detection of Hypoglycemia with the GlucoWatch Biographer”, Diabetes Care, vol. 24, No. 5, 2001, pp. 881-885.
Poirier, J. Y., et al., “Clinical and Statistical Evaluation of Self-Monitoring Blood Glucose Meters”, Diabetes Care, vol. 21, No. 11, 1998, pp. 1919-1924.
Poitout, V., et al., “A Glucose Monitoring System for on Line Estimation in Man of Blood Glucose Concentration Using a Miniaturized Glucose Sensor Implanted in the Subcutaneous Tissue and a Wearable Control Unit”, Diabetolgia, vol. 36, 1993, pp. 658-663.
Poitout, V., et al., “Calibration in Dogs of a Subcutaneous Miniaturized Glucose Sensor Using a Glucose Meter for Blood Glucose Determination”, Biosensors & Bioelectronics, vol. 7, 1992, pp. 587-592.
Poitout, V., et al., “In Vitro and In Vivo Evaluation in Dogs of a Miniaturized Glucose Sensor”, ASAIO Transactions, vol. 37, No. 3, 1991, pp. M298-M300.
Pollak, A., et al., “Enzyme Immobilization by Condensation Copolymerization into Cross-Linked Polyacrylamide Gels”, Journal of the American Chemical Society, vol. 102, No. 20, 1980, pp. 6324-6336.
Postlethwaite, T. A., et al., “Interdigitated Array Electrode as an Alternative to the Rotated Ring—Disk Electrode for Determination of the Reaction Products of Dioxygen Reduction”, Analytical Chemistry, vol. 68, No. 17, 1996, pp. 2951-2958.
Quinn, C. A. P., et al., “Biocompatible, Glucose-Permeable Hydrogel for In Situ Coating of Implantable Biosensors”, Biomaterials, vol. 18, No. 24, 1997, pp. 1665-1670.
Quinn, C. P., et al., “Kinetics of Glucose Delivery to Subcutaneous Tissue in Rats Measured with 0.3-mm Amperometric Microsensors”, The American Physiological Society, 1995, E155-E161.
Ratner, B. D., “Reducing Capsular Thickness and Enhancing Angeiogenesis Around Implant Drug Release Systems”, Journal of Controlled Release, vol. 78, 2002, pp. 211-218.
Reach, G., “Which Threshold to Detect Hypoglycemia?”, Diabetes Care, vol. 24, No. 5, 2001, pp. 803-804.
Reach, G., et al., “A Method of Evaluating In Vivo the Functional Characteristics of Glucose Sensors”, Biosensors 2, 1986, pp. 211-220.
Reach, G., et al., “Can Continuous Glucose Monitoring Be Used for the Treatment of Diabetes?”, Analytical Chemistry, vol. 64, No. 6, 1992, pp. 381-386.
Reach, G., et al., “Letters to the Editor: Re: Diabetes Technology & Therapeutics, 2000; 2:49-56”, Diabetes Technology & Therapeutics, vol. 3, No. 1, 2001, pp. 129-131.
Rebrin, K., et al., “Automated Feedback Control of Subcutaneous Glucose Concentration in Diabetic Dogs”, Diabetologia, vol. 32, 1989, pp. 573-576.
Rebrin, K., et al., “Subcutaneous Glucose Predicts Plasma Glucose Independent of Insulin: Implications for Continuous Monitoring”, The American Physiological Society, 1999, pp. E561-E571.
Reusch, W., “Other Topics: Group Organometallic Chemistry: Organometallic Compounds: Main Group Organometallic Compounds,” Virtual Textbook of Organic Chemistry, 1999, Rev. 2007, 25 pages.
Rhodes, R. K., et al., “Prediction of Pocket-Portable and Implantable Glucose Enzyme Electrode Performance from Combined Species Permeability and Digital Simulation Analysis”, Analytical Chemistry, vol. 66, No. 9, 1994, pp. 1520-1529.
Rinken, T., et al., “Calibration of Glucose Biosensors By Using Pre-Study State Kinetic Data”, Biosensors & Bioelectronics, vol. 13, 1998, pp. 801-807.
Roe, J. N., et al., “Bloodless Glucose Measurements”, Critical Review in Therapeutic Drug Carrier Systems, vol. 15, Issue 3, 1998, pp. 199-241.
Sacks (ED), “Guidelines Recommendations for Laboratory Analysis in the Diagnosis and Management of Diabetes Mellitus,” The National Academy of Clinical Biochemistry Presents Laboratory Medicine Practice and Guidelines, vol. 13, 2002, pp. 8-11, 21-23, 52-56, 63.
Sakakida, M., et al., “Development of Ferrocene-Mediated Needle-Type Glucose Sensor as a Measure of True Subcutaneous Tissue Glucose Concentrations”, Artificial Organs Today, vol. 2, No. 2, 1992, pp. 145-158.
Sakakida, M., et al., “Ferrocene-Mediated Needle-Type Glucose Sensor Covered with Newly Designed Biocompatible Membrane”, Sensors and Actuators B, vol. 13-14, 1993, pp. 319-322.
Salehi, C., et al., “A Telemetry-Instrumentation System for Long-Term Implantable Glucose and Oxygen Sensors”, Analytical Letters, vol. 29, No. 13, 1996, pp. 2289-2308.
Samuels, G. J., et al., “An Electrode-Supported Oxidation Catalyst Based on Ruthenium (IV). pH ‘Encapsulation’ in a Polymer Film”, Journal of the American Chemical Society, vol. 103, No. 2, 1981, pp. 307-312.
Sansen, W., et al., “A Smart Sensor for the Voltammetric Measurement of Oxygen or Glucose Concentrations”, Sensors and Actuators B1, 1990, pp. 298-302.
Sansen, W., et al., “Chapter 12: Glucose Sensor with Telemetry Systems”, Implantable Sensors for Closed-Loop Prosthetic Systems, 1985, pp. 167-175.
Sasso, S. V., et al., “Electropolymerized 1,2-Diaminobenzene as a Means to Prevent Interferences and Fouling and to Stabilize Immobilized Enzyme in Electrochemical Biosensors”, Analytical Chemistry, vol. 62, No. 11, 1990, pp. 1111-1117.
Scheller, F. W., et al., “Second Generation Biosensors,” Biosensors & Bioelectronics, vol. 6, 1991, pp. 245-253.
Scheller, F., et al., “Enzyme Electrodes and Their Application”, Philosophical Transactions of The Royal Society of London B, vol. 316, 1987, pp. 85-94.
Schmehl, R. H., et al., “The Effect of Redox Site Concentration on the Rate of Mediated Oxidation of Solution Substrates by a Redox Copolymer Film”, Journal of ElectroAnalytical Chemistry, vol. 152, 1983, pp. 97-109.
Schmidt, F. J., et al., “Calibration of a Wearable Glucose Sensor”, The International Journal of Artificial Organs, vol. 15, No. 1, 1992, pp. 55-61.
Schmidt, F. J., et al., “Glucose Concentration in Subcutaneous Extracellular Space”, Diabetes Care, vol. 16, No. 5, 1993, pp. 695-700.
Schmidtke, D. W., et al., “Accuracy of the One-Point In Vivo Calibration of ‘Wired’ Glucose Oxidase Electrodes Implanted in Jugular Veins of Rats in Periods of Rapid Rise and Decline of the Glucose Concentration”, Analytical Chemistry, vol. 70, No. 10, 1998, pp. 2149-2155.
Schmidtke, D. W., et al., “Measurement and Modeling of the Transient Difference Between Blood and Subcutaneous Glucose Concentrations in the Rat After Injection of Insulin”, Proceedings of the National Academy of Sciences, vol. 95, 1998, pp. 294-299.
Schoemaker, M., et al., “The SCHM1 System: Subcutaneous Continuous Glucose Monitoring Based on Microdialysis Technique”, Diabetes Technology & Therapeutics, vol. 5, No. 4, 2003, pp. 599-608.
Schwarz, M., et al., “Micro Implantable Visual Prostheses”, 1st Annual International IEEE-EMBS Special Topic Conference on Microtechnologies in Medicine & Biology, Lyon, France, 2000, pp. 461-465.
Selam, J. L., “Management of Diabetes with Glucose Sensors and Implantable Insulin Pumps: From the Dream of the 60s to the Realities of the 90s”, American Society for Artificial Internal Organs Journal, 1997, pp. 137-142.
Service, R. F., “Can Sensors Make a Home in the Body?”, Science, vol. 297, 2002, pp. 962-963.
Shaw, G. W., et al., “In Vitro Testing of a Simply Constructed, Highly Stable Glucose Sensor Suitable for Implantation in Diabetic Patients”, Biosensors & Bioelectronics, vol. 6, 1991, pp. 401-406.
Shichiri, M., et al., “Glycaemic Control in Pancreatectomized Dogs with a Wearable Artificial Endocrine Pancreas”, Diabetologia, vol. 24, 1983, pp. 179-184.
Shichiri, M., et al., “In Vivo Characteristics of Needle-Type Glucose Sensor—Measurements of Subcutaneous Glucose Concentrations in Human Volunteers”, Hormone and Metabolic Research Supplement Series, vol. 20, 1988, pp. 17-20.
Shichiri, M., et al., “Membrane Design for Extending the Long-Life of an Implantable Glucose Sensor”, Diabetes Nutrition and Metabolism, vol. 2, 1989, pp. 309-313.
Shichiri, M., et al., “Needle-type Glucose Sensor for Wearable Artificial Endocrine Pancreas”, Implantable Sensors for Closed-Loop Prosthetic Systems, Chapter 15, 1985, pp. 197-210.
Shichiri, M., et al., “Telemetry Glucose Monitoring Device With Needle-Type Glucose Sensor: A Useful Tool for Blood Glucose Monitoring in Diabetic Individuals”, Diabetes Care, vol. 9, No. 3, 1986, pp. 298-301.
Shichiri, M., et al., “Wearable Artificial Endocrine Pancreas With Needle-Type Glucose Sensor”, The Lancet, 1982, pp. 1129-1131.
Shults, M. C., et al., “A Telemetry-Instrumentation System for Monitoring Multiple Subcutaneously Implanted Glucose Sensors”, IEEE Transactions on Biomedical Engineering, vol. 41, No. 10, 1994, pp. 937-942.
Sieminski, A. L., et al., “Biomaterial-Microvasculature Interactions”, Biomaterials, vol. 21, 2000, pp. 2233-2241.
Sittampalam, G., et al., “Surface-Modified Electrochemical Detector for Liquid Chromatography”, Analytical Chemistry, vol. 55, No. 9, 1983, pp. 1608-1610.
Skoog, D. A., et al., “Evaluation of Analytical Data,” Fundamentals of Analytical Chemistry, 1966, pp. 55.
Skyler, J. S., “The Economic Burden of Diabetes and the Benefits of Improved Glycemic Control: The Potential Role of a Continuous Glucose Monitoring System”, Diabetes Technology & Therapeutics, vol. 2, Sup. 1, 2000, pp. S7-S12.
Soegijoko, S., et al., “External Artificial Pancreas: A New Control Unit Using Microprocessor”, Hormone and Metabolic Research Supplement Series, vol. 12, 1982, pp. 165-169.
Sokolov, S., et al., “Metrological Opportunities of the Dynamic Mode of Operating an Enzyme Amperometric Biosensor”,Medical Engineering and Physics, vol. 17, No. 6, 1995, pp. 471-476.
Sproule, B. A., et al., “Fuzzy Pharmacology: Theory and Applications”, Trends in Pharmacological Sciences vol. 23, No. 9, 2002, pp. 412-417.
Sprules, S. D., et al., “Evaluation of a New Disposable Screen-Printed Sensor Strip for the Measurement of NADH and Its Modification to Produce a Lactate Biosensor Employing Microliter Volumes”, Electroanalysis, vol. 8, No. 6, 1996, pp. 539-543.
Sriyudthsak, M., et al., “Enzyme-Epoxy Membrane Based Glucose Analyzing System and Medical Applications”, Biosensors & Bioelectronics, vol. 11, No. 8, 1996, pp. 735-742.
Steil, G. M., et al., “Determination of Plasma Glucose During Rapid Glucose Excursions with a Subcutaneous Glucose Sensor”, Diabetes Technology & Therapeutics, vol. 5, No. 1, 2003, pp. 27-31.
Sternberg, F., et al., “Calibration Problems of Subcutaneous Glucosensors when Applied ‘In-Situ’ in Man”, Hormone and Metabolic Research, vol. 26, 1994, pp. 523-526.
Sternberg, F., et al., “Does Fall In Tissue Glucose Precede Fall In Blood Glucose?” Diabetologia. vol. 29, 1996, pp. 609-612.
Sternberg, R., et al., “Covalent Enzyme Coupling on Cellulose Acetate Membranes for Glucose Sensor Development”, Analytical Chemistry, vol. 60, No. 24, 1988, pp. 2781-2786.
Sternberg, R., et al., “Study and Development of Multilayer Needle-Type Enzyme-Based Glucose Microsensors”, Biosensors, vol. 4, 1988, pp. 27-40.
Street, J. O., et al., “A Note on Computing Robust Regression Estimates Via Interactively Reweighted Least Squares”, The American Statistician, vol. 42, No. 2, 1988, pp. 152-154.
Suaning, G. J., et al., “CMOS Neurostimulation ASIC with 100 Channels, Scaleable Output, and Bidirectional Radio-Frequency Telemetry” IEEE Transactions on Biomedical Engineering, vol. 48, No. 2, 2001, pp. 248-260.
Suekane, M , “Immobilization of Glucose Isomerase”, Zettschrift fur Allgemeine Mikrobiologie, vol. 22, No. 8, 1982, pp. 565-576.
Tajima, S., et al., “Simultaneous Determination of Glucose and 1,5-Anydroglucitol”, Chemical Abstracts, vol. 111, No. 25, 1989, pp. 394.
Takamura, A., et al., Drug release from Poly(vinyl alcohol) Gel Prepared by Freeze-Thaw Procedure, Journal of Controlled Release, vol. 20, 1992, pp. 21-27.
Tamura, T., et al., “Preliminary Study of Continuous Glucose Monitoring with a Microdialysis Technique and a Null Method—a Numerical Analysis”, Frontiers Medical and Biological Engineering, vol. 10, No. 2, 2000, pp. 147-156.
Tanenberg, R. J., et al., “Continuous Glucose Monitoring System: A New Approach to the Diabetes Diagnosis of Diabetic Gastroparesis”, Diabetes Technology & Therapeutics, vol. 2, Sup. 1, 2000, pp. S73-S80.
Tang, L, et al., “Fibrin(ogen) Mediates Acute Inflammatory Responses to Biomaterials”, Journal of Experimental Medicine, vol. 178, 1993, pp. 2147-2156.
Tang, L., et al., “Inflammatory Responses to Biomaterials”, American Journal of Clinical Pathology, vol. 103, No. 4, 1995, pp. 466-471.
Tang, L., et al., “Mast Cells Mediate Acute Inflammatory Responses to Implanted Biomaterials”, Proceedings of the National Academy of Sciences USA, vol. 95, 1998, pp. 8841-8846.
Tang, L., et al., “Molecular Determinants of Acute Inflammatory Responses to Biomaterials”, Journal of Clinical Investigation, vol. 97, No. 5, 1996, pp. 1329-1334.
Tang, Z., et al., “Data Transmission from an Implantable Biotelemeter by Load-Shift Keying Using Circuit Configuration Modulator”, IEEE Transactions on Biomedical Engineering, vol. 42, No. 5, 1995, pp. 524-528.
Tarasevich, M. R., “Bioelectrocatalysis”, Comprehensive Treatise of Electrochemistry, vol. 10, 1985, pp. 231-295.
Tatsuma, T., et al., “Enzyme Monolayer- and Bilayer-Modified Tin Oxide Electrodes for the Determination of Hydrogen Peroxide and Glucose”, Analytical Chemistry, vol. 61, No. 21, 1989, pp. 2352-2355.
Taylor, C., et al., “‘Wiring’ of Glucose Oxidase Within a Hydrogel Made with Polyvinyl Imidazole Complexed with [(Os-4,4′-dimethoxy-2,2′-bipyridine)C1]+/2+”, Journal of ElectroAnalytical Chemistry, vol. 396, 1995, pp. 511-515.
Thome-Duret, V., et al., “Continuous Glucose Monitoring in the Free-Moving Rat”, Metabolism, vol. 47, No. 7, 1998, pp. 799-803.
Thome-Duret, V., et al., “Modification of the Sensitivity of Glucose Sensor Implanted into Subcutaneous Tissue”, Diabetes & Metabolism, vol. 22, No. 3, 1996, pp. 174-178.
Thompson, M., et al., “In Vivo Probes: Problems and Perspectives”, Clinical Biochemistry, vol. 19, 1986, pp. 255-261.
Tibell, A., et al., “Survival of Macroencapsulated Allogeneic Parathyriod Tissue One Year After Transplantation in Nonimmunosuppressed Humans”, Cell Transplantation, vol. 10, No. 7, 2001, pp. 591-599.
Tierney, M. J., “The GlucoWatch® Biographer: A Frequent, Automatic and Noninvasive Glucose Monitor”, Annals of Medicine, vol. 32, 2000, pp. 632-641.
Tierney, M. J., et al., “Effect of Acetaminophen on the Accuracy of Glucose Measurements Obtained with the GlucoWatch Biographer”, Diabetes Technology & Therapeutics, vol. 2, No. 2, 2000, pp. 199-207.
Tilbury, J. B., et al., “Receiver Operating Characteristic Analysis for Intelligent Medical Systems—A New Approach for Finding Confidence Intervals”, IEEE Transactions on Biomedical Engineering, vol. 47, No. 7, 2000, pp. 952-963.
Trajanoski, Z., et al., “Neural Predictive Controller for Insulin Delivery Using the Subcutaneous Route”, IEEE Transactions on Biomedical Engineering, vol. 45, No. 9, 1998, pp. 1122-1134.
Trecroci, D., “A Glimpse Into the Future: Continuous Monitoring of Glucose with a Microfiber”, Diabetes Interview, 2002, pp. 42-43.
Trojanowicz, M., et al., “Enzyme Entrapped Polypyrrole Modified Electrode for Flow-Injection Determination of Glucose”, Biosensors & Bioelectronics, vol. 5, 1990, pp. 149-156.
Tsalikian, E., et al., “Accuracy of the GlucoWatch G2® Biographer and the Continuous Glucose Monitoring System During Hypoglycemia: Experience of the Diabetes Research in Children Network”, Diabetes Care, vol. 27, No. 3, 2004, pp. 722-726.
Turner, A., et al., “Diabetes Mellitus: Biosensors for Research and Management”, Biosensors, vol. 1, 1985, pp. 85-115.
Turner, R. F., et al., “A Biocompatible Enzyme Electrode for Continuous in vivo Glucose Monitoring in Whole Blood”, Sensors and Actuators B, vol. 1, 1990, pp. 561-564.
Tuzhi, P., et al., “Constant Potential Pretreatment of Carbon Fiber Electrodes for In Vivo Electrochemistry”, Analytical Letters, vol. 24, No. 6, 1991, pp. 935-945.
U.S. Department of Health and Human Services, “Off-The-Shelf-Software Use in Medical Devices”, Guidance for Industry, FDA Reviewers and Compliance on, 1999, pp. 1-26.
U.S. Patent Reexamination Application No. 90/007,903, Request for Reexamination of U.S. Patent No. 6,565,509, filed Jan. 25, 2006.
U.S. Patent Reexamination Application No. 90/007,910, Request for Reexamination of U.S. Patent No. 6,175,752, filed Feb. 1, 2006.
U.S. Appl. No. 90/007,913, Request for Reexamination of U.S. Patent No. 6,284,478, filed Feb. 1, 2006.
U.S. Appl. No. 90/007,914, Request for Reexamination of U.S. Patent No. 6,329,161, filed Feb. 1, 2006.
U.S. Appl. No. 90/008,172, Request for Reexamination of U.S. Patent No. 6,990,366, filed Aug. 16, 2006.
U.S. Appl. No. 90/008,173, Request for Reexamination of U.S. Patent No. 6,134,461, filed Aug. 16, 2006.
U.S. Appl. No. 90/008,457, Request for Reexamination of U.S. Patent No. 6,990,366, filed Jan. 23, 2007.
U.S. Appl. No. 90/008,665, Request for Reexamination of U.S. Patent No. 6,284,478, filed May 25, 2007.
U.S. Appl. No. 90/008,713, Request for Reexamination of U.S. Patent No. 6,329,161, filed Jul. 25, 2007.
U.S. Appl. No. 90/008,909, Request for Reexamination of U.S. Patent No. 5,899,855, filed Dec. 11, 2007.
U.S. Appl. No. 90/009,104, Request for Reexamination of U.S. Patent No. 6,990,366, filed Apr. 8, 2008.
Umana, M., “Protein-Modified Electrochemically Active Biomaterial Surface”, U.S. Army Research Office, Analytical and Chemical Sciences Research Triangle Institute, 1988, pp. 1-9.
Updike, S. J., et al., “A Subcutaneous Glucose Sensor with Improved Longevity, Dynamic Range, and Stability of Calibration”, Diabetes Care, vol. 23, No. 2, 2000, pp. 208-214.
Updike, S. J., et al., “Continuous Glucose Monitor Based on an Immobilized Enzyme Electrode Detector”, The Journal of Laboratory and Clinical Medicine, vol. 93, No. 4, 1979, pp. 518-527.
Updike, S. J., et al., “Enzymatic Glucose Sensors: Improved Long-Term Performance In Vitro and In Vivo”, American Society for Artificial Internal Organs Journal, 1994, pp. 157-163.
Updike, S. J., et al., “Implanting the Glucose Enzyme Electrode: Problems, Progress, and Alternative Solutions”, Diabetes Care, vol. 5, No. 3, 1982, pp. 207-212.
Updike, S. J., et al., “Principles of Long-Term Fully Implanted Sensors with Emphasis on Radiotelemetric Monitoring of Blood Glucose from Inside a Subcutaneous Foreign Body Capsule (FBC)”, Biosensors in the Body: Continuous in vivo Monitoring, Chapter 4, 1997, pp. 117-137.
Updike, S. J., et al., “The Enzyme Electrode”, Nature, vol. 214, 1967, pp. 986-988.
Urban, G., et al., “Miniaturized Thin-Film Biosensors Using Covalently Immobilized Glucose Oxidase”, Biosensors & Bioelectronics, vol. 6, 1991, pp. 555-562.
Valdes, T. I., et al., “In Vitro and In Vivo Degradation of Glucose Oxidase Enzyme Used for an Implantable Glucose Biosensor”, Diabetes Technology & Therapeutics, vol. 2, No. 3, 2000, pp. 367-376.
Velho, G., et al., “In Vitro and In Vivo Stability of Electrode Potentials in Needle-Type Glucose Sensors”, Diabetes, vol. 38, No. 2, 1989, pp. 164-171.
Velho, G., et al., “Strategies for Calibrating a Subcutaneous Glucose Sensor”, Biomedica Biochimica Acta, vol. 48, 1989, pp. 957-964.
Von Woedtke, T., et al., “In Situ Calibration of Implanted Electrochemical Glucose Sensors”, Biomedica Biochimica Acta, vol. 48, 1989, pp. 943-952.
Vreeke, M. S., et al., “Hydrogen Peroxide Electrodes Based on Electrical Connection of Redox Centers of Various Peroxidases to Electrodes through a Three-Dimensional Electron-Relaying Polymer Network”, Diagnostic Biosensors Polymers, Chapter 15, 1993, pp. 180-193.
Vreeke, M., et al., “Hydrogen Peroxide and β-Nicotinamide Adenine Dinucleotide Sensing Amperometric Electrodes Based on Electrical Connection of Horseradish Peroxidase Redox Centers to Electrodes through a Three-Dimensional Electron Relaying Polymer Network”, Analytical Chemistry, vol. 64, No. 24, 1992, pp. 3084-3090.
Wade Jr., L. G., “Chapter 17: Reactions of Aromatic Compounds”, Organic Chemistry, Sixth Edition, 2006, pp. 762-763.
Wagner, J. G., et al., “Continuous Amperometric Monitoring of Glucose in a Brittle Diabetic Chimpanzee with a Miniature Subcutaneous Electrode”, Proceedings of the National Academy of Sciences USA, 1998, pp. 6379-6382.
Wang, D. L., et al., “Miniaturized Flexible Amperometric Lactate Probe”, Analytical Chemistry, vol. 65, No. 8, 1993, pp. 1069-1073.
Wang, J., et al., “Activation of Glassy Carbon Electrodes by Alternating Current Electrochemical Treatment”, Analytica Chimica Acta, vol. 167, 1985, pp. 325-334.
Wang, J., et al., “Amperometric Biosensing of Organic Peroxides with Peroxidase-Modified Electrodes”, Analytica Chimica Acta, vol. 254, 1991, pp. 81-88.
Wang, J., et al., “Highly Selective Membrane-Free, Mediator-Free Glucose Biosensor”, Analytical Chemistry, vol. 66, No. 21, 1994, pp. 3600-3606.
Wang, J., et al., “Screen-Printable Sol-Gel Enzyme-Containing Carbon Inks”, Analytical Chemistry, vol. 68, No. 15, 1996, pp. 2705-2708.
Wang, J., et al., “Sol-Gel-Derived Metal-Dispersed Carbon Composite Amperometric Biosensors”, Electroanalysis, vol. 9, No. 1, 1997, pp. 52-55.
Wang, X., et al., “Improved Ruggedness for Membrane-Based Amperometric Sensors Using a Pulsed Amperometric Method”, Analytical Chemistry, vol. 69, No. 21, 1997, pp. 4482-4489.
Ward, W. K., et al., “A New Amperometric Glucose Microsensor: In Vitro and Short-Term In Vivo Evaluation”, Biosensors & Bioelectronics, vol. 17, 2002, pp. 181-189.
Ward, W. K., et al., “Assessment of Chronically Implanted Subcutaneous Glucose Sensors in Dogs: The Effect of Surrounding Fluid Masses”, American Society for Artificial Internal Organs Journal, 1999, pp. 555-561.
Ward, W. K., et al., “Rise in Background Current Over Time in a Subcutaneous Glucose Sensor in the Rabbit: Relevance to Calibration and Accuracy”, Biosensors & Bioelectronics, vol. 15, 2000, pp. 53-61.
Ward, W. K., et al., “Understanding Spontaneous Output Fluctuations of an Amperometric Glucose Sensor: Effect of Inhalation Anesthesia and Use of a Nonenzyme Containing Electrode”, American Society for Artificial Internal Organs Journal, 2000, pp. 540-546.
Wientjes, K. J. C., Development of a Glucose Sensor for Diabetic Patients, 2000, pp. vii-xiii.
Wilkins, E., et al., “Glucose Monitoring: State of the Art and Future Possibilities”, Medical Engineering and Physics, vol. 18, No. 4, 1995, pp. 273-288.
Wilkins, E., et al., “Integrated Implantable Device for Long-Term Glucose Monitoring”, Biosensors & Bioelectronics, vol. 10, 1995, pp. 485-494.
Williams, D. L., et al., “Electrochemical-Enzymatic Analysis of Blood Glucose and Lactate”, Analytical Chemistry, vol. 42, No. 1, 1970, pp. 118-121.
Wilson, G. S., et al., “Enzyme-Based Biosensors for In Vivo Measurements”, Chemical Reviews, vol. 100, No. 7, 2000, pp. 2693-2704.
Wilson, G. S., et al., “Progress Toward the Development of an Implantable Sensor for Glucose”, Clinical Chemistry, vol. 38, No. 9, 1992, pp. 1613-1617.
Wood, W. D., et al., “Hermetic Sealing with Epoxy”, Mechanical Engineering, 1990, pp. 46-48.
Wu, H., et al., “In Situ Electrochemical Oxygen Generation with an Immunoisolation Device”, Annals of the new York Academy of Sciences, vol. 875, 1999, pp. 105-125.
Yabuki, S., et al., “Electro-Conductive Enzyme Membrane”, Journal of the Chemical Society, Chemical Communications, 1989, pp. 945-946.
Yang, C., et al., “A Comparison of Physical Properties and Fuel Cell Performance of Nafion and Zirconium Phosphate/Nafion Composite Membranes,” Journal of Membrane Science, vol. 237, 2004, pp. 145-161.
Yang, L., et al., “Determination of Oxidase Enzyme Substrates Using Cross-Flow Thin-Layer Amperometry”, Electroanalysis, vol. 8, No. 8-9, 1996, pp. 716-721.
Yang, Q., et al., “Development of Needle-Type Glucose Sensor with High Selectivity”, Sensors and Actuators B, vol. 46, 1998, pp. 249-256.
Yao, S. J., et al., “The Interference of Ascorbate and Urea in Low-Potential Electrochemical Glucose Sensing”, Proceedings of the Twelfth Annual International Conference of the IEEE Engineering in Medicine and Biology Society, vol. 12, Part 2, 1990, pp. 487-489.
Yao, T., “A Chemically-Modified Enzyme Membrane Electrode as an Amperometric Glucose Sensor”, Analytica Chimica Acta, vol. 148, 1983, pp. 27-33.
Ye, L., et al., “High Current Density ‘Wired’ Quinoprotein Glucose Dehydrogenase Electrode”, Analytical Chemistry, vol. 65, No. 3, 1993, pp. 238-241.
Yildiz, A., et al., “Evaluation of an Improved Thin-Layer Electrode”, Analytical Chemistry, vol. 40, No. 7, 1968, pp. 1018-1024.
Zamzow, K., et al., “New Wearable Continuous Blood Glucose Monitor (BGM) and Artificial Pancreas (AP)”, Diabetes, vol. 39, 1990, pp. 5A-20.
Zavalkoff, S. R., et al., “Evaluation of Conventional Blood Glucose Monitoring as an Indicator of Integrated Glucose Values Using a Continuous Subcutaneous Sensor”, Diabetes Care, vol. 25, No. 9, 2002, pp. 1603-1606.
Zhang, Y., et al., “Application of Cell Culture Toxicity Tests to the Development of Implantable Biosensors”, Biosensors & Bioelectronics, vol. 6, 1991, pp. 653-661.
Zhang, Y., et al., “Elimination of the Acetaminophen Interference in an Implantable Glucose Sensor”, Analytical Chemistry, vol. 66, No. 7, 1994, pp. 1183-1188.
Zhu, J., et al., “Planar Amperometric Glucose Sensor Based on Glucose Oxidase Immobilized by Chitosan Film on Prussian Blue Layer”, Sensors, vol. 2, 2002, pp. 127-136.
U.S. Appl. No. 09/447,227, Shults.
U.S. Appl. No. 11/737,671, Wolpert, et al.
U.S. Appl. No. 11/766,747, Say, et al.
U.S. Appl. No. 11/849,200, Peyser, et al.
U.S. Appl. No. 11/928,574, Heller, et al.
U.S. Appl. No. 11/928,668, Heller, et al.
U.S. Appl. No. 11/928,743, Heller, et al.
U.S. Appl. No. 11/928,795, Heller, et al.
U.S. Appl. No. 11/928,891, Heller, et al.
U.S. Appl. No. 11/928,968, Heller, et al.
U.S. Appl. No. 11/941,078, Say, et al.
“Poretics Polycarbonate Membrane”, Osmonics Filtration and Separation Group, 2002.
Bellucci, F., et al., “Electrochemical Behaviour of Graphite-Epoxy Composite Materials (GECM) in Aqueous Salt Solutions”, Journal of Applied Electrochemistry, vol. 16, 1986, pp. 15-22.
Biermann, E., et al., “How Would Patients Behave if They Were Continually Informed of Their Blood Glucose Levels? A Simulation Study Using a ‘Virtual’ Patient”, Diabetes Technology & Therapeutics, vol. 10, No. 3, 2008, pp. 178-187.
Candas, B., et al., “An Adaptive Plasma Glucose Controller Based on a Nonlinear Insulin/Glucose Model”, IEEE Transactions on Biomedical Engineering, vol. 41, No. 2, 1994, pp. 116-124.
Davies, M. L., et al., “Polymer Membranes in Clinical Sensor Applications”, Biomaterials, vol. 13, No. 14, 1992, pp. 971-978.
Eighth Annual Diabetes Technology Meeting Abstracts, Nov. 13-15, 2008, pp. A1-A182.
El-Khatib, F. H, et al., “Adaptive Closed-Loop Control Provides Blood-Glucose Regulation Using Subcutaneous Insulin and Glucagon Infusion in Diabetic Swine”, Journal of Diabetes Science and Technology, vol. 1, No. 2, 2007, pp. 181-192.
Fabietti, P. G., et al. “Clinical Validation of a New Control-Oriented Model of Insulin and Glucose Dynamics in Subjects with Type 1 Diabetes”, Diabetes Technology & Therapeutics, vol. 9, No. 4, 2007, pp. 327-338.
Guerci, B., et al., “Clinical Performance of CGMS in Type 1 Diabetic Patients Treated by Continuous Subcutaneous Insulin Infusion Using Insulin Analogs”, Diabetes Care, vol. 26, 2003, pp. 582-589.
Hicks, J. M., “In Situ Monitoring”, Clinical Chemistry, vol. 31 No. 12, 1985, pp. 1931-1935.
Hu, Y., et al., “A Needle-Type Enzyme-Based Lactate Sensor for In Vivo Monitoring”, Analytica Chimica Acta, vol. 281, 1993, pp. 503-511.
Isermann, R., “Supervision, Fault-Detection and Fault-Diagnosis Methods—An Introduction”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 639-652.
Isermann, R., et al., “Trends in the Application of Model-Based Fault Detection and Diagnosis of Technical Processes”, Control Engineering Practice, vol. 5, No. 5, 1997, pp. 709-719.
Jobst, G., et al., “Thin-Film Microbiosensors for Glucose-Lactate Monitoring”, Analytical Chemistry, vol. 68, No. 18, 1996, pp. 3173-3179.
Kamath, A., et al., “Calibration of a Continuous Glucose Monitor: Effect of Glucose Rate of Change”, Eighth Annual Diabetes Technology Meeting Abstracts, Nov. 13-15, 2008, pp. A88.
Kawagoe, J. L., et al., “Enzyme-Modified Organic Conducting Salt Microelectrode”, Analytical Chemistry, vol. 63, No. 24, 1991, pp. 2961-2965.
Kusano, H., “Glucose Enzyme Electrode with Percutaneous Interface Which Operates Independently of Dissolved Oxygen”, Clinical Physics and Physicological Measurement, vol. 10, No. 1, 1989, pp. 1-9.
Lewis, R. J., ed., “2-hydroxyethyl methacrylate”, Hawley's Condensed Chemical Dictionary, Twelfth Edition, 1993, pp. 596.
Lohn, A., et al., “A Knowledge-Based System for Real-Time Validation of Calibrations and Measurements”, Chemometrics and Intelligent Laboratory Systems, vol. 46, 1999, pp. 57-66.
Mazze, R. S., et al., “Characterizing Glucose Exposure for Individuals with Normal Glucose Tolerance Using Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis”, Diabetes Technology & Therapeutics, vol. 10, No. 3, 2008, pp. 149-159.
Murphy, S. M., et al., “Polymer Membranes in Clinical Sensor Applications”, Biomaterials, vol. 13, No. 14, 1992, pp. 979-990.
Park, T., et al., “Sol-Gel-based Amperometric Glucose Biosensor Incorporating an Osmium Redox Polymer as Mediator”, Analytical Communications, vol. 33, 1996, pp. 271-273.
Petrou, P. S., et al., “Microdevice with Integrated Dialysis Probe and Biosensor Array for Continuous Multi-Analyte Monitoring”, Biosensors & Bioelectronics, vol. 18, 2003, pp. 613-619.
Poscia, A., et al., “A Microdialysis Technique for Continuous Subcutaneous Glucose Monitoring in Diabetic Patients (Part 1)”, Biosensors & Bioelectronics, vol. 18, 2003, pp. 891-898.
Prabhu, V. G., et al., “Electrochemical Studies of Hydrogen Peroxide at a Platinum Disc Electrode”, Electrochimica Acta, vol. 26, No. 6, 1981, pp. 725-729.
Rigla, M, et al., “Real-Time Continuous Glucose Monitoring Together with Telemedical Assistance Improves Glycemic Control and Glucose Stability in Pump-Treated Patients”, Diabetes Technology & Therapeutics, vol. 10, No. 3, 2008, pp. 194-199.
Service, F. J., et al., “Mean Amplitude of Glycemic Excursions, a Measure of Diabetic Instability”, Diabetes, vol. 19, No. 9, 1970, pp. 644-655.
Sokol, L., et al , “Immobilized-Enzyme Rate-Determination Method for Glucose Analysis”, Clinical Chemistry, vol. 26, No. 1, 1980, pp. 89-92.
Stedman's Medical Dictionary, 26th Edition, 1995, pp. 665.
Varalli, M., et al., “A Microdialysis Technique for Continuous Subcutaneous Glucose Monitoring in Diabetic Patients (Part 2)”, Biosensors & Bioelectronics, vol. 18, 2003, pp. 899-905.
Yang, S., et al., “A Glucose Biosensor Based on an Oxygen Electrode: In-Vitro Performances in Blood Plasma”, Biomedical Instrumentation & Technology, vol. 30, No. 1, 1996, pp. 55-61.
Canadian Patent Application No. 2,433,144, Examiner's Report mailed Nov. 2, 2010.
Canadian Patent Application No. 2,433,144, Examiner's Report mailed Sep. 8, 2008.
Chinese Patent Application No. 01822786.4, Office Action mailed Feb. 2, 2007.
Chinese Patent Application No. 01822786.4, Office Action mailed Sep. 21, 2007.
European Patent Application No. 01 994 499.0, Examination Report mailed Dec. 7, 2006.
European Patent Application No. 01 994 499.0, Examination Report mailed Feb. 10, 2009.
European Patent Application No. 01 994 499.0, Examination Report mailed Oct. 11, 2007.
European Patent Application No. 06 839 640.7, Extended European Search Report mailed Oct. 21, 2010.
European Patent Application No. 09 010 614.7, Extended European Search Report mailed Mar. 2, 2010.
European Patent Application No. 99 903 239.4, Examination Report mailed Apr. 14, 2008.
European Patent Application No. 99 903 239.4, Examination Report mailed Dec. 20, 2004.
European Patent Application No. 99 903 239.4, Examination Report mailed Oct. 7, 2005.
European Patent Application No. 99 903 239.4, Invitation Pursuant to Article 94(3) and Rule 71(1) EPC mailed Dec. 15, 2010.
Japanese Patent Application No. 2000-546653, Office Action mailed Dec. 15, 2009.
Japanese Patent Application No. 2000-546653, Office Action mailed Jan. 6, 2009.
Japanese Patent Application No. 2002-558875, Office Action mailed Sep. 26, 2006.
PCT Application No. PCT/US1999/001229, International Preliminary Examination Report mailed Aug. 1, 2000.
PCT Application No. PCT/US1999/001229, International Search Report mailed May 6, 1999.
PCT Application No. PCT/US1999/001229, Written Opinion of the International Preliminary Examining Authority mailed Feb. 7, 2000.
PCT Application No. PCT/US2001/050832, International Preliminary Examination Report mailed Nov. 4, 2003.
PCT Application No. PCT/US2001/050832, International Search Report mailed Dec. 17, 2002.
PCT Application No. PCT/US2006/060400, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed May 15, 2008.
PCT Application No. PCT/US2006/060400, International Search Report and Written Opinion of the International Searching Authority mailed Oct. 16, 2007.
PCT Application No. PCT/US2008/074469, International Search Report and Written Opinion of the International Searching Authority mailed Nov. 3, 2008.
PCT Application No. PCT/US2010/040117, International Search Report and Written Opinion of the International Searching Authority mailed Sep. 1, 2010.
PCT Application No. PCT/US2010/040118, International Search Report and Written Opinion of the International Searching Authority mailed Sep. 17, 2010.
PCT Application No. PCT/US2010/040119, International Search Report and Written Opinion of the International Searching Authority mailed Sep. 17, 2010.
U.S. Appl. No. 09/070,677, Notice of Allowance mailed Aug. 1, 2000.
U.S. Appl. No. 09/070,677, Notice of Allowance mailed Jun. 6, 2000.
U.S. Appl. No. 09/070,677, Office Action mailed Apr. 27, 1999.
U.S. Appl. No. 09/070,677, Office Action mailed Nov. 15, 1999.
U.S. Appl. No. 09/667,199, Notice of Allowance mailed Nov. 25, 2002.
U.S. Appl. No. 09/667,199, Office Action mailed Jul. 24, 2002.
U.S. Appl. No. 09/753,746, Notice of Allowance mailed Oct. 9, 2002.
U.S. Appl. No. 09/753,746, Office Action mailed Jul. 3, 2002.
U.S. Appl. No. 10/336,195, Office Action mailed Apr. 29, 2005.
U.S. Appl. No. 10/336,195, Office Action mailed Dec. 28, 2007.
U.S. Appl. No. 10/336,195, Office Action mailed Feb. 6, 2006.
U.S. Appl. No. 10/336,195, Office Action mailed Jul. 16, 2008.
U.S. Appl. No. 10/336,195, Office Action mailed Jun. 17, 2004.
U.S. Appl. No. 10/336,195, Office Action mailed Mar. 25, 2009.
U.S. Appl. No. 10/336,195, Office Action mailed Nov. 10, 2009.
U.S. Appl. No. 10/336,195, Office Action mailed Oct. 26, 2006.
U.S. Appl. No. 10/420,057, Advisory Action mailed Jan. 27, 2009.
U.S. Appl. No. 10/420,057, Office Action mailed Apr. 4, 2006.
U.S. Appl. No. 10/420,057, Office Action mailed Aug. 21, 2008.
U.S. Appl. No. 10/420,057, Office Action mailed Jul. 25, 2007.
U.S. Appl. No. 10/420,057, Office Action mailed Jun. 1, 2005.
U.S. Appl. No. 10/420,057, Office Action mailed Jun. 24, 2010.
U.S. Appl. No. 10/420,057, Office Action mailed Nov. 23, 2007.
U.S. Appl. No. 10/420,057, Office Action mailed Oct. 17, 2006.
U.S. Appl. No. 10/420,057, Office Action mailed Sep. 30, 2009.
U.S. Appl. No. 10/722,246, Office Action mailed Dec. 28, 2005.
U.S. Appl. No. 10/722,246, Office Action mailed Oct. 12, 2006.
U.S. Appl. No. 10/722,251, Notice of Allowance mailed Jul. 22, 2005.
U.S. Appl. No. 10/722,253, Notice of Allowance mailed Jul. 5, 2005.
U.S. Appl. No. 10/722,264, Notice of Allowance mailed Jan. 26, 2005.
U.S. Appl. No. 10/783,675, Office Action mailed Dec. 2, 2008.
U.S. Appl. No. 10/783,675, Office Action mailed Mar. 24, 2010.
U.S. Appl. No. 10/783,675, Office Action mailed Oct. 9, 2007.
U.S. Appl. No. 10/783,675, Patent Office Communication mailed Apr. 15, 2009.
U.S. Appl. No. 10/789,776, Office Action mailed Apr. 3, 2009.
U.S. Appl. No. 10/789,776, Office Action mailed Aug. 13, 2008.
U.S. Appl. No. 10/789,776, Office Action mailed Jan. 7, 2010.
U.S. Appl. No. 10/789,776, Office Action mailed Nov. 1, 2007.
U.S. Appl. No. 10/789,776, Office Action mailed Sep. 3, 2009.
U.S. Appl. No. 11/027,423, Office Action mailed Feb. 20, 2009.
U.S. Appl. No. 11/027,423, Office Action mailed Nov. 4, 2009.
U.S. Appl. No. 11/041,404, Advisory Action mailed May 28, 2008.
U.S. Appl. No. 11/041,404, Office Action mailed Mar. 14, 2008.
U.S. Appl. No. 11/041,404, Office Action mailed May 29, 2007.
U.S. Appl. No. 11/041,404, Office Action mailed Sep. 11, 2006.
U.S. Appl. No. 11/265,787, Office Action mailed Aug. 4, 2010.
U.S. Appl. No. 11/265,787, Office Action mailed Nov. 12, 2010.
U.S. Appl. No. 11/681,730, Office Action mailed Jan. 27, 2010.
U.S. Appl. No. 11/681,730, Office Action mailed Mar. 6, 2009.
U.S. Appl. No. 11/681,730, Office Action mailed Oct. 15, 2010.
U.S. Appl. No. 11/681,730, Office Action mailed Sep. 15, 2009.
U.S. Appl. No. 11/683,371, Office Action mailed Aug. 13, 2010.
U.S. Appl. No. 11/683,371, Office Action mailed Jun. 24, 2010.
U.S. Appl. No. 11/683,371, Office Action mailed Mar. 11, 2009.
U.S. Appl. No. 11/683,371, Office Action mailed Sep. 23, 2009.
U.S. Appl. No. 11/683,408, Notice of Allowance mailed Oct. 19, 2010.
U.S. Appl. No. 11/683,408, Office Action mailed Jul. 12, 2010.
U.S. Appl. No. 11/683,408, Office Action mailed Mar. 10, 2009.
U.S. Appl. No. 11/683,408, Office Action mailed Oct. 19, 2009.
U.S. Appl. No. 11/690,826, Office Action mailed Dec. 29, 2009.
U.S. Appl. No. 11/690,826, Office Action mailed Mar. 26, 2009.
U.S. Appl. No. 11/695,605, Advisory Action mailed Apr. 7, 2010.
U.S. Appl. No. 11/695,605, Office Action mailed Apr. 16, 2009.
U.S. Appl. No. 11/695,605, Office Action mailed Jan. 22, 2010.
U.S. Appl. No. 11/695,607, Office Action mailed Mar. 4, 2010.
U.S. Appl. No. 11/695,608, Office Action mailed Dec. 28, 2009.
U.S. Appl. No. 11/695,608, Office Action mailed Jul. 22, 2010.
U.S. Appl. No. 11/695,608, Office Action mailed Jun. 29, 2009.
U.S. Appl. No. 11/734,782, Office Action mailed Apr. 3, 2009.
U.S. Appl. No. 11/734,782, Office Action mailed Jul. 19, 2010.
U.S. Appl. No. 11/734,782, Office Action mailed Oct. 28, 2009.
U.S. Appl. No. 11/742,453, Office Action mailed Apr. 16, 2009.
U.S. Appl. No. 11/742,453, Office Action mailed Jan. 11, 2010.
U.S. Appl. No. 11/742,507, Notice of Allowance mailed Apr. 2, 2010.
U.S. Appl. No. 11/742,507, Office Action mailed Aug. 12, 2009.
U.S. Appl. No. 11/742,546, Office Action mailed Dec. 9, 2009.
U.S. Appl. No. 11/742,571, Office Action mailed Dec. 29, 2009.
U.S. Appl. No. 11/766,686, Office Action mailed Jun. 25, 2010.
U.S. Appl. No. 11/766,686, Office Action mailed Oct. 6, 2009.
U.S. Appl. No. 11/766,708, Office Action mailed Jul. 9, 2010.
U.S. Appl. No. 11/766,708, Office Action mailed Oct. 8, 2009.
U.S. Appl. No. 11/766,726, Office Action mailed Mar. 9, 2010.
U.S. Appl. No. 11/766,726, Office Action mailed Oct. 27, 2009.
U.S. Appl. No. 11/766,747, Office Action mailed Feb. 5, 2009.
U.S. Appl. No. 11/766,747, Office Action mailed Nov. 13, 2009.
U.S. Appl. No. 11/928,574, Office Action mailed Dec. 30, 2009.
U.S. Appl. No. 11/928,574, Office Action mailed Jul. 21, 2010.
U.S. Appl. No. 11/928,668, Office Action mailed Apr. 1, 2010.
U.S. Appl. No. 11/928,668, Office Action mailed Dec. 23, 2010.
U.S. Appl. No. 11/928,795, Office Action mailed Sep. 15, 2010.
U.S. Appl. No. 11/928,968, Office Action mailed Apr. 28, 2010.
U.S. Appl. No. 11/928,968, Office Action mailed Jul. 22, 2009.
U.S. Appl. No. 11/941,078, Office Action mailed Dec. 22, 2010.
U.S. Appl. No. 12/039,565, Office Action mailed Feb. 4, 2010.
U.S. Appl. No. 12/052,489, Office Action mailed Dec. 31, 2009.
U.S. Appl. No. 12/109,049, Office Action mailed Jun. 14, 2010.
U.S. Appl. No. 12/135,937, Office Action mailed Mar. 30, 2010.
U.S. Appl. No. 12/397,281, Office Action mailed Apr. 16, 2010.
U.S. Appl. No. 12/397,281, Office Action mailed Oct. 15, 2010.
U.S. Appl. No. 12/397,293, Office Action mailed Dec. 1, 2010.
U.S. Appl. No. 12/397,293, Office Action mailed May 6, 2010.
U.S. Appl. No. 12/397,301, Office Action mailed Apr. 29, 2010.
U.S. Appl. No. 12/397,301, Office Action mailed Dec. 1, 2010.
U.S. Appl. No. 12/405,515, Office Action mailed Sep. 23, 2010.
U.S. Appl. No. 12/405,958, Office Action mailed Feb. 8, 2010.
U.S. Appl. No. 12/405,987, Office Action mailed Mar. 9, 2010.
U.S. Appl. No. 12/406,800, Office Action mailed Jul. 20, 2010.
U.S. Appl. No. 12/414,456, Office Action mailed Sep. 17, 2010.
U.S. Appl. No. 12/643,974, Office Action mailed Oct. 1, 2010.
U.S. Appl. No. 12/643,980, Office Action mailed Oct. 29, 2010.
U.S. Appl. No. 12/643,982, Office Action mailed Oct. 28, 2010.
U.S. Appl. No. 12/643,986, Office Action mailed Oct. 29, 2010.
U.S. Appl. No. 12/717,937, Office Action mailed Sep. 22, 2010.
U.S. Appl. No. 12/852,436, Notice of Allowance mailed Oct. 21, 2010.
U.S. Appl. No. 12/852,436, Office Action mailed Sep. 29, 2010.
U.S. Appl. No. 12/852,439, Notice of Allowance mailed Oct. 14, 2010.
U.S. Appl. No. 12/855,682, Office Action mailed Sep. 22, 2010.
U.S. Appl. No. 90/007,903, Advisory Action mailed Nov. 20, 2008.
U.S. Appl. No. 90/007,903, Examiner's Answer to Appeal Brief mailed Oct. 2, 2009.
U.S. Appl. No. 90/007,903, Office Action mailed Feb. 13, 2008.
U.S. Appl. No. 90/007,903, Office Action mailed Sep. 19, 2008.
U.S. Appl. No. 90/007,903, Order Granting Request for Reexamination mailed Mar. 27, 2006.
U.S. Appl. No. 90/007,910, Advisory Action mailed Feb. 6, 2009.
U.S. Appl. No. 90/007,910, Advisory Action mailed Jul. 30, 2009.
U.S. Appl. No. 90/007,910, Examiner's Answer to Appeal Brief mailed Nov. 19, 2010.
U.S. Appl. No. 90/007,910, Office Action mailed Feb. 13, 2008.
U.S. Appl. No. 90/007,910, Office Action mailed Oct. 2, 2008.
U.S. Appl. No. 90/007,910, Order Granting Request for Reexamination mailed Mar. 27, 2006.
U.S. Appl. No. 90/008,234, Request for Reexamination of U.S. Patent No. 5,899,855, filed Oct. 31, 2006.
U.S. Appl. No. 90/008,457, Order Granting Request for Reexamination mailed Feb. 23, 2007.
U.S. Appl. No. 90/008,928, Request for Reexamination of U.S. Patent No. 6,134,461 filed Nov. 16, 2007.
U.S. Appl. No. 90/009,104 & U.S. Appl. No. 90/009,328, Notice of Intent to Issue Reexamination Certificate mailed Nov. 20, 2009.
U.S. Appl. No. 90/009,104 & U.S. Appl. No. 90/009,328, Office Action mailed Aug. 4, 2009.
U.S. Appl. No. 90/009,104 & U.S. Appl. No. 90/009,328, Office Action mailed Sep. 30, 2009.
U.S. Appl. No. 90/009,104, Office Action mailed Oct. 16, 2008.
U.S. Appl. No. 90/009,104, Order Granting Request for Reexamination mailed Jun. 5, 2008.
U.S. Appl. No. 90/009,270, Order Denying Request for Reexamination mailed Dec. 1, 2008.
U.S. Appl. No. 90/009,270, Request for Reexamination of U.S. Patent No. 6,175,752 filed Sep. 8, 2008.
U.S. Appl. No. 90/009,279, Order Denying Request for Reexamination mailed Dec. 1, 2008.
U.S. Appl. No. 90/009,279, Request for Reexamination of U.S. Patent No. 6,565,509 filed Sep. 17, 2008.
U.S. Appl. No. 90/009,328, Order Granting Request for Reexamination mailed Dec. 9, 2008.
U.S. Appl. No. 90/009,328, Request for Reexamination of U.S. Patent No. 6,990,366 filed Nov. 10, 2008.
U.S. Appl. No. 90/009,352, Request for Reexamination of U.S. Patent No. 5,899,855 filed Dec. 4, 2008.
U.S. Appl. No. 90/009,390, Office Action mailed Aug. 23, 2010.
U.S. Appl. No. 90/009,390, Office Action mailed Nov. 26, 2010.
U.S. Appl. No. 90/009,390, Order Granting Request for Reexamination mailed May 1, 2009.
U.S. Appl. No. 90/009,390, Request for Reexamination of U.S. Patent No. 6,565,509 filed Jan. 21, 2009.
U.S. Appl. No. 90/009,472, Replacement Request for Reexamination of U.S. Patent No. 6,284,478 filed Sep. 3, 2009.
U.S. Appl. No. 90/009,472, Request for Reexamination of U.S. Patent No. 6,284,478 filed May 27, 2009.
U.S. Appl. No. 90/009,488, Replacement Request for Reexamination of U.S. Patent No. 6,329,161 filed Jul. 31, 2009.
U.S. Appl. No. 90/009,488, Request for Reexamination of U.S. Patent No. 6,329,161 filed Jun. 10, 2009.
U.S. Appl. No. 90/009,497, Notice of Intent to Issue Reexamination Certificate mailed Aug. 23, 2010.
U.S. Appl. No. 90/009,497, Order Granting Request for Reexamination mailed Jul. 30, 2009.
U.S. Appl. No. 90/009,497, Request for Reexamination of U.S. Patent No. 6,175,752 filed Jun. 17, 2009.
U.S. Appl. No. 90/009,620, Request for Reexamination of U.S. Patent No. 6,329,161 filed Oct. 27, 2009.
U.S. Appl. No. 90/009,763, Request for Reexamination of U.S. Patent No. 6,134,461 filed Jun. 18, 2010.
U.S. Patent Reexamination Application No. 90/010,791, Order Granting Request for Reexamination mailed Feb. 22, 2010.
U.S. Appl. No. 90/010,791, Request for Reexamination of U.S. Patent No. 6,990,366 filed Dec. 22, 2009.
U.S. Appl. No. 90/010,835, Request for Reexamination of U.S. Patent No. 6,134,461 filed Jan. 27, 2010.
U.S. Appl. No. 90/011,317, Request for Reexamination of U.S. Patent No. 6,484,046 filed Nov. 5, 2010.
Gough, D. A., et al., “The Implantable Glucose Sensor: An Example of Bioengineering Design”, Introduction to Bioengineering, Chapter 3, 2001, pp. 57-66.
Gunasingham, et al., “Electrochemically Modulated Optrode for Glucose”, Biosensors & Bioelectronics, vol. 7, 1992, pp. 353-359.
Ikeda, T., et al., “Artificial Pancreas—Investigation of the Stability of Glucose Sensors Using a Telemetry System” (English language translation of abstract), Jpn. J. Artif. Organs, vol. 19, No. 2, 1990, 889-892.
Koudelka, M., et al., “Planar Amperometric Enzyme-Based Glucose Microelectrode”, Sensors and Actuators, vol. 18, 1989, pp. 157-165.
Minimed Technologies, “Tape Tips and Other Infusion Site Information”, 1995.
PCT Application No. PCT/US2008/074469, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Mar. 11, 2010.
PCT Application No. PCT/US2010/040117, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Jan. 12, 2012.
PCT Application No. PCT/US2010/040118, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Jan. 12, 2012.
PCT Application No. PCT/US2010/040119, International Preliminary Report on Patentability and Written Opinion of the International Searching Authority mailed Jan. 12, 2012.
U.S. Appl. No. 11/737,671, Office Action mailed Oct. 16, 2012.
U.S. Appl. No. 11/849,200, Office Action mailed Nov. 6, 2012.
U.S. Appl. No. 11/941,078, Office Action mailed Dec. 22, 2011.
U.S. Appl. No. 12/135,937, Notice of Allowance mailed May 18, 2012.
U.S. Appl. No. 12/249,644, Notice of Allowance mailed Mar. 14, 2012.
U.S. Appl. No. 12/371,539, Notice of Allowance mailed May 31, 2012.
U.S. Appl. No. 12/397,301, Advisory Action mailed Jun. 29, 2012.
U.S. Appl. No. 12/397,301, Office Action mailed Mar. 16, 2012.
U.S. Appl. No. 12/397,301, Office Action mailed Sep. 13, 2012.
U.S. Appl. No. 12/405,515, Office Action mailed Jun. 8, 2012.
U.S. Appl. No. 12/405,643, Advisory Action mailed Mar. 9, 2012.
U.S. Appl. No. 12/405,643, Notice of Allowance mailed Oct. 17, 2012.
U.S. Appl. No. 12/405,643, Office Action mailed Jun. 13, 2012.
U.S. Appl. No. 12/406,746, Notice of Allowance mailed Mar. 23, 2012.
U.S. Appl. No. 12/406,800, Office Action mailed Jun. 8, 2012.
U.S. Appl. No. 12/414,487, Notice of Allowance mailed Sep. 5, 2012.
U.S. Appl. No. 12/414,542, Office Action mailed Sep. 24, 2012.
U.S. Appl. No. 12/422,269, Office Action mailed May 8, 2012.
U.S. Appl. No. 12/422,269, Office Action mailed Oct. 25, 2012.
U.S. Appl. No. 12/495,803, Office Action mailed Jun. 14, 2012.
U.S. Appl. No. 12/495,807, Office Action mailed Jun. 18, 2012.
U.S. Appl. No. 12/533,680, Advisory Action mailed Mar. 9, 2012.
U.S. Appl. No. 12/533,680, Office Action mailed Jul. 24, 2012.
U.S. Appl. No. 12/614,974, Office Action mailed Jun. 7, 2012.
U.S. Appl. No. 12/614,990, Office Action mailed Jun. 7, 2012.
U.S. Appl. No. 12/615,069, Notice of Allowance mailed Dec. 29, 2011.
U.S. Appl. No. 12/615,128, Notice of Allowance mailed Jul. 2, 2012.
U.S. Appl. No. 12/615,128, Office Action mailed Jun. 14, 2012.
U.S. Appl. No. 12/643,974, Notice of Allowance mailed Jan. 13, 2012.
U.S. Appl. No. 12/643,975, Notice of Allowance mailed Aug. 31, 2012.
U.S. Appl. No. 12/643,977, Advisory Action mailed Mar. 9, 2012.
U.S. Appl. No. 12/643,977, Office Action mailed Oct. 4, 2012.
U.S. Appl. No. 12/643,978, Advisory Action mailed Mar. 13, 2012.
U.S. Appl. No. 12/643,980, Notice of Allowance mailed Apr. 5, 2012.
U.S. Appl. No. 12/643,982, Advisory Action mailed Mar. 13, 2012.
U.S. Appl. No. 12/643,986, Advisory Action mailed Mar. 13, 2012.
U.S. Appl. No. 12/648,143, Notice of Allowance mailed May 31, 2012.
U.S. Appl. No. 12/648,143, Office Action mailed Jan. 20, 2011.
U.S. Appl. No. 12/648,143, Office Action mailed May 11, 2011.
U.S. Appl. No. 12/648,143, Office Action mailed Oct. 11, 2011.
U.S. Appl. No. 12/859,054, Office Action mailed Dec. 29, 2011.
U.S. Appl. No. 12/859,054, Office Action mailed Jul. 13, 2011.
U.S. Appl. No. 12/902,138, Notice of Allowance, mailed Feb. 23, 2012.
U.S. Appl. No. 12/902,138, Office Action mailed Jan. 27, 2012.
U.S. Appl. No. 12/959,337, Office Action, mailed Mar. 5, 2012.
U.S. Appl. No. 13/481,256, Office Action mailed Aug. 22, 2012.
U.S. Appl. No. 90/009,472, Office Action mailed Sep. 6, 2012.
U.S. Appl. No. 90/011,730, Notice of Intent to Issue Reexam Certificate for U.S. Patent No. 6,990,366 mailed Apr. 5, 2012.
U.S. Appl. No. 90/011,730, Office Action mailed Jan. 11, 2012.
U.S. Appl. No. 95/002,113, Request for Reexamination of U.S. Patent No. 6,990,366 filed Aug. 30, 2012.
U.S. Appl. No. 95/002,162, Request for Reexamination of U.S. Patent No. 8,175,673 filed Sep. 7, 2012.
European Patent Application No. 10012409.8, Extended European Search Report mailed Mar. 15, 2011.
European Patent Application No. 10012414.8, Extended European Search Report mailed Mar. 15, 2011.
European Patent Application No. 10012960.0, Extended European Search Report mailed Mar. 2, 2011.
European Patent Application No. 10012961.8, Extended European Search Report mailed Mar. 2, 2011.
Japanese Patent Application No. 2007-270411, Office Action mailed Aug. 17, 2010.
Japanese Patent Application No. 2007-270411, Office Action mailed Jun. 21, 2011.
U.S. Appl. No. 10/783,675, Office Action mailed Dec. 14, 2010.
U.S. Appl. No. 10/783,675, Office Action mailed Jun. 2, 2011.
U.S. Appl. No. 11/681,730, Office Action mailed Apr. 27, 2011.
U.S. Appl. No. 11/681,730, Office Action mailed Dec. 15, 2011.
U.S. Appl. No. 11/683,371, Office Action mailed Mar. 8, 2011.
U.S. Appl. No. 11/683,396, Office Action mailed Jan. 18, 2011.
U.S. Appl. No. 11/690,826, Office Action mailed Aug. 9, 2011.
U.S. Appl. No. 11/695,607, Office Action mailed Mar. 2, 2011.
U.S. Appl. No. 11/695,608, Office Action mailed Mar. 29, 2011.
U.S. Appl. No. 11/742,453, Office Action mailed Oct. 28, 2011.
U.S. Appl. No. 11/742,507, Office Action mailed Apr. 13, 2011.
U.S. Appl. No. 11/742,507, Office Action mailed Jun. 12, 2009.
U.S. Appl. No. 11/766,708, Office Action mailed Mar. 3, 2011.
U.S. Appl. No. 11/928,795, Office Action mailed May 12, 2011.
U.S. Appl. No. 11/941,078, Office Action mailed Apr. 22, 2011.
U.S. Appl. No. 11/941,078, Office Action mailed Mar. 18, 2010.
U.S. Appl. No. 12/109,049, Office Action mailed Mar. 4, 2011.
U.S. Appl. No. 12/135,937, Office Action mailed Dec. 19, 2011.
U.S. Appl. No. 12/249,644, Office Action mailed Apr. 15, 2011.
U.S. Appl. No. 12/249,644, Office Action mailed Nov. 17, 2011.
U.S. Appl. No. 12/371,539, Office Action mailed Mar. 7, 2011.
U.S. Appl. No. 12/371,539, Office Action mailed Sep. 26, 2011.
U.S. Appl. No. 12/397,281, Office Action mailed May 12, 2011.
U.S. Appl. No. 12/397,293, Office Action mailed Aug. 5, 2011.
U.S. Appl. No. 12/397,301, Office Action mailed Aug. 22, 2011.
U.S. Appl. No. 12/405,515, Office Action mailed Apr. 29, 2011.
U.S. Appl. No. 12/405,515, Office Action mailed Nov. 22, 2011.
U.S. Appl. No. 12/405,568, Office Action mailed Jan. 25, 2011.
U.S. Appl. No. 12/405,568, Office Action mailed Sep. 16, 2011.
U.S. Appl. No. 12/405,643, Office Action mailed Mar. 30, 2011.
U.S. Appl. No. 12/405,643, Office Action mailed Nov. 14, 2011.
U.S. Appl. No. 12/405,690, Office Action mailed Mar. 10, 2011.
U.S. Appl. No. 12/405,739, Office Action mailed Mar. 15, 2011.
U.S. Appl. No. 12/405,843, Office Action mailed Mar. 24, 2011.
U.S. Appl. No. 12/405,987, Office Action mailed Nov. 16, 2010.
U.S. Appl. No. 12/406,746, Office Action mailed Apr. 5, 2011.
U.S. Appl. No. 12/406,746, Office Action mailed Jul. 23, 2010.
U.S. Appl. No. 12/406,746, Office Action mailed Sep. 1, 2011.
U.S. Appl. No. 12/406,800, Office Action mailed Apr. 20, 2011.
U.S. Appl. No. 12/406,800, Office Action mailed Nov. 29, 2011.
U.S. Appl. No. 12/414,456, Notice of Allowance mailed Dec. 19, 2011.
U.S. Appl. No. 12/414,456, Office Action mailed Apr. 29, 2011.
U.S. Appl. No. 12/414,474, Office Action mailed Mar. 15, 2011.
U.S. Appl. No. 12/414,487, Notice of Allowance mailed Dec. 20, 2011.
U.S. Appl. No. 12/414,487, Office Action mailed Mar. 3, 2011.
U.S. Appl.n No. 12/414,487, Office Action mailed Oct. 31, 2011.
U.S. Appl. No. 12/414,531, Office Action mailed Mar. 22, 2011.
U.S. Appl. No. 12/414,542, Office Action mailed Apr. 13, 2011.
U.S. Appl. No. 12/414,542, Office Action mailed Nov. 14, 2011.
U.S. Appl. No. 12/414,558, Office Action mailed Apr. 4, 2011.
U.S. Appl. No. 12/422,269, Office Action mailed Apr. 14, 2011.
U.S. Appl. No. 12/422,269, Office Action mailed Nov. 18, 2011.
U.S. Appl. No. 12/468,775, Office Action mailed Feb. 4, 2011.
U.S. Appl. No. 12/468,782, Office Action mailed Feb. 18, 2011.
U.S. Appl. No. 12/468,787, Office Action mailed Mar. 7, 2011.
U.S. Appl. No. 12/495,798, Office Action mailed Dec. 1, 2011.
U.S. Appl. No. 12/495,798, Office Action mailed Jun. 30, 2011.
U.S. Appl. No. 12/495,803, Office Action mailed Dec. 1, 2011.
U.S. Appl. No. 12/495,803, Office Action mailed Jun. 30, 2011.
U.S. Appl. No. 12/495,807, Office Action mailed Jul. 21, 2011.
U.S. Appl. No. 12/495,807, Office Action mailed Nov. 25, 2011.
U.S. Appl. No. 12/533,680, Office Action mailed Mar. 3, 2011.
U.S. Appl. No. 12/533,680, Office Action mailed Nov. 14, 2011.
U.S. Appl. No. 12/614,974, Office Action mailed Apr. 12, 2011.
U.S. Appl. No. 12/614,974, Office Action mailed Nov. 21, 2011.
U.S. Appl. No. 12/614,990, Office Action mailed Apr. 14, 2011.
U.S. Appl. No. 12/614,990, Office Action mailed Dec. 15, 2011.
U.S. Appl. No. 12/615,069, Office Action mailed Jun. 9, 2011.
U.S. Appl. No. 12/615,128, Office Action mailed Aug. 19 2011.
U.S. Appl. No. 12/615,128, Office Action mailed Dec. 20, 2011.
U.S. Appl. No. 12/643,974, Office Action mailed May 4, 2011.
U.S. Appl. No. 12/643,975, Advisory Action mailed Dec. 19, 2011.
U.S. Appl. No. 12/643,975, Office Action mailed Feb. 18, 2011.
U.S. Appl. No. 12/643,975, Office Action mailed Sep. 22, 2011.
U.S. Appl. No. 12/643,977, Office Action mailed Apr. 14, 2011.
U.S. Appl. No. 12/643,977, Office Action mailed Oct. 19, 2011.
U.S. Appl. No. 12/643,978, Office Action mailed Oct. 18, 2011.
U.S. Appl. No. 12/643,978, Office Action mailed Apr. 15, 2011.
U.S. Appl. No. 12/643,980, Office Action mailed Dec. 1, 2011.
U.S. Appl. No. 12/643,980, Office Action mailed Jun. 24, 2011.
U.S. Appl. No. 12/643,982, Office Action mailed Jun. 17, 2011.
U.S. Appl. No. 12/643,982, Office Action mailed Nov. 23, 2011.
U.S. Appl. No. 12/643,986, Office Action mailed Jun. 17, 2011.
U.S. Appl. No. 12/643,986, Office Action mailed Nov. 23, 2011.
U.S. Appl. No. 12/779,941, Office Action mailed Jan. 25, 2011.
U.S. Appl. No. 12/779,944, Office Action mailed Jan. 25, 2011.
U.S. Appl. No. 12/779,947, Office Action mailed Apr. 8, 2011.
U.S. Appl. No. 12/825,180, Office Action mailed Mar. 4, 2011.
U.S. Appl. No. 12/825,186, Office Action mailed Mar. 31, 2011.
U.S. Appl. No. 12/825,202 Office Action mailed Jun. 8, 2011.
U.S. Appl. No. 12/846,803, Office Action mailed Feb. 17, 2011.
U.S. Appl. No. 12/902,138 Office Action mailed Jun. 7, 2011.
U.S. Appl. No. 90/007,903, Decision on Appeal mailed Jan. 18, 2011.
U.S. Appl. No. 90/007,910, Decision on Appeal mailed Jan. 18, 2011.
U.S. Appl. No. 90/010,791, Notice of Intent to Issue Reexamination Certificate mailed May 17, 2011.
U.S. Appl. No. 90/010,791, Office Action mailed Dec. 17, 2010.
U.S. Appl. No. 90/010,791, Office Action mailed May 28, 2010.
U.S. Appl. No. 90/011,317, Replacement Request for Reexamination of U.S. Patent No. 6,484,046 filed Jan. 14, 2011.
U.S. Appl. No. 90/011,346, Request for Reexamination of U.S. Patent No. 6,103,033 filed Nov. 19, 2010.
U.S. Appl. No. 90/011,730, Request for Reexamination of U.S. Patent No. 6,990,366 filed Jun. 3, 2011.
U.S. Appl. No. 90/011,730, Order Granting Request for Reexamination of U.S. Patent No. 6,990,366 mailed Aug. 24, 2011.
Related Publications (1)
Number Date Country
20070161879 A1 Jul 2007 US
Continuations (3)
Number Date Country
Parent 10420057 Apr 2003 US
Child 11683396 US
Parent 09667199 Sep 2000 US
Child 10420057 US
Parent 09070677 Apr 1998 US
Child 09667199 US